[
  {
    "genericName": "https://www.health.gov.za/nhi",
    "brandName": "edp",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.health.gov.za/nhi-edp-stgs-eml/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the parts reproduced are distributed free of charge or at no cost",
    "brandName": "not for profit.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the parts reproduced are distributed free of charge or at no cost – not for profit.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Right to Care",
    "brandName": "RTC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Right to Care (RTC),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "USAID: Global Health Supply Chain Programme",
    "brandName": "Technical Assistance",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "USAID: Global Health Supply Chain Programme-Technical Assistance (GHSC-TA),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health Economics and Epidemiology Research Office",
    "brandName": "HE2RO",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Health Economics and Epidemiology Research Office (HE2RO).",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adult Hospital Level",
    "brandName": "AHL",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adult Hospital Level (AHL) Standard Treatment Guidelines (STGs) and Essential",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicines List",
    "brandName": "EML",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicines List (EML). These guidelines aim to enhance transparency and support the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "delivery of high",
    "brandName": "quality treatment options at both PHC and hospital",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "delivery of high-quality treatment options at both PHC and hospital levels. They reflect",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Universal Health Coverage",
    "brandName": "UHC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Universal Health Coverage (UHC) aims to eliminate disparities in healthcare access and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicines List Committee",
    "brandName": "NEMLC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicines List Committee (NEMLC) has incrementally increased the use of Health",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "transparent priority",
    "brandName": "setting and value",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "transparent priority-setting and value-based guidance for efficient resource allocation. The",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "I commend the diligent work of the PHC and AHL Expert Review Committee",
    "brandName": "ERC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "I commend the diligent work of the PHC and AHL Expert Review Committee (ERC), along",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "according to good governance and evidence",
    "brandName": "based decision principles.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "according to good governance and evidence-based decision principles.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Guidelines",
    "brandName": "STGs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Guidelines (STGs) and Essential Medicines List (EML) enable the equitable access to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cycle for these STGs commenced at the onset of the COVID",
    "brandName": "19 pandemic, necessitating",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cycle for these STGs commenced at the onset of the COVID-19 pandemic, necessitating",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "experts, clinical pharmacologists and evidence",
    "brandName": "review and guideline",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "experts, clinical pharmacologists and evidence-review and guideline-development",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and Blood",
    "brandName": "Forming Organs, HIV, Mental Health, Obstetrics and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and Blood-Forming Organs, HIV, Mental Health, Obstetrics and Gynaecology, as well as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DIRECTOR",
    "brandName": "GENERAL: HEALTH",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "DIRECTOR-GENERAL: HEALTH",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Treatment Guidelines",
    "brandName": "STGs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Treatment Guidelines (STGs) and Essential Medicines List (EML) is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "National Essential Medicines List Committee",
    "brandName": "NEMLC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "National Essential Medicines List Committee (NEMLC). For continuum of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paediatric Hospital Level",
    "brandName": "2023 edition",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Paediatric Hospital Level (2023 edition) STGs and EML, in collaboration with",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "various stakeholders through the public comment stages of the 2020",
    "brandName": "2024",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "various stakeholders through the public comment stages of the 2020-2024",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NEMLC members in office during the 2020",
    "brandName": "2024 review cycle of the combined PHC/AHL STGs",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NEMLC members in office during the 2020-2024 review cycle of the combined PHC/AHL STGs",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prof G Reubenson",
    "brandName": "Vice",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prof G Reubenson (Vice-Chairperson)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The ERC members and co",
    "brandName": "opted members in office during the 2020",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The ERC members and co-opted members in office during the 2020-2024 review cycle of the",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dr A Gray",
    "brandName": "Chairperson",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dr A Gray (Chairperson)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ms Melanie Harding",
    "brandName": "Skeen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ms Melanie Harding (Skeen)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amgen",
    "brandName": "Pty",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Amgen (Pty) Ltd.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Essential Medical Guidance",
    "brandName": "EMGuidance",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Essential Medical Guidance (EMGuidance)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "National Advisory Group on Immunisation",
    "brandName": "NAGI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "National Advisory Group on Immunisation (NAGI)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Organon",
    "brandName": "Pty",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Organon (Pty) Ltd.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Society for Endocrinology, Metabolism and Diabetes of South Africa",
    "brandName": "SEMDSA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gastro",
    "brandName": "oesophageal reflux/ disease, in infants",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gastro-oesophageal reflux/ disease, in infants",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nausea and vomiting, non",
    "brandName": "specific",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nausea and vomiting, non-specific",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3.2.3 Not growing well",
    "brandName": "including failure to thrive/growth",
    "strength": "3.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3.2.3 Not growing well (including failure to thrive/growth",
    "commonDosage": "3.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "faltering",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "faltering)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cardiac failure, congestive",
    "brandName": "CCF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cardiac failure, congestive (CCF)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4.6.1   Cardiac failure, congestive",
    "brandName": "CCF",
    "strength": "4.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4.6.1   Cardiac failure, congestive (CCF), adults",
    "commonDosage": "4.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4.6.2   Cardiac failure, congestive",
    "brandName": "CCF",
    "strength": "4.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4.6.2   Cardiac failure, congestive (CCF), children",
    "commonDosage": "4.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Itching",
    "brandName": "pruritus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Itching (pruritus)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.5.2.1   Ringworm",
    "brandName": "Tinea corporis",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.5.2.1   Ringworm – Tinea corporis",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.5.2.5   Nail infections",
    "brandName": "Tinea unguium",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.5.2.5   Nail infections – Tinea unguium",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.6.3   Nail infections",
    "brandName": "Tinea unguium",
    "strength": "5.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.6.3   Nail infections – Tinea unguium",
    "commonDosage": "5.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Termination of pregnancy",
    "brandName": "TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Termination of pregnancy (TOP)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6.7.1   Postpartum haemorrhage",
    "brandName": "PPH",
    "strength": "6.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6.7.1   Postpartum haemorrhage (PPH)",
    "commonDosage": "6.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6.11.2   Post",
    "brandName": "menopausal bleeding",
    "strength": "6.11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6.11.2   Post–menopausal bleeding",
    "commonDosage": "6.11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7.2.2   Levonorgestrel intra",
    "brandName": "uterine device",
    "strength": "7.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7.2.2   Levonorgestrel intra-uterine device",
    "commonDosage": "7.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Glomerular diseases",
    "brandName": "GN",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Glomerular diseases (GN)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benign prostatic hyperplasia",
    "brandName": "BPH",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benign prostatic hyperplasia (BPH)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "9.3.2   Severe hyperglycaemia",
    "brandName": "diabetic ketoacidosis",
    "strength": "9.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "9.3.2   Severe hyperglycaemia (diabetic ketoacidosis",
    "commonDosage": "9.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rubella",
    "brandName": "German measles",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rubella (German measles)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Shingles",
    "brandName": "Herpes zoster",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Shingles (Herpes zoster)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Viral haemorrhagic fever",
    "brandName": "VHF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Viral haemorrhagic fever (VHF)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "11.3.11 Herpes zoster",
    "brandName": "Shingles",
    "strength": "11.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "11.3.11 Herpes zoster (Shingles)",
    "commonDosage": "11.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management of HIV infected children",
    "brandName": "<10",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management of HIV infected children (<10",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vaginal discharge syndrome",
    "brandName": "VDS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vaginal discharge syndrome (VDS)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Scrotal swelling",
    "brandName": "SSW",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Scrotal swelling (SSW)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Genital ulcer syndrome",
    "brandName": "GUS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Genital ulcer syndrome (GUS)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Genital molluscum contagiosum",
    "brandName": "MC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Genital molluscum contagiosum (MC)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Genital warts",
    "brandName": "GW",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Genital warts (GW): Condylomata Accuminata",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adverse Events Following Immunisation",
    "brandName": "AEFI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adverse Events Following Immunisation (AEFI)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "neuralgia",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "neuralgia)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Psychiatric patients",
    "brandName": "general monitoring and care",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Psychiatric patients - general monitoring and care",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17.2.1   Croup",
    "brandName": "laryngotracheobronchitis",
    "strength": "17.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17.2.1   Croup (laryngotracheobronchitis) in children",
    "commonDosage": "17.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17.4.4   Multi",
    "brandName": "drug",
    "strength": "17.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17.4.4   Multi-drug-resistant tuberculosis (MDR TB)",
    "commonDosage": "17.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18.1.2   Conjunctivitis, bacterial",
    "brandName": "excluding conjunctivitis of",
    "strength": "18.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18.1.2   Conjunctivitis, bacterial (excluding conjunctivitis of",
    "commonDosage": "18.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18.3.3   Eye injury",
    "brandName": "blunt or penetrating",
    "strength": "18.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18.3.3   Eye injury (blunt or penetrating)",
    "commonDosage": "18.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "23.STANDARD PAEDIATRIC WEIGHT",
    "brandName": "BAND DOSING TABLES",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "23.STANDARD PAEDIATRIC WEIGHT-BAND DOSING TABLES",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The concept of essential medicines is forward",
    "brandName": "looking. It incorporates the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The concept of essential medicines is forward-looking. It incorporates the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "care and informed decision",
    "brandName": "making.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "care and informed decision-making.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Programme",
    "brandName": "EDP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Programme (EDP) forms an integral part of this strategy, with continued",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The National Drug Policy1 provides for an Essential Drugs Programme",
    "brandName": "EDP",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The National Drug Policy1 provides for an Essential Drugs Programme (EDP) -",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "or removed from the Essential Medicines List",
    "brandName": "EML",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "or removed from the Essential Medicines List (EML) following an evidence-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The perspective adopted in the Primary Healthcare",
    "brandName": "PHC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The perspective adopted in the Primary Healthcare (PHC) STGs is that of a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "use through targeted de",
    "brandName": "prescribing is vital in managing chronic condition",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "use through targeted de-prescribing is vital in managing chronic conditions,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a progression to the Adult and Paediatric hospital",
    "brandName": "level EMLs and STGs.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a progression to the Adult and Paediatric hospital-level EMLs and STGs.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "programmes, and gateway or out",
    "brandName": "patient clinics at hospitals.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "programmes, and gateway or out-patient clinics at hospitals.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "implementing bodies of medicine",
    "brandName": "related governance in the provinces,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "implementing bodies of medicine-related governance in the provinces,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 National Drugs Policy, 1996. https://www.gov.za/documents/national",
    "brandName": "drugs",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 National Drugs Policy, 1996. https://www.gov.za/documents/national-drugs-policy",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PHC level for specific patients through down",
    "brandName": "referral from higher levels of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PHC level for specific patients through down-referral from higher levels of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "subjected to robust evidence",
    "brandName": "based interrogation and consideration of cost",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "subjected to robust evidence-based interrogation and consideration of cost",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The EML has been developed to the generic or International Non",
    "brandName": "Propriety",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The EML has been developed to the generic or International Non-Propriety",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Name",
    "brandName": "INN",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Name (INN) level. Each province, through the provincial PTC, is expected to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "class, such as ‘HMG",
    "brandName": "CoA reductase inhibitors",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "class, such as ‘HMG-CoA reductase inhibitors (statins), e.g., simvastatin’.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Each chapter covers a broad organ system, with cross",
    "brandName": "referral to other",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Each chapter covers a broad organ system, with cross-referral to other",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the accurate recording of diagnoses. The primary ICD",
    "brandName": "10 code may be",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the accurate recording of diagnoses. The primary ICD-10 code may be",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "manifestation from the primary aetiology.",
    "brandName": "For example, uncomplicated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "manifestation from the primary aetiology. (For example, uncomplicated",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "broncho",
    "brandName": "pneumonia with severe penicillin allergy would be ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "broncho-pneumonia with severe penicillin allergy would be coded as:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "J18.0+",
    "brandName": "Z88.0",
    "strength": "18.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "J18.0+(Z88.0)). All the rules and guidelines for using ICD-10 must be applied as",
    "commonDosage": "18.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "per the World Health Organization",
    "brandName": "WHO",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "per the World Health Organization (WHO), the agreed South African Morbidity",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Available at: https://www.health.gov.za/icd",
    "brandName": "10",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Available at: https://www.health.gov.za/icd-10-master-industry-table/",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicines may be listed in a preferential order",
    "brandName": "e.g., the first medicine is the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicines may be listed in a preferential order (e.g., the first medicine is the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paediatric doses are usually provided as weight",
    "brandName": "band dosing tables according",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Paediatric doses are usually provided as weight-band dosing tables according",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "not possible, choose a dose from the weight",
    "brandName": "band tables. Only use the dose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "not possible, choose a dose from the weight-band tables. Only use the dose",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "paediatric weight",
    "brandName": "band medicines dosing tables are in an appendix. W",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "paediatric weight-band medicines dosing tables are in an appendix. Where a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "packages",
    "brandName": ";",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "packages);",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "• medicine name",
    "brandName": "preferably the generic name or INN",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "• medicine name (preferably the generic name or INN), strength",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Greek mu",
    "brandName": "ų",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Greek mu (ų): write mcg as an abbreviation for micrograms.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hours",
    "brandName": "e.g., ‘8 hourly’",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hours (e.g., ‘8 hourly’) or times per day in numerals (e.g., ‘3x/d’).",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the signature if there are problems",
    "brandName": "print your name, use a stamp, or use a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the signature if there are problems (print your name, use a stamp, or use a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nurses granted authorisation provided in terms of Section 56",
    "brandName": "6",
    "strength": "56",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nurses granted authorisation provided in terms of Section 56(6) of the Nursing",
    "commonDosage": "56",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PHC nurses with section 56",
    "brandName": "6",
    "strength": "56",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PHC nurses with section 56(6) permits are limited to prescribing medicines up",
    "commonDosage": "56",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to Schedule 4",
    "brandName": "GN.R. 2418 of 1984",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "to Schedule 4 (GN.R. 2418 of 1984).",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the National Department of Health website:  https://www.health.gov.za/nhi",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the National Department of Health website:  https://www.health.gov.za/nhi-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "edp",
    "brandName": "stgs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "edp-stgs-eml/.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dispensing and Distribution",
    "brandName": "CCMDD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dispensing and Distribution (CCMDD) programme (See Central Chronic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "www.health.gov.za/ccmdd",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "www.health.gov.za/ccmdd).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Event Monitoring Centre",
    "brandName": "NADEMC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Event Monitoring Centre (NADEMC). The Adverse Drug Reaction form and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.sahpra.org.za/document/adverse",
    "brandName": "drug",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.sahpra.org.za/document/adverse-drug-reactions-and-quality-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "problem",
    "brandName": "reporting",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "problem-reporting-form/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Adherence to long term pharmacotherapy",
    "brandName": "incomplete or non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Adherence to long term pharmacotherapy – incomplete or non-adherence",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adherence is the extent to which a person’s behaviour",
    "brandName": "taking medication,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adherence is the extent to which a person’s behaviour – taking medication,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "not promote understanding and self",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "not promote understanding and self-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "such as a lunchtime dose in a school",
    "brandName": "going child who remains at school for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "such as a lunchtime dose in a school-going child who remains at school for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "normal progression of the illness",
    "brandName": "especially important in those",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "normal progression of the illness - especially important in those",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Never blame anyone or anything for non",
    "brandName": "adherence before fully investigating",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Never blame anyone or anything for non-adherence before fully investigating",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If the clinical outcome is unsatisfactory",
    "brandName": "investigate adherence",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If the clinical outcome is unsatisfactory - investigate adherence (note that side",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "regimen, consider an alternative",
    "brandName": "not to treat might be one option, but be",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "regimen, consider an alternative - not to treat might be one option, but be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Self",
    "brandName": "Reporting",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Self-Reporting",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Visual Analogue Scale",
    "brandName": "VAS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Visual Analogue Scale (VAS)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "had been used or an emergency prescription obtained, then the calculation will be invalid",
    "brandName": "skip to adherence",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "had been used or an emergency prescription obtained, then the calculation will be invalid – skip to adherence",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Improved availability of reliable data to inform decision",
    "brandName": "making at:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Improved availability of reliable data to inform decision-making at:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The World Health Organization",
    "brandName": "WHO",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "The World Health Organization (WHO) has categorised antibiotics into three",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Highly selected patients",
    "brandName": "life",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Highly selected patients (life-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "threatening infections due to multi",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "threatening infections due to multi-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "drug resistant bacteria",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "drug resistant bacteria).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral, 10",
    "brandName": "20 mg/kg 8 hourly for 5 days.",
    "strength": "10",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral, 10–20 mg/kg 8 hourly for 5 days.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃11",
    "brandName": "25 kg",
    "strength": "11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃11–25 kg",
    "commonDosage": "11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 10",
    "brandName": "15 mg/kg/dose 6 hourly when required. See dosing t",
    "strength": "10",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 10–15 mg/kg/dose 6 hourly when required. See dosing table:",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 500 mg to 1 g, 4 to 6 hourly as required",
    "brandName": "to a maximum of 4 g in",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 500 mg to 1 g, 4 to 6 hourly as required (to a maximum of 4 g in",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» prolonged use of broad",
    "brandName": "spectrum antibiotics or corticosteroids",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "» prolonged use of broad-spectrum antibiotics or corticosteroids (including inhaled),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "difficulty in swallowing in an HIV",
    "brandName": "infected patient with oral candidiasis suggest",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "difficulty in swallowing in an HIV-infected patient with oral candidiasis suggest",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medicine measure of table salt in a glass of lukewarm water",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medicine measure of table salt in a glass of lukewarm water).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is a self",
    "brandName": "limiting infection with symptoms subsiding within ",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is a self-limiting infection with symptoms subsiding within 10 days.",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antiviral,",
    "brandName": "active against herpes simplex",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antiviral, (active against herpes simplex) e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Teething is a normal physiological process; simple self",
    "brandName": "care measures are",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Teething is a normal physiological process; simple self-care measures are",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Gentle massage to the gum or biting on objects",
    "brandName": "such as teething rings",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Gentle massage to the gum or biting on objects (such as teething rings) may",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "produce relief by producing counter",
    "brandName": "pressure against the gums",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "produce relief by producing counter-pressure against the gums (beware of choking",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All children with systemic symptoms",
    "brandName": "e.g., high fever or diarrhoea",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All children with systemic symptoms (e.g., high fever or diarrhoea) that cannot be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicine Review: Dental rinses as IPC for COVID",
    "brandName": "19, 20 May 2021. https://www.knowledgehub.org.za/c",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicine Review: Dental rinses as IPC for COVID-19, 20 May 2021. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» signs of peritonitis",
    "brandName": "peri",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» signs of peritonitis (peri-umbilical percussion and guarding),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» possible associated diseases",
    "brandName": "e.g. HIV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» possible associated diseases (e.g. HIV).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IM, 5",
    "brandName": "10 mg,",
    "strength": "5",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IM, 5–10 mg, (Doctor prescribed)",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Administer morphine, IV, 3",
    "brandName": "5 mg as a single dose, then further boluses of 1",
    "strength": "3",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "» Administer morphine, IV, 3–5 mg as a single dose, then further boluses of 1–",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "caused by gastro",
    "brandName": "oesophageal reflux or gastroduodenal pathology. Th",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "caused by gastro-oesophageal reflux or gastroduodenal pathology. These",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Proton",
    "brandName": "pump inhibitor e.g.:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Proton-pump inhibitor e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Also indicated for short",
    "brandName": "term use in pregnancy.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Also indicated for short-term use in pregnancy.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» No response within 7 days of starting proton",
    "brandName": "pump inhibitor therapy",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» No response within 7 days of starting proton-pump inhibitor therapy",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2.3 GASTRO",
    "brandName": "OESOPHAGEAL REFLUX/DISEASE IN",
    "strength": "2.3 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2.3 GASTRO-OESOPHAGEAL REFLUX/DISEASE IN",
    "commonDosage": "2.3 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of milk/food. Gastro",
    "brandName": "oesophageal reflux disease",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of milk/food. Gastro-oesophageal reflux disease (GORD) is when GOR results in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "necessitate referral",
    "brandName": "e.g. features of GORD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "necessitate referral (e.g. features of GORD).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Failure to thrive",
    "brandName": "growth faltering",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Failure to thrive (growth faltering).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Abnormal posturing with opisthotonus or torticollis",
    "brandName": "Sandifer’s syndrome",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Abnormal posturing with opisthotonus or torticollis (Sandifer’s syndrome).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "life",
    "brandName": "threatening events.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "life-threatening events.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» gastro",
    "brandName": "intestinal disease",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» gastro-intestinal disease",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Exclude pregnancy in women of child",
    "brandName": "bearing age.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Exclude pregnancy in women of child-bearing age.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not use anti",
    "brandName": "emetics. Give small volumes of fluids more frequen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not use anti-emetics. Give small volumes of fluids more frequently.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Associated abdominal tenderness with guarding during peri",
    "brandName": "umbilical",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Associated abdominal tenderness with guarding during peri-umbilical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lactulose, oral, 10",
    "brandName": "20 mL once daily.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lactulose, oral, 10–20 mL once daily.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Bismuth subgallate compound, ointment, topical, applied 2",
    "brandName": "4 times daily.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Bismuth subgallate compound, ointment, topical, applied 2–4 times daily.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» High",
    "brandName": "fibre diet.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» High-fibre diet.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Caused by organisms spreading through the wall of the anus into peri",
    "brandName": "anal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Caused by organisms spreading through the wall of the anus into peri-anal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Sudden peri",
    "brandName": "umbilical pain often migrating to the right iliac ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Sudden peri-umbilical pain often migrating to the right iliac fossa.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Abdominal tenderness with guarding and rigidity during peri",
    "brandName": "umbilical",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Abdominal tenderness with guarding and rigidity during peri-umbilical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rehydrate aggressively with oral rehydration solution",
    "brandName": "ORS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rehydrate aggressively with oral rehydration solution (ORS).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ringers lactate, IV",
    "brandName": "preferred",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ringers lactate, IV (preferred).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zinc",
    "brandName": "elemental",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zinc (elemental), oral 10 mg/day for 14 days.",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Increase intake of fibre",
    "brandName": "rich food, e.g. vegetables, coarse maize meal, bra",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Increase intake of fibre-rich food, e.g. vegetables, coarse maize meal, bran,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for multidisciplinary bowel care",
    "brandName": "e.g. frail older people, postpartum women",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for multidisciplinary bowel care (e.g. frail older people, postpartum women",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lactulose, oral 10",
    "brandName": "20 mL once or twice daily.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lactulose, oral 10–20 mL once or twice daily.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dehydration immediately whilst awaiting referral",
    "brandName": "see below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dehydration immediately whilst awaiting referral (see below).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Assess level of hydration and start with appropriate management plan",
    "brandName": "Plan A, B or C",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Assess level of hydration and start with appropriate management plan (Plan A, B or C). Re-assess and review management regularly.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "severe decrease in skin turgor",
    "brandName": "skin pinch",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "severe decrease in skin turgor (skin pinch",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "returning ≥ 2 seconds",
    "brandName": "",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "returning ≥ 2 seconds)",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "turgor",
    "brandName": "by slow skin pinch,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "turgor - by slow skin pinch,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "calcium",
    "brandName": "containing fluids in neonates.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "calcium-containing fluids in neonates.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "100",
    "brandName": "200 mL.",
    "strength": "100",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "100–200 mL.",
    "commonDosage": "100",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "insert a nasogastric",
    "brandName": "NG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "insert a nasogastric (NG) tube.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Avoid giving calcium",
    "brandName": "containing IV fluids",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Avoid giving calcium-containing IV fluids (e.g. Ringers Lactate) together",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If ≤ 28 days old, avoid calcium",
    "brandName": "containing IV fluids for 48 hours after",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If ≤ 28 days old, avoid calcium-containing IV fluids for 48 hours after",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If > 28 days old, ceftriaxone and calcium",
    "brandName": "containing IV fluids may be",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If > 28 days old, ceftriaxone and calcium-containing IV fluids may be",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Homemade sugar and salt solution",
    "brandName": "SSS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Homemade sugar and salt solution (SSS) for use at home to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Assess for possible HIV infection and manage appropriately",
    "brandName": "see Section",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Assess for possible HIV infection and manage appropriately (see Section",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "products such as amasi",
    "brandName": "maas",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "products such as amasi (maas) or yoghurt, if available.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zinc",
    "brandName": "elemental",
    "strength": "10mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zinc (elemental), oral 10mg/day for 14 days.",
    "commonDosage": "10mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Acute diarrhoea is usually self",
    "brandName": "limiting and is managed by fluid replacement.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Acute diarrhoea is usually self-limiting and is managed by fluid replacement.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of 2 mg tablets per day",
    "brandName": "",
    "strength": "2 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of 2 mg tablets per day)",
    "commonDosage": "2 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10 mg",
    "brandName": "5 tablets",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10 mg (5 tablets)",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12 mg",
    "brandName": "6 tablets",
    "strength": "12 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12 mg (6 tablets)",
    "commonDosage": "12 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "14 mg",
    "brandName": "7 tablets",
    "strength": "14 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "14 mg (7 tablets)",
    "commonDosage": "14 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "16 mg",
    "brandName": "8 tablets",
    "strength": "16 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "16 mg (8 tablets)",
    "commonDosage": "16 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dysentery",
    "brandName": "see Adult Hospital Level STGs and EML, Section 1.3",
    "strength": "1.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dysentery (see Adult Hospital Level STGs and EML, Section 1.3.5: Amoebic",
    "commonDosage": "1.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prevent spread of micro",
    "brandName": "organism by:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prevent spread of micro-organism by:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Acute abdominal signs",
    "brandName": "severe pain, acute tenderness, persistent or bilio",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Acute abdominal signs (severe pain, acute tenderness, persistent or bilious",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "vomiting",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "vomiting).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» beef tapeworm",
    "brandName": "Taenia saginata",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» beef tapeworm – Taenia saginata",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» flat white worm segments seen in the stool",
    "brandName": "blunt ended",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» flat white worm segments seen in the stool (blunt ended)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Children 1",
    "brandName": "2 years:                      200 mg",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Children 1–2 years:                      200 mg",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Up to 25",
    "brandName": "30cm long.",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Up to 25–30cm long.",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 2.2: Types of helminthic infestations",
    "brandName": "excluding taenia",
    "strength": "2.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 2.2: Types of helminthic infestations (excluding taenia) and their signs and symptoms",
    "commonDosage": "2.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "anaemia and failure to thrive",
    "brandName": "growth faltering",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "anaemia and failure to thrive (growth faltering).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "after passing stool",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "after passing stool(s),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» De",
    "brandName": "worm all children between 1",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» De-worm all children between 1–5 years of age every 6 months as part of",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children 1",
    "brandName": "2 years of age:",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children 1-2 years of age:",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All other helminths excluding Enterobius",
    "brandName": "pinworm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All other helminths excluding Enterobius (pinworm) and Taenia",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Associated with a change in stool form",
    "brandName": "appearance",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Associated with a change in stool form (appearance).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Reassure patient while their symptoms are not due to life",
    "brandName": "threatening disease,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Reassure patient while their symptoms are not due to life-threatening disease,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High fibre/bran diets do not have a significant effect on global IBS",
    "brandName": "i.e. all",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High fibre/bran diets do not have a significant effect on global IBS (i.e. all",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A septicaemic illness with fever caused by the micro",
    "brandName": "organism Salmonella",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A septicaemic illness with fever caused by the micro-organism Salmonella",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IM",
    "brandName": "adults",
    "strength": "14",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IM (adults): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IV",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IV (adults): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EML, 2020",
    "brandName": "4. http://www.health.gov.za/",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EML, 2020-4. http://www.health.gov.za/",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gastroenterol 2022;117:27",
    "brandName": "56. https://doi.org/10.14309/ajg.0000000000001538;",
    "strength": "2022",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gastroenterol 2022;117:27–56. https://doi.org/10.14309/ajg.0000000000001538; published online November 22, 2021.",
    "commonDosage": "2022",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ringers lactate",
    "brandName": "",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ringers lactate -): Global Task Force on Cholera Control. October 2019.",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nelson EJ et al. Cholera outbreak training and shigellosis program",
    "brandName": "COTSPROGRAM",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nelson EJ et al. Cholera outbreak training and shigellosis program (COTSPROGRAM). V2 may 2018",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ciprofloxacin, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Ciprofloxacin, oral (children -): National Department of Health, Essential Drugs Programme: Paediatric Hospital Level",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single",
    "brandName": "dose ciprofloxacin versus 12",
    "strength": "12",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single-dose ciprofloxacin versus 12- dose",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "erythromycin for childhood cholera: a randomised controlled trial. Lancet",
    "brandName": "London, England",
    "strength": "2005",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "erythromycin for childhood cholera: a randomised controlled trial. Lancet (London, England) 2005; 366:1085–1093.",
    "commonDosage": "2005",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Package Insert",
    "brandName": "US",
    "strength": "27 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Package Insert (US). Ciprofloxacin. Dr Reddy’s Laboratories limited. Last accessed online 27 June 2023",
    "commonDosage": "27 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f6e4a86",
    "brandName": "5fc1",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f6e4a86-5fc1-45b1-adab-",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ciprofloxacin 500 mg film",
    "brandName": "coated tablets",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Ciprofloxacin 500 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ciprofloxacin, oral",
    "brandName": "adults",
    "strength": "2019",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Ciprofloxacin, oral (adults):  Global Task Force on Cholera Control. October 2019.",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dhingra U, et al. Lower",
    "brandName": "Dose Zinc for Childhood Diarrhea",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dhingra U, et al. Lower-Dose Zinc for Childhood Diarrhea - A Randomized, Multicenter Trial. N Engl J Med. 2020 Sep",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ceftriaxone",
    "brandName": "IV admin",
    "strength": "31 ",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ceftriaxone (IV admin): Package Insert. Rocephin Injection. . Roche Products (Pty) Ltd. Text last revised 31 October",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Loperamide",
    "brandName": "max dose",
    "strength": "04 ",
    "form": "tablet",
    "category": "Gastrointestinal",
    "schedule": "Schedule 2",
    "description": "Loperamide (max dose). Package Insert. Imodium. Johnson & Johnson (Pty) Ltd.. Renewal of authorisation 04 March",
    "commonDosage": "04 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Smalley W, Falck",
    "brandName": "Ytter C, Carrasco",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA Clinical Practice Guidelines on the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gastroenterology. 2019 Sep;157",
    "brandName": "3",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gastroenterology. 2019 Sep;157(3):851-854. doi: 10.1053/j.gastro.2019.07.004. Epub 2019 Jul 11. PMID: 31302098.",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.niddk.nih.gov/health",
    "brandName": "information/digestive",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/definition-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "single",
    "brandName": "dose and triple",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "controlled trial. PLoSOne. 2011;6",
    "brandName": "9",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "controlled trial. PLoSOne. 2011;6(9):e25003. https://www.ncbi.nlm.nih.gov/pubmed/21980373",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Albendazole, oral: Mabaso ML, Appleton CC, Hughes JC, Gouws E. Hookworm",
    "brandName": "Necator americanus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Albendazole, oral: Mabaso ML, Appleton CC, Hughes JC, Gouws E. Hookworm (Necator americanus) transmission in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for soil",
    "brandName": "transmitted helminths, 31Jan2017. http://www.healt",
    "strength": "31",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for soil-transmitted helminths, 31Jan2017. http://www.health.gov.za/",
    "commonDosage": "31",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lacy B et al. Bowel disorders. Gastroenterology 2016;150:1393",
    "brandName": "1407.",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lacy B et al. Bowel disorders. Gastroenterology 2016;150:1393–1407.",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Not growing well",
    "brandName": "including failure to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Not growing well (including failure to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "thrive/ growth faltering",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "thrive/ growth faltering)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A condition characterised by low haemoglobin",
    "brandName": "Hb",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A condition characterised by low haemoglobin (Hb), clinically recognised by pallor,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Blood loss",
    "brandName": "bleeding/haemorrhage",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Blood loss (bleeding/haemorrhage) e.g. caused by parasites, ulcers, tumours,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If MCV is high",
    "brandName": "macrocytic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If MCV is high (macrocytic):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Signs of chronic disease",
    "brandName": "investigate for HIV and TB before referral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Signs of chronic disease (investigate for HIV and TB before referral).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Children with Hb ≤ 7 g/dL",
    "brandName": "If Hb cannot be done, look for severe palmar pallo",
    "strength": "7 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Children with Hb ≤ 7 g/dL (If Hb cannot be done, look for severe palmar pallor).",
    "commonDosage": "7 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A common cause of anaemia in young children and women of child",
    "brandName": "bearing age.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A common cause of anaemia in young children and women of child-bearing age.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Iron deficiency anaemia in children > 5 years of age, adult males and non",
    "brandName": "",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Iron deficiency anaemia in children > 5 years of age, adult males and non-",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase vitamin C intake",
    "brandName": "e.g. citrus fruit, orange juice, broccoli, caulifl",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase vitamin C intake (e.g. citrus fruit, orange juice, broccoli, cauliflower,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guavas, strawberries",
    "brandName": "with meals to increase iron absorption from the di",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guavas, strawberries) with meals to increase iron absorption from the diet.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Iron, oral, 1",
    "brandName": "2 mg/kg/dose of elemental iron 8 hourly with meals",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Iron, oral, 1–2 mg/kg/dose of elemental iron 8 hourly with meals.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous sulphate compound BPC",
    "brandName": "dried",
    "strength": "170 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous sulphate compound BPC (dried), oral, 170 mg (± 55 mg elemental iron) 12",
    "commonDosage": "170 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous fumarate, oral, 200 mg",
    "brandName": "± 65 mg elemental iron",
    "strength": "200 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous fumarate, oral, 200 mg (± 65 mg elemental iron) 12 hourly.",
    "commonDosage": "200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If daily iron is poorly tolerated",
    "brandName": "e.g. epigastric pain, nausea, vomiting and constip",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If daily iron is poorly tolerated (e.g. epigastric pain, nausea, vomiting and constipation),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous sulfate compound BPC",
    "brandName": "dried",
    "strength": "340 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous sulfate compound BPC (dried), oral, 340 mg per week, (± 110 mg elemental",
    "commonDosage": "340 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous fumarate, oral, 400 mg per week",
    "brandName": "± 130 mg elemental iron",
    "strength": "400 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous fumarate, oral, 400 mg per week (± 130 mg elemental iron).",
    "commonDosage": "400 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous lactate, oral, 0.6 mL daily",
    "brandName": "provides ± 15 mg elemental iron",
    "strength": "0.6 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous lactate, oral, 0.6 mL daily (provides ± 15 mg elemental iron) until 6  months",
    "commonDosage": "0.6 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous gluconate syrup, oral, 2.5 mL daily",
    "brandName": "provides ± 15 mg elemental iron",
    "strength": "2.5 mL",
    "form": "syrup",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous gluconate syrup, oral, 2.5 mL daily (provides ± 15 mg elemental iron) until 6",
    "commonDosage": "2.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Children > 5 years of age, men and non",
    "brandName": "menstruating women.",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Children > 5 years of age, men and non-menstruating women.",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vitamin B12 deficiency occurs mainly in middle",
    "brandName": "aged or older adults and can cause",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vitamin B12 deficiency occurs mainly in middle-aged or older adults and can cause",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High protein diet is recommended",
    "brandName": "1.5 g/kg/day",
    "strength": "1.5 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High protein diet is recommended (1.5 g/kg/day).",
    "commonDosage": "1.5 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase intake of dietary vitamin B12 sources, including meat",
    "brandName": "especially liver",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase intake of dietary vitamin B12 sources, including meat (especially liver),",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diagnostic criteria for SAM in children aged 6",
    "brandName": "60 months",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Diagnostic criteria for SAM in children aged 6–60 months (any one of the following):",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Weight",
    "brandName": "for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Weight-for-Height z-score (WHZ)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "clinically severe wasting",
    "brandName": "usually clinically reflective of marasmus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "clinically severe wasting (usually clinically reflective of marasmus – thin arms, thin",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "legs, “old man” appearance, baggy pants folds around buttocks, wasted buttocks",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "legs, “old man” appearance, baggy pants folds around buttocks, wasted buttocks).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Babies who were premature and are growing parallel to or better than the z",
    "brandName": "score lines,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Babies who were premature and are growing parallel to or better than the z-score lines,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "respiratory distress",
    "brandName": "including fast breathing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "respiratory distress (including fast breathing)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lethargy",
    "brandName": "not alert",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lethargy (not alert)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "sugar water: Dissolve 4 level teaspoons of sugar",
    "brandName": "20 g",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "sugar water: Dissolve 4 level teaspoons of sugar (20 g) in a 200 mL cup of clean",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Avoid giving calcium",
    "brandName": "containing IV fluids",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Avoid giving calcium-containing IV fluids (e.g. Ringer Lactate) together with ceftriaxone:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If >28 days old, ceftriaxone and calcium",
    "brandName": "containing IV fluids may be given sequentially",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If >28 days old, ceftriaxone and calcium-containing IV fluids may be given sequentially",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The child is alert",
    "brandName": "not lethargic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The child is alert (not lethargic), and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The child does not have any danger signs or severe classification",
    "brandName": "and does not",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The child does not have any danger signs or severe classification (and does not",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Regular follow",
    "brandName": "up to ensure that the child gains weight and remai",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Regular follow-up to ensure that the child gains weight and remains well.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WHZ",
    "brandName": "weight",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WHZ (weight-for-height z-score): > -2 WHZ for two consecutive visits at least one",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» When regular nutritional supplements",
    "brandName": "e.g. RTUF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» When regular nutritional supplements (e.g. RTUF) cannot be provided and follow-up",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The child develops pitting oedema or any of the danger signs",
    "brandName": "see above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The child develops pitting oedema or any of the danger signs (see above).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» No pitting oedema or SAM danger signs",
    "brandName": "see above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» No pitting oedema or SAM danger signs (see above).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Follow",
    "brandName": "up frequently to ensure that the child gains weigh",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Follow-up frequently to ensure that the child gains weight and remains well.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "GROWTH FALTERING",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "GROWTH FALTERING)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Unsatisfactory weight gain",
    "brandName": "growth curve flattening or weight loss",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Unsatisfactory weight gain (growth curve flattening or weight loss) on the Road to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Low weight for age",
    "brandName": "but WHZ >",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Low weight for age (but WHZ > -2).",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Babies who were premature and are growing parallel to or better than the z",
    "brandName": "score",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Babies who were premature and are growing parallel to or better than the z-score",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Counselling on nutrition",
    "brandName": "see below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Counselling on nutrition (see below).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Assess for other long",
    "brandName": "term health conditions and manage appropriately.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Assess for other long-term health conditions and manage appropriately.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Continue breastfeeding",
    "brandName": "breastfeed before giving foods",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Continue breastfeeding (breastfeed before giving foods).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Introduce complementary foods at six months of age. Start by giving 2",
    "brandName": "3 teaspoons of",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Introduce complementary foods at six months of age. Start by giving 2–3 teaspoons of",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "iron",
    "brandName": "rich food such as mashed vegetables or cooked drie",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "iron-rich food such as mashed vegetables or cooked dried beans.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children 6",
    "brandName": "8 months should be given two meals daily, graduall",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children 6–8 months should be given two meals daily, gradually increasing the number",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Maternal medications: sedating psychotherapeutic medicines, anti",
    "brandName": "epileptic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Maternal medications: sedating psychotherapeutic medicines, anti-epileptic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Infants of mothers who are failing second",
    "brandName": "or third",
    "strength": "1000",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Infants of mothers who are failing second- or third-line ARV treatment (VL >1000",
    "commonDosage": "1000",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "copies/mL",
    "brandName": "should be advised not to breastfeed.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "copies/mL) should be advised not to breastfeed.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Body mass index",
    "brandName": "BMI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Body mass index (BMI) is a simple index of weight-for-height that is commonly used to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "classify overweight and obesity in adults",
    "brandName": "> 19 years",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "classify overweight and obesity in adults (> 19 years). It is defined as a person's weight in",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "kilograms divided by the square of his height in meters",
    "brandName": "kg/m2",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "kilograms divided by the square of his height in meters (kg/m2).",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children aged between 5",
    "brandName": "19 years:",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children aged between 5–19 years:",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» overweight is BMI",
    "brandName": "for",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» overweight is BMI-for-age > 1 standard deviation above the WHO Growth Reference",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» overweight is weight",
    "brandName": "for",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» overweight is weight-for-height > 2 standard deviations above WHO Child Growth",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» obesity is weight",
    "brandName": "for",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» obesity is weight-for-height > 3 standard deviations above the WHO Child Growth",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» regular moderate aerobic exercise, e.g. 30 minutes brisk walking 3",
    "brandName": "5 times/week",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» regular moderate aerobic exercise, e.g. 30 minutes brisk walking 3–5 times/week (150",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» calculate risk of developing cardiovascular events and manage appropriately",
    "brandName": "See",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» calculate risk of developing cardiovascular events and manage appropriately (See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is most common in children of 1",
    "brandName": "5 years of age.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is most common in children of 1–5 years of age.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vitamin A",
    "brandName": "retinol",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vitamin A (retinol), oral, every 6 months up to the age of 5 years.",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If any clinical eye signs of vitamin A deficiency are present",
    "brandName": "see clinical features above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If any clinical eye signs of vitamin A deficiency are present (see clinical features above),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "give a pre",
    "brandName": "referral dose:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "give a pre-referral dose:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Children",
    "brandName": "6 months to 5 years of age",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Children (6 months to 5 years of age) who received a routine prophylactic dose within",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "VITAMIN B3/NICOTINIC ACID DEFICIENCY",
    "brandName": "PELLAGRA",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "VITAMIN B3/NICOTINIC ACID DEFICIENCY (PELLAGRA)",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» dermatitis with darkening of sun",
    "brandName": "exposed skin.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» dermatitis with darkening of sun-exposed skin.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pyridoxine, oral, 25 mg daily as maintenance dose",
    "brandName": "for patients on TB therapy/",
    "strength": "25 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pyridoxine, oral, 25 mg daily as maintenance dose (for patients on TB therapy/",
    "commonDosage": "25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Albendazole, oral: Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN. Efficacy of single",
    "brandName": "dose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Albendazole, oral: Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN. Efficacy of single-dose",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and triple",
    "brandName": "dose albendazole and mebendazole against soil",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PLoSOne. 2011;6",
    "brandName": "9",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PLoSOne. 2011;6(9):e25003. https://www.ncbi.nlm.nih.gov/pubmed/21980373",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Albendazole, oral:Mabaso ML, Appleton CC, Hughes JC, Gouws E. Hookworm",
    "brandName": "Necatoramericanus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Albendazole, oral:Mabaso ML, Appleton CC, Hughes JC, Gouws E. Hookworm (Necatoramericanus) transmission in inland areas",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of sandy soils in KwaZulu",
    "brandName": "Natal, South Africa. Trop  MedInt Health. 2004 Apr",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of sandy soils in KwaZulu-Natal, South Africa. Trop  MedInt Health. 2004 Apr;9(4):471-6. https://www.ncbi.nlm.nih.gov/pubmed/15078265",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment of soil",
    "brandName": "transmitted helminthiasis. Acta Trop. 2003 May;86",
    "strength": "2003 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment of soil-transmitted helminthiasis. Acta Trop. 2003 May;86(2-3):223-32. https://www.ncbi.nlm.nih.gov/pubmed/12745139",
    "commonDosage": "2003 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "transmitted helminths, 31Jan2017. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "31",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "transmitted helminths, 31Jan2017. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "31",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous sulphate/fumarate, oral: Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron",
    "brandName": "deficiency anaemia in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous sulphate/fumarate, oral: Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy. Cochrane Database Syst Rev. 2011 Oct 5;",
    "brandName": "10",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD003094. https://www.ncbi.nlm.nih.gov/pubmed/21975735",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "anemia in adults. Am J Med. 2008 Nov;121",
    "brandName": "11",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "anemia in adults. Am J Med. 2008 Nov;121(11):943-8. http://www.ncbi.nlm.nih.gov/pubmed/18954837",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "on consecutive versus alternate days and as single morning doses versus twice",
    "brandName": "daily  split dosing in iron",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "on consecutive versus alternate days and as single morning doses versus twice-daily  split dosing in iron-depleted women: two open-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "label, randomised controlled trials. Lancet Haematol. 2017 Nov;4",
    "brandName": "11",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533. https://www.ncbi.nlm.nih.gov/pubmed/29032957",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Intermittent iron supplementation: Pena",
    "brandName": "Rosas JP, De",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Intermittent iron supplementation: Pena-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Iron treatment",
    "brandName": "causes for failure to respond: National Department",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Iron treatment – causes for failure to respond: National Department of Health, Essential Drugs Programme: Adult Hospital Level",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "STGs and EML, 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "STGs and EML, 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Iron prophylaxis",
    "brandName": "preterm infants: National Department of Health, Es",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Iron prophylaxis - preterm infants: National Department of Health, Essential Drugs Programme: Paediatric Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EML, 2020",
    "brandName": "draft format",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EML, 2020 (draft format).",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "prevention of iron deficiency and iron",
    "brandName": "deficiency anemia in infants and young children",
    "strength": "0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010",
    "commonDosage": "0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nov;126",
    "brandName": "5",
    "strength": "126",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nov;126(5):1040-50. https://www.ncbi.nlm.nih.gov/pubmed/20923825",
    "commonDosage": "126",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health. 2018 Nov;23",
    "brandName": "11",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Health. 2018 Nov;23(11):1158-1175. https://pubmed.ncbi.nlm.nih.gov/30151939/",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rehabilitation referral",
    "brandName": "malnourished",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rehabilitation referral (malnourished – developmental delay): Hwang AW, Chao MY, Liu SW. A randomized controlled trial of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vitamin A, oral",
    "brandName": "MAM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vitamin A, oral (MAM): National Department of Health. Integrated management of children with acute malnutrition in South Africa:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Multivitamin, oral",
    "brandName": "MAM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Multivitamin, oral (MAM): National Department of Health. Integrated management of children with acute malnutrition in South Africa:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mebendazole, oral",
    "brandName": "MAM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mebendazole, oral (MAM): National Department of Health. Integrated management of children with acute malnutrition in South",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Supplementary infant feeding",
    "brandName": "Mothers failing 2nd or 3rd line ART",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Supplementary infant feeding (Mothers failing 2nd or 3rd line ART): National Department of Health, Essential Drugs Programme:",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paediatric Hospital Level STGs and EML, 2020",
    "brandName": "draft format",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Paediatric Hospital Level STGs and EML, 2020 (draft format).",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rev. 2019 Jul 23;7",
    "brandName": "7",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rev. 2019 Jul 23;7(7):CD001871. https://pubmed.ncbi.nlm.nih.gov/31332776/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nicotinamide, oral",
    "brandName": "duration of therapy",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nicotinamide, oral (duration of therapy): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pyridoxine, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pyridoxine, oral (children – medicine induced neuropathy): National Department of Health, Essential Drugs Programme: Paediatric",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hospital Level STGs and EML, 2020",
    "brandName": "draft format",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hospital Level STGs and EML, 2020 (draft format).",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3/I65.8",
    "brandName": "9/I73.8",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3/I65.8-9/I73.8-9/G45.0-2/G45.8-9",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "benefit from lifestyle modification and lipid",
    "brandName": "lowering medicine therapy. Patients should be",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "benefit from lifestyle modification and lipid-lowering medicine therapy. Patients should be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Diabetes with chronic kidney disease",
    "brandName": "eGFR <60 mL/min",
    "strength": "60 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Diabetes with chronic kidney disease (eGFR <60 mL/min).",
    "commonDosage": "60 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disease",
    "brandName": "other than the categories above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disease (other than the categories above)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "These patients should be managed according to their 10",
    "brandName": "year risk of a cardiovascular",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "These patients should be managed according to their 10-year risk of a cardiovascular",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "event",
    "brandName": "See Appendix III: Cardiovascular risk assessment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "event (See Appendix III: Cardiovascular risk assessment), as calculated using either:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "B. Framingham risk score",
    "brandName": "cholesterol",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "B. Framingham risk score (cholesterol-based assessment).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management is based on the patient’s 10",
    "brandName": "year risk of a cardiovascular event as follows:",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management is based on the patient’s 10-year risk of a cardiovascular event as follows:",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hypercholesterolaemia or other heritable dyslipidaemias",
    "brandName": ", regardless of their",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hypercholesterolaemia or other heritable dyslipidaemias), regardless of their",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 for females.",
    "brandName": "1 standard drink = a can of beer = a glass of wine",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 for females. (1 standard drink = a can of beer = a glass of wine = a shot of",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» When lipid",
    "brandName": "lowering medicines are used, this is ALWAYS in con",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» When lipid-lowering medicines are used, this is ALWAYS in conjunction with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HMGCoA reductase inhibitors",
    "brandName": "statins",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HMGCoA reductase inhibitors (statins), according to table below:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HMGCoA REDUCTASE INHIBITOR",
    "brandName": "STATIN",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HMGCoA REDUCTASE INHIBITOR (STATIN)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A: Primary prevention",
    "brandName": "no existing CVD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A: Primary prevention - no existing CVD",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "B: Secondary prevention",
    "brandName": "existing CVD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "B: Secondary prevention – existing CVD",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Patients on amlodipine",
    "brandName": "and not on",
    "strength": "N/A",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Patients on amlodipine (and not on",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Simvastatin, oral, 10",
    "brandName": "20 mg at night.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Simvastatin, oral, 10–20 mg at night.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dyslipidaemia",
    "brandName": "specifically hypertriglyceridaemia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dyslipidaemia (specifically hypertriglyceridaemia) than atazanavir/ritonavir.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Patients at high risk",
    "brandName": ">20% risk of developing a CV event in 10 years or ",
    "strength": "20%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Patients at high risk (>20% risk of developing a CV event in 10 years or existing",
    "commonDosage": "20%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "CVD",
    "brandName": "should switch to atazanavir/ritonavir and repeat t",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "CVD) should switch to atazanavir/ritonavir and repeat the fasting lipid profile in 3",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy. Criteria for initiating lipid lowering therapy are the same as for HIV",
    "brandName": "negative",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy. Criteria for initiating lipid lowering therapy are the same as for HIV-negative",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients. Many statins",
    "brandName": "including simvastatin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients. Many statins (including simvastatin) cannot be used with protease",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Random cholesterol >7.5 mmol/L",
    "brandName": "to be evaluated for genetic disorders",
    "strength": "7.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Random cholesterol >7.5 mmol/L (to be evaluated for genetic disorders), after",
    "commonDosage": "7.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Characteristic chest pain",
    "brandName": "burning or heavy discomfort behind the sternum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Characteristic chest pain (burning or heavy discomfort behind the sternum), of duration",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Long",
    "brandName": "term prophylaxis for thrombosis:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Long-term prophylaxis for thrombosis:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If beta",
    "brandName": "blocker cannot be tolerated or is contraindicated,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If beta-blocker cannot be tolerated or is contraindicated, consider long-acting calcium",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isosorbide mononitrate, oral, 10",
    "brandName": "20 mg twice daily.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isosorbide mononitrate, oral, 10–20 mg twice daily.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isosorbide dinitrate, oral, 20",
    "brandName": "30 mg twice daily.",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isosorbide dinitrate, oral, 20–30 mg twice daily.",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Angina is a high",
    "brandName": "risk condition for cardiovascular disease and an i",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Angina is a high-risk condition for cardiovascular disease and an indication for a statin.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ANGINA PECTORIS, UNSTABLE / NON",
    "brandName": "ST ELEVATION",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ANGINA PECTORIS, UNSTABLE / NON-ST ELEVATION",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not administer oxygen to acutely ill patients who are not hypoxic",
    "brandName": "SPO2   ≥96%",
    "strength": "2   ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not administer oxygen to acutely ill patients who are not hypoxic (SPO2   ≥96%).",
    "commonDosage": "2   ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aspirin, oral, 150 mg as a single dose",
    "brandName": "chewed or dissolved",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Aspirin, oral, 150 mg as a single dose (chewed or dissolved) as soon as possible.",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aspirin, oral, 150 mg daily",
    "brandName": "continued indefinitely in absence of contraindicat",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Aspirin, oral, 150 mg daily (continued indefinitely in absence of contraindications).",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cardio",
    "brandName": "selective beta",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cardio-selective beta-blocker, e.g.: (doctor initiated)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ACE",
    "brandName": "inhibitor, e.g.:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ACE-inhibitor, e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enalapril, oral, target dose 10 mg 12 hourly",
    "brandName": "usually titrated from 2.5 mg 12 hourly",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Enalapril, oral, target dose 10 mg 12 hourly (usually titrated from 2.5 mg 12 hourly).",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Angioedema is a potentially serious complication of ACE",
    "brandName": "inhibitor treatment and if it",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Angioedema is a potentially serious complication of ACE-inhibitor treatment and if it",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "occurs it is a contraindication to continue therapy or to re",
    "brandName": "challenge.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "occurs it is a contraindication to continue therapy or to re-challenge.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not administer oxygen to acutely ill patients who are not hypoxic",
    "brandName": "SPO2 ≥ 96%",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not administer oxygen to acutely ill patients who are not hypoxic (SPO2 ≥ 96%)",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thrombolytic",
    "brandName": "see table for time window below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thrombolytic (see table for time window below) (Doctor initiated), e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Streptokinase is antigenic and should not be re",
    "brandName": "administered in the period of 5",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Streptokinase is antigenic and should not be re-administered in the period of 5",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preceding month, or recent",
    "brandName": "<3 weeks",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preceding month, or recent (<3 weeks) major surgery,",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "occurs it is a contraindication to continued therapy or to re",
    "brandName": "challenge.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "occurs it is a contraindication to continued therapy or to re-challenge.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "precipitating factor",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "precipitating factor(s) must be identified and treated to prevent further damage to the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Progressive effort intolerance",
    "brandName": "worsening breathlessness, or fatigue with",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Progressive effort intolerance (worsening breathlessness, or fatigue with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "heavy load",
    "brandName": ". If severe, breathlessness, or fatigue, may occur",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "heavy load). If severe, breathlessness, or fatigue, may occur when doing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Orthopnoea",
    "brandName": "breathless when lying down flat",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Orthopnoea (breathless when lying down flat).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Ankle",
    "brandName": "or body",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Ankle (or body) swelling.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Salt",
    "brandName": "sodium chloride",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Salt (sodium chloride) restriction to less than 2 to 3 g/day.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Significant volume overload or abnormal renal function",
    "brandName": "loop diuretic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Significant volume overload or abnormal renal function – loop diuretic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Higher doses may be needed if co",
    "brandName": "morbid kidney impairment is present.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Higher doses may be needed if co-morbid kidney impairment is present.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Use a lower diuretic dose when given in combination with an ACE",
    "brandName": "inhibitor.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Use a lower diuretic dose when given in combination with an ACE-inhibitor.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Absolute contraindications include:",
    "brandName": "refer to package insert for a complete list",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Absolute contraindications include: (refer to package insert for a complete list)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o history of angioedema associated with previous ACE",
    "brandName": "inhibitor or angiotensin II",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o history of angioedema associated with previous ACE-inhibitor or angiotensin II",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "beta blocker",
    "brandName": "unless contra",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "beta blocker) unless contra-indicated (Refer to package insert for full prescribing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Increase dose at two",
    "brandName": "weekly intervals by doubling the daily dose until ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Increase dose at two-weekly intervals by doubling the daily dose until a maximum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Spironolactone, oral, 25 mg daily",
    "brandName": "doctor initiated",
    "strength": "25 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Spironolactone, oral, 25 mg daily (doctor initiated).",
    "commonDosage": "25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and use of NSAIDs. Do not use in kidney failure",
    "brandName": "Do not use if eGFR <30 mL/min",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and use of NSAIDs. Do not use in kidney failure (Do not use if eGFR <30 mL/min).",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lung conditions",
    "brandName": "e.g. cor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lung conditions (e.g. cor-pulmonale due to bronchiectasis in children living with HIV).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mmHg and diastolic <90 mmHg",
    "brandName": "applicable to patients of all ages with uncomplica",
    "strength": "90 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mmHg and diastolic <90 mmHg (applicable to patients of all ages with uncomplicated",
    "commonDosage": "90 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Serum creatinine concentration",
    "brandName": "and eGFR",
    "strength": "8.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Serum creatinine concentration (and eGFR) – see Section 8.1: Chronic Kidney",
    "commonDosage": "8.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Serum potassium concentration, if on ACE",
    "brandName": "inhibitor or eGFR <30 mL/min.",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Serum potassium concentration, if on ACE-inhibitor or eGFR <30 mL/min. (See",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Finger prick blood glucose",
    "brandName": "see Section 9.2.2: Type 2 Diabetes Mellitus, Adult",
    "strength": "9.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Finger prick blood glucose (see Section 9.2.2: Type 2 Diabetes Mellitus, Adults).",
    "commonDosage": "9.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Serum creatinine concentration",
    "brandName": "and eGFR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Serum creatinine concentration (and eGFR) in patients who have:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "chronic kidney disease",
    "brandName": "eGFR <60 mL/min",
    "strength": "60 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "chronic kidney disease (eGFR <60 mL/min).",
    "commonDosage": "60 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Screen for presence of compelling indications",
    "brandName": "see table below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Screen for presence of compelling indications (see table below) and manage patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pregnancy",
    "brandName": "induced hypertension",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Pregnancy-induced hypertension",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with 2 agents",
    "brandName": "Step 3",
    "strength": "2 ",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "with 2 agents (Step 3), one of which should be low dose hydrochlorothiazide and",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "complications such as are seen in hypertensive emergencies",
    "brandName": "see Section 4.7.2:",
    "strength": "4.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "complications such as are seen in hypertensive emergencies (see Section 4.7.2:",
    "commonDosage": "4.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hypertensive emergency",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hypertensive emergency).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Start treatment with 2 oral agents",
    "brandName": "Step 3",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Start treatment with 2 oral agents (Step 3) with the aim to lower diastolic BP to 100",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mmHg slowly, over 48",
    "brandName": "72 hours.",
    "strength": "48",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mmHg slowly, over 48–72 hours.",
    "commonDosage": "48",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "insufficiency or evidence of pulmonary congestion",
    "brandName": "see Section 4.6.1: Cardiac",
    "strength": "4.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "insufficiency or evidence of pulmonary congestion (see Section 4.6.1: Cardiac",
    "commonDosage": "4.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "failure, congestive",
    "brandName": "CCF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "failure, congestive (CCF), adults).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In patients without co",
    "brandName": "existing disease, initiate medicine treatment only",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In patients without co-existing disease, initiate medicine treatment only when the BP",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "levels, additional risk factors, hypertension",
    "brandName": "mediated organ damage",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "levels, additional risk factors, hypertension-mediated organ damage (HMOD), and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Other risk factors include: Age",
    "brandName": ">65 years",
    "strength": "65 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Other risk factors include: Age (>65 years), sex (male>female), heart rate (>80",
    "commonDosage": "65 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "beats/min",
    "brandName": ", increased body weight, diabetes, high LDL",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "beats/min), increased body weight, diabetes, high LDL-C/triglyceride, family history",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of CVD, family history of hypertension, early",
    "brandName": "onset menopause, smoking habits,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "of CVD, family history of hypertension, early-onset menopause, smoking habits,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» HMOD includes: LVH",
    "brandName": "LVH on ECG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» HMOD includes: LVH (LVH on ECG), moderate-severe CKD (eGFR",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "<60 mL/min/1.73m2",
    "brandName": ", any other available measure of organ damage.",
    "strength": "60 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "<60 mL/min/1.73m2), any other available measure of organ damage.",
    "commonDosage": "60 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Caution: Consider monotherapy in low",
    "brandName": "risk grade 1 hypertension and patients >80 years o",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Caution: Consider monotherapy in low-risk grade 1 hypertension and patients >80 years or the frail (monitor for postural hypotension).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "STEP 2: Add thiazide/thiazide",
    "brandName": "like diuretic e.g.:hydrochlorothiazide.",
    "strength": "2",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "STEP 2: Add thiazide/thiazide-like diuretic e.g.:hydrochlorothiazide.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thiazide/thiazide",
    "brandName": "like diuretic e.g.:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thiazide/thiazide-like diuretic e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not use in kidney failure",
    "brandName": "Do not use if eGFR <30 mL/min",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not use in kidney failure (Do not use if eGFR <30 mL/min).",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "current antihypertensive and/or add additional medicine",
    "brandName": ". Evidence suggests that",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "current antihypertensive and/or add additional medicine). Evidence suggests that",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hypertension urgency",
    "brandName": "see Section 4.7.2: Hypertensive emergency",
    "strength": "4.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "hypertension urgency (see Section 4.7.2: Hypertensive emergency).",
    "commonDosage": "4.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "by ECG",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "by ECG)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» kidney impairment",
    "brandName": "eGFR <30 mL/min",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» kidney impairment (eGFR <30 mL/min),",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» severe renal impairment",
    "brandName": "eGFR <30 mL/min",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» severe renal impairment (eGFR <30 mL/min), unless dose-adjusted usage is",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Advise all patients receiving ACE",
    "brandName": "inhibitors about the symptoms of ACE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Advise all patients receiving ACE-inhibitors about the symptoms of ACE-induced",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Young adults",
    "brandName": "<30 years of age",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Young adults (<30 years of age).",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Signs of hypertension",
    "brandName": "mediated organ damage e.g. oedema, dyspnoea,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Signs of hypertension-mediated organ damage e.g. oedema, dyspnoea,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Furosemide, IV, 40 mg as a single dose",
    "brandName": "see Section 21.2.8: Pulmonary oedema,",
    "strength": "40 mg",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Furosemide, IV, 40 mg as a single dose (see Section 21.2.8: Pulmonary oedema,",
    "commonDosage": "40 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a cuff that is slightly too large than one that is too small. Large cuffs, if covered with linen",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a cuff that is slightly too large than one that is too small. Large cuffs, if covered with linen-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infants and preschool",
    "brandName": "aged children are almost never diagnosed with esse",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infants and preschool-aged children are almost never diagnosed with essential",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adapted from U.S Department of Health and Human Services National Institutes of Health",
    "brandName": "National Heart, Lung, and Blood Institute",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adapted from U.S Department of Health and Human Services National Institutes of Health (National Heart, Lung, and Blood Institute):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The 4th report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, May 2005",
    "brandName": "using the",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The 4th report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, May 2005 (using the",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "50th height percentile",
    "brandName": ".",
    "strength": "50",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "50th height percentile).",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children: 18 months",
    "brandName": "11 years of age",
    "strength": "18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children: 18 months–11 years of age",
    "commonDosage": "18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">2.5",
    "brandName": "3.5 kg",
    "strength": "2.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">2.5–3.5 kg",
    "commonDosage": "2.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">3.5",
    "brandName": "5 kg",
    "strength": "3.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">3.5–5 kg",
    "commonDosage": "3.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">11",
    "brandName": "17.5 kg",
    "strength": "11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">11–17.5 kg",
    "commonDosage": "11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">17.5",
    "brandName": "25 kg",
    "strength": "17.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">17.5–25 kg",
    "commonDosage": "17.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">25",
    "brandName": "35 kg",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">25–35 kg",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "adrenaline",
    "brandName": "epinephrine",
    "strength": "3 mL",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "adrenaline (epinephrine) or 3 mL water for injection.",
    "commonDosage": "3 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1.2 MU in 3.2 mL lidocaine 1% without adrenaline",
    "brandName": "epinephrine",
    "strength": "1.2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1.2 MU in 3.2 mL lidocaine 1% without adrenaline (epinephrine) or 3 mL water",
    "commonDosage": "1.2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral, 50 mg/kg",
    "brandName": "maximum dose: 2 g",
    "strength": "50 mg",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral, 50 mg/kg (maximum dose: 2 g), 1 hour before the procedure.",
    "commonDosage": "50 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Risk factors for prevention of ischaemic heart disease and atherosclerosis",
    "brandName": "diabetes",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Risk factors for prevention of ischaemic heart disease and atherosclerosis (diabetes): de Vries FM, Kolthof J, Postma MJ, Denig",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "events in diabetes patients: a meta",
    "brandName": "analysis. PLoS One. 2014 Nov 5;9",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "events in diabetes patients: a meta-analysis. PLoS One. 2014 Nov 5;9(11):e111247. http://www.ncbi.nlm.nih.gov/pubmed/25372483",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lancet. 2004 Sep 11",
    "brandName": "17;364",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lancet. 2004 Sep 11-17;364(9438):937-52. http://www.ncbi.nlm.nih.gov/pubmed/15364185",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 Ideal BMI: McGee DL. McGee DL; Diverse Populations Collaboration. Body mass index and mortality: a meta",
    "brandName": "analysis based on",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 Ideal BMI: McGee DL. McGee DL; Diverse Populations Collaboration. Body mass index and mortality: a meta-analysis based on",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Report No.: 98",
    "brandName": "4083. https://www.ncbi.nlm.nih.gov/books/NBK2003/",
    "strength": "98",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Report No.: 98-4083. https://www.ncbi.nlm.nih.gov/books/NBK2003/",
    "commonDosage": "98",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rosuvastatin 10mg, oral",
    "brandName": "secondary prevention of ischaemic events",
    "strength": "10mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rosuvastatin 10mg, oral (secondary prevention of ischaemic events): National Department of Health. Affordable Medicines,",
    "commonDosage": "10mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta",
    "brandName": "analysis of data from 170 000 participants in 26 r",
    "strength": "170 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised",
    "commonDosage": "170 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "trials. The Lancet 2010; 376",
    "brandName": "9753",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "trials. The Lancet 2010; 376(9753): 1670-81. https://www.ncbi.nlm.nih.gov/pubmed/21067804",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "controlled trials. European journal of preventive cardiology 2013; 20",
    "brandName": "4",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "controlled trials. European journal of preventive cardiology 2013; 20(4): 658-70. https://www.ncbi.nlm.nih.gov/pubmed/23529608",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atorvastatin 10 mg, oral",
    "brandName": "secondary prevention of ischaemic events",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atorvastatin 10 mg, oral (secondary prevention of ischaemic events – patients on protease inhibitors): Chastain DB, Stover",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22;8:6",
    "brandName": "14. https://www.ncbi.nlm.nih.gov/pubmed/29067253",
    "strength": "22",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22;8:6-14. https://www.ncbi.nlm.nih.gov/pubmed/29067253",
    "commonDosage": "22",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health. Affordable Medicines, EDP",
    "brandName": "Primary Health Care. Cost",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Health. Affordable Medicines, EDP-Primary Health Care. Cost-effectiveness analysis of high, intermediate, and low dose statins for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the secondary prevention of cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the secondary prevention of cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Trialists'",
    "brandName": "CTT",
    "strength": "170",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170",
    "commonDosage": "170",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "000 participants in 26 randomised trials. The Lancet 2010; 376",
    "brandName": "9753",
    "strength": "000 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "000 participants in 26 randomised trials. The Lancet 2010; 376(9753): 1670-81. https://www.ncbi.nlm.nih.gov/pubmed/21067804",
    "commonDosage": "000 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "individuals in 181 randomized controlled trials. European journal of preventive cardiology 2013; 20",
    "brandName": "4",
    "strength": "181 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "individuals in 181 randomized controlled trials. European journal of preventive cardiology 2013; 20(4): 658-70.",
    "commonDosage": "181 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atorvastatin, oral",
    "brandName": "drug",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atorvastatin, oral (drug-drug interaction with protease inhibitors): University of Liverpool. HIV drug interaction database.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.hiv",
    "brandName": "druginteractions.org/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.hiv-druginteractions.org/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2005;28",
    "brandName": "3",
    "strength": "2005",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2005;28(3):223–7. https://www.ncbi.nlm.nih.gov/pubmed/16097365",
    "commonDosage": "2005",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pharmacokinetic interaction model for co",
    "brandName": "administration of simvastatin and amlodipine. Drug",
    "strength": "2014",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120–",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High dose statins",
    "brandName": "management of adverse drug reactions",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High dose statins (management of adverse drug reactions): NICE: Cardiovascular disease: risk assessment and reduction,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aspirin, oral",
    "brandName": "stable angina",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Aspirin, oral (stable angina): Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002 Jan 12;324",
    "brandName": "7329",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002 Jan 12;324(7329):71-86. Erratum in:",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BMJ 2002 Jan 19;324",
    "brandName": "7330",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BMJ 2002 Jan 19;324(7330):141. https://www.ncbi.nlm.nih.gov/pubmed/11786451",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isosorbide dinitrate, sublingual",
    "brandName": "dosing",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isosorbide dinitrate, sublingual (dosing): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isosorbide mononitrate, oral: Thadani U, Lipicky RJ. Short and long",
    "brandName": "acting oral nitrates for stable angina pectoris. C",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isosorbide mononitrate, oral: Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ther. 1994 Aug;8",
    "brandName": "4",
    "strength": "1994 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ther. 1994 Aug;8(4):611-23. https://www.ncbi.nlm.nih.gov/pubmed/7848896",
    "commonDosage": "1994 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isosorbide mononitrate, oral: Parker JO. Eccentric dosing with isosorbide",
    "brandName": "5",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isosorbide mononitrate, oral: Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris.  Am J Cardiol. 1993 Oct",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15;72",
    "brandName": "12",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15;72(12):871-6. https://www.ncbi.nlm.nih.gov/pubmed/8213541",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Organic nitrates",
    "brandName": "Isosorbide mononitrate and dinitrate, oral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Organic nitrates (Isosorbide mononitrate and dinitrate, oral): Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "angina pectoris.Cardiovasc Drugs Ther. 1994 Aug;8",
    "brandName": "4",
    "strength": "1994 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "angina pectoris.Cardiovasc Drugs Ther. 1994 Aug;8(4):611-23. https://www.ncbi.nlm.nih.gov/pubmed/7848896",
    "commonDosage": "1994 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Organic nitrates",
    "brandName": "Isosorbide mononitrate and dinitrate, oral",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Organic nitrates (Isosorbide mononitrate and dinitrate, oral): Parker JO. Eccentric dosing with isosorbide-5-mononitrate in",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "angina pectoris.Am J Cardiol. 1993 Oct 15;72",
    "brandName": "12",
    "strength": "1993 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "angina pectoris.Am J Cardiol. 1993 Oct 15;72(12):871-6. https://www.ncbi.nlm.nih.gov/pubmed/8213541",
    "commonDosage": "1993 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Primary Health Care. Cost",
    "brandName": "effectiveness analysis of high, intermediate, and ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Primary Health Care. Cost-effectiveness analysis of high, intermediate, and low dose statins for the secondary prevention of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and safety of more intensive lowering of LDL cholesterol: a meta",
    "brandName": "analysis of data from 170 000 participants in 26 r",
    "strength": "170 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The",
    "commonDosage": "170 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lancet 2010; 376",
    "brandName": "9753",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lancet 2010; 376(9753): 1670-81. https://www.ncbi.nlm.nih.gov/pubmed/21067804",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "European journal of preventive cardiology 2013; 20",
    "brandName": "4",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "European journal of preventive cardiology 2013; 20(4): 658-70. https://www.ncbi.nlm.nih.gov/pubmed/23529608",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "secondary prevention of cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "secondary prevention of cardiovascular disease, 31 January 2018. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Trialists'",
    "brandName": "CTT",
    "strength": "170 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000",
    "commonDosage": "170 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "participants in 26 randomised trials. The Lancet 2010; 376",
    "brandName": "9753",
    "strength": "26 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "participants in 26 randomised trials. The Lancet 2010; 376(9753): 1670-81. https://www.ncbi.nlm.nih.gov/pubmed/21067804",
    "commonDosage": "26 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Simvastatin 40 mg, oral",
    "brandName": "amlodipine drug interaction",
    "strength": "40 mg",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Simvastatin 40 mg, oral (amlodipine drug interaction): Lexicomp: Drug Interactions database. [Accessed 7 February 2018] Available",
    "commonDosage": "40 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "at: https://www.uptodate.com/drug",
    "brandName": "interactions",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "at: https://www.uptodate.com/drug-interactions",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "S; Clopidogrel in Unstable angina to prevent Recurrent Events",
    "brandName": "CURE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "S; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Recurrent Events",
    "brandName": "CURE",
    "strength": "2003 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Recurrent Events  (CURE) study. Circulation. 2003 Oct 7;108(14):1682-7. https://www.ncbi.nlm.nih.gov/pubmed/14504182",
    "commonDosage": "2003 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen",
    "brandName": "medically ill patients",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen (medically ill patients): National Department of Health. Affordable Medicines, EDP-Primary Healthcare and Adult",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neary JD, Alhazzani W. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy",
    "brandName": "IOTA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neary JD, Alhazzani W. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "systematic review and meta",
    "brandName": "analysis. Lancet. 2018 Apr 28;391",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-1705. https://www.ncbi.nlm.nih.gov/pubmed/29726345",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "acute ST",
    "brandName": "elevation myocardial infarction: systematic review",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "acute ST-elevation myocardial infarction: systematic review and meta-analysis. Eur J Emerg Med. 2021 Jan 1;28(1):11-18.",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enalapril",
    "brandName": "cardiac failure/ LV dysfunction",
    "strength": "14",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Enalapril (cardiac failure/ LV dysfunction): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Harrington RA, Califf RM, Peterson ED. Initial aspirin dose and outcome among ST",
    "brandName": "elevation myocardial infarction patients treated w",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Harrington RA, Califf RM, Peterson ED. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fibrinolytic therapy. Circulation. 2008 Jan 15;117",
    "brandName": "2",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fibrinolytic therapy. Circulation. 2008 Jan 15;117(2):192-9. https://www.ncbi.nlm.nih.gov/pubmed/18086929",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aspirin, oral",
    "brandName": "STEMI",
    "strength": "7 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Aspirin, oral (STEMI): CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA,",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "acute coronary syndromes. N Engl J Med. 2010 Sep 2;363",
    "brandName": "10",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930-42. https://www.ncbi.nlm.nih.gov/pubmed/20818903",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Review: Thrombolytics, therapeutic class for STEMI, July 2015. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Review: Thrombolytics, therapeutic class for STEMI, July 2015. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with ST",
    "brandName": "segment elevation myocardial infarction: a systema",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017 Aug 19;390(10096):747-",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and low",
    "brandName": "molecular",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "meta",
    "brandName": "analysis of the randomized trials. Circulation. 20",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "meta-analysis of the randomized trials. Circulation. 2005 Dec 20;112(25):3855-67. https://www.ncbi.nlm.nih.gov/pubmed/16344381",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "reappraisal of the golden hour. Lancet. 1996 Sep 21;348",
    "brandName": "9030",
    "strength": "1996 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5. http://www.ncbi.nlm.nih.gov/pubmed/8813982",
    "commonDosage": "1996 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002 Feb;82",
    "brandName": "2",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002 Feb;82(2):149-58.",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrochlorothiazide, oral",
    "brandName": "mild CCF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Hydrochlorothiazide, oral (mild CCF): McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al; ESC",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2021 Sep 21;42",
    "brandName": "36",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2021 Sep 21;42(36):3599-3726. https://pubmed.ncbi.nlm.nih.gov/34447992/",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrochlorothiazide, oral",
    "brandName": "mild CCF",
    "strength": "14",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Hydrochlorothiazide, oral (mild CCF): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2018 Apr;78",
    "brandName": "4",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2018 Apr;78(4):673-681.e9. https://www.ncbi.nlm.nih.gov/pubmed/29217346",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern  Med. 2017 Oct;282",
    "brandName": "4",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern  Med. 2017 Oct;282(4):322-331.",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "21;42",
    "brandName": "36",
    "strength": "21",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "21;42(36):3599-3726. https://pubmed.ncbi.nlm.nih.gov/34447992/",
    "commonDosage": "21",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Carvedilol",
    "brandName": "dosing if >85 kg",
    "strength": "85 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Carvedilol (dosing if >85 kg): McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al; ESC Scientific",
    "commonDosage": "85 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "African perspective. Cardiovasc J Afr. 2019 Mar/Apr;30",
    "brandName": "2",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "African perspective. Cardiovasc J Afr. 2019 Mar/Apr;30(2):71-73. https://pubmed.ncbi.nlm.nih.gov/31155633/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1;178",
    "brandName": "1",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1;178(1):28-36. https://pubmed.ncbi.nlm.nih.gov/29131895/",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "42 Ideal BMI: McGee DL. McGee DL; Diverse Populations Collaboration. Body mass index and mortality: a meta",
    "brandName": "analysis based on",
    "strength": "42 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "42 Ideal BMI: McGee DL. McGee DL; Diverse Populations Collaboration. Body mass index and mortality: a meta-analysis based on",
    "commonDosage": "42 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lifestyle modification",
    "brandName": "hypertension: National Department of Health: Essen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Lifestyle modification - hypertension: National Department of Health: Essential Drugs Programme. Adult Hospital level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Duhamel TA. Effects of High",
    "brandName": "Intensity Interval Training Versus Moderate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Duhamel TA. Effects of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training On Blood Pressure in Adults with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38",
    "brandName": "6",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982-1004.",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antihypertensives",
    "brandName": "fixed dose combinations: Gupta P, Patel P, Štrauch",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antihypertensives – fixed dose combinations: Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38",
    "brandName": "6",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982-1004.",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2020 Jun;38",
    "brandName": "6",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2020 Jun;38(6):982-1004. https://pubmed.ncbi.nlm.nih.gov/32371787/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrochlorothiazide, oral",
    "brandName": "1st line treatment",
    "strength": "1",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 4",
    "description": "Hydrochlorothiazide, oral (1st line treatment - hypertension without compelling indications): National Department of Health:",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "compelling indications, July 2021. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "compelling indications, July 2021. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enalapril, oral",
    "brandName": "daily dosing",
    "strength": "20 mg",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Enalapril, oral (daily dosing): Girvin B, McDermott BJ, Johnston GD. A comparison of enalapril 20 mg once daily versus 10 mg twice",
    "commonDosage": "20 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enalapril, oral",
    "brandName": "daily dosing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Enalapril, oral (daily dosing): Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "J Clin Pharmacol. 1984;18 Suppl 2:215S",
    "brandName": "229S. https://www.ncbi.nlm.nih.gov/pubmed/6099737",
    "strength": "1984",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "J Clin Pharmacol. 1984;18 Suppl 2:215S-229S. https://www.ncbi.nlm.nih.gov/pubmed/6099737",
    "commonDosage": "1984",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Spironolactone",
    "brandName": "hypertension",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Spironolactone (hypertension):Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug",
    "brandName": "resistant hypertension",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suboptimal BP control",
    "brandName": "treatment inertia: Tiffe T, Wagner M, Rucker V, Mo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suboptimal BP control – treatment inertia: Tiffe T, Wagner M, Rucker V, Morbach C, Gelbrich G, Stork S, Heuschmann PU.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Control of cardiovascular risk factors and its determinants in the general population",
    "brandName": "findings from the STAAB cohort study. BMC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Control of cardiovascular risk factors and its determinants in the general population- findings from the STAAB cohort study. BMC",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Quantifying unmet need for hypertension care in South Africa through a care cascade: evidence from the SANHANES, 2011",
    "brandName": "2012.",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Quantifying unmet need for hypertension care in South Africa through a care cascade: evidence from the SANHANES, 2011-2012.",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BMJ Glob Health. 2017 Aug 16;2",
    "brandName": "3",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BMJ Glob Health. 2017 Aug 16;2(3):e000348. https://www.ncbi.nlm.nih.gov/pubmed/29082013",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of skin cancer associated with hydrochlorothiazide, 6 March 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "6 ",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "of skin cancer associated with hydrochlorothiazide, 6 March 2019. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Spironolactone, oral",
    "brandName": "contra",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Spironolactone, oral (contra-indications): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral (children): Clegg HW, Ryan AG, Dallas SD, Kaplan EL, Johnson DR, Norton HJ, Roddey OF, Martin ES,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Swetenburg RL, Koonce EW, Felkner MM, Giftos PM. Treatment of streptococcal pharyngitis with once",
    "brandName": "daily compared with twice",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Swetenburg RL, Koonce EW, Felkner MM, Giftos PM. Treatment of streptococcal pharyngitis with once-daily compared with twice-daily",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "amoxicillin: a noninferiority trial. Pediatr Infect Dis J. 2006 Sep;25",
    "brandName": "9",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "amoxicillin: a noninferiority trial. Pediatr Infect Dis J. 2006 Sep;25(9):761-7. https://www.ncbi.nlm.nih.gov/pubmed/16940830",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "penicillin G. Pediatr Infect Dis J. 1998 Oct;17",
    "brandName": "10",
    "strength": "1998 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "penicillin G. Pediatr Infect Dis J. 1998 Oct;17(10):890-3. http://www.ncbi.nlm.nih.gov/pubmed/9802630",
    "commonDosage": "1998 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in South Africa. S Afr Med J. 2015 Apr 6;105",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in South Africa. S Afr Med J. 2015 Apr 6;105(5):344-52. http://www.ncbi.nlm.nih.gov/pubmed/26242659",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Phenoxymethylpenicillin vs amoxicillin for tonsilitis_pharyngitis, October 2016. https://www.knowledgehub.org.za/content/standard",
    "brandName": "",
    "strength": "2016",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Phenoxymethylpenicillin vs amoxicillin for tonsilitis_pharyngitis, October 2016. https://www.knowledgehub.org.za/content/standard-",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment",
    "brandName": "guidelines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.5.2.1 Ringworm",
    "brandName": "tinea corporis",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.5.2.1 Ringworm – tinea corporis",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.5.2.5 Nail infections",
    "brandName": "tinea unguium",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.5.2.5 Nail infections – tinea unguium",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nail infections",
    "brandName": "tinea unguium",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nail infections – tinea unguium",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Milder forms",
    "brandName": "xeroderma",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Milder forms (xeroderma), seen as dryness with only slight scaling are common in the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aqueous cream",
    "brandName": "UEA",
    "strength": "N/A",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aqueous cream (UEA).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emulsifying ointment",
    "brandName": "UE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emulsifying ointment (UE)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Introduce topical retinoids gradually as a night",
    "brandName": "time application to limit skin irritant",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Introduce topical retinoids gradually as a night-time application to limit skin irritant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "effects, as they are not photo",
    "brandName": "stable and degrade when exposed to sunlight",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "effects, as they are not photo-stable and degrade when exposed to sunlight (e.g. start",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Flucloxacillin, oral, 12",
    "brandName": "25 mg/kg/dose 6 hourly for 5 days.",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Flucloxacillin, oral, 12–25 mg/kg/dose 6 hourly for 5 days.",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Post",
    "brandName": "streptococcal glomerulonephritis is a potential co",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Post-streptococcal glomerulonephritis is a potential complication.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If extensive or systemic signs of infection",
    "brandName": "fever, unwell, fatigued",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If extensive or systemic signs of infection (fever, unwell, fatigued), ADD:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: If impetigo has improved, but has not completely cured, give a 2nd 5",
    "brandName": "day course of",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: If impetigo has improved, but has not completely cured, give a 2nd 5-day course of",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Children who have significant pain, swelling or loss of function",
    "brandName": "to exclude",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Children who have significant pain, swelling or loss of function (to exclude",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Non",
    "brandName": "urgent",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Non-urgent",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If the ulcer is oedema",
    "brandName": "or stasis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If the ulcer is oedema- or stasis-related, rest the leg in an elevated position.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» In venous insufficiency, compression",
    "brandName": "bandages or stockings",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» In venous insufficiency, compression (bandages or stockings) are essential to achieve",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use bland, non",
    "brandName": "toxic products to clean the ulcer and surrounding ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use bland, non-toxic products to clean the ulcer and surrounding skin.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Povidone",
    "brandName": "iodine 5% cream, topical apply daily",
    "strength": "5%",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Povidone-iodine 5% cream, topical apply daily",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vaginal candidiasis: See Section 12.1: Vaginal discharge syndrome",
    "brandName": "VDS",
    "strength": "12.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vaginal candidiasis: See Section 12.1: Vaginal discharge syndrome (VDS).",
    "commonDosage": "12.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» neck folds, peri",
    "brandName": "anal, perineum and groins in infants",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» neck folds, peri-anal, perineum and groins in infants",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» are red raw",
    "brandName": "looking patches",
    "strength": "N/A",
    "form": "patch",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» are red raw-looking patches",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» appear moist",
    "brandName": "weeping",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» appear moist (weeping)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fungal infections affecting the body",
    "brandName": "tinea corporis; tinea versicolor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fungal infections affecting the body (tinea corporis; tinea versicolor), feet (tinea pedis),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "scalp",
    "brandName": "tinea capitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "scalp (tinea capitis) and nails (tinea unguium). These infections may be contagious.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "itchy ring",
    "brandName": "like patches",
    "strength": "N/A",
    "form": "patch",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "itchy ring-like patches",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: For nail infection, see Section 5.6.3: Nail infections",
    "brandName": "tinea unguium.",
    "strength": "5.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: For nail infection, see Section 5.6.3: Nail infections – tinea unguium.",
    "commonDosage": "5.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Do not give to women of child",
    "brandName": "bearing age unless they are on",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Do not give to women of child-bearing age unless they are on",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Round macules which are often lighter than normal skin",
    "brandName": "but may be darker",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Round macules which are often lighter than normal skin (but may be darker).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 5.6.3: Nail infections",
    "brandName": "tinea unguium.",
    "strength": "5.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 5.6.3: Nail infections – tinea unguium.",
    "commonDosage": "5.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroid, potent, topical, e.g.:",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroid, potent, topical, e.g.: (Doctor prescribed)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with antibiotics",
    "brandName": "see Section 5.4.2: Impetigo",
    "strength": "5.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "with antibiotics (see Section 5.4.2: Impetigo).",
    "commonDosage": "5.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Head lice are common in children. The eggs",
    "brandName": "nits",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Head lice are common in children. The eggs (nits) appear as fixed white specks on the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "as dark spots",
    "brandName": "like ground pepper",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "as dark spots (like ground pepper).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with normal shampoo",
    "brandName": "more than one foaming might be needed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with normal shampoo (more than one foaming might be needed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "− Itching may continue for 2",
    "brandName": "3 weeks after treatment.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "− Itching may continue for 2–3 weeks after treatment.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Apply to the eyelid margins",
    "brandName": "cover the eyelashes",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Apply to the eyelid margins (cover the eyelashes) daily for 10 days to smother lice",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Leave on overnight",
    "brandName": "8 to 12 hours",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Leave on overnight (8 to 12 hours) and wash off the following",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Leave on overnight",
    "brandName": "8",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Leave on overnight (8–12 hours) and wash off the following",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Itching may continue for 2",
    "brandName": "3 weeks after treatment.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Itching may continue for 2–3 weeks after treatment.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Creeping eruption",
    "brandName": "cutaneous larva migrans",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Creeping eruption (cutaneous larva migrans) caused by Ancylostoma braziliense, a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and cause a winding thread",
    "brandName": "like trail of inflammation with itching, scratchin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and cause a winding thread-like trail of inflammation with itching, scratching dermatitis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Eczema is usually a chronic condition and requires long",
    "brandName": "term care.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Eczema is usually a chronic condition and requires long-term care.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Avoid soap, use soap substitutes such as aqueous cream",
    "brandName": "UEA",
    "strength": "N/A",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Avoid soap, use soap substitutes such as aqueous cream (UEA).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children: 2",
    "brandName": "6 years of age",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children: 2–6 years of age",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Stop all suspected agents e.g. ACE",
    "brandName": "inhibitor.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Stop all suspected agents e.g. ACE-inhibitor.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline",
    "brandName": "epinephrine",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline (epinephrine), 1:1000 solution, 0.5 mL into the lateral thigh, administered",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline",
    "brandName": "epinephrine",
    "strength": "0.01 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline (epinephrine), IM, 0.01 mL/kg of 1:1000 solution, administered",
    "commonDosage": "0.01 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Severe ACE",
    "brandName": "inhibitor induced angioedema.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Severe ACE-inhibitor induced angioedema.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Stop the suspected offending medicine",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Stop the suspected offending medicine(s).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chlorphenamine, oral, 0.1 mg/kg/dose 6",
    "brandName": "8 hourly. See dosing table:",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chlorphenamine, oral, 0.1 mg/kg/dose 6–8 hourly. See dosing table:",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chlorphenamine, oral, 4 mg, 6",
    "brandName": "8 hourly.",
    "strength": "4 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chlorphenamine, oral, 4 mg, 6–8 hourly.",
    "commonDosage": "4 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children 2",
    "brandName": "6 years of age:",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children 2–6 years of age:",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A self",
    "brandName": "limiting and commonly recurrent inflammatory erupt",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A self-limiting and commonly recurrent inflammatory eruption of the skin.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Symmetrically distributed crops of target lesions",
    "brandName": "dark centre, an inner, pale ring",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Symmetrically distributed crops of target lesions (dark centre, an inner, pale ring",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "surrounded by an outer red ring",
    "brandName": "occur on the extremities, and in particular, on th",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "surrounded by an outer red ring) occur on the extremities, and in particular, on the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» An acute, systemic condition with vesico",
    "brandName": "bullous lesions involving the skin and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» An acute, systemic condition with vesico-bullous lesions involving the skin and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The condition is usually caused by medicines e.g. sulphonamides, anti",
    "brandName": "retrovirals",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The condition is usually caused by medicines e.g. sulphonamides, anti-retrovirals",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lamotrigine",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lamotrigine).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Systemic involvement with multi",
    "brandName": "organ dysfunction is common.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Systemic involvement with multi-organ dysfunction is common.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the thorax characteristically lie parallel to the long axis of the ribs",
    "brandName": "“Christmas tree”",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the thorax characteristically lie parallel to the long axis of the ribs (“Christmas tree”",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "limiting and resolves within about 6",
    "brandName": "8 weeks.",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "limiting and resolves within about 6–8 weeks.",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In non",
    "brandName": "genital molluscum contagiosum:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In non-genital molluscum contagiosum:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Peri",
    "brandName": "ocular lesions to an ophthalmologist.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Peri-ocular lesions to an ophthalmologist.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Primary herpes infection involving gingivostomatitis",
    "brandName": "usually type 1",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Primary herpes infection involving gingivostomatitis (usually type 1) or the genital area",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 11.3.11: Herpes zoster",
    "brandName": "Shingles",
    "strength": "11.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 11.3.11: Herpes zoster (Shingles).",
    "commonDosage": "11.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A common, infectious, self",
    "brandName": "limiting condition of the skin or mucous membrane ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A common, infectious, self-limiting condition of the skin or mucous membrane caused by",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Present as smooth, flat, skin",
    "brandName": "coloured or slightly pigmented surface.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Present as smooth, flat, skin-coloured or slightly pigmented surface.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Commonly appear on the pressure",
    "brandName": "bearing areas of the soles and can be painful and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Commonly appear on the pressure-bearing areas of the soles and can be painful and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 12.12: Genital warts",
    "brandName": "GW",
    "strength": "12.12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 12.12: Genital warts (GW): condylomata accuminata.",
    "commonDosage": "12.12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For flares",
    "brandName": "if delay experienced in obtaining a dermatological",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For flares (if delay experienced in obtaining a dermatological consultation):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Flare",
    "brandName": "ups may be triggered by perspiration, hormonal cha",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Flare-ups may be triggered by perspiration, hormonal changes (such as menstrual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cycles",
    "brandName": ", humidity and heat, and friction from clothing.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cycles), humidity and heat, and friction from clothing.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Avoid tight clothing or clothing made of non",
    "brandName": "breathable material.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Avoid tight clothing or clothing made of non-breathable material.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Avoid sun exposure during periods of maximum intensity",
    "brandName": "i.e. between 10:00 and",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Avoid sun exposure during periods of maximum intensity (i.e. between 10:00 and",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Wear a wide",
    "brandName": "brimmed hat and long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Wear a wide-brimmed hat and long-sleeved top when exposed to the sun.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Wear sunscreens with a high sun protection factor",
    "brandName": "SPF",
    "strength": "20 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Wear sunscreens with a high sun protection factor (SPF); a SPF of between 20 and",
    "commonDosage": "20 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High potency",
    "brandName": "SPF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High potency (SPF) sunblock, topical (UV block).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Repositioning and turning at regular intervals, every 2",
    "brandName": "4 hours. Individual receiving",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Repositioning and turning at regular intervals, every 2-4 hours. Individual receiving",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chlorphenamine, oral",
    "brandName": "dosing in children",
    "strength": "2022",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chlorphenamine, oral (dosing in children): British National Formulary for children 2022-2023. (2022). 84th ed. BMJ Publishing and",
    "commonDosage": "2022",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Topical retinoids",
    "brandName": "caution in pregnancy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Topical retinoids (caution in pregnancy): Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "following first",
    "brandName": "trimester exposure to topical retinoids: a systema",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015 Nov;173(5):1132-41.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "multicenter prospective study. J Clin Pharmacol. 2012 Dec;52",
    "brandName": "12",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "multicenter prospective study. J Clin Pharmacol. 2012 Dec;52(12):1844-51. https://www.ncbi.nlm.nih.gov/pubmed/22174426",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gynaecologist 2014;16:7",
    "brandName": "11. http://onlinelibrary.wiley.com/doi/10.1111/tog",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gynaecologist 2014;16:7–11. http://onlinelibrary.wiley.com/doi/10.1111/tog.12075/pdf",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adult Hospital level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adult Hospital level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluconazole, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fluconazole, oral (children): Chen X, Jiang X, Yang M, González U, Lin X, Hua X, Xue S, Zhang M, Bennett C.  Systemic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016 May 12;",
    "brandName": "5",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016 May 12;(5):CD004685.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep;37",
    "brandName": "9",
    "strength": "37",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep;37(9):703-5. http://www.ncbi.nlm.nih.gov/pubmed/9762826",
    "commonDosage": "37",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Apr;136",
    "brandName": "4",
    "strength": "136",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Apr;136(4):575-7. https://pubmed.ncbi.nlm.nih.gov/9155961/",
    "commonDosage": "136",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrocortisone 0.1%, topical",
    "brandName": "chronic paronychia",
    "strength": "0.1%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hydrocortisone 0.1%, topical (chronic paronychia): Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic",
    "commonDosage": "0.1%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antifungals in the treatment of chronic paronychia: an open, randomized double",
    "brandName": "blind and double dummy study. J Am Acad Dermatol.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2002 Jul;47",
    "brandName": "1",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2002 Jul;47(1):73-6. https://www.ncbi.nlm.nih.gov/pubmed/12077585",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nov",
    "brandName": "Dec;21",
    "strength": "21",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nov-Dec;21(6):670-4. http://www.ncbi.nlm.nih.gov/pubmed/15575855",
    "commonDosage": "21",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lice. Pediatrics2010;126:392",
    "brandName": "403. http://www.ncbi.nlm.nih.gov/pubmed/20660553",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lice. Pediatrics2010;126:392-403. http://www.ncbi.nlm.nih.gov/pubmed/20660553",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Safety Considerations. Pediatrics2007;119",
    "brandName": "5",
    "strength": "2007",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Safety Considerations. Pediatrics2007;119(5):965-974. http://www.ncbi.nlm.nih.gov/pubmed/17473098",
    "commonDosage": "2007",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "protection. Guidelines for treatment of pediculosiscapitis",
    "brandName": "head lice",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "protection. Guidelines for treatment of pediculosiscapitis (head lice). August 2008. [Online 2008][Cited 2013] Available at:",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://novascotia.ca/dhw/publications/Public",
    "brandName": "Health",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://novascotia.ca/dhw/publications/Public-Health-Education/Head_Lice_Guidelines_for_Treatment.pdf",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Permethrin 5% lotion: Roberts RJ. Head lice. N Engl J Med 2002;346",
    "brandName": "21",
    "strength": "5%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Permethrin 5% lotion: Roberts RJ. Head lice. N Engl J Med 2002;346(21):1645-1650.",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Permethrin 5% lotion: MCC registered package insert for Skabi",
    "brandName": "rid®.",
    "strength": "5%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Permethrin 5% lotion: MCC registered package insert for Skabi-rid®.",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Permethrin 5% lotion: Diamantis SA, Morrell DS, Burkhart CN.Treatment of head lice. Dermatologic Therapy 2009;22:273",
    "brandName": "278.",
    "strength": "5%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Permethrin 5% lotion: Diamantis SA, Morrell DS, Burkhart CN.Treatment of head lice. Dermatologic Therapy 2009;22:273–278.",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pediculosis Capitis.Clinical Infectious Diseases 2003; 36:1355",
    "brandName": "61. http://www.ncbi.nlm.nih.gov/pubmed/12766828",
    "strength": "2003",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pediculosis Capitis.Clinical Infectious Diseases 2003; 36:1355–61. http://www.ncbi.nlm.nih.gov/pubmed/12766828",
    "commonDosage": "2003",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Permethrin 5% lotion: British National Formulary for children 2016",
    "brandName": "2017.",
    "strength": "5%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Permethrin 5% lotion: British National Formulary for children 2016-2017. (2016). 1st ed. London: BMJ Group, Pharmaceutical",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Feb;41",
    "brandName": "1",
    "strength": "41",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Feb;41(1):9-14. http://www.ncbi.nlm.nih.gov/pubmed/20177574",
    "commonDosage": "41",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18;",
    "brandName": "3",
    "strength": "18",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18;(3):CD000320. http://www.ncbi.nlm.nih.gov/pubmed/17636630",
    "commonDosage": "18",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzoyl benzoate",
    "brandName": "Directions for <6 years of age",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzoyl benzoate (Directions for <6 years of age): South African Medicines Formulary, 14th Edition.  Division of Clinical",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Potent and very potent corticosteroids, topical: Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost",
    "brandName": "effectiveness",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Potent and very potent corticosteroids, topical: Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "evaluation. Health Technol Assess. 2004 Nov;8",
    "brandName": "47",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "evaluation. Health Technol Assess. 2004 Nov;8(47):iii,iv, 1-120. https://www.ncbi.nlm.nih.gov/pubmed/15527669",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22 Chlorphenamine, oral",
    "brandName": "dosing in children",
    "strength": "22 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22 Chlorphenamine, oral (dosing in children): British National Formulary for children 2022-2023. (2022). 84th ed. BMJ Publishing and",
    "commonDosage": "22 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Molluscum contagiosum: Centers for Disease Control. https://www.cdc.gov/poxvirus/molluscum",
    "brandName": "contagiosum/treatment.html",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Molluscum contagiosum: Centers for Disease Control. https://www.cdc.gov/poxvirus/molluscum-contagiosum/treatment.html",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Iodine: van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom",
    "brandName": "Smit LW, Koning S. Interventions for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Iodine: van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom-Smit LW, Koning S. Interventions for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017 May 17;5",
    "brandName": "5",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017 May 17;5(5):CD004767. doi:",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antiviral therapy, oral",
    "brandName": "herpes simplex",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antiviral therapy, oral (herpes simplex): Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P, Chosidow O.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Syst Rev. 2014 Aug 3;",
    "brandName": "8",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Syst Rev. 2014 Aug 3;(8):CD009036. https://www.ncbi.nlm.nih.gov/pubmed/25086573",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64",
    "brandName": "RR",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum in: MMWR Recomm",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rep. 2015 Aug 28;64",
    "brandName": "33",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rep. 2015 Aug 28;64(33):924. https://pubmed.ncbi.nlm.nih.gov/26042815/",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salicylic acid, 2%, topical: Dall'oglio F, D'Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence",
    "brandName": "based review.",
    "strength": "2%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Salicylic acid, 2%, topical: Dall'oglio F, D'Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence-based review.",
    "commonDosage": "2%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Am J ClinDermatol. 2012 Apr 1;13",
    "brandName": "2",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Am J ClinDermatol. 2012 Apr 1;13(2):73-96. http://www.ncbi.nlm.nih.gov/pubmed/22292461",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salicylic acid, 2%, topical: Sterling JC, Handfield",
    "brandName": "Jones S, Hudson PM; British Association of Dermato",
    "strength": "2%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Salicylic acid, 2%, topical: Sterling JC, Handfield-Jones S, Hudson PM; British Association of Dermatologists. Guidelines for the",
    "commonDosage": "2%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management of cutaneous warts.Br J Dermatol. 2001 Jan;144",
    "brandName": "1",
    "strength": "2001 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management of cutaneous warts.Br J Dermatol. 2001 Jan;144(1):4-11. http://www.ncbi.nlm.nih.gov/pubmed/11167676",
    "commonDosage": "2001 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zinc oxide ointment",
    "brandName": "albinism",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zinc oxide ointment (albinism): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Titanium dioxide ointment/cream",
    "brandName": "albinism",
    "strength": "14",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Titanium dioxide ointment/cream (albinism): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High Potency Sunblock",
    "brandName": "SPF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High Potency Sunblock (SPF)/ (UV block) (vitiligo): Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with vitiligo 2021. Br J Dermatol. 2022 Jan;186",
    "brandName": "1",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with vitiligo 2021. Br J Dermatol. 2022 Jan;186(1):18-29. https://pubmed.ncbi.nlm.nih.gov/34160061/",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Whitton ME, Pinart M, Batchelor J, Leonardi",
    "brandName": "Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K. Interventions for vitiligo.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cochrane Database Syst Rev. 2015 Feb 24;",
    "brandName": "2",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263. https://www.ncbi.nlm.nih.gov/pubmed/25710794",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Assess Ser. 2009;9",
    "brandName": "2",
    "strength": "2009",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Assess Ser. 2009;9(2):1-104. https://www.ncbi.nlm.nih.gov/pubmed/23074524",
    "commonDosage": "2009",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zinc and castor oil ointment: Langemo D, Haesler E, Naylor W, Tippett A, Young T. Evidence",
    "brandName": "based guidelines for pressure ulcer",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zinc and castor oil ointment: Langemo D, Haesler E, Naylor W, Tippett A, Young T. Evidence-based guidelines for pressure ulcer",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management at the end of life. Int J Palliat Nurs. 2015 May;21",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management at the end of life. Int J Palliat Nurs. 2015 May;21(5):225-32. https://www.ncbi.nlm.nih.gov/pubmed/26107544",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Referral for rehabilitation",
    "brandName": "pressure ulcers",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Referral for rehabilitation (pressure ulcers):  Arora M, Harvey LA, Glinsky JV, Nier L, Lavrencic L, Kifley A, Cameron ID. Electrical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "stimulation for treating pressure ulcers. Cochrane Database Syst Rev. 2020 Jan 22;1",
    "brandName": "1",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "stimulation for treating pressure ulcers. Cochrane Database Syst Rev. 2020 Jan 22;1(1):CD012196.",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Referral for rehabilitation",
    "brandName": "if at high risk of pressure ulcers",
    "strength": "22 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Referral for rehabilitation (if at high risk of pressure ulcers): Harvey LA, Glinsky JV, Bowden JL. The effectiveness of 22 commonly",
    "commonDosage": "22 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mobilization on the prognosis of critically ill patients: A systematic review and meta",
    "brandName": "analysis. Int J Nurs Stud. 2020 Oct;110:103708.",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mobilization on the prognosis of critically ill patients: A systematic review and meta-analysis. Int J Nurs Stud. 2020 Oct;110:103708.",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Postpartum haemorrhage",
    "brandName": "PPH",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Postpartum haemorrhage (PPH)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6.11.2 Post",
    "brandName": "menopausal bleeding",
    "strength": "6.11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6.11.2 Post-menopausal bleeding",
    "commonDosage": "6.11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Miscarriage is considered to be safe or unsafe",
    "brandName": "septic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Miscarriage is considered to be safe or unsafe (septic) miscarriage:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Unsafe",
    "brandName": "septic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Unsafe (septic) miscarriage",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For perinatal mortality audit and statistics",
    "brandName": "DHIS or PPIP",
    "strength": "500 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For perinatal mortality audit and statistics (DHIS or PPIP), all fetuses ≥500 g are included.",
    "commonDosage": "500 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "125 mL/hour",
    "brandName": "avoid where threatened miscarriage is suspected",
    "strength": "125 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "125 mL/hour (avoid where threatened miscarriage is suspected).",
    "commonDosage": "125 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For all Rh",
    "brandName": "negative non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For all Rh-negative non-sensitised women who had a surgical procedure to manage a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anti",
    "brandName": "D immunoglobulin, IM, 50 mcg preferably within 72 ",
    "strength": "50 mcg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anti-D immunoglobulin, IM, 50 mcg preferably within 72 hours but may be given up",
    "commonDosage": "50 mcg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If unsafe",
    "brandName": "septic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If unsafe (septic) miscarriage is suspected, also give before referral:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not administer calcium",
    "brandName": "containing fluids, e.g. Ringer’s Lactate, concurre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not administer calcium-containing fluids, e.g. Ringer’s Lactate, concurrently with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to a maximum of 10 mg",
    "brandName": "Doctor prescribed",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "to a maximum of 10 mg (Doctor prescribed).",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "week of gestation",
    "brandName": "12 weeks and 0 days",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "week of gestation (12 weeks and 0 days)",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 500 mg",
    "brandName": "1 g, 4",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 500 mg–1 g, 4–6 hourly as required (to a maximum of 4 g in 24",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "designation",
    "brandName": "The Choice on Termination of Pregnancy Act, 1996",
    "strength": "1996 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "designation - The Choice on Termination of Pregnancy Act, 1996 (as amended by Act 38",
    "commonDosage": "1996 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of 2004",
    "brandName": ", expanded access to abortions, allows registered ",
    "strength": "2004",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of 2004), expanded access to abortions, allows registered nurses, as well as registered",
    "commonDosage": "2004",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Pre",
    "brandName": "and post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Pre- and post-termination counselling is essential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Consent for TOP and related procedures",
    "brandName": "e.g. laparotomy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Consent for TOP and related procedures (e.g. laparotomy) may be given by minors.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "abdominally, or the woman is obese or difficult to examine, arrange pre",
    "brandName": "procedure",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "abdominally, or the woman is obese or difficult to examine, arrange pre-procedure",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Ultrasound is mandatory if suspected ectopic pregnancy",
    "brandName": "refer if uncertain.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Ultrasound is mandatory if suspected ectopic pregnancy – refer if uncertain.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Check HIV status, Hb and blood group",
    "brandName": "Rh",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Check HIV status, Hb and blood group (Rh).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medical TOP",
    "brandName": "if gestation ≤12 weeks and 0 days:",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medical TOP - if gestation ≤12 weeks and 0 days:",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol, SL, 800 mcg by self",
    "brandName": "administration at home*.",
    "strength": "800 mcg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol, SL, 800 mcg by self-administration at home*.",
    "commonDosage": "800 mcg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "misoprostol on",
    "brandName": "site",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "misoprostol on-site (early morning) due to the risk of heavy bleeding.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TOP using manual vacuum aspiration",
    "brandName": "MVA",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TOP using manual vacuum aspiration (MVA) - if gestation ≤12 weeks and 0 days:",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Twelfth week of gestation",
    "brandName": "12 weeks and 0 days",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Twelfth week of gestation (12 weeks and 0 days)",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For both medical and surgical TOPs",
    "brandName": "MVA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For both medical and surgical TOPs (MVA):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In Rh",
    "brandName": "negative, non",
    "strength": "36.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In Rh-negative, non-sensitised women: (O36.0)",
    "commonDosage": "36.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Counsel all women on effective contraception, especially long",
    "brandName": "acting reversible",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Counsel all women on effective contraception, especially long-acting reversible",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Co",
    "brandName": "morbid conditions",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Co-morbid conditions (heart disease, asthma, diabetes, anaemia, clotting disorder,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Large fibroids",
    "brandName": "may interfere with determining gestation age and/o",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Large fibroids (may interfere with determining gestation age and/or MVA).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Any signs of sepsis",
    "brandName": "tachycardia, hypotension, pyrexia, tachypnoea, off",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Any signs of sepsis (tachycardia, hypotension, pyrexia, tachypnoea, offensive",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "vaginal discharge",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "vaginal discharge).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o All women intending to become pregnant or pregnant women",
    "brandName": "first trimester of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o All women intending to become pregnant or pregnant women (first trimester of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy and women of child",
    "brandName": "bearing potential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy and women of child-bearing potential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous sulfate compound BPC",
    "brandName": "dried",
    "strength": "170 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous sulfate compound BPC (dried), oral, 170 mg (± 55 mg elemental iron) 12",
    "commonDosage": "170 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous fumarate, oral, 200 mg once daily",
    "brandName": "± 65 mg elemental iron",
    "strength": "200 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous fumarate, oral, 200 mg once daily (± 65 mg elemental iron).",
    "commonDosage": "200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tolerability.",
    "brandName": "Note: Do not take iron tablets with milk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tolerability. (Note: Do not take iron tablets with milk).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "From confirmation of pregnancy",
    "brandName": "all women",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "From confirmation of pregnancy (all women):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Although the benefit is greatest in high",
    "brandName": "risk women, consider use of this agent in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Although the benefit is greatest in high-risk women, consider use of this agent in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Calcium reduces iron absorption from the gastro",
    "brandName": "intestinal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Calcium reduces iron absorption from the gastro-intestinal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hypertension in pregnancy, pre",
    "brandName": "eclampsia and eclampsia may have very serious and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Hypertension in pregnancy, pre-eclampsia and eclampsia may have very serious and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Hypertension with proteinuria, with onset ≥20 weeks of pregnancy",
    "brandName": "high risk patients",
    "strength": "20 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Hypertension with proteinuria, with onset ≥20 weeks of pregnancy (high risk patients",
    "commonDosage": "20 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disease, diabetes, pre",
    "brandName": "eclampsia in a previous pregnancy, advanced matern",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "disease, diabetes, pre-eclampsia in a previous pregnancy, advanced maternal age",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "or adolescent pregnancy",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "or adolescent pregnancy).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Generalised tonic",
    "brandName": "clonic seizures in women with pre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Generalised tonic-clonic seizures in women with pre-eclampsia.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Acute severe hypertension",
    "brandName": "diastolic BP of 110 mmHg and/or systolic >160 mmHg",
    "strength": "110 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Acute severe hypertension (diastolic BP of 110 mmHg and/or systolic >160 mmHg).",
    "commonDosage": "110 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Hypertension with severe features",
    "brandName": "refer to high risk labour ward urgently",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Hypertension with severe features (refer to high risk labour ward urgently).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Urgent",
    "brandName": "within 2 days",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Urgent (within 2 days)",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "height of fundus",
    "brandName": "every two weeks",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "height of fundus (every two weeks)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Educate on signs requiring urgent follow",
    "brandName": "up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Educate on signs requiring urgent follow-up (headache, epigastric pain, visual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disturbances, vaginal bleeding etc.",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disturbances, vaginal bleeding etc.).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management is the same as for treatment of pre",
    "brandName": "eclampsia with severe features",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management is the same as for treatment of pre-eclampsia with severe features – See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy",
    "brandName": "significant proteinuria defined as ≥1+ proteinuria",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy (significant proteinuria defined as ≥1+ proteinuria).",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The following indicate a higher risk of developing pre",
    "brandName": "eclampsia: nulliparity, obesity,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The following indicate a higher risk of developing pre-eclampsia: nulliparity, obesity,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "multiple pregnancy, chronic hypertension, kidney disease, diabetes, pre",
    "brandName": "eclampsia in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "multiple pregnancy, chronic hypertension, kidney disease, diabetes, pre-eclampsia in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "visual disturbances, epigastric pain",
    "brandName": "not discomfort",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "visual disturbances, epigastric pain (not discomfort).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nifedipine, oral, 10 mg",
    "brandName": "not sublingual",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nifedipine, oral, 10 mg (not sublingual) as a single dose.",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tolerability",
    "brandName": "Note: Do not take iron tablets with milk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tolerability (Note: Do not take iron tablets with milk).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Urgent",
    "brandName": "same day",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Urgent (same day)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Hb = 6",
    "brandName": "7.9 g/dL with symptoms",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Hb = 6-7.9 g/dL with symptoms (dizziness, tachycardia, shortness of breath at rest).",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Non",
    "brandName": "urgent",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Non-urgent (within 1 week)",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Hb = 8",
    "brandName": "9.9 g/dL and no improvement after one month of tre",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Hb = 8-9.9 g/dL and no improvement after one month of treatment (to high-risk",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "maternal syphilis may lead to miscarriage, stillbirth, non",
    "brandName": "immune hydrops fetalis, or",
    "strength": "N/A",
    "form": "drops",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "maternal syphilis may lead to miscarriage, stillbirth, non-immune hydrops fetalis, or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Available as rapid on",
    "brandName": "site finger",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Available as rapid on-site finger-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "improving to 1:64",
    "brandName": ", or",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "improving to 1:64), or",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "syphilis",
    "brandName": "reverse testing algorithm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "syphilis (reverse testing algorithm).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "syphilis, may retain life",
    "brandName": "long positive RPR results at",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "syphilis, may retain life-long positive RPR results at",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "low titres",
    "brandName": "≤1:8",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "low titres (≤1:8), which does not change by more",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Reconstitute with 6 mL of lidocaine 1% without adrenaline",
    "brandName": "epinephrine",
    "strength": "6 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Reconstitute with 6 mL of lidocaine 1% without adrenaline (epinephrine).",
    "commonDosage": "6 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Follow up at 3 months after the last injection to confirm a fourfold",
    "brandName": "i.e. 2 dilution",
    "strength": "3 ",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Follow up at 3 months after the last injection to confirm a fourfold (i.e. 2 dilution)",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzathine benzylpenicillin",
    "brandName": "depot formulation",
    "strength": "50 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Benzathine benzylpenicillin (depot formulation), IM, 50 000 units/kg as a single dose",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzathine benzylpenicillin",
    "brandName": "depot formulation",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Benzathine benzylpenicillin (depot formulation) must never be given intravenously.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Desquamative rash",
    "brandName": "especially involving",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Desquamative rash (especially involving",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "awaiting results",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "awaiting results).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "backache, diarrhoea and vomiting, and/or signs of meningitis",
    "brandName": "headache, neck stiffness,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "backache, diarrhoea and vomiting, and/or signs of meningitis (headache, neck stiffness,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "During outbreaks, if signs of meningitis are present, give pre",
    "brandName": "referral treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "During outbreaks, if signs of meningitis are present, give pre-referral treatment (see",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preterm delivery in the next pregnancy. Refer the following high",
    "brandName": "risk cases for cervical",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preterm delivery in the next pregnancy. Refer the following high-risk cases for cervical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A history of 2nd trimester miscarriage",
    "brandName": "between 16 and 26 weeks",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A history of 2nd trimester miscarriage (between 16 and 26 weeks).",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To improve fetal lung maturity at 26",
    "brandName": "34 weeks:",
    "strength": "26",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To improve fetal lung maturity at 26–34 weeks:",
    "commonDosage": "26",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To improve fetal lung maturity at 26 to 34 weeks:",
    "brandName": "Z29.2",
    "strength": "26 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To improve fetal lung maturity at 26 to 34 weeks: (Z29.2)",
    "commonDosage": "26 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Severe penicillin allergy:",
    "brandName": "Z88.0",
    "strength": "88.0",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Severe penicillin allergy:(Z88.0)",
    "commonDosage": "88.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prolonged pre",
    "brandName": "labour rupture of membranes >12 hours/ suspected c",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prolonged pre-labour rupture of membranes >12 hours/ suspected chorio-",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Suspected chorio",
    "brandName": "amnionitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "» Suspected chorio-amnionitis (refer after starting antibiotics).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Prolonged pre",
    "brandName": "labour rupture of membranes",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Prolonged pre-labour rupture of membranes (>12 hours).",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Salbutamol 1 mL",
    "brandName": "0.5 mg/mL",
    "strength": "1 mL",
    "form": "injection",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Salbutamol 1 mL (0.5 mg/mL) added to 9 mL of water for injection, to make a 50",
    "commonDosage": "1 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Inject 5 mL",
    "brandName": "250 mcg",
    "strength": "5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Inject 5 mL (250 mcg) over at least 2 minutes. Monitor pulse.",
    "commonDosage": "5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prevention of post",
    "brandName": "partum haemorrhage",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prevention of post-partum haemorrhage (PPH):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If >500 mL blood loss, manage as postpartum haemorrhage",
    "brandName": "see Section 6.7.1:",
    "strength": "500 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If >500 mL blood loss, manage as postpartum haemorrhage (see Section 6.7.1:",
    "commonDosage": "500 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Check baby’s Rh status; do not given anti",
    "brandName": "D if the baby is Rh",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Check baby’s Rh status; do not given anti-D if the baby is Rh-negative, or if the mother",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Administer to Rh",
    "brandName": "negative mother, if baby is Rh",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Administer to Rh-negative mother, if baby is Rh-positive or baby's Rh group is unknown:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anti",
    "brandName": "D immunoglobulin, IM, 100 mcg, preferably within 7",
    "strength": "100 mcg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anti-D immunoglobulin, IM, 100 mcg, preferably within 72 hours but can be given up",
    "commonDosage": "100 mcg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If baby not breathing well, clamp and cut the cord and start resuscitation",
    "brandName": "see",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If baby not breathing well, clamp and cut the cord and start resuscitation (see",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If any of the following, provide immediate management",
    "brandName": "see Section 6.6.3: Care of",
    "strength": "6.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If any of the following, provide immediate management (see Section 6.6.3: Care of",
    "commonDosage": "6.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Mother blood group O and/or Rh",
    "brandName": "ve.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Mother blood group O and/or Rh –ve.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Possible social problem",
    "brandName": "mother has died or is ill, teenage caregiver, soci",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Possible social problem (mother has died or is ill, teenage caregiver, social",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Place the baby skin",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Place the baby skin-to-skin with mother and initiate breastfeeding immediately.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Administer in the antero lateral aspect of the mid",
    "brandName": "thigh.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Administer in the antero lateral aspect of the mid-thigh.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BCG vaccination, intradermal, once neonate is stable.",
    "brandName": "Z23.2",
    "strength": "23.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BCG vaccination, intradermal, once neonate is stable. (Z23.2)",
    "commonDosage": "23.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "oximetry readings",
    "brandName": "if pulse oximeter is available",
    "strength": "100",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "oximetry readings (if pulse oximeter is available), and restores a heart rate >100",
    "commonDosage": "100",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "beats/minute. Bag and mask ventilation should be initially done with room air.",
    "brandName": "There",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "beats/minute. Bag and mask ventilation should be initially done with room air. (There",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "normal heart rate and colour response to bag",
    "brandName": "mask ventilation, but has not initiated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "normal heart rate and colour response to bag-mask ventilation, but has not initiated",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dilution",
    "brandName": "0.1 mg/kg/dose",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dilution (0.1 mg/kg/dose).",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2.5",
    "brandName": "5 mL/kg of 10% dextrose",
    "strength": "2.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2.5–5 mL/kg of 10% dextrose",
    "commonDosage": "2.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "injection",
    "brandName": "mix by agitating the",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "injection – mix by agitating the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mL/kg, slow IV",
    "brandName": "5",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mL/kg, slow IV (5–10 minutes).",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Fast breathing",
    "brandName": ">60 breaths/min",
    "strength": "60 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Fast breathing (>60 breaths/min)",
    "commonDosage": "60 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Vomiting everything/bile",
    "brandName": "stained",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Vomiting everything/bile-stained",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Keep the neonate warm",
    "brandName": "skin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Keep the neonate warm (skin-to-skin/kangaroo mother care or in an incubator), the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Check blood glucose concentration and treat if low",
    "brandName": "<2.6 mmol/L",
    "strength": "2.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Check blood glucose concentration and treat if low (<2.6 mmol/L). Check blood",
    "commonDosage": "2.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treat as severe hypoglycaemia",
    "brandName": "see below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treat as severe hypoglycaemia (see below).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If ≤28 days old, avoid calcium",
    "brandName": "containing IV fluids for 48 hours after ceftriaxon",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If ≤28 days old, avoid calcium-containing IV fluids for 48 hours after ceftriaxone",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Breastfeed or give expressed breastmilk",
    "brandName": "only if breastfeeding is not possible, give",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Breastfeed or give expressed breastmilk (only if breastfeeding is not possible, give",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "replacement milk feed 10 mL/kg",
    "brandName": ".",
    "strength": "10 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "replacement milk feed 10 mL/kg).",
    "commonDosage": "10 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All other neonates with increasing, deep or persistent",
    "brandName": ">10 days",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All other neonates with increasing, deep or persistent (>10 days) jaundice should be",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All small neonates",
    "brandName": "<2.5 kg",
    "strength": "2.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All small neonates (<2.5 kg) not able to feed.",
    "commonDosage": "2.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mothers who are HBsAg",
    "brandName": "positive or HBeAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mothers who are HBsAg-positive or HBeAg-positive.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Check the baby's hepatitis B surface antigen",
    "brandName": "HBsAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Check the baby's hepatitis B surface antigen (HBsAg) and hepatitis B surface",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If HBsAg positive: baby has hepatitis B infection",
    "brandName": "refer.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If HBsAg positive: baby has hepatitis B infection – refer.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Primary postpartum haemorrhage",
    "brandName": "PPH",
    "strength": "500 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Primary postpartum haemorrhage (PPH) is blood loss >500 mL that occurs within 24",
    "commonDosage": "500 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "makeshift balloon catheter",
    "brandName": "into uterus, inflate with 400 to 500 mL of saline ",
    "strength": "400 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "makeshift balloon catheter) into uterus, inflate with 400 to 500 mL of saline and",
    "commonDosage": "400 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "haemorrhage is life threatening",
    "brandName": "woman haemodynamically unstable",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "haemorrhage is life threatening (woman haemodynamically unstable).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "accompanied by offensive vaginal discharge",
    "brandName": "lochia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "accompanied by offensive vaginal discharge (lochia) and/or abdominal pain within the first",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» chin touching breast",
    "brandName": "or very close",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» chin touching breast (or very close),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Without intervention, 25",
    "brandName": "40% of infants born to women living with HIV may b",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Without intervention, 25–40% of infants born to women living with HIV may become",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For comprehensive information on the care of HIV",
    "brandName": "infected pregnant women refer to the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For comprehensive information on the care of HIV-infected pregnant women refer to the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "current National Consolidated Guidelines for the Prevention of Mother",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "current National Consolidated Guidelines for the Prevention of Mother-to-Child",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Transmission of HIV",
    "brandName": "PMTCT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Transmission of HIV (PMTCT) and the management of HIV in Children, Adolescents and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Provide routine counselling and voluntary HIV testing to all pregnant women",
    "brandName": "if HIV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Provide routine counselling and voluntary HIV testing to all pregnant women (if HIV",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "status is negative or unknown",
    "brandName": "at their very first antenatal visit, and treat oth",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "status is negative or unknown) at their very first antenatal visit, and treat other STIs if",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "throughout pregnancy, at labour/delivery, at the 6",
    "brandName": "week EPI visit and 3",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "throughout pregnancy, at labour/delivery, at the 6-week EPI visit and 3-monthly",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Provide with individual 'post",
    "brandName": "refusal' counselling and offer HIV testing at ever",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Provide with individual 'post-refusal' counselling and offer HIV testing at every",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All confirmed HIV",
    "brandName": "infected women must be fast",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All confirmed HIV-infected women must be fast-tracked for ART regardless of CD4",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If CD4 <200 cells/mm3, do a serum cryptococcal antigen",
    "brandName": "CrAg",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If CD4 <200 cells/mm3, do a serum cryptococcal antigen (CrAg) test.",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Start ART on the day of diagnosis",
    "brandName": "unless there are symptoms of TB",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Start ART on the day of diagnosis (unless there are symptoms of TB).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» HIV",
    "brandName": "infected women",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» HIV-infected women (WLHIV) must return 1 week after their initial ANC visit to get",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pregnant women already known to be HIV",
    "brandName": "infected",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pregnant women already known to be HIV-infected",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If not on ART, do clinical staging; take blood for CD4 count",
    "brandName": "to determine eligibility for",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If not on ART, do clinical staging; take blood for CD4 count (to determine eligibility for",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cryptococcal antigen",
    "brandName": "CrAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cryptococcal antigen (CrAg) test.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Opportunistic infection treatment and prophylaxis for HIV",
    "brandName": "infected pregnant",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Opportunistic infection treatment and prophylaxis for HIV-infected pregnant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If CrAg",
    "brandName": "positive, consult an infectious disease expert, an",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If CrAg-positive, consult an infectious disease expert, and refer.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: All CrAg positive women need a LP, unless contra",
    "brandName": "indicated, regardless of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: All CrAg positive women need a LP, unless contra-indicated, regardless of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "FIRST",
    "brandName": "LINE ART REGIMENS",
    "strength": "11.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "FIRST-LINE ART REGIMENS (Also see Section 11.1: Antiretroviral therapy, adults and",
    "commonDosage": "11.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Start alternative regimen",
    "brandName": "Doctor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Start alternative regimen (Doctor",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "on TDF",
    "brandName": "containing regimen.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "on TDF-containing regimen.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WLHIV failing a DTG",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WLHIV failing a DTG-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "VL <50 c/mL",
    "brandName": "pregnant",
    "strength": "50 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "VL <50 c/mL (pregnant",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "VL ≥ 50 c/mL",
    "brandName": "pregnant",
    "strength": "50 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "VL ≥ 50 c/mL (pregnant",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 11.5: The HIV",
    "brandName": "exposed infant, to decide whether infant is low ri",
    "strength": "11.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 11.5: The HIV-exposed infant, to decide whether infant is low risk or high risk and",
    "commonDosage": "11.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Known HIV",
    "brandName": "positive women, who are not currently on ART, but ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Known HIV-positive women, who are not currently on ART, but are ART exposed (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "previous PMTCT, or ART loss to follow",
    "brandName": "up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "previous PMTCT, or ART loss to follow-up) and who are initiating a DTG-containing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "life event,",
    "brandName": "e.g. bereavement",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "life event, (e.g. bereavement) early childhood adversity/ abuse, domestic violence, a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "history of trauma, displacement from home of origin, low socio",
    "brandName": "economic status, food",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "history of trauma, displacement from home of origin, low socio-economic status, food",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» screened positive using the 3",
    "brandName": "item tool in the Maternity Case Record.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» screened positive using the 3-item tool in the Maternity Case Record.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patient consents to use",
    "brandName": "if valproate use, sign acknowledgement of risk for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patient consents to use (if valproate use, sign acknowledgement of risk form",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.sahpra.org.za/wp",
    "brandName": "content/uploads/2025/05/GLF",
    "strength": "2025",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.sahpra.org.za/wp-content/uploads/2025/05/GLF-CEM-PV-S01_v2-",
    "commonDosage": "2025",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Valproate",
    "brandName": "Annual",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Valproate-Annual-Risk-Acknowledgement-Form-ARF.pdf.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Ensure psychosocial support",
    "brandName": "partner/ family/ NGO/ welfare support.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Ensure psychosocial support – partner/ family/ NGO/ welfare support.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Do not leave unattended if high risk of self",
    "brandName": "harm.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Do not leave unattended if high risk of self-harm.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "home visits; watch for preterm labour and/or SGA baby; follow",
    "brandName": "up on any up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "home visits; watch for preterm labour and/or SGA baby; follow-up on any up-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stress management/coping skills",
    "brandName": "refer for counselling e.g. at www.sadag.org.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stress management/coping skills – refer for counselling e.g. at www.sadag.org.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Relationship and family issues",
    "brandName": "refer for counselling, e.g. at www.famsa.org.za",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Relationship and family issues – refer for counselling, e.g. at www.famsa.org.za",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Abuse or interpersonal violence",
    "brandName": "refer to a social worker and for support, e.g. by",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Abuse or interpersonal violence - refer to a social worker and for support, e.g. by",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Encourage breastfeeding, if not contraindicated medically.",
    "brandName": "Breastfeeding difficulties",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Encourage breastfeeding, if not contraindicated medically. (Breastfeeding difficulties",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Optimise psychosocial and parenting support",
    "brandName": "utilise support groups e.g. at",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Optimise psychosocial and parenting support – utilise support groups e.g. at",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "www.sadag.org  Refer to Social Welfare if suspect child",
    "brandName": "care is seriously impaired.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "www.sadag.org  Refer to Social Welfare if suspect child-care is seriously impaired.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "support from mothers’ groups, NGOs, counsellors",
    "brandName": "and monitor response.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "support from mothers’ groups, NGOs, counsellors) and monitor response.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» May severely impair mother",
    "brandName": "infant bonding and child",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» May severely impair mother-infant bonding and child-care.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage aggressive or disruptive behaviour",
    "brandName": "see Section 16.1.2: Aggressive",
    "strength": "16.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage aggressive or disruptive behaviour (see Section 16.1.2: Aggressive",
    "commonDosage": "16.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage all pregnancies as high",
    "brandName": "risk in conjunction with obstetrician and psychiat",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage all pregnancies as high-risk in conjunction with obstetrician and psychiatrist.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "based care and outpatient follow",
    "brandName": "up before discharge.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "based care and outpatient follow-up before discharge.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» vaginal bleeding",
    "brandName": "os closed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» vaginal bleeding (os closed),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Combined oral contraceptive pill",
    "brandName": "ethinylestradiol/levonorgestrel",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Combined oral contraceptive pill (ethinylestradiol/levonorgestrel) for 3 to 6 months.",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraceptive device",
    "brandName": "IUCD",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraceptive device (IUCD) or chronic salpingitis (see Chapter 12: Sexually",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Known or suspected estrogen",
    "brandName": "dependent malignant tumours",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Known or suspected estrogen-dependent malignant tumours (such as endometrial",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "menstrual period",
    "brandName": "menopause",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "menstrual period (menopause) over a year ago, as they will not usually cause bleeding",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medroxyprogesterone acetate, oral, 5",
    "brandName": "10 mg daily from day 12 to 21.",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medroxyprogesterone acetate, oral, 5 -10 mg daily from day 12 to 21.",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medroxyprogesterone acetate, oral, 5",
    "brandName": "10 mg daily from day 12 to 21.",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medroxyprogesterone acetate, oral, 5–10 mg daily from day 12 to 21.",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Estradiol valerate, oral, 1",
    "brandName": "2 mg daily.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Estradiol valerate, oral, 1–2 mg daily.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Management difficulties, e.g. where oestrogen therapy is contra",
    "brandName": "indicated, poorly",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Management difficulties, e.g. where oestrogen therapy is contra-indicated, poorly",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 12.5: Genital ulcer syndrome",
    "brandName": "GUS",
    "strength": "12.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 12.5: Genital ulcer syndrome (GUS).",
    "commonDosage": "12.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Sections 12.1: Vaginal discharge syndrome",
    "brandName": "VDS",
    "strength": "12.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Sections 12.1: Vaginal discharge syndrome (VDS) and 12.2: Lower abdominal pain",
    "commonDosage": "12.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anti",
    "brandName": "D immunoglobulin, IM: Karanth L, JaafarSH, Kanagas",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anti-D immunoglobulin, IM: Karanth L, JaafarSH, Kanagasabai S, Nair NS, Barua A. Anti-D administration after spontaneous",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "miscarriage for preventing Rhesus alloimmunisation. The Cochrane database of systematic reviews. 2013",
    "brandName": "3",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "miscarriage for preventing Rhesus alloimmunisation. The Cochrane database of systematic reviews. 2013(3): Cd009617.",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis. PLoS One. 2020;15",
    "brandName": "9",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis. PLoS One. 2020;15(9):e0238844.",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "rhesus D",
    "brandName": "RhD",
    "strength": "13",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "rhesus D (RhD)-negative women having an abortion of a pregnancy up to 13+6 weeks’ gestation: a systematic review and new NICE",
    "commonDosage": "13",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consensus guidelines. BMJ Sex Reprod Health. 2020 Jan 20;bmjsrh",
    "brandName": "2019",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consensus guidelines. BMJ Sex Reprod Health. 2020 Jan 20;bmjsrh-2019-200536. https://pubmed.ncbi.nlm.nih.gov/31959599/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anti",
    "brandName": "D immunoglobulin, IM: NICE. Ectopic pregnancy and ",
    "strength": "24 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anti-D immunoglobulin, IM: NICE. Ectopic pregnancy and miscarriage: diagnosis and initial management, 24 November 2021.",
    "commonDosage": "24 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol",
    "brandName": "medical abortion",
    "strength": "25 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol  (medical abortion): NICE. Guideline: Abortion Care, 25 September 2019. https://www.nice.org.uk/guidance/ng140",
    "commonDosage": "25 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol",
    "brandName": "medical abortion",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol (medical abortion): WHO. Guideline: Medical management of abortion, 2018.",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.who.int/reproductivehealth/publications/medical",
    "brandName": "management",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.who.int/reproductivehealth/publications/medical-management-abortion/en/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IM",
    "brandName": "Incomplete 1st trimester miscarriage",
    "strength": "1",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IM (Incomplete 1st trimester miscarriage): National Department of Health, Essential Drugs Programme: Adult Hospital",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Level STGs and EML, updated edition.  https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Level STGs and EML, updated edition.  https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medical abortion",
    "brandName": "follow",
    "strength": "25 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medical abortion (follow-up pregnancy test): NICE. Guideline: Abortion Care, 25 September 2019.",
    "commonDosage": "25 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medical abortion",
    "brandName": "follow",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medical abortion (follow-up pregnancy test): Barnhart K, Sammel MD, Chung K, Zhou L, Hummel AC, Guo W. Decline of serum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol. 2004 Nov;104",
    "brandName": "5 Pt",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol. 2004 Nov;104(5 Pt",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mifepristone",
    "brandName": "Medical TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mifepristone (Medical TOP): Royal College of Obstetrics and Gynaecology Guidelines.The Care of Women Requesting Induced",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Abortion",
    "brandName": "Evidence",
    "strength": "7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Abortion (Evidence-based Clinical Guideline No. 7), 2011. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/the-care-",
    "commonDosage": "7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mifepristone",
    "brandName": "Medical TOP",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mifepristone (Medical TOP): WHO.Safe abortion: technical and policy guidance for health systems, 2014.",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "updated version. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "updated version. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "http://www.gov.za/documents/choice",
    "brandName": "termination",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "http://www.gov.za/documents/choice-termination-pregnancy-amendment-act",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol",
    "brandName": "Medical TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol (Medical TOP): Royal College of Obstetrics and Gynaecology Guidelines. The Care of Women Requesting Induced",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol",
    "brandName": "Medical TOP",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol (Medical TOP): WHO.Safe abortion: technical and policy guidance for health systems, 2014.",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "updated version.  https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "updated version.  https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7 Misoprostol, oral/PV",
    "brandName": "TOP",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7 Misoprostol, oral/PV (TOP - Up to 12 weeks and 0 days): World Health Organisation. Medical management of abortion, 2018.",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "http://www.who.int/reproductivehealth/publications/medical",
    "brandName": "management",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "http://www.who.int/reproductivehealth/publications/medical-management-abortion/en/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral",
    "brandName": "Medical TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral (Medical TOP): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EML, updated version.  https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EML, updated version.  https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ibuprofen, oral",
    "brandName": "Medical TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Ibuprofen, oral (Medical TOP): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "updated version.    https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "updated version.    https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IM",
    "brandName": "MVA TOP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IM (MVA TOP): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "updated version.   https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "updated version.   https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anti",
    "brandName": "D immunoglobulin, IM",
    "strength": "156 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anti-D immunoglobulin, IM (dose): NICE Clinical Guideline: 156 - Routine antenatal anti-D prophylaxis for women who are rhesus",
    "commonDosage": "156 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "D negative, 2008. https://www.nice.org.uk/guidance/ta156/resources/routine",
    "brandName": "antenatal",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "D negative, 2008. https://www.nice.org.uk/guidance/ta156/resources/routine-antenatal-antid-prophylaxis-for-women-who-are-rhesus-d-",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "negative",
    "brandName": "pdf",
    "strength": "82598318102725",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "negative-pdf-82598318102725",
    "commonDosage": "82598318102725",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Contraception",
    "brandName": "TOP",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Contraception (TOP): WHO. Safe abortion: technical and policy guidance for health systems, 2012.",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Folic acid, oral: De",
    "brandName": "Regil LM, Peña",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Folic acid, oral: De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015 Dec 14;",
    "brandName": "12",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015 Dec 14;(12):CD007950.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Folic acid, oral: Atta CA, Fiest KM, Frolkis AD, Jette N, Pringsheim T, St Germaine",
    "brandName": "Smith C, Rajapakse T, Kaplan GG, Metcalfe A.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Folic acid, oral: Atta CA, Fiest KM, Frolkis AD, Jette N, Pringsheim T, St Germaine-Smith C, Rajapakse T, Kaplan GG, Metcalfe A.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta",
    "brandName": "Analysis. Am J Public Health.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Global Birth Prevalence of Spina Bifida by Folic Acid Fortification Status: A Systematic Review and Meta-Analysis. Am J Public Health.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2016 Jan;106",
    "brandName": "1",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2016 Jan;106(1):e24-34. https://www.ncbi.nlm.nih.gov/pubmed/26562127",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Preventive Services Task Force. JAMA. 2017 Jan 10;317",
    "brandName": "2",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Preventive Services Task Force. JAMA. 2017 Jan 10;317(2):190-203. https://www.ncbi.nlm.nih.gov/pubmed/28097361",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Folic acid, oral: ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Folic acid, oral: ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "gynecologists. Number 44, July 2003.",
    "brandName": "Replaces Committee Opinion Number 252, March 2001",
    "strength": "44",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "gynecologists. Number 44, July 2003. (Replaces Committee Opinion Number 252, March 2001) Obstet. Gynecol. 2003;102(1):203–",
    "commonDosage": "44",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Task Force recommendation statement. Ann Intern Med. 2009 May 5;150",
    "brandName": "9",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Task Force recommendation statement. Ann Intern Med. 2009 May 5;150(9):626-31. https://www.ncbi.nlm.nih.gov/pubmed/19414842",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Langlois S, Murphy",
    "brandName": "Kaulbeck L, Okun N, Pastuck M; Special Contributor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Langlois S, Murphy-Kaulbeck L, Okun N, Pastuck M; Special Contributors, Deb-Rinker P, Dodds L, Leon JA, Lowel HL, Luo W,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid",
    "brandName": "Sensitive Congenital",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anomalies. J ObstetGynaecol Can. 2015 Jun;37",
    "brandName": "6",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anomalies. J ObstetGynaecol Can. 2015 Jun;37(6):534-52. https://www.ncbi.nlm.nih.gov/pubmed/26334606",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Valproic acid",
    "brandName": "caution in pregnancy: European Medicines Agency",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Valproic acid – caution in pregnancy: European Medicines Agency - Pharmacovigilance Risk Assessment Committee.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Assessment report EMA/198940/2018",
    "brandName": "valproate exposure in pregnancy, 8 February 2018. ",
    "strength": "198940",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Assessment report EMA/198940/2018 - valproate exposure in pregnancy, 8 February 2018. https://www.sahpra.org.za/6-",
    "commonDosage": "198940",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with epilepsy: a systematic review and meta",
    "brandName": "analysis of published pregnancy registries and coh",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008 Sep;81(1):1-",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous",
    "brandName": "Iron",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous (Iron) supplements, oral - intermittent dosing: National Department of Health: Affordable Medicines, EDP-Primary Health",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015 Oct 19;",
    "brandName": "10",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015 Oct 19;(10):CD009997.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "primary health care",
    "brandName": "PHC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "primary health care (PHC) level for reducing the risk of early onset pre-eclampsia in pregnant women with risk factors for the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "development of early onset pre",
    "brandName": "eclampsia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "development of early onset pre-eclampsia (e.g. pre-eclampsia in a previous pregnancy, chronic hypertension, diabetes, antiphospholipid",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Methyldopa, oral",
    "brandName": "dosing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Methyldopa, oral (dosing): Wright JM, Orozco-Gonzalez M, Polak G, Dollery CT. Duration of effect of single daily dose methyldopa",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy. Br J Clin Pharmacol. 1982 Jun;13",
    "brandName": "6",
    "strength": "1982 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy. Br J Clin Pharmacol. 1982 Jun;13(6):847-54. https://www.ncbi.nlm.nih.gov/pubmed/7093115",
    "commonDosage": "1982 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metabolism, and Blood Pressure Control Caused by Ferrous Sulphate and Ferrous Gluconate. ClinPharmacolTher, 1988, 43:381",
    "brandName": "6.",
    "strength": "1988",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Metabolism, and Blood Pressure Control Caused by Ferrous Sulphate and Ferrous Gluconate. ClinPharmacolTher, 1988, 43:381-6.",
    "commonDosage": "1988",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Magnesium sulfate, IV/IM",
    "brandName": "severe cases of preclampsia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Magnesium sulfate, IV/IM (severe cases of preclampsia): Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Ananth",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "International Journal of Women's Cardiovascular Health",
    "brandName": "2021",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "International Journal of Women's Cardiovascular Health (2021), doi: https://doi.org/10.1016/j.preghy.2021.09.008",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Magpie Trial Collaboration Group. Do women with pre",
    "brandName": "eclampsia, and their babies, benefit from magnesiu",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Trial: a randomised placebo",
    "brandName": "controlled trial. Lancet. 2002 Jun 1;359",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90. https://pubmed.ncbi.nlm.nih.gov/12057549/",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nifedipine, oral: Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta",
    "brandName": "analysis and trial",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Nifedipine, oral: Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "version. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "version. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lidocaine 1% without adrenaline",
    "brandName": "epinephrine",
    "strength": "1%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lidocaine 1% without adrenaline (epinephrine) - diluent:Kingston M, French P, Higgins S, McQuillanO,Sukthankar A, Stott C,",
    "commonDosage": "1%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "J STD AIDS. 2016 May;27",
    "brandName": "6",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "J STD AIDS. 2016 May;27(6):421-46. https://www.ncbi.nlm.nih.gov/pubmed/26721608",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "High",
    "brandName": "risk cases for preterm delivery: National Departme",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "High-risk cases for preterm delivery: National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "<36 weeks PTL",
    "brandName": "no tocylosis",
    "strength": "36 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "<36 weeks PTL (no tocylosis):  Department of Health, Republic of South Africa. 2015. Guidelines for Maternity care in South",
    "commonDosage": "36 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Betamethasone, IM: FIGO Working Group on Good Clinical Practice in Maternal",
    "brandName": "Fetal Medicine. Good clinical practice advice:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Betamethasone, IM: FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antenatal corticosteroids for fetal lung maturation. Int J Gynaecol Obstet. 2019 Mar;144",
    "brandName": "3",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antenatal corticosteroids for fetal lung maturation. Int J Gynaecol Obstet. 2019 Mar;144(3):352-355.",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Syst Rev. 2013 Dec 2;",
    "brandName": "12",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Syst Rev. 2013 Dec 2;(12):CD001058. https://pubmed.ncbi.nlm.nih.gov/24297389/",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotic therapy",
    "brandName": "PROM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotic therapy (PROM): Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Respiratory Diseases, Centers for Disease Control and Prevention",
    "brandName": "CDC",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 Nov 19;59",
    "brandName": "RR",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36. https://pubmed.ncbi.nlm.nih.gov/21088663/",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotic therapy",
    "brandName": "PROM",
    "strength": "217",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotic therapy (PROM):  ACOG. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217. Obstet Gynecol.",
    "commonDosage": "217",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2020 Mar;135",
    "brandName": "3",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2020 Mar;135(3):e80-e97. https://pubmed.ncbi.nlm.nih.gov/32080050/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for the management of preterm premature rupture of membranes. Am J Obstet Gynecol. 2019 Aug;221",
    "brandName": "2",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for the management of preterm premature rupture of membranes. Am J Obstet Gynecol. 2019 Aug;221(2):144.e1-144.e8.",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotic prophylaxis for term or near",
    "brandName": "term premature rupture of membranes: metaanalysis ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotic prophylaxis for term or near-term premature rupture of membranes: metaanalysis of randomized trials. Am J Obstet Gynecol.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2015 May;212",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2015 May;212(5):627.e1-9. https://pubmed.ncbi.nlm.nih.gov/25555659/",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dextrose, 10%, IV: National Department of Health: Integrated Management of Childhood Illness",
    "brandName": "IMCI",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dextrose, 10%, IV: National Department of Health: Integrated Management of Childhood Illness (IMCI) Guidelines, 2019",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midwife Obstetric Units in South Africa: Neonate care charts, March 2014. https://www.knowledgehub.org.za/e",
    "brandName": "library",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midwife Obstetric Units in South Africa: Neonate care charts, March 2014. https://www.knowledgehub.org.za/e-library",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hospital Level STGs and EML, 2023 draft version.  https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hospital Level STGs and EML, 2023 draft version.  https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "STGs and EML, 2023 draft version.  https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "STGs and EML, 2023 draft version.  https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "postpartum haemorrhage: a systematic review and  meta",
    "brandName": "analysis of maternal deaths and dose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "postpartum haemorrhage: a systematic review and  meta-analysis of maternal deaths and dose-related effects. Bull World Health",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Organ. 2009 Sep;87",
    "brandName": "9",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Organ. 2009 Sep;87(9):666-77. http://www.ncbi.nlm.nih.gov/pubmed/19784446",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxytocin IV:Gülmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, Abdel",
    "brandName": "Aleem H, Cheng L, Hofmeyr G,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxytocin IV:Gülmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, Abdel-Aleem H, Cheng L, Hofmeyr G,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lumbiganon P, Unger C, Prendiville W, Pinol A, Elbourne D, El",
    "brandName": "Refaey H, Schulz K; WHO Collaborative Group To Eva",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lumbiganon P, Unger C, Prendiville W, Pinol A, Elbourne D, El-Refaey H, Schulz K; WHO Collaborative Group To Evaluate Misoprostol",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of labour. Lancet. 2001 Sep 1;358",
    "brandName": "9283",
    "strength": "2001 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of labour. Lancet. 2001 Sep 1;358(9283):689-95. http://www.ncbi.nlm.nih.gov/pubmed/11551574",
    "commonDosage": "2001 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and Treatment of Postpartum Hemorrhage. New England Journal of Medicine. 2023 May 9;0",
    "brandName": "0",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and Treatment of Postpartum Hemorrhage. New England Journal of Medicine. 2023 May 9;0(0):null.",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Misoprostol: Widmer M, Blum J, HofmeyrGJ, Carroli G, Abdel",
    "brandName": "Aleem H, Lumbiganon P, Nguyen TN, Wojdyla D, Think",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Misoprostol: Widmer M, Blum J, HofmeyrGJ, Carroli G, Abdel-Aleem H, Lumbiganon P, Nguyen TN, Wojdyla D, Thinkhamrop J,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Singata M, Mignini LE, Abdel",
    "brandName": "Aleem MA, Tran ST, Winikoff B. Misoprostol as an a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Singata M, Mignini LE, Abdel-Aleem MA, Tran ST, Winikoff B. Misoprostol as an adjunct to standard uterotonics for treatment of post-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "partum haemorrhage: a multicentre, double",
    "brandName": "blind randomised trial. Lancet. 2010 May 22;375",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "partum haemorrhage: a multicentre, double-blind randomised trial. Lancet. 2010 May 22;375(9728):1808-13.",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "risk of birth defects. N Engl J Med. 2013 Aug 29;369",
    "brandName": "9",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "risk of birth defects. N Engl J Med. 2013 Aug 29;369(9):830-9. http://www.ncbi.nlm.nih.gov/pubmed/23984730",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016 Jan 5;315",
    "brandName": "1",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016 Jan 5;315(1):58-67.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Karstaedt AS, Maartens G, McCarthy KM, Rabie H, Variava E, Venter WDF",
    "brandName": "Expert panel members",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Karstaedt AS, Maartens G, McCarthy KM, Rabie H, Variava E, Venter WDF(Expert panel members), Boulware DR, Chiller T, Meya DB,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Scriven J",
    "brandName": "Reviewers",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Scriven J (Reviewers). Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "persons: 2013 update. S Afr J HIV Med 2013;14",
    "brandName": "2",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "persons: 2013 update. S Afr J HIV Med 2013;14(2):76-86. http://www.sajhivmed.org.za/index.php/hivmed/article/view/82/128",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluconazole, oral",
    "brandName": "breastfeeding",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fluconazole, oral (breastfeeding): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir",
    "brandName": "WOCP & pregnancy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir (WOCP & pregnancy): National Department of Health: Affordable Medicines, EDP-PHC/Adult Hospital level.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicine Review: Dolutegravir in pregnancy, Jun2 2021. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicine Review: Dolutegravir in pregnancy, Jun2 2021. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir",
    "brandName": "WOCP & pregnancy",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir (WOCP & pregnancy): South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for the",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children and Infants and Prevention of Mother",
    "brandName": "to",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children and Infants and Prevention of Mother-to-Child Transmission, June 2020. https://www.knowledgehub.org.za/elibrary/national-",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consolidated",
    "brandName": "guidelines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consolidated-guidelines-management-hiv-adults-adolescents-children-and-infants",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "48  Second line",
    "brandName": "NNRTI",
    "strength": "48  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "48  Second line (NNRTI-failure) and HbsAg positive: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service",
    "commonDosage": "48  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Second line",
    "brandName": "NNRTI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Second line (NNRTI-failure) and HbsAg positive: National Department of Health: National Consolidated Guidelines for the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management of HIV in Adults, Adolescents, Children and Infants and Prevention of Mother",
    "brandName": "to",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management of HIV in Adults, Adolescents, Children and Infants and Prevention of Mother-to-Child Transmission, June 2020.",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.knowledgehub.org.za/elibrary/national",
    "brandName": "consolidated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.knowledgehub.org.za/elibrary/national-consolidated-guidelines-management-hiv-adults-adolescents-children-and-infants",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ART in pregnancy",
    "brandName": "Previous PMTCT or ART loss to follow",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ART in pregnancy (Previous PMTCT or ART loss to follow-up): WHO. Consolidated guidelines on HIV prevention, testing,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for the Management of HIV in Adults, Adolescents, Children and Infants and Prevention of Mother",
    "brandName": "to",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for the Management of HIV in Adults, Adolescents, Children and Infants and Prevention of Mother-to-Child Transmission, June 2020.",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "AOSIS; 2020 Jul 8;21",
    "brandName": "1",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "AOSIS; 2020 Jul 8;21(1). Available from: http://dx.doi.org/10.4102/sajhivmed.v21i1.1079",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "53Antenatal care",
    "brandName": "actively support labour companionship",
    "strength": "53",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "53Antenatal care (actively support labour companionship): Bohren MA, Hofmeyr GJ, Sakala C, Fukuzawa RK, Cuthbert A.",
    "commonDosage": "53",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Continuous support for women during childbirth. Cochrane Database Syst Rev. 2017 Jul 6;7",
    "brandName": "7",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Continuous support for women during childbirth. Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD003766.",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breastfeeding practices",
    "brandName": "impacted by maternal health",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breastfeeding practices (impacted by maternal health): Coo S, García MI, Mira A, Valdés V. The Role of Perinatal Anxiety and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Depression in Breastfeeding Practices. Breastfeed Med. 2020 Aug;15",
    "brandName": "8",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Depression in Breastfeeding Practices. Breastfeed Med. 2020 Aug;15(8):495-500. https://pubmed.ncbi.nlm.nih.gov/32522015/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ferrous sulfate, oral: Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron",
    "brandName": "deficiency anaemia in pregnancy. Cochrane",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ferrous sulfate, oral: Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Database Syst Rev. 2011 Oct 5;",
    "brandName": "10",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Database Syst Rev. 2011 Oct 5;(10):CD003094. https://www.ncbi.nlm.nih.gov/pubmed/21975735",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "we giving too much iron? Low",
    "brandName": "dose iron therapy is effective in octogenarians. A",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005 Oct;118(10):1142-7.",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hormone therapy",
    "brandName": "HT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hormone therapy (HT): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "planning such as pre",
    "brandName": "conception care. Refer to the National",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "planning such as pre-conception care. Refer to the National",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contra",
    "brandName": "indications to using a particular method. Provide ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contra-indications to using a particular method. Provide counselling and always exclude",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Provides long",
    "brandName": "term protection, i.e.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Provides long-term protection, i.e.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "child",
    "brandName": "bearing age.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "child-bearing age.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "device",
    "brandName": "LNG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "device (LNG-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LNG",
    "brandName": "IUD  must be inserted",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LNG-IUD  must be inserted",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "progestin",
    "brandName": "only",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "progestin-only",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 years",
    "brandName": "etonogestrel",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 years (etonogestrel) or 5 years",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Long",
    "brandName": "acting, i.e. given every 8 or",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Long-acting, i.e. given every 8 or",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "irregularities",
    "brandName": "irregular,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "irregularities (irregular,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bleeding, or amenorrhoea",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bleeding, or amenorrhoea).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sterilisation: female",
    "brandName": "tubal ligation",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sterilisation: female - tubal ligation",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "breastfeeding",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "breastfeeding)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The copper IUCD",
    "brandName": "also known as the Copper T",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The copper IUCD (also known as the Copper T)  is a long-term contraceptive method that",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "IUCDs are often the most suitable contraceptive for women on enzyme",
    "brandName": "inducing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "IUCDs are often the most suitable contraceptive for women on enzyme-inducing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "been excluded",
    "brandName": "by clinical history or with a pregnancy test if re",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "been excluded (by clinical history or with a pregnancy test if required). Insertion at",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "choice termination of pregnancy",
    "brandName": "CTOP",
    "strength": "48 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "choice termination of pregnancy (CTOP) within 48 hours, by specially trained healthcare",
    "commonDosage": "48 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "membranes for more than 18 hours, or postpartum haemorrhage",
    "brandName": ".",
    "strength": "18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "membranes for more than 18 hours, or postpartum haemorrhage).",
    "commonDosage": "18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Complications",
    "brandName": "excessive bleeding, excessive pain, fever, or foul",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Complications (excessive bleeding, excessive pain, fever, or foul-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "smelling discharge",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "smelling discharge).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "inflammatory disease",
    "brandName": "PID",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "inflammatory disease (PID), purulent cervicitis, unexplained uterine bleeding, cervical and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Signs of infection within 7 days of insertion",
    "brandName": "e.g. fever, abdominal pain and/or foul",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Signs of infection within 7 days of insertion (e.g. fever, abdominal pain and/or foul-",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The subdermal implant is an effective, safe, reversible, and convenient long",
    "brandName": "term",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The subdermal implant is an effective, safe, reversible, and convenient long-term",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Etonogestrel, subdermal, 68 mg, single",
    "brandName": "rod implant.",
    "strength": "68 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Etonogestrel, subdermal, 68 mg, single-rod implant.",
    "commonDosage": "68 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The progestin",
    "brandName": "only subdermal implant can be inserted at any time",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The progestin-only subdermal implant can be inserted at any time during the menstrual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Women receiving any of the above listed hepatic enzyme",
    "brandName": "inducing medicines should be",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Women receiving any of the above listed hepatic enzyme-inducing medicines should be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "continue using the subdermal implant, women should be advised to also use a non",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "continue using the subdermal implant, women should be advised to also use a non-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hormonal contraceptive method during the time of concomitant use",
    "brandName": "the subdermal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hormonal contraceptive method during the time of concomitant use (the subdermal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "implant is not contra",
    "brandName": "indicated when using the above medicines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "implant is not contra-indicated when using the above medicines). Dolutegravir, however,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Training on the techniques for insertion and removal of the sub",
    "brandName": "dermal implant is",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Training on the techniques for insertion and removal of the sub-dermal implant is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epicondyle of the humerus and 3 to 5 cm posterior to the sulcus",
    "brandName": "groove between the",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epicondyle of the humerus and 3 to 5 cm posterior to the sulcus (groove between the",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "biceps and triceps muscles",
    "brandName": ". This location is intended to avoid large blood v",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "biceps and triceps muscles). This location is intended to avoid large blood vessels",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "implant in this location",
    "brandName": "e.g. in women with thin arms",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "implant in this location (e.g. in women with thin arms), it should be inserted as far",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mark. This second mark",
    "brandName": "guiding mark",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mark. This second mark (guiding mark) will later serve as a direction guide during",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Use the scalpel to make a small incision",
    "brandName": "about 2 mm",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Use the scalpel to make a small incision (about 2 mm) just through the dermis of the",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "implants. If an implant is contaminated",
    "brandName": "e.g. falls on the ﬂoor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "implants. If an implant is contaminated (e.g. falls on the ﬂoor), leave it for later disposal,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "plane horizontally by pointing it slightly upwards and raising the skin",
    "brandName": "tenting",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "plane horizontally by pointing it slightly upwards and raising the skin (tenting). Failure",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the first implant with the left fore",
    "brandName": "ﬁnger and advance the trocar along the side of the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the first implant with the left fore-ﬁnger and advance the trocar along the side of the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Removal of progestin",
    "brandName": "only subdermal implants:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Removal of progestin-only subdermal implants:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Locate the implant/s by palpation. If impalpable, refer for ultrasound",
    "brandName": "guided removal.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Locate the implant/s by palpation. If impalpable, refer for ultrasound-guided removal.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Mark the distal end",
    "brandName": "end closest to the elbow",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Mark the distal end (end closest to the elbow) with a surgical marker.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Make a longitudinal",
    "brandName": "parallel to the implant",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Make a longitudinal (parallel to the implant) incision of approximately 2 mm towards",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Very gently remove the implant, using a small forceps",
    "brandName": "preferably curved mosquito",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Very gently remove the implant, using a small forceps (preferably curved mosquito",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LEVONORGESTREL INTRA",
    "brandName": "UTERINE DEVICE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LEVONORGESTREL INTRA-UTERINE DEVICE (LNG-IUD)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The LNG",
    "brandName": "IUD is an effective, safe, reversible, long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The LNG-IUD is an effective, safe, reversible, long-term contraceptive method that has",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV infection is NOT a contra",
    "brandName": "indication to the use of an LNG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV infection is NOT a contra-indication to the use of an LNG-IUD.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LNG",
    "brandName": "IUD may be inserted immediately postpartum or post",
    "strength": "48 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LNG-IUD may be inserted immediately postpartum or post miscarriage (within 48 hours),",
    "commonDosage": "48 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for more than 18 hours or postpartum haemorrhage",
    "brandName": ". Providers require specific training",
    "strength": "18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for more than 18 hours or postpartum haemorrhage). Providers require specific training",
    "commonDosage": "18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LNG",
    "brandName": "IUD may also be inserted 4 or more weeks postpartu",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LNG-IUD may also be inserted 4 or more weeks postpartum.",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Expulsion of LNG",
    "brandName": "IUD or if strings of the LNG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Expulsion of LNG-IUD or if strings of the LNG-IUD protrude.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "uterine bleeding, cervical",
    "brandName": "breast",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "uterine bleeding, cervical- breast- ovarian- or endometrial cancers, or other uterine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medroxyprogesterone",
    "brandName": "long",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medroxyprogesterone (long-acting), IM, 150 mg, 12 weekly.",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medroxyprogesterone",
    "brandName": "long",
    "strength": "104 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medroxyprogesterone (long-acting), SC, 104 mg, 12 weekly.",
    "commonDosage": "104 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Using the Progestin",
    "brandName": "only IM Injection",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Using the Progestin-only IM Injection",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "acetate DMPA",
    "brandName": "long",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "acetate DMPA (long-acting), or 2 weeks late if using norethisterone enanthate",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Assess the need for emergency contraception in the event of a late injection",
    "brandName": "See Section",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Assess the need for emergency contraception in the event of a late injection (See Section",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7.4: Contraception, Emergency",
    "brandName": ".",
    "strength": "7.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7.4: Contraception, Emergency).",
    "commonDosage": "7.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "May be administered by a healthcare professional",
    "brandName": "HCP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "May be administered by a healthcare professional (HCP) or with adequate training when",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The second and subsequent injections should be given at a 3 month interval",
    "brandName": "12",
    "strength": "3 ",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The second and subsequent injections should be given at a 3 month interval (12 -14",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Can be started immediately postpartum in both breastfeeding and non",
    "brandName": "breastfeeding",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Can be started immediately postpartum in both breastfeeding and non-breastfeeding",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medroxyprogesterone acetate",
    "brandName": "IM or SC",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medroxyprogesterone acetate (IM or SC) is extended beyond 2 years. All",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A small increased risk of meningiomas",
    "brandName": "rare, and mostly benign tumours",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A small increased risk of meningiomas (rare, and mostly benign tumours)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "have been reported following long",
    "brandName": "term administration of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "have been reported following long-term administration of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medroxyprogesterone acetate",
    "brandName": "long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medroxyprogesterone acetate (long-acting).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medroxyprogesterone",
    "brandName": "long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medroxyprogesterone (long-acting) should be discontinued if a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Caution is advised when recommending medroxyprogesterone",
    "brandName": "long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Caution is advised when recommending medroxyprogesterone (long-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "acting",
    "brandName": "to patients with a history of meningioma.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "acting) to patients with a history of meningioma.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraceptives",
    "brandName": "see Section 7.6: Breakthrough bleeding with contra",
    "strength": "7.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraceptives (see Section 7.6: Breakthrough bleeding with contraceptive use).",
    "commonDosage": "7.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "regard",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "regard).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enzyme",
    "brandName": "inducing medicines interacting with oral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Enzyme-inducing medicines interacting with oral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "seizures. Change to IUCD or progesterone only methods",
    "brandName": "i.e levonorgestrel implant,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "seizures. Change to IUCD or progesterone only methods (i.e levonorgestrel implant,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "etonogestrel implant, or LNG",
    "brandName": "IUD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "etonogestrel implant, or LNG-IUD), if lamotrigine is going to be used long term.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Give emergency contraception",
    "brandName": "see Section 7.4",
    "strength": "7.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Give emergency contraception (see Section 7.4).",
    "commonDosage": "7.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "should be used in combination with other contraceptive methods",
    "brandName": "e.g. copper IUCD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "should be used in combination with other contraceptive methods (e.g. copper IUCD).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Forgotten tablets",
    "brandName": "see Section 7.2.5: Missed pills",
    "strength": "7.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Forgotten tablets (see Section 7.2.5: Missed pills).",
    "commonDosage": "7.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Injectable contraception given late",
    "brandName": ">2 weeks for NET",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Injectable contraception given late (>2 weeks for NET-EN, >4 weeks for DMPA).",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consider a longer",
    "brandName": "acting and more effective family planning method.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consider a longer-acting and more effective family planning method.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "+ 150 μg levonorgestrel",
    "brandName": "e.g. Nordette®/Oralcon®",
    "strength": "150 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "+ 150 μg levonorgestrel (e.g. Nordette®/Oralcon®):",
    "commonDosage": "150 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enzyme inhibitors",
    "brandName": "ketoconazole, fluconazole",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Enzyme inhibitors (ketoconazole, fluconazole) significantly increase the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "testing and PEP",
    "brandName": "see Section 21.3.6.2: Post exposure prophylaxis, r",
    "strength": "21.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "testing and PEP (see Section 21.3.6.2: Post exposure prophylaxis, rape and sexual",
    "commonDosage": "21.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sterilisation does not protect against sexually transmitted infections",
    "brandName": "STIs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sterilisation does not protect against sexually transmitted infections (STIs), including",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Risk of sexual transmitted infections",
    "brandName": "e.g. Chlamydia trachomatis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Risk of sexual transmitted infections (e.g. Chlamydia trachomatis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer",
    "brandName": "see Section 7.2.2: Levonorgestrel intra",
    "strength": "7.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer – see Section 7.2.2: Levonorgestrel intra-",
    "commonDosage": "7.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "uterine device",
    "brandName": "LNG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "uterine device (LNG-IUD)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Abnormal cervix on speculum examination",
    "brandName": "e.g. polyps",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Abnormal cervix on speculum examination (e.g. polyps).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Family Planning: A Global Handbook for Providers",
    "brandName": "2022 update",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Family Planning: A Global Handbook for Providers (2022 update). Baltimore and Geneva: CCP and WHO, 2022.",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NDoH.National Contraception Clinical Guidelines.2019. https://knowledgehub.health.gov.za/elibrary/national",
    "brandName": "contraception",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NDoH.National Contraception Clinical Guidelines.2019. https://knowledgehub.health.gov.za/elibrary/national-contraception-clinical-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidelines",
    "brandName": "2019",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidelines-2019",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel IUD",
    "brandName": "advantages",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel IUD (advantages – immediate postpartum insertion): Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "early vs. delayed postpartum insertion of the LNG",
    "brandName": "IUS on breastfeeding continuation: a systematic re",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "early vs. delayed postpartum insertion of the LNG-IUS on breastfeeding continuation: a systematic review and meta-analysis of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Research",
    "brandName": "WHO/RHR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for Health Project. Family Planning: A Global Handbook for Providers",
    "brandName": "2018 update",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO, 2018.",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.who.int/reproductivehealth/publications/fp",
    "brandName": "global",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.who.int/reproductivehealth/publications/fp-global-handbook/en/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hormonal injectable: progestin",
    "brandName": "only",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hormonal injectable: progestin-only (menstrual irregularities): South African Medicines Formulary, 14th Edition.  Division of Clinical",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hormonal injectable: progestin",
    "brandName": "only",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hormonal injectable: progestin-only (menstrual irregularities): Faculty of Sexual &",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.fsrh.org/standards",
    "brandName": "and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.fsrh.org/standards-and-guidance/fsrh-guidelines-and-statements/management-of-srh-issues/problematic-bleeding/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraceptive use, Fifth edition, 2015. http://www.who.int/reproductivehealth/publications/family_planning/MEC",
    "brandName": "5/en/",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraceptive use, Fifth edition, 2015. http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5 World Health Organization Department of Sexual and Reproductive Health and Research",
    "brandName": "WHO/SRH",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5 World Health Organization Department of Sexual and Reproductive Health and Research (WHO/SRH) and Johns Hopkins Bloomberg",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "School of Public Health/ Center for Communication Programs",
    "brandName": "CCP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "School of Public Health/ Center for Communication Programs (CCP), Knowledge SUCCESS. Family Planning: A Global Handbook for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Providers",
    "brandName": "2022 update",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Providers (2022 update). Baltimore and Geneva: CCP and WHO; 2022.",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Copper IUCD",
    "brandName": "patient to return",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Copper IUCD (patient to return): National Contraception and Fertility Planning and Service Delivery Guidelines, 2019 (Draft",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "8     Stalter RM, Amorim G, Mocello AR, Jakait B, Shepherd BE, Musick B, Bernard C, Bukusi EA, Wools",
    "brandName": "Kaloustian K, Cohen CR,",
    "strength": "8     ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "8     Stalter RM, Amorim G, Mocello AR, Jakait B, Shepherd BE, Musick B, Bernard C, Bukusi EA, Wools-Kaloustian K, Cohen CR,",
    "commonDosage": "8     ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Todd CS, Lorenzetti L, Mussa A, Ridgeway K, Morroni C, Nanda K. Drug",
    "brandName": "drug interactions between antiretrovirals and horm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Todd CS, Lorenzetti L, Mussa A, Ridgeway K, Morroni C, Nanda K. Drug-drug interactions between antiretrovirals and hormonal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Westhoff CL, Morroni C. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Westhoff CL, Morroni C. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levnorgestrel IUD: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Primary Healthcare level. Medicine Review:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levnorgestrel IUD: National Department of Health: Affordable Medicines, EDP- Primary Healthcare level. Medicine Review:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel",
    "brandName": "releasing intrauterine system for contraception, A",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel-releasing intrauterine system for contraception, April 2013. https://www.knowledgehub.org.za/e-library",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel IUD: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Primary Healthcare level. Medicine Review: Low",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel IUD: National Department of Health: Affordable Medicines, EDP- Primary Healthcare level. Medicine Review: Low-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dose levonorgestrel",
    "brandName": "releasing intrauterine system for contraception, A",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dose levonorgestrel-releasing intrauterine system for contraception, August 2020. https://www.knowledgehub.org.za/content/standard-",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and Research",
    "brandName": "WHO/RHR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Knowledge for Health Project. Family Planning: A Global Handbook for Providers",
    "brandName": "2018 update",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WHO, 2018. https://www.who.int/reproductivehealth/publications/fp",
    "brandName": "global",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WHO, 2018. https://www.who.int/reproductivehealth/publications/fp-global-handbook/en/",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in South Africa: A randomized controlled trial. PLoS Med. 2020 May 22;17",
    "brandName": "5",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in South Africa: A randomized controlled trial. PLoS Med. 2020 May 22;17(5):e1003110. https://pubmed.ncbi.nlm.nih.gov/32442189/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel IUD",
    "brandName": "HIV",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel IUD (HIV-infected): World Health Organization. Medical eligibility criteria for contraceptive use, Fifth edition (2015).",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Project. Family Planning: A Global Handbook for Providers",
    "brandName": "2018 update",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO, 2018.",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel IUD",
    "brandName": "referral for first time migrane/ severe headache",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel IUD (referral for first time migrane/ severe headache): South African Medicines Formulary, 14th Edition.  Division of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medroxyprogesterone versus norethisteroneoenanthate for long",
    "brandName": "acting progestogenic contraception. Cochrane Datab",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medroxyprogesterone versus norethisteroneoenanthate for long-acting progestogenic contraception. Cochrane Database Syst Rev.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2006 Jul 19;",
    "brandName": "3",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2006 Jul 19;(3):CD005214. http://www.ncbi.nlm.nih.gov/pubmed/16856087",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Progestin",
    "brandName": "only injectables",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Progestin-only injectables (postpartum): National Contraception and Fertility Planning and Service Delivery Guidelines, 2019 (Draft",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraception: what should the longest interval be for reinjections? Contraception. 2008 Jun;77",
    "brandName": "6",
    "strength": "2008 ",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraception: what should the longest interval be for reinjections? Contraception. 2008 Jun;77(6):410-4. doi:",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://fphandbook.org/sites/default/files/WHO",
    "brandName": "JHU",
    "strength": "2022",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://fphandbook.org/sites/default/files/WHO-JHU-FPHandbook-2022Ed-v221115a.pdf",
    "commonDosage": "2022",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "meningioma: national case",
    "brandName": "control study. BMJ. 2024 Mar 27;384:e078078. doi: ",
    "strength": "2024 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "meningioma: national case-control study. BMJ. 2024 Mar 27;384:e078078. doi: 10.1136/bmj-2023-078078. Erratum in: BMJ. 2024 Mar",
    "commonDosage": "2024 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Monophasic",
    "brandName": "progestin only pills",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Monophasic-progestin only pills (therapeutic class): van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "MEGA case",
    "brandName": "control study. BMJ. 2009 Aug 13;339:b2921. https:/",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "MEGA case-control study. BMJ. 2009 Aug 13;339:b2921. https://www.ncbi.nlm.nih.gov/pubmed/19679614",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "study, 2001",
    "brandName": "9. BMJ. 2011 Oct 25;343:d6423. https://www.ncbi.nl",
    "strength": "2001",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "study, 2001-9. BMJ. 2011 Oct 25;343:d6423. https://www.ncbi.nlm.nih.gov/pubmed/22027398",
    "commonDosage": "2001",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of the MEGA case",
    "brandName": "control study. BMJ. 2009 Aug 13;339:b2921. https:/",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of the MEGA case-control study. BMJ. 2009 Aug 13;339:b2921. https://www.ncbi.nlm.nih.gov/pubmed/19679614",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "doses: Danish cohort study, 2001",
    "brandName": "9. BMJ. 2011 Oct 25;343:d6423. https://www.ncbi.nl",
    "strength": "2001",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "doses: Danish cohort study, 2001-9. BMJ. 2011 Oct 25;343:d6423. https://www.ncbi.nlm.nih.gov/pubmed/22027398",
    "commonDosage": "2001",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Triphasic",
    "brandName": "progestin/estrogen combination pills",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Triphasic- progestin/estrogen combination pills (therapeutic class): van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Progestin",
    "brandName": "only pill",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Progestin-only pill (contra-indication: myocardial infarction): South African Medicines Formulary, 14th Edition.  Division of Clinical",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Combined oral contraceptives",
    "brandName": "missing pills",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Combined oral contraceptives (missing pills): National Contraception and Fertility Planning and Service Delivery Guidelines, 2019",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "26Copper IUD",
    "brandName": "emergency contraception",
    "strength": "26",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "26Copper IUD (emergency contraception): Turok DK, Jacobson JC, Dermish AI, Simonsen SE, Gurtcheff S, McFadden M, Murphy",
    "commonDosage": "26",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PA. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1",
    "brandName": "year pregnancy rates.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PA. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Contraception. 2014 Mar;89",
    "brandName": "3",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Contraception. 2014 Mar;89(3):222-8. https://pubmed.ncbi.nlm.nih.gov/24332433/",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Copper IUD",
    "brandName": "emergency contraception",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Copper IUD (emergency contraception): FSRH Guideline (April 2019) Overweight, Obesity and Contraception. BMJ Sex Reprod",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health. 2019 Apr;45",
    "brandName": "Suppl 2",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Health. 2019 Apr;45(Suppl 2):1-69. https://pubmed.ncbi.nlm.nih.gov/31053605/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "27Levonorgestrel 1.5 mg oral",
    "brandName": "emergency contraception",
    "strength": "27",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "27Levonorgestrel 1.5 mg oral (emergency contraception): Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for",
    "commonDosage": "27",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "emergency contraception. Cochrane Database Syst Rev. 2019 Jan 20;1",
    "brandName": "1",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "emergency contraception. Cochrane Database Syst Rev. 2019 Jan 20;1(1):CD001324.",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "28Levonorgesterol, oral",
    "brandName": "emergency contraception",
    "strength": "28",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "28Levonorgesterol, oral - emergency contraception (double dose): FSRH Guideline (April 2019) Overweight, Obesity and",
    "commonDosage": "28",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Contraception. BMJ Sex Reprod Health. 2019 Apr;45",
    "brandName": "Suppl 2",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Contraception. BMJ Sex Reprod Health. 2019 Apr;45(Suppl 2):1-69. https://pubmed.ncbi.nlm.nih.gov/31053605/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgesterol, oral",
    "brandName": "emergency contraception",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgesterol, oral - emergency contraception (double dose): Turok DK, Jacobson JC, Dermish AI, Simonsen SE, Gurtcheff S,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "McFadden M, Murphy PA. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1",
    "brandName": "year",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "McFadden M, Murphy PA. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy rates. Contraception. 2014 Mar;89",
    "brandName": "3",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy rates. Contraception. 2014 Mar;89(3):222-8. https://pubmed.ncbi.nlm.nih.gov/24332433/",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of obesity on the pharmacokinetics of levonorgestrel",
    "brandName": "based emergency contraception: single and double d",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception. 2016",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jul;94",
    "brandName": "1",
    "strength": "94",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jul;94(1):52-7. https://pubmed.ncbi.nlm.nih.gov/27000996/",
    "commonDosage": "94",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DF et al. Double Dosing Levonorgestrel",
    "brandName": "Based Emergency Contraception for Individuals With",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "DF et al. Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity, Obstetrics & Gynecology: June",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "9, 2022",
    "brandName": "Volume",
    "strength": "9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "9, 2022 - Volume - Issue - 10.1097/AOG.0000000000004717 doi: 10.1097/AOG.0000000000004717",
    "commonDosage": "9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "emergency contraceptive pills among women with obesity: a systematic review. Contraception 94",
    "brandName": "2016",
    "strength": "94 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "emergency contraceptive pills among women with obesity: a systematic review. Contraception 94 (2016) 605–611.",
    "commonDosage": "94 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel",
    "brandName": "Plan B",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. ClinPharmacokinet. 2015 Jan;54",
    "brandName": "1",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. ClinPharmacokinet. 2015 Jan;54(1):23-34.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levonorgestrel",
    "brandName": "https://go.drugbank.com/drugs/DB00367",
    "strength": "00367",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levonorgestrel- https://go.drugbank.com/drugs/DB00367",
    "commonDosage": "00367",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "http://www.who.int/reproductivehealth/publications/family_planning/MEC",
    "brandName": "5/en/",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Combined oral contraceptive",
    "brandName": "containing ethinylestradiol 30",
    "strength": "30",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Combined oral contraceptive (containing ethinylestradiol 30-35 mcg) for breakthrough bleeding on progestin-only injectable",
    "commonDosage": "30",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clinical Effectiveness Unit, July 2015. https://www.fsrh.org/standards",
    "brandName": "and",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clinical Effectiveness Unit, July 2015. https://www.fsrh.org/standards-and-guidance/fsrh-guidelines-and-statements/management-of-srh-",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "issues/problematic",
    "brandName": "bleeding/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "issues/problematic-bleeding/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "glomerular filtration rate",
    "brandName": "eGFR",
    "strength": "60 ml",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "glomerular filtration rate (eGFR) falls <60 ml/min/1.73m2, and especially when eGFR<15",
    "commonDosage": "60 ml",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "be found in the South African Medicines formulary",
    "brandName": "SAMF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "be found in the South African Medicines formulary (SAMF), package insert, and from",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "decreased glomerular filtration rate",
    "brandName": "eGFR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "decreased glomerular filtration rate (eGFR).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use eGFR and albumin: creatinine ratio to put patient into prognostic category",
    "brandName": "see Table",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use eGFR and albumin: creatinine ratio to put patient into prognostic category - see Table",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The calculation eGFR using the CKD",
    "brandName": "EPI equation is currently the formula of choice fo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The calculation eGFR using the CKD-EPI equation is currently the formula of choice for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Adults with mild to moderate decline in eGFR",
    "brandName": "G3a",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Adults with mild to moderate decline in eGFR (G3a) and no albuminuria can be",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eGFR categories",
    "brandName": "ml/min per 1.73m2",
    "strength": "1.73",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eGFR categories (ml/min per 1.73m2)",
    "commonDosage": "1.73",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Green: low risk",
    "brandName": "if no other markers of kidney disease, no CKD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Green: low risk (if no other markers of kidney disease, no CKD); yellow: moderately increased risk; orange: high risk; red: very high",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Send blood annually for measurement of creatinine in all patients at increased risk",
    "brandName": "eGFR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Send blood annually for measurement of creatinine in all patients at increased risk (eGFR",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Limit total daily salt intake",
    "brandName": "including salt in food",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Limit total daily salt intake (including salt in food). Consult with dietician as required.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "urine protein",
    "brandName": "creatinine ratio. Significant proteinuria = spot u",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "urine protein-creatinine ratio. Significant proteinuria = spot urine protein-creatinine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ratio",
    "brandName": "PCR",
    "strength": "0.15 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ratio (PCR) of > 0.15 g/mmol. This is equivalent to 1 g per 24 hours.",
    "commonDosage": "0.15 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ACE",
    "brandName": "inhibitors can be used in renal impairment",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ACE-inhibitors can be used in renal impairment (eGFR < 30 mL/min/1.73m2) if potassium",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If hyperlipidaemia is a co",
    "brandName": "existent risk factor, manage according to Section ",
    "strength": "4.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If hyperlipidaemia is a co-existent risk factor, manage according to Section 4.1: Prevention",
    "commonDosage": "4.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Target BP: Systolic < 140 mmHg and diastolic < 90 mmHg",
    "brandName": "See Sections 4.7",
    "strength": "140 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Target BP: Systolic < 140 mmHg and diastolic < 90 mmHg (See Sections 4.7",
    "commonDosage": "140 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not give IV fluids",
    "brandName": "use heparin lock or similar IV access.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not give IV fluids – use heparin lock or similar IV access.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All cases of suspected chronic kidney disease stages 3",
    "brandName": "5 for assessment and",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All cases of suspected chronic kidney disease stages 3–5 for assessment and",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» In addition, patients with chronic kidney disease stages 3",
    "brandName": "5 may also require",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» In addition, patients with chronic kidney disease stages 3–5 may also require",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "significant proteinuria with urine protein",
    "brandName": "creatinine ratio > 0.1 g/mmol.",
    "strength": "0.1 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "significant proteinuria with urine protein-creatinine ratio > 0.1 g/mmol.",
    "commonDosage": "0.1 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» fluid overload",
    "brandName": "e.g. pulmonary oedema",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» fluid overload (e.g. pulmonary oedema),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Give oxygen, and nurse in Semi",
    "brandName": "Fowlers position if patient has respiratory distre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Give oxygen, and nurse in Semi-Fowlers position if patient has respiratory distress.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Currently, the most reliable measure of eGFR is CKD",
    "brandName": "EPI in adults and Schwartz",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Currently, the most reliable measure of eGFR is CKD-EPI in adults and Schwartz",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» In acute kidney injury",
    "brandName": "AKI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» In acute kidney injury (AKI) the once-off eGFR is not reliable as kidney function",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If fluid overloaded",
    "brandName": "rapid respiration, chest indrawing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If fluid overloaded (rapid respiration, chest indrawing):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nifedipine, oral, 0.25",
    "brandName": "0.5 mg/kg squirted into mouth.",
    "strength": "0.25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nifedipine, oral, 0.25–0.5 mg/kg squirted into mouth.",
    "commonDosage": "0.25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If blood pressure is elevated hypertension is present",
    "brandName": "Diastolic BP > 100 mmHg or systolic",
    "strength": "100 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "If blood pressure is elevated hypertension is present (Diastolic BP > 100 mmHg or systolic",
    "commonDosage": "100 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BP > 150 mmHg",
    "brandName": ":",
    "strength": "150 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BP > 150 mmHg):",
    "commonDosage": "150 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amlodipine, oral, 5 mg as a pre",
    "brandName": "referral dose.",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Amlodipine, oral, 5 mg as a pre-referral dose.",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Furosemide, oral, 40",
    "brandName": "80 mg as a pre",
    "strength": "40",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Furosemide, oral, 40–80 mg as a pre-referral dose.",
    "commonDosage": "40",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» adults: ≥ 2.5 g/day, as determined by a spot urine protein",
    "brandName": "creatinine ratio",
    "strength": "2.5 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» adults: ≥ 2.5 g/day, as determined by a spot urine protein-creatinine ratio",
    "commonDosage": "2.5 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Signs and symptoms are related to the age of the child and are often non",
    "brandName": "specific.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Signs and symptoms are related to the age of the child and are often non-specific.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin/clavulanic acid oral, 15",
    "brandName": "25 mg/kg/dose of amoxicillin component, 8 hourly",
    "strength": "15",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin/clavulanic acid oral, 15–25 mg/kg/dose of amoxicillin component, 8 hourly",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">14",
    "brandName": "17.5 kg",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">14–17.5 kg",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of the manifestations requiring referral",
    "brandName": "see referral criteria below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of the manifestations requiring referral (see referral criteria below). All other patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ciprofloxacin, oral, 500 mg 12 hourly for 7",
    "brandName": "10 days.",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Ciprofloxacin, oral, 500 mg 12 hourly for 7–10 days.",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o It is essential to give at least a 7",
    "brandName": "day course of therapy.",
    "strength": "7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o It is essential to give at least a 7-day course of therapy.",
    "commonDosage": "7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The condition may be chronic, bacterial or non",
    "brandName": "bacterial, the latter usually being assessed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The condition may be chronic, bacterial or non-bacterial, the latter usually being assessed",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If there are features of associated urethritis",
    "brandName": "STI regimen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If there are features of associated urethritis (STI regimen):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BPH is a noncancerous",
    "brandName": "benign",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BPH is a noncancerous (benign) growth of the prostate gland.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and irritative",
    "brandName": "frequency, nocturia and urgency",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and irritative (frequency, nocturia and urgency) voiding symptoms.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Annual follow",
    "brandName": "up with digital rectal examination.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Annual follow-up with digital rectal examination.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Organic causes include neurogenic, vasculogenic, endocrinological",
    "brandName": "e.g. diabetes",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Organic causes include neurogenic, vasculogenic, endocrinological (e.g. diabetes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Consider the removal of medicines",
    "brandName": "e.g. beta",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Consider the removal of medicines (e.g. beta-blockers) possibly associated with the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bladder as a result of urine which is supersaturated with respect to a stone",
    "brandName": "forming salt.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bladder as a result of urine which is supersaturated with respect to a stone-forming salt.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IM, 0.1 mg/kg 30 minutes, to a maximum of 10 mg",
    "brandName": "doctor initiated",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IM, 0.1 mg/kg 30 minutes, to a maximum of 10 mg (doctor initiated).",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pregnant woman",
    "brandName": "refer postpartum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pregnant woman (refer postpartum).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Patients with inherited metabolic disorders of kidney function.",
    "brandName": "e.g. Fanconi syndrome,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Patients with inherited metabolic disorders of kidney function.(e.g. Fanconi syndrome,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and inherited conditions resulting in renal tubular acidosis or nephrolithiasis.",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and inherited conditions resulting in renal tubular acidosis or nephrolithiasis.)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "limit future episodes",
    "brandName": "to a nephrologist is indicated as follows:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "limit future episodes) to a nephrologist is indicated as follows:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "New Creatinine",
    "brandName": "and Cystatin C",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.N Engl J Med. 2021 November 4, 385 (19):1737-",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 Kidney Disease: Improving Global Outcomes",
    "brandName": "KDIGO",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105",
    "brandName": "4S",
    "strength": "2024 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi:",
    "commonDosage": "2024 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2024 Aug 1]. Available from: https://heartfoundation.co.za/topical_articles/5",
    "brandName": "ways",
    "strength": "2024 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2024 Aug 1]. Available from: https://heartfoundation.co.za/topical_articles/5-ways-to-5-grams/",
    "commonDosage": "2024 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Why should I limit the salt in my food?",
    "brandName": "MyDynamics [Internet]. MyDynamics. 2021 [cited 202",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Why should I limit the salt in my food? - MyDynamics [Internet]. MyDynamics. 2021 [cited 2024 Aug 1]. Available from:",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "systematic review. J Physiother. 2017 Apr;63",
    "brandName": "2",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "systematic review. J Physiother. 2017 Apr;63(2):76-83. https://pubmed.ncbi.nlm.nih.gov/28433237/",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Systematic Review. Worldviews Evid Based Nurs. 2021 Feb;18",
    "brandName": "1",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Systematic Review. Worldviews Evid Based Nurs. 2021 Feb;18(1):33-41. https://pubmed.ncbi.nlm.nih.gov/33247619/",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disease. Cochrane Database Syst Rev. 2019 May 26;5",
    "brandName": "5",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disease. Cochrane Database Syst Rev. 2019 May 26;5(5):CD012625. https://pubmed.ncbi.nlm.nih.gov/31129916/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Furosemide, oral",
    "brandName": "eGFR cut",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Furosemide, oral (eGFR cut-off): Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidance, and a framework for moving forward. Kidney Int. 2014 Jan;85",
    "brandName": "1",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidance, and a framework for moving forward. Kidney Int. 2014 Jan;85(1):49-61. https://www.ncbi.nlm.nih.gov/pubmed/24284513",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Furosemide, oral",
    "brandName": "eGFR cut",
    "strength": "14",
    "form": "tablet",
    "category": "Cardiovascular",
    "schedule": "Schedule 2",
    "description": "Furosemide, oral (eGFR cut-off): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suppl:64",
    "brandName": "70. https://pubmed.ncbi.nlm.nih.gov/22018988/",
    "strength": "64",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suppl:64-70. https://pubmed.ncbi.nlm.nih.gov/22018988/",
    "commonDosage": "64",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gentamicin, parenteral: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Adult Hospital level. Medicine Review:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gentamicin, parenteral: National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gentamicin for uncomplicated UTI, November 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gentamicin for uncomplicated UTI, November 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gentamicin, parenteral: Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single",
    "brandName": "Dose Aminoglycoside Therapy for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gentamicin, parenteral: Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother. 2018 Dec 21;63",
    "brandName": "1",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02165-18.",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antimicrobials for uncomplicated UTI in adults, October 2020. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antimicrobials for uncomplicated UTI in adults, October 2020. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gentamicin dosing for uncomplicated UTI in adults, October 2020. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gentamicin dosing for uncomplicated UTI in adults, October 2020. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2010 Sep;65",
    "brandName": "9",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2010 Sep;65(9):1862-77. http://www.ncbi.nlm.nih.gov/pubmed/20587612",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "FP, Perovic O. Antimicrobial susceptibility of organisms causing community",
    "brandName": "acquired urinary tract infections in Gauteng Provi",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "FP, Perovic O. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Africa. S Afr Med J. 2013 Mar 15;103",
    "brandName": "6",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Africa. S Afr Med J. 2013 Mar 15;103(6):377-81. http://www.ncbi.nlm.nih.gov/pubmed/23725955",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "meta",
    "brandName": "analysis of controlled trials. J Antimicrob Chemot",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64. https://www.ncbi.nlm.nih.gov/pubmed/26066581",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Obstet Gynecol. 2013 Feb;121",
    "brandName": "2 Pt 1",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Obstet Gynecol. 2013 Feb;121(2 Pt 1):306-13. http://www.ncbi.nlm.nih.gov/pubmed/23344280",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep;65",
    "brandName": "9",
    "strength": "65",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep;65(9):1862-77. http://www.ncbi.nlm.nih.gov/pubmed/20587612",
    "commonDosage": "65",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin/clavulanic acid",
    "brandName": "Children ≤ 35 kg: Bosch FJ, van Vuuren C, Joubert ",
    "strength": "35 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin/clavulanic acid – Children ≤ 35 kg: Bosch FJ, van Vuuren C, Joubert G. Antimicrobial resistance patterns in outpatient",
    "commonDosage": "35 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "urinary tract infections",
    "brandName": "",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "urinary tract infections--the constant need to revise prescribing habits. S Afr Med J. 2011 May;101(5):328-31.",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "infections. ClinMicrobiol Rev. 2005 Apr;18",
    "brandName": "2",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "infections. ClinMicrobiol Rev. 2005 Apr;18(2):417-22. http://www.ncbi.nlm.nih.gov/pubmed/15831830",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Maseko V, Kekana V, Smuts FP, Perovic O. Antimicrobial susceptibility of organisms causing community",
    "brandName": "acquired urinary tract",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Maseko V, Kekana V, Smuts FP, Perovic O. Antimicrobial susceptibility of organisms causing community-acquired urinary tract",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "infections in Gauteng Province, South Africa. S Afr Med J. 2013 Mar 15;103",
    "brandName": "6",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "infections in Gauteng Province, South Africa. S Afr Med J. 2013 Mar 15;103(6):377-81. http://www.ncbi.nlm.nih.gov/pubmed/23725955",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and long",
    "brandName": "course antibiotic therapy for urinary tract infect",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "and long-course antibiotic therapy for urinary tract infections in children. Pediatrics. 2002 May;109(5):E70-0.",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Apr;103",
    "brandName": "4",
    "strength": "103",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Apr;103(4):e54. http://www.ncbi.nlm.nih.gov/pubmed/10103346",
    "commonDosage": "103",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1999 Jul;104",
    "brandName": "1 Pt 1",
    "strength": "1999 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1999 Jul;104(1 Pt 1):118. 2000 Jan;105(1 Pt 1):141. http://www.ncbi.nlm.nih.gov/pubmed/10103321",
    "commonDosage": "1999 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non",
    "brandName": "inferiority trial. BMJ. 2007 Aug",
    "strength": "2007 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ. 2007 Aug",
    "commonDosage": "2007 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "25;335",
    "brandName": "7616",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "25;335(7616):386. http://www.ncbi.nlm.nih.gov/pubmed/17611232",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Azithromycin, oral: Azithromycin: Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Azithromycin, oral: Azithromycin: Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "analysis of randomized clinical trials. Sex Transm Dis. 2002 Sep;29",
    "brandName": "9",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "analysis of randomized clinical trials. Sex Transm Dis. 2002 Sep;29(9):497-502. http://www.ncbi.nlm.nih.gov/pubmed/12218839",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ciprofloxacin",
    "brandName": "cystitis associated with prostatitis: Lewis DA, Gu",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Ciprofloxacin – cystitis associated with prostatitis: Lewis DA, Gumede LY, van der Hoven LA, de Gita GN, de Kock EJ, de Lange",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "T, Maseko V, Kekana V, Smuts FP, Perovic O. Antimicrobial susceptibility of organisms causing community",
    "brandName": "acquired urinary tract",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "T, Maseko V, Kekana V, Smuts FP, Perovic O. Antimicrobial susceptibility of organisms causing community-acquired urinary tract",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "9.3.2 Severe hyperglycaemia",
    "brandName": "diabetic",
    "strength": "9.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "9.3.2 Severe hyperglycaemia (diabetic",
    "commonDosage": "9.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hyperglycaemic state",
    "brandName": "HHS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hyperglycaemic state (HHS)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» 2",
    "brandName": "hour plasma glucose in a 75 g oral glucose toleran",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» 2-hour plasma glucose in a 75 g oral glucose tolerance test ≥ 11.1",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Dietary emphasis should be on regulating carbohydrate, fibre and fat intake",
    "brandName": "See",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Dietary emphasis should be on regulating carbohydrate, fibre and fat intake (See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Finger",
    "brandName": "prick blood glucose.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Finger-prick blood glucose.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "*FBG: fasting blood glucose; PPG: post",
    "brandName": "prandial blood glucose.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "*FBG: fasting blood glucose; PPG: post-prandial blood glucose.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "proportions, e.g.  30/70",
    "brandName": "30% regular insulin and 70% intermediate acting",
    "strength": "30",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "proportions, e.g.  30/70 (30% regular insulin and 70% intermediate acting",
    "commonDosage": "30",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "combined intermediate acting",
    "brandName": "basal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "combined intermediate acting (basal) and short acting insulin (bolus). This consists of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pre",
    "brandName": "meal, short acting insulin and bedtime intermediat",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "pre-meal, short acting insulin and bedtime intermediate acting insulin not later than",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Twice daily pre",
    "brandName": "mixed insulin, i.e. a mixture of intermediate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "Twice daily pre-mixed insulin, i.e. a mixture of intermediate- or short acting insulin",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients may need a snack at night, about 3",
    "brandName": "4 hours after the evening meal.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients may need a snack at night, about 3–4 hours after the evening meal.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Self",
    "brandName": "monitoring of blood glucose and how to self",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "» Self-monitoring of blood glucose and how to self-adjust insulin doses.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "length",
    "brandName": "needles are usually 0.6",
    "strength": "0.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "length (needles are usually 0.6–1.2 cm long).",
    "commonDosage": "0.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» To avoid insulin leakage, wait 5",
    "brandName": "10 seconds before withdrawing the needle.",
    "strength": "5",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "» To avoid insulin leakage, wait 5–10 seconds before withdrawing the needle.",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Patients on basal/bolus insulin should measure glucose 3",
    "brandName": "4 times daily.",
    "strength": "3",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "Patients on basal/bolus insulin should measure glucose 3-4 times daily.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Blood lipids",
    "brandName": "fasting total cholesterol, triglycerides, HDL and ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Blood lipids (fasting total cholesterol, triglycerides, HDL and LDL cholesterol).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» HbA1c, in patients who meet treatment goals",
    "brandName": "3",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» HbA1c, in patients who meet treatment goals (3–6 monthly in patients whose",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy has changed, until stable",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy has changed, until stable).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Lifestyle modification, including self",
    "brandName": "care practices.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Lifestyle modification, including self-care practices.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» regular, evenly",
    "brandName": "spaced meals, with small portions",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» regular, evenly-spaced meals, with small portions",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "whole grains",
    "brandName": "e.g. whole wheat bread, oats, brown rice, pearled ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "whole grains (e.g. whole wheat bread, oats, brown rice, pearled wheat, maise",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "meal porridge, sorghum porridge, samp, wheat rice",
    "brandName": ", legumes",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "meal porridge, sorghum porridge, samp, wheat rice), legumes (lentils, beans),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "especially those with added fats, sugars, or salt",
    "brandName": "e.g. takeaways, deep",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "especially those with added fats, sugars, or salt (e.g. takeaways, deep-fried",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "foods, pies, doughnuts, cakes, biscuits, white bread, sugary drinks",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "foods, pies, doughnuts, cakes, biscuits, white bread, sugary drinks)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Aim for 5 servings of fruit or vegetables per day",
    "brandName": "e.g. vegetables: spinach, morogo,",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Aim for 5 servings of fruit or vegetables per day (e.g. vegetables: spinach, morogo,",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cabbage, tomato, imifino",
    "brandName": "amadumbe, amaranth, cowpea, pumpkin and sweet",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cabbage, tomato, imifino (amadumbe, amaranth, cowpea, pumpkin and sweet",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "potato leaves",
    "brandName": "; fruit: apple, orange, naartjie, banana, mango, p",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "potato leaves); fruit: apple, orange, naartjie, banana, mango, pear, peach)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Encourage patients to eat oily fish e.g. sardines and pilchards 2",
    "brandName": "3 times a week.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Encourage patients to eat oily fish e.g. sardines and pilchards 2-3 times a week.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "milk/drinking yoghurt, flavoured water",
    "brandName": ", sweets, desserts and baked goods.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "milk/drinking yoghurt, flavoured water), sweets, desserts and baked goods.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "processed foods",
    "brandName": "e.g. stock cubes, gravy and soup powders, deli mea",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "processed foods (e.g. stock cubes, gravy and soup powders, deli meats like polony",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Make protein",
    "brandName": "e.g. fish, chicken, or meat",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Make protein (e.g. fish, chicken, or meat) food portions the size of the palm of your",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hand",
    "brandName": "about 90 g or 1/2 cup",
    "strength": "90 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hand (about 90 g or 1/2 cup).",
    "commonDosage": "90 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Make fruit, vegetables and starchy food",
    "brandName": "such as rice, pasta and potatoes",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Make fruit, vegetables and starchy food (such as rice, pasta and potatoes) portions",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "no greater than the size of your clenched fist",
    "brandName": "1 cup",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "no greater than the size of your clenched fist (1 cup).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Make hard cheese or peanut butter portions the length of your thumb",
    "brandName": "1 tablespoon",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Make hard cheese or peanut butter portions the length of your thumb (1 tablespoon).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "metformin alone",
    "brandName": "together with dietary modifications and physical a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "metformin alone (together with dietary modifications and physical activity/exercise)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "finger",
    "brandName": "prick blood",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "finger-prick blood",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "glucose: 8",
    "brandName": "10 mmol/L.",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "glucose: 8–10 mmol/L.",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fasting finger",
    "brandName": "prick blood",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fasting finger-prick blood",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "glucose: 6",
    "brandName": "8 mmol/L.",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "glucose: 6–8 mmol/L.",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eGFR 45",
    "brandName": "60 mL/min",
    "strength": "45",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eGFR 45–60 mL/min",
    "commonDosage": "45",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Standard dose, measure eGFR 3",
    "brandName": "6 monthly.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Standard dose, measure eGFR 3–6 monthly.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eGFR 30",
    "brandName": "45 mL/min",
    "strength": "30",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eGFR 30–45 mL/min",
    "commonDosage": "30",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Maximum dose 1 g per day; measure eGFR 3",
    "brandName": "6 monthly.",
    "strength": "1 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Maximum dose 1 g per day; measure eGFR 3–6 monthly.",
    "commonDosage": "1 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "% or fasting finger",
    "brandName": "prick",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "% or fasting finger-prick",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients may need a snack at night about 3",
    "brandName": "4 hours after the evening meal.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients may need a snack at night about 3–4 hours after the evening meal.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "gradually to 20 units",
    "brandName": "2",
    "strength": "20 units",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "gradually to 20 units (2–4 units",
    "commonDosage": "20 units",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» hyperglycaemia diabetic ketoacidosis",
    "brandName": "DKA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» hyperglycaemia diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "intercurrent illness",
    "brandName": "e.g. diarrhoea",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "intercurrent illness (e.g. diarrhoea); missed meals; inadvertent intramuscular injections",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Children, particularly < 6 years of age, generally are not capable of self",
    "brandName": "",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Children, particularly < 6 years of age, generally are not capable of self-",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dissolve 3 teaspoons of sugar",
    "brandName": "15 g",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dissolve 3 teaspoons of sugar (15 g) in 200 mL cup of water, administer 5 mL/kg",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o dissolve 3 teaspoons of sugar",
    "brandName": "15 g",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o dissolve 3 teaspoons of sugar (15 g) in 200 mL cup of water, administer 5 mL/kg",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dextrose 10%, IV, 2",
    "brandName": "5 mL/kg.",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dextrose 10%, IV, 2–5 mL/kg.",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If low, i.e. < 2.5 mmol/L or if testing strips are not available, administer 2",
    "brandName": "5",
    "strength": "2.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If low, i.e. < 2.5 mmol/L or if testing strips are not available, administer 2–5",
    "commonDosage": "2.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Re",
    "brandName": "check the blood glucose after infusion.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Re-check the blood glucose after infusion.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» After recovery, maintain with 5",
    "brandName": "10% dextrose solution until blood glucose is",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» After recovery, maintain with 5–10% dextrose solution until blood glucose is",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dextrose 10% solution, IV, 2",
    "brandName": "5 mL/kg.",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dextrose 10% solution, IV, 2–5 mL/kg.",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dextrose 5 or 10%, infusion, 3",
    "brandName": "5 mL/kg/hour to prevent blood glucose",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dextrose 5 or 10%, infusion, 3–5 mL/kg/hour to prevent blood glucose",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SEVERE HYPERGLYCAEMIA",
    "brandName": "DIABETIC KETOACIDOSIS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SEVERE HYPERGLYCAEMIA (DIABETIC KETOACIDOSIS",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» acetone/fruity",
    "brandName": "smelling breath",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» acetone/fruity-smelling breath",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sodium chloride 0.9%, IV, 15",
    "brandName": "20 mL/kg in the first hour.",
    "strength": "0.9%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sodium chloride 0.9%, IV, 15–20 mL/kg in the first hour.",
    "commonDosage": "0.9%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "shock",
    "brandName": "in children awaiting transfer.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "shock) in children awaiting transfer.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rate",
    "brandName": "mL/hr",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rate(mL/hr)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "E10.4/E11.4 +",
    "brandName": "G63.2*/G99.0*/G59.0*",
    "strength": "10.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "E10.4/E11.4 + (G63.2*/G99.0*/G59.0*)",
    "commonDosage": "10.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amitriptyline, oral, 10",
    "brandName": "25 mg at night increasing to 100 mg, if necessary.",
    "strength": "10",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Amitriptyline, oral, 10–25 mg at night increasing to 100 mg, if necessary.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Relieve pressure: non",
    "brandName": "weight bearing is essential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Relieve pressure: non-weight bearing is essential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Frequent",
    "brandName": "e.g. weekly",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Frequent (e.g. weekly) removal of excess keratin by a chiropodist with a scalpel",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Cleanse with sodium chloride 0.9% solution daily and apply non",
    "brandName": "adherent dressing.",
    "strength": "0.9%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Cleanse with sodium chloride 0.9% solution daily and apply non-adherent dressing.",
    "commonDosage": "0.9%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "negative, send urine to laboratory for albumin: creatinine ratio. If ratio > 30 mg/g",
    "brandName": "3",
    "strength": "30 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "negative, send urine to laboratory for albumin: creatinine ratio. If ratio > 30 mg/g (3",
    "commonDosage": "30 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mg/mmol",
    "brandName": ", diagnose nephropathy.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mg/mmol), diagnose nephropathy.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Start treatment with an ACE",
    "brandName": "inhibitor and increase gradually to maximal dose i",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Start treatment with an ACE-inhibitor and increase gradually to maximal dose if",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Intensify other renal and cardiovascular protection measures",
    "brandName": "not smoking, aspirin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Intensify other renal and cardiovascular protection measures (not smoking, aspirin",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy, lipid",
    "brandName": "lowering therapy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy, lipid-lowering therapy).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BMI",
    "brandName": "kg/m2",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BMI (kg/m2)",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "triglycerides",
    "brandName": "> 1.7 mmol/L",
    "strength": "1.7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "triglycerides (> 1.7 mmol/L), decreased HDL cholesterol (< 1.0 mmol/L in men and < 1.3",
    "commonDosage": "1.7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "have existing cardiovascular disease",
    "brandName": "for example angina pectoris, previous",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "have existing cardiovascular disease (for example angina pectoris, previous",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "have chronic kidney disease",
    "brandName": "eGFR < 60 mL/minute",
    "strength": "60 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "have chronic kidney disease (eGFR < 60 mL/minute);",
    "commonDosage": "60 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fasting",
    "brandName": "14 hours",
    "strength": "14 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fasting (14 hours) triglycerides > 10 mmol/L.",
    "commonDosage": "14 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "common causes are toxic single or multinodular goitre and sub",
    "brandName": "acute thyroiditis.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "common causes are toxic single or multinodular goitre and sub-acute thyroiditis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diabetes Care. 2014 Jan;37 Suppl 1:S120",
    "brandName": "43. https://www.ncbi.nlm.nih.gov/pubmed/24357208",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Diabetes Care. 2014 Jan;37 Suppl 1:S120-43. https://www.ncbi.nlm.nih.gov/pubmed/24357208",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diet recommendations",
    "brandName": "diabetes mellitus",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Diet recommendations (diabetes mellitus): The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metformin",
    "brandName": "renal impairment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 4",
    "description": "Metformin (renal impairment): Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2013;37",
    "brandName": "suppl 1",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "2013;37(suppl 1):S1-S212. http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metformin",
    "brandName": "renal impairment",
    "strength": "2 ",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 4",
    "description": "Metformin (renal impairment): The National Institute for Health and Care Excellence. Type 2 diabetes in adults: management",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "insufficiency. Diabetes Care. 2011 Jun;34",
    "brandName": "6",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "insufficiency. Diabetes Care. 2011 Jun;34(6):1431-7. http://www.ncbi.nlm.nih.gov/pubmed/21617112",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metformin",
    "brandName": "renal impairment",
    "strength": "12",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "Metformin (renal impairment): South African Medicines Formulary.  12th Edition.  Division of Clinical Pharmacology. University of",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Insulin, SC",
    "brandName": "stop sulphonylureas",
    "strength": "N/A",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "Insulin, SC (stop sulphonylureas): Swinnen SG, Dain MP, Mauricio D, DeVries JH, Hoekstra JB, Holleman F. Continuation versus",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes ObesMetab. 2010 Oct;12",
    "brandName": "10",
    "strength": "2 ",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 4",
    "description": "discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes ObesMetab. 2010 Oct;12(10):923-5.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Insulin, biphasic, SC",
    "brandName": "starting dose",
    "strength": "2 ",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 4",
    "description": "Insulin, biphasic, SC (starting dose): The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "controlled trial.Emerg Med J. 2005 Jul;22",
    "brandName": "7",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "controlled trial.Emerg Med J. 2005 Jul;22(7):512-5. https://www.ncbi.nlm.nih.gov/pubmed/15983093",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Albumin: creatinine ratio",
    "brandName": "diabetic nephropathy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Albumin: creatinine ratio (diabetic nephropathy): Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ACE",
    "brandName": "inhibitor, oral: South African Medicines Formulary",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ACE-inhibitor, oral: South African Medicines Formulary.  12th Edition.  Division of Clinical Pharmacology. University of Cape Town.",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "review and meta",
    "brandName": "analysis. Eur Heart J. 2013 Jun;34",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "review and meta-analysis. Eur Heart J. 2013 Jun;34(24):1807-17. https://www.ncbi.nlm.nih.gov/pubmed/23470492",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.11 Rubella",
    "brandName": "german measles",
    "strength": "10.11 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.11 Rubella (german measles)",
    "commonDosage": "10.11 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.13 Shingles",
    "brandName": "herpes zoster",
    "strength": "10.13 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.13 Shingles (herpes zoster)",
    "commonDosage": "10.13 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.18 Viral haemorrhagic fever",
    "brandName": "VHF",
    "strength": "10.18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.18 Viral haemorrhagic fever (VHF)",
    "commonDosage": "10.18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.19 Emerging respiratory pathogens, e.g. COVID",
    "brandName": "19:",
    "strength": "10.19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.19 Emerging respiratory pathogens, e.g. COVID-19:",
    "commonDosage": "10.19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Disinfectants are used to kill micro",
    "brandName": "organisms on working surfaces and instruments, but",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Disinfectants are used to kill micro-organisms on working surfaces and instruments, but",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cannot be relied on to destroy all micro",
    "brandName": "organisms.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cannot be relied on to destroy all micro-organisms.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Cleansing",
    "brandName": "removal of visible soiling",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Cleansing (removal of visible soiling) is the first and most important step in chemical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The infection is self",
    "brandName": "limiting, with a duration of about 1 week.",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The infection is self-limiting, with a duration of about 1 week.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aciclovir, oral, 20 mg/kg/dose 6 hourly for 7 days",
    "brandName": "Doctor prescribed",
    "strength": "20 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aciclovir, oral, 20 mg/kg/dose 6 hourly for 7 days (Doctor prescribed).",
    "commonDosage": "20 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Caregivers should offer the child fluids regularly to keep them well hydrated",
    "brandName": "where a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Caregivers should offer the child fluids regularly to keep them well hydrated (where a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the child develops a non",
    "brandName": "blanching rash,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the child develops a non-blanching rash,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "breathing difficulties, i.e. respiratory rate >60, nasal flaring, chest in",
    "brandName": "drawing or",
    "strength": "60",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "breathing difficulties, i.e. respiratory rate >60, nasal flaring, chest in-drawing or",
    "commonDosage": "60",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "toxic",
    "brandName": "looking patient",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "toxic-looking patient",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for",
    "brandName": "travellers/item/330",
    "strength": "330",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for-travellers/item/330-malaria-risk-map-for-south-africa-2017.html",
    "commonDosage": "330",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Malaria is an infection of red blood cells by a parasite micro",
    "brandName": "organism called Plasmodium.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Malaria is an infection of red blood cells by a parasite micro-organism called Plasmodium.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Symptoms and signs of malaria are non",
    "brandName": "specific.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Symptoms and signs of malaria are non-specific.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "endemic and non",
    "brandName": "endemic areas. Any person resident in or returning",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "endemic and non-endemic areas. Any person resident in or returning from a malaria area",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mosquito bites",
    "brandName": "should be tested for malaria.  The progression of ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mosquito bites) should be tested for malaria.  The progression of P. falciparum malaria to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» prostration",
    "brandName": "severe general body weakness",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» prostration (severe general body weakness),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» severe anaemia",
    "brandName": "Hb <7 g/dL",
    "strength": "7 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» severe anaemia (Hb <7 g/dL),",
    "commonDosage": "7 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "used to diagnose malaria within 10",
    "brandName": "15 minutes.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "used to diagnose malaria within 10–15 minutes.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In areas with high incidence of malaria",
    "brandName": "whether locally transmitted or imported",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In areas with high incidence of malaria (whether locally transmitted or imported) it",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Artemether/lumefantrine, oral, 20/120 mg, with fat",
    "brandName": "containing food/full cream milk to",
    "strength": "20",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Artemether/lumefantrine, oral, 20/120 mg, with fat-containing food/full cream milk to",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tablet",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tablet(s)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All patients with any sign of severe",
    "brandName": "complicated",
    "strength": "10.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All patients with any sign of severe (complicated) malaria, see Section 10.7.2: Malaria,",
    "commonDosage": "10.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Any one of the following is a sign of severe",
    "brandName": "complicated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Any one of the following is a sign of severe (complicated) malaria, is associated",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with a higher mortality, and requires urgent referral",
    "brandName": "after initial artesunate dose as",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with a higher mortality, and requires urgent referral (after initial artesunate dose as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "malaria control programme provided they have facilities to diagnose malaria",
    "brandName": "either",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "malaria control programme provided they have facilities to diagnose malaria (either",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "microscopy or rapid antigen point of care tests",
    "brandName": "and healthcare workers trained in the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "microscopy or rapid antigen point of care tests) and healthcare workers trained in the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "measures against mosquito bites, from September to May in moderate",
    "brandName": "risk malaria",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "measures against mosquito bites, from September to May in moderate-risk malaria-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Guidelines for the Prevention of Malaria",
    "brandName": "2018",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Guidelines for the Prevention of Malaria (2018) found at: https://www.nicd.ac.za/wp-",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "content/uploads/2019/03/National",
    "brandName": "Guidelines",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "content/uploads/2019/03/National-Guidelines-for-prevention-of-Malaria_updated-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Malaria chemoprophylaxis is recommended for persons intending to travel to malaria",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Malaria chemoprophylaxis is recommended for persons intending to travel to malaria-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "endemic areas within and outside of South Africa. There are moderate",
    "brandName": "and high",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "endemic areas within and outside of South Africa. There are moderate- and high-risk",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Use di",
    "brandName": "ethyl 3",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Use di-ethyl 3-methylbenzamid (DEET) insecticide-impregnated mosquito nets,",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "avoid visiting malaria",
    "brandName": "endemic areas, as they are more prone to the serio",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "avoid visiting malaria-endemic areas, as they are more prone to the serious",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "recommended by the National Guidelines for the Prevention of Malaria",
    "brandName": "2018",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "recommended by the National Guidelines for the Prevention of Malaria (2018) found at:",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.nicd.ac.za/wp",
    "brandName": "content/uploads/2019/03/National",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.nicd.ac.za/wp-content/uploads/2019/03/National-Guidelines-for-prevention-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Doxycycline is contra",
    "brandName": "indicated in pregnant women, and in children <8 ye",
    "strength": "8 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Note: Doxycycline is contra-indicated in pregnant women, and in children <8 years of age.",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Cough or coryza",
    "brandName": "runny nose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Cough or coryza (runny nose) or conjunctivitis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "After 2",
    "brandName": "3 days of the initial clinical features, a few tin",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "After 2–3 days of the initial clinical features, a few tiny white spots, like salt grains appear",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The skin rash appears 1",
    "brandName": "2 days later, lasting about 5 days and:",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The skin rash appears 1–2 days later, lasting about 5 days and:",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Counsel the caregiver to isolate the patient in the home",
    "brandName": "if feasible",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Counsel the caregiver to isolate the patient in the home (if feasible).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vitamin A",
    "brandName": "retinol",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vitamin A (retinol), oral, as a single dose.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Suspected meningo",
    "brandName": "encephalitis.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Suspected meningo-encephalitis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "no oedema, and no shortness of breath. See Section 8.3: Glomerular diseases",
    "brandName": "GN",
    "strength": "8.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "no oedema, and no shortness of breath. See Section 8.3: Glomerular diseases (GN).",
    "commonDosage": "8.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Praziquantel may cause life",
    "brandName": "threatening deterioration if given in acute",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Praziquantel may cause life-threatening deterioration if given in acute",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Isolate patient from immunocompromised or pregnant non",
    "brandName": "immune individuals",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Isolate patient from immunocompromised or pregnant non-immune individuals (who",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aciclovir, oral, 800 mg five times daily for 7 days",
    "brandName": "4 hourly missing the",
    "strength": "800 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aciclovir, oral, 800 mg five times daily for 7 days (4 hourly missing the",
    "commonDosage": "800 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "middle of the night dose",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "middle of the night dose).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tramadol, oral, 50 to 100 mg, 6 hourly as a starting dose.",
    "brandName": "Doctor prescribed.",
    "strength": "50 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Tramadol, oral, 50 to 100 mg, 6 hourly as a starting dose. (Doctor prescribed.)",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To treat post",
    "brandName": "herpetic neuralgia:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To treat post-herpetic neuralgia:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amitriptyline, oral, 25 mg at night.",
    "brandName": "Doctor prescribed.",
    "strength": "25 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Amitriptyline, oral, 25 mg at night. (Doctor prescribed.)",
    "commonDosage": "25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tick",
    "brandName": "borne infection due to Rickettsia conorii, acquire",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tick-borne infection due to Rickettsia conorii, acquired from dogs, or Rickettsia africae,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of fever, eschar, and rash occurs in 50",
    "brandName": "75% of patients. Signs of severe tick bite fever",
    "strength": "50",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of fever, eschar, and rash occurs in 50-75% of patients. Signs of severe tick bite fever",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Extra",
    "brandName": "pulmonary tuberculosis is defined as infection of ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Extra-pulmonary tuberculosis is defined as infection of organ systems other than the lung",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "symptoms such as unintentional weight loss",
    "brandName": ">1.5 kg in a month",
    "strength": "1.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "symptoms such as unintentional weight loss (>1.5 kg in a month), night sweats, and fever",
    "commonDosage": "1.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "common types of extra",
    "brandName": "pulmonary TB are listed below along with commonly ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "common types of extra-pulmonary TB are listed below along with commonly associated",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Typically nodes are large",
    "brandName": ">2 cm",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Typically nodes are large (>2 cm), tender, non-symmetrical,",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Low",
    "brandName": "grade fever.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Low-grade fever.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Numbness, tingling, or weakness below the infection",
    "brandName": "if the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Numbness, tingling, or weakness below the infection (if the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Signs and symptoms of right",
    "brandName": "sided heart failure",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Signs and symptoms of right-sided heart failure",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "During the early phase of TB meningitis, malaise, low",
    "brandName": "grade",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "During the early phase of TB meningitis, malaise, low-grade",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In children, TB meningitis may be acute, sub",
    "brandName": "acute or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In children, TB meningitis may be acute, sub-acute or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "chronic and typically presents between 23",
    "brandName": "49 months of age",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "chronic and typically presents between 23-49 months of age",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Viral haemorrhagic fevers",
    "brandName": "VHF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Viral haemorrhagic fevers (VHF) are uncommon conditions in South Africa. They may",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "present with non",
    "brandName": "specific signs or with signs strongly suggestive o",
    "strength": "10.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "present with non-specific signs or with signs strongly suggestive of VHF (Table 10.4).",
    "commonDosage": "10.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Other haemorrhagic signs",
    "brandName": "e.g.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Other haemorrhagic signs (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Myalgia",
    "brandName": "especially lower back pain",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Myalgia (especially lower back pain).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 10.4: Signs and symptoms of viral haemorrhagic fevers",
    "brandName": "VHF",
    "strength": "10.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 10.4: Signs and symptoms of viral haemorrhagic fevers (VHF)",
    "commonDosage": "10.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Endemic causes of VHF in South Africa are Crimean",
    "brandName": "Congo fever and Rift Valley Fever,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Endemic causes of VHF in South Africa are Crimean-Congo fever and Rift Valley Fever,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Obtaining a history of possible exposure to infection",
    "brandName": "including a detailed travel history",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Obtaining a history of possible exposure to infection (including a detailed travel history) is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» long",
    "brandName": "sleeved disposable gown,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» long-sleeved disposable gown,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Non",
    "brandName": "specific signs:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Non-specific signs:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "arrange transfer with EMS",
    "brandName": "providing patient’s VHF status, and names, address",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "arrange transfer with EMS (providing patient’s VHF status, and names, addresses",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "respiratory illness; respiratory failure, septic shock and multi",
    "brandName": "organ failure resulting in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "respiratory illness; respiratory failure, septic shock and multi-organ failure resulting in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» fever",
    "brandName": ">38°C",
    "strength": "38",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» fever (>38°C), chills or rigors, cough, shortness of breath",
    "commonDosage": "38",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "should be applied when performing aerosol",
    "brandName": "generating procedures.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "should be applied when performing aerosol-generating procedures.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.knowledgehub.org.za/content/covid",
    "brandName": "19",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.knowledgehub.org.za/content/covid-19",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The elderly are at high risk for severe COVID",
    "brandName": "19 disease. Other risk factors include",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The elderly are at high risk for severe COVID-19 disease. Other risk factors include",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A suspected COVID",
    "brandName": "19 case includes any person presenting with an acu",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A suspected COVID-19 case includes any person presenting with an acute (≤14",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "anosmia",
    "brandName": "loss of smell",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "anosmia (loss of smell) or dysgeusia (loss of taste).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "myalgia or diarrhoea",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "myalgia or diarrhoea).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "syndrome",
    "brandName": "ARDS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "syndrome (ARDS), long-COVID and multisystem inflammatory syndrome in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Rapid antigen tests or PCR",
    "brandName": "based tests are both acceptable options to use for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Rapid antigen tests or PCR-based tests are both acceptable options to use for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Upper respiratory tract",
    "brandName": "nasopharyngeal or oropharyngeal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Upper respiratory tract (nasopharyngeal or oropharyngeal) samples should be sent",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A single positive rapid or PCR test is sufficient proof of COVID",
    "brandName": "19 infection.",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A single positive rapid or PCR test is sufficient proof of COVID-19 infection.",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Due to poor sensitivity within the first 1",
    "brandName": "2 weeks after symptom onset, serology",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Due to poor sensitivity within the first 1-2 weeks after symptom onset, serology",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "provided they can safely self",
    "brandName": "isolate and seek urgent health care if required.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "provided they can safely self-isolate and seek urgent health care if required.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Give strict advice to patients who self",
    "brandName": "isolate at home and how to reduce possible",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Give strict advice to patients who self-isolate at home and how to reduce possible",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Criteria for management at home",
    "brandName": "for age >12 years",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Criteria for management at home (for age >12 years):",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preference to nonsteroidal anti",
    "brandName": "inflammatory drugs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preference to nonsteroidal anti-inflammatory drugs (NSAIDs).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use healthcare worker PPE: gloves, gown",
    "brandName": "or apron",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use healthcare worker PPE: gloves, gown (or apron), and a medical mask.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use either disposable or dedicated equipment",
    "brandName": "e.g. stethoscopes, blood pressure",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use either disposable or dedicated equipment (e.g. stethoscopes, blood pressure",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cuffs and thermometers",
    "brandName": ". If equipment needs to be shared among patients, ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cuffs and thermometers). If equipment needs to be shared among patients, clean",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antivirals to treat varicella zoster, oral",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antivirals to treat varicella zoster, oral- adults (therapeutic class):Tunbridge AJ, Breuer J, Jeffery KJ; British Infection Society.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chickenpox in adults",
    "brandName": "clinical management. J Infect. 2008 Aug;57",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chickenpox in adults - clinical management. J Infect. 2008 Aug;57(2):95-102. https://www.ncbi.nlm.nih.gov/pubmed/18555533",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Artesunate, IV",
    "brandName": "standard dosing",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Artesunate, IV (standard dosing): South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Artesunate, IV",
    "brandName": "dosing for <20kg",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Artesunate, IV (dosing for <20kg): Hendriksen IC, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. Population",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clin Pharmacol Ther. 2013 May;93",
    "brandName": "5",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clin Pharmacol Ther. 2013 May;93(5):443-50. https://pubmed.ncbi.nlm.nih.gov/23511715/",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2022",
    "brandName": "WHO/UCN/GMP/2022.01 Rev.3",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2022 (WHO/UCN/GMP/2022.01 Rev.3). License: CC BY-NC-SA 3.0 IGO.",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycyline, oral",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Doxycyline, oral (non-pregnant adults): National Department of Health: Affordable Medicines, EDP-PHC/Adult Hospital level.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicine Review: Malaria chemoprophylaxis, June 2021. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicine Review: Malaria chemoprophylaxis, June 2021. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycyline, oral",
    "brandName": "children",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Doxycyline, oral (children): South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.  University",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Praziquantel, oral",
    "brandName": "dosing in children and adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Praziquantel, oral (dosing in children and adults): Kramer CV, Zhang F, Sinclair D, Olliaro PL. Drugs for treating urinary",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "schistosomiasis. Cochrane Database Syst Rev. 2014 Aug 6;",
    "brandName": "8",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "schistosomiasis. Cochrane Database Syst Rev. 2014 Aug 6;(8):CD000053. https://www.ncbi.nlm.nih.gov/pubmed/25099517",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013 Feb 28;",
    "brandName": "2",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000528.",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antivirals to treat herpes zoster, oral",
    "brandName": "therapeutic class",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antivirals to treat herpes zoster, oral (therapeutic class): McDonald EM, De Kock J, Ram FS. Antivirals for management of herpes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "zoster including ophthalmicus: a systematic review of high",
    "brandName": "quality randomized controlled trials. Antiviral Th",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antiviral Therapy 2012; 17(2): 255-264.",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Database Syst Rev. 2015 Jul 6;2015",
    "brandName": "7",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Database Syst Rev. 2015 Jul 6;2015(7):CD008242. https://pubmed.ncbi.nlm.nih.gov/26146793/",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Azithromycin, oral",
    "brandName": "children < 45 kg",
    "strength": "45 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Azithromycin, oral (children < 45 kg): Meloni G, Meloni T. Azithromycin vs. doxycycline for Mediterranean spotted fever.",
    "commonDosage": "45 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pediatr Infect Dis J. 1996;15",
    "brandName": "11",
    "strength": "1996",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pediatr Infect Dis J. 1996;15(11):1042-4. https://www.ncbi.nlm.nih.gov/pubmed/8933556",
    "commonDosage": "1996",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mountain spotted fever, ehrlichioses, and anaplasmosis",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "public health  professionals. MMWR Recomm Rep. 2006 Mar 31;55",
    "brandName": "RR",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "public health  professionals. MMWR Recomm Rep. 2006 Mar 31;55(RR-4):1-27. https://www.ncbi.nlm.nih.gov/pubmed/16572105",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Recomm Rep. 2006 Mar 31;55",
    "brandName": "RR‐4",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Recomm Rep. 2006 Mar 31;55(RR‐4):1‐27. https://www.ncbi.nlm.nih.gov/pubmed/16572105",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycycline",
    "brandName": "pregnancy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Doxycycline (pregnancy – tick bite fever): Frean J, Grayson W. South African Tick Bite Fever: An Overview.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dermatopathology",
    "brandName": "Basel",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dermatopathology (Basel). 2019 Jun 26;6(2):70-76. https://pubmed.ncbi.nlm.nih.gov/31700846/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy and early childhood",
    "brandName": "",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367-82.",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cohort and a case series analysis. PLoS Negl Trop Dis. 2014 Nov 20;8",
    "brandName": "11",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cohort and a case series analysis. PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3327. https://pubmed.ncbi.nlm.nih.gov/25412503/",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycycline",
    "brandName": "pregnancy",
    "strength": "14",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Doxycycline (pregnancy – tick bite fever): South African Medicines Formulary.  14th Edition.  Division of Clinical",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Epidemiol. 2009 Jan;23",
    "brandName": "1",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Epidemiol. 2009 Jan;23(1):18-28. https://pubmed.ncbi.nlm.nih.gov/19228311/",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Programme: Paediatric Hospital Level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Programme: Paediatric Hospital Level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ceftriaxone, IM",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ceftriaxone, IM (adults): National Department of Health. National guidelines for recognition & management of viral haemorrhagic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "16 Risk factors for COVID",
    "brandName": "19: National Department of Health. Clinical manage",
    "strength": "16 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "16 Risk factors for COVID-19: National Department of Health. Clinical management of suspected or confirmed COVID-19 disease",
    "commonDosage": "16 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "version 6",
    "brandName": "September 2021",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "version 6 (September 2021). https://www.knowledgehub.org.za/elibrary/clinical-management-suspected-or-confirmed-covid-19-",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Risk factors for COVID",
    "brandName": "19: Mendelson M, Boloko L,  Boutall A et al. Clini",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Risk factors for COVID-19: Mendelson M, Boloko L,  Boutall A et al. Clinical management of COVID-19: Experiences of the",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "COVID",
    "brandName": "19 epidemic from Groote Schuur Hospital, Cape Town",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "COVID-19 epidemic from Groote Schuur Hospital, Cape Town, South Africa. S Afr Med J 2020;110(10):973-981.",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17 Antigen and PCR tests",
    "brandName": "COVID",
    "strength": "17 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17 Antigen and PCR tests (COVID-19): National Department of Health. Guide to antigen testing for SARS-COV-2 in South Africa,",
    "commonDosage": "17 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18 Covid",
    "brandName": "19: National Department of Health. Clinical manage",
    "strength": "18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18 Covid-19: National Department of Health. Clinical management of suspected or confirmed Covid-19 disease",
    "commonDosage": "18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management of HIV",
    "brandName": "infected children",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management of HIV-infected children (<10 years)",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "glandular fever",
    "brandName": "type illness,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "glandular fever-type illness,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Provide adequate pre",
    "brandName": "and post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Provide adequate pre- and post-test counselling.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of immune suppression",
    "brandName": "see WHO staging below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of immune suppression (see WHO staging below) both provide independent",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Unexplained moderate weight loss",
    "brandName": "<10% of presumed or",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Unexplained moderate weight loss (<10% of presumed or",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "measured body weight",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "measured body weight).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pharyngitis",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pharyngitis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Herpes zoster",
    "brandName": "shingles",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Herpes zoster (shingles).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Unexplained severe weight loss",
    "brandName": ">10% of presumed or measured",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Unexplained severe weight loss (>10% of presumed or measured",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "body weight",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "body weight).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pyomyositis, bone or joint infection, meningitis, or bacteraemia",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pyomyositis, bone or joint infection, meningitis, or bacteraemia).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Unexplained anaemia",
    "brandName": "<8 g/dL",
    "strength": "8 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Unexplained anaemia (<8 g/dL), neutropaenia (<0.5 × 109/L) and/or",
    "commonDosage": "8 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chronic herpes simplex infection",
    "brandName": "orolabial, genital or anorectal of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chronic herpes simplex infection (orolabial, genital or anorectal of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oesophageal candidiasis",
    "brandName": "or candidiasis of trachea, bronchi or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oesophageal candidiasis (or candidiasis of trachea, bronchi or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lungs",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lungs).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cytomegalovirus infection",
    "brandName": "retinitis or infection of other organs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cytomegalovirus infection (retinitis or infection of other organs).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Recurrent septicaemia",
    "brandName": "including non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Recurrent septicaemia (including non-typhoidal Salmonella).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lymphoma",
    "brandName": "cerebral or B cell non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lymphoma (cerebral or B cell non-Hodgkin).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraindication, and the patient is willing to start after receiving pre",
    "brandName": "ART counselling.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraindication, and the patient is willing to start after receiving pre-ART counselling.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ART initiation",
    "brandName": "see below for timing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ART initiation (see below for timing).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In TB co",
    "brandName": "infection, start with TB treatment first, followed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In TB co-infection, start with TB treatment first, followed by ART initiation according",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to CD4 count",
    "brandName": "except TB meningitis",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "to CD4 count (except TB meningitis – see below):",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TB meningitis co",
    "brandName": "infection:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TB meningitis co-infection:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In patients with TB meningitis",
    "brandName": "irrespective of CD4 count",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In patients with TB meningitis (irrespective of CD4 count), defer ART until 8 weeks",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cryptococcal meningitis co",
    "brandName": "infection:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cryptococcal meningitis co-infection:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Defer ART until 4",
    "brandName": "6 weeks after starting antifungal therapy",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Defer ART until 4–6 weeks after starting antifungal therapy (earlier initiation has",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is essential that patients have good insight into the need for long",
    "brandName": "term therapy and high",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is essential that patients have good insight into the need for long-term therapy and high",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TDF + 3TC + DTG",
    "brandName": "“TLD”",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TDF + 3TC + DTG (“TLD”)",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: DTG",
    "brandName": "based regimens are now recommended as first",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: DTG-based regimens are now recommended as first",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "line ART in all women of child",
    "brandName": "bearing potential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "line ART in all women of child-bearing potential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Start protease inhibitor",
    "brandName": "based regimen:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Start protease inhibitor-based regimen:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment, substitute ATV/r with LPV/r at 800/200 mg 12",
    "brandName": "",
    "strength": "800",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment, substitute ATV/r with LPV/r at 800/200 mg 12-",
    "commonDosage": "800",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "titrated upward over 1",
    "brandName": "2 weeks",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "titrated upward over 1-2 weeks (e.g. 600/150 mg and then",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "800/200 mg",
    "brandName": ".",
    "strength": "800",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "800/200 mg).",
    "commonDosage": "800",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If chronic hepatitis B coinfection and eGFR 30",
    "brandName": "50 ml/min:",
    "strength": "30",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If chronic hepatitis B coinfection and eGFR 30-50 ml/min:",
    "commonDosage": "30",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "available NRTIs, the following alternative dual",
    "brandName": "therapy regimens may be used after consulting",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "available NRTIs, the following alternative dual-therapy regimens may be used after consulting",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DTG + 3TC",
    "brandName": "if no resistance/intolerance to 3TC and VL <500 00",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "DTG + 3TC (if no resistance/intolerance to 3TC and VL <500 000 copies/mL)",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "999 copies/mL",
    "brandName": ", or adherence suboptimal, repeat VL at",
    "strength": "999 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "999 copies/mL), or adherence suboptimal, repeat VL at",
    "commonDosage": "999 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "copies/mL",
    "brandName": "or 1 VL 1000 copies/mL plus CD4 <200 or",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "copies/mL (or 1 VL 1000 copies/mL plus CD4 <200 or",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EXISTING CLIENTS TO DTG",
    "brandName": "CONTAINING REGIMENS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EXISTING CLIENTS TO DTG-CONTAINING REGIMENS",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Switch to DTG",
    "brandName": "containing regimen regardless of VL result:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Switch to DTG-containing regimen regardless of VL result:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If adherence <80%. switch to DTG",
    "brandName": "containing regimen:",
    "strength": "80%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If adherence <80%. switch to DTG-containing regimen:",
    "commonDosage": "80%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "may be required",
    "brandName": "available from TLART@health.gov.za or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "may be required (available from TLART@health.gov.za or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://knowledgehub.health.gov.za/elibrary/third",
    "brandName": "line",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://knowledgehub.health.gov.za/elibrary/third-line-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Always check hepatitis B surface antigen",
    "brandName": "HBsAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Always check hepatitis B surface antigen (HBsAg) before stopping TDF:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Source: Contract circular HP13",
    "brandName": "2022ARV http://www.health.gov.za/",
    "strength": "13",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Source: Contract circular HP13-2022ARV http://www.health.gov.za/",
    "commonDosage": "13",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Switching existing clients to DTG",
    "brandName": "containing regimens",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Switching existing clients to DTG-containing regimens",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.1: Switching existing clients to DTG",
    "brandName": "containing regimens",
    "strength": "11.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.1: Switching existing clients to DTG-containing regimens (adopted from the NDoH",
    "commonDosage": "11.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WHO staging",
    "brandName": "See table above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WHO staging (See table above).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Check cryptococcal antigen",
    "brandName": "If positive, perform LP regardless",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Check cryptococcal antigen (If positive, perform LP regardless",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of whether symptoms are present or not",
    "brandName": ". CrAg testing is done",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of whether symptoms are present or not). CrAg testing is done",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "CD4 is 100",
    "brandName": "199, a serum CrAg test must be ordered",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "CD4 is 100-199, a serum CrAg test must be ordered",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Screen for TB using the WHO screening questionnaire",
    "brandName": "any one of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Screen for TB using the WHO screening questionnaire (any one of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cough, fever, night sweats, or weight loss",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cough, fever, night sweats, or weight loss).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sputum TB",
    "brandName": "NAAT* in all who can produce sputum, regardless of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sputum TB-NAAT* in all who can produce sputum, regardless of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If planning to use TDF: check creatinine",
    "brandName": "avoid TDF if eGFR <50",
    "strength": "50",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If planning to use TDF: check creatinine (avoid TDF if eGFR <50",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mL/minute",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mL/minute).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Check HBsAg",
    "brandName": "if positive, TDF should form part of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Check HBsAg (if positive, TDF should form part of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the regimen",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the regimen).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "*TB",
    "brandName": "NAAT: TB Nucleic Acid Amplification Test",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "*TB-NAAT: TB Nucleic Acid Amplification Test (e.g. GeneXpert  Ultra",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» CD4 at 10 months after initiating ART",
    "brandName": "align with VL",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» CD4 at 10 months after initiating ART (align with VL). Stop CD4 count",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If on a protease inhibitor",
    "brandName": "PI",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If on a protease inhibitor (PI): cholesterol and triglycerides at 3 months",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DC:  Dispensing cycle; MMD: Multi",
    "brandName": "month dispensing; RPCs: Repeat prescription collec",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "DC:  Dispensing cycle; MMD: Multi-month dispensing; RPCs: Repeat prescription collection",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DTG initiation",
    "brandName": "due to inhibition of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "DTG initiation) due to inhibition of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "impairment",
    "brandName": "eGFR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "impairment (eGFR",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "<50 mL/min",
    "brandName": ".",
    "strength": "50 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "<50 mL/min).",
    "commonDosage": "50 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Decline in eGFR",
    "brandName": "months to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Decline in eGFR (months to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eGFR 10",
    "brandName": "30",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eGFR 10-30",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eGFR 15",
    "brandName": "29 mL/min:",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eGFR 15-29 mL/min:",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "available as a single",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "available as a single-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The time",
    "brandName": "onset information with respect to adverse drug rea",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The time-onset information with respect to adverse drug reactions (ADRs) serves as an estimate.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "integrase strand transfer inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "integrase strand transfer inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ART: DRUG",
    "brandName": "DRUG INTERACTIONS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ART: DRUG-DRUG INTERACTIONS",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "No dose adjustment required",
    "brandName": "600 mg",
    "strength": "600 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "No dose adjustment required (600 mg",
    "commonDosage": "600 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "at night",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "at night).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mg 12",
    "brandName": "hourly.",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mg 12-hourly.",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dose gradually over 1",
    "brandName": "2 weeks.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dose gradually over 1-2 weeks.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "rifampicin with rifabutin",
    "brandName": "doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "rifampicin with rifabutin (doctor prescribed) – see Adult Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Magnesium",
    "brandName": "and aluminum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Magnesium- and aluminum-containing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Initiate metformin at a low dose",
    "brandName": "500 mg to",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Diabetes",
    "schedule": "Schedule 2",
    "description": "Initiate metformin at a low dose (500 mg to",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1000 mg total daily dose",
    "brandName": ", titrating up as",
    "strength": "1000 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1000 mg total daily dose), titrating up as",
    "commonDosage": "1000 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "not co",
    "brandName": "prescribe if eGFR <30 mL/min.",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "not co-prescribe if eGFR <30 mL/min.",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3A4",
    "brandName": "e.g. most",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3A4 (e.g. most",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "gradually titrated upward over 1",
    "brandName": "2 weeks",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "gradually titrated upward over 1-2 weeks",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cells/mm3 when cotrimoxazole was commenced",
    "brandName": "e.g. patients with TB",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cells/mm3 when cotrimoxazole was commenced (e.g. patients with TB) continue for",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cough",
    "brandName": "any duration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cough (any duration)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adults and adolescents initiating a DTG",
    "brandName": "containing ART regimen:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adults and adolescents initiating a DTG-containing ART regimen:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For patients who are already virally suppressed on a DTG",
    "brandName": "based regimen:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For patients who are already virally suppressed on a DTG-based regimen:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A weekly combination of isoniazid",
    "brandName": "900 mg if weight >30 kg",
    "strength": "900 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A weekly combination of isoniazid (900 mg if weight >30 kg) plus rifapentine (900 mg",
    "commonDosage": "900 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "if weight >30 kg",
    "brandName": "for three months may be used.",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "if weight >30 kg) for three months may be used.",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Do not use rifapentine",
    "brandName": "containing TPT in patients on protease inhibitor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Do not use rifapentine-containing TPT in patients on protease inhibitor-based",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "database for details regarding the rifapentine",
    "brandName": "containing TPT regimen].",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "database for details regarding the rifapentine-containing TPT regimen].",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Educate patients on the symptoms of hepatotoxicity",
    "brandName": "nausea, vomiting, yellow",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Educate patients on the symptoms of hepatotoxicity (nausea, vomiting, yellow",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "eyes, brown urine, and pain in right upper quadrant",
    "brandName": "associated with TPT.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "eyes, brown urine, and pain in right upper quadrant) associated with TPT.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "oesophageal candidiasis. See Section 1.2: Candidiasis, oral",
    "brandName": "thrush",
    "strength": "1.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "oesophageal candidiasis. See Section 1.2: Candidiasis, oral (thrush).",
    "commonDosage": "1.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A life",
    "brandName": "threatening fungal infection caused by the fungus ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A life-threatening fungal infection caused by the fungus Cryptococcus. The fungi remain",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "serum cryptococcal antigen",
    "brandName": "CrAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "serum cryptococcal antigen (CrAg) test done (unless confirmed diagnosis of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All patients with a positive serum CrAg test should have a lumbar puncture",
    "brandName": "LP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All patients with a positive serum CrAg test should have a lumbar puncture (LP) to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer for liposomal amphotericin B, IV",
    "brandName": "induction phase",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer for liposomal amphotericin B, IV (induction phase) and monitoring of intracranial",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pressure symptoms",
    "brandName": "See Adult Hospital STGs and EML, Section 10.2.4: C",
    "strength": "10.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pressure symptoms - See Adult Hospital STGs and EML, Section 10.2.4: Cryptococcosis.",
    "commonDosage": "10.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "No symptoms present and CSF CrAg negative",
    "brandName": "LP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "No symptoms present and CSF CrAg negative (LP):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Cryptococcal meningitis: 4",
    "brandName": "6 weeks after starting antifungal therapy.",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Cryptococcal meningitis: 4–6 weeks after starting antifungal therapy.",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer all patients that are CSF CrAg positive",
    "brandName": "cryptococcal meningitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer all patients that are CSF CrAg positive (cryptococcal meningitis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer all symptomatic patients that are CSF CrAg negative",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer all symptomatic patients that are CSF CrAg negative (non-meningeal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diarrhoea persisting for 4 weeks is a WHO stage 3 condition",
    "brandName": "if there is weight loss or",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Diarrhoea persisting for 4 weeks is a WHO stage 3 condition (if there is weight loss or",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fever it is stage 4",
    "brandName": ".",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fever it is stage 4).",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cotrimoxazole, oral, 320/1600 mg",
    "brandName": "4 single strength",
    "strength": "320",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cotrimoxazole, oral, 320/1600 mg (4 single strength (80/400 mg) tablets) 12 hourly",
    "commonDosage": "320",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Followed by 160/800 mg",
    "brandName": "2 single strength",
    "strength": "160",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Followed by 160/800 mg (2 single strength (80/400 mg tablets) daily until CD4",
    "commonDosage": "160",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antiviral",
    "brandName": "active against herpes simplex",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antiviral (active against herpes simplex) e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Severe pain can occur after shingles has healed",
    "brandName": "post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Severe pain can occur after shingles has healed (post-herpetic neuralgia).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Shingles is less infectious than varicella",
    "brandName": "chickenpox",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Shingles is less infectious than varicella (chickenpox) and isolation is not warranted.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 500mg to 1 g, 4 to 6 hourly as required",
    "brandName": "maximum of 4 g in 24",
    "strength": "500mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 500mg to 1 g, 4 to 6 hourly as required (maximum of 4 g in 24",
    "commonDosage": "500mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For prolonged pain occurring after shingles has healed",
    "brandName": "post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For prolonged pain occurring after shingles has healed (post-herpetic neuralgia),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Disseminated disease",
    "brandName": "many vesicles extending beyond the main area",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Disseminated disease (many vesicles extending beyond the main area).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Features of meningitis",
    "brandName": "headache and neck stiffness",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Features of meningitis (headache and neck stiffness).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Severe post",
    "brandName": "herpetic neuralgia not responding to amitriptyline",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Severe post-herpetic neuralgia not responding to amitriptyline.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "from further disease progression and for adjusting the dose of relevant medicines",
    "brandName": "See",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "from further disease progression and for adjusting the dose of relevant medicines (See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 11.3: Dosing and important adverse effects associated with ART",
    "brandName": ".",
    "strength": "11.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 11.3: Dosing and important adverse effects associated with ART).",
    "commonDosage": "11.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Patients with persistent significant proteinuria",
    "brandName": "1+ or more",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Patients with persistent significant proteinuria (1+ or more).",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV is a retrovirus affecting immune cells, especially CD4 T",
    "brandName": "lymphocytes. In advanced",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV is a retrovirus affecting immune cells, especially CD4 T-lymphocytes. In advanced",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV",
    "brandName": "exposed, unknown infection status",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV-exposed, unknown infection status (at risk of becoming HIV-infected).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children <10 years of age: follow the paediatric antiretroviral therapy",
    "brandName": "ART",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children <10 years of age: follow the paediatric antiretroviral therapy (ART)",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adolescents",
    "brandName": "10 to 19 years of age",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adolescents (10 to 19 years of age): follow the adult ART guidelines.",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ear discharge",
    "brandName": "ever",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ear discharge (ever).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "repeat age",
    "brandName": "appropriate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "repeat age-appropriate",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "persistent generalised lymphadenopathy",
    "brandName": "PGL",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "persistent generalised lymphadenopathy (PGL).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lineal gingival erythema",
    "brandName": "LGE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lineal gingival erythema (LGE),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "moderate unexplained malnutrition",
    "brandName": "not adequately responding to standard therapy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "moderate unexplained malnutrition (not adequately responding to standard therapy).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "unexplained persistent fever",
    "brandName": "above 37.5°C, intermittent or constant, for longer",
    "strength": "37.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "unexplained persistent fever (above 37.5°C, intermittent or constant, for longer than one",
    "commonDosage": "37.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "chronic HIV",
    "brandName": "associated lung disease including bronchiectasis.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "chronic HIV-associated lung disease including bronchiectasis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "CMV infection",
    "brandName": "CMV retinitis or infections of organs other than l",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "CMV infection (CMV retinitis or infections of organs other than liver, spleen or lymph nodes;",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "onset at age one month of more",
    "brandName": ",",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "onset at age one month of more),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV associated recto",
    "brandName": "vaginal fistula,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV associated recto-vaginal fistula,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cerebral or B cell non",
    "brandName": "Hodgkin lymphoma,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cerebral or B cell non-Hodgkin lymphoma,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "progressive multifocal leukoencephalopathy",
    "brandName": "PML",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "progressive multifocal leukoencephalopathy (PML),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "An HIV",
    "brandName": "exposed infant or child is one born to a mother li",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "An HIV-exposed infant or child is one born to a mother living with HIV, until HIV infection",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "VL and giving post",
    "brandName": "exposure prophylaxis to the infant, a strategy now",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "VL and giving post-exposure prophylaxis to the infant, a strategy now known as Vertical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "“HIV Testing in Children”.",
    "brandName": "See section above: HIV infection in children",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "“HIV Testing in Children”. (See section above: HIV infection in children (<10 years",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "effort is made to regain viral suppression. Their infants should receive high",
    "brandName": "risk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "effort is made to regain viral suppression. Their infants should receive high-risk",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infants of mothers who are failing third",
    "brandName": "line PI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infants of mothers who are failing third-line PI-based treatment.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thereafter, the HIV",
    "brandName": "exposed infant may be classified into one of the f",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thereafter, the HIV-exposed infant may be classified into one of the following categories",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Unknown risk, e.g. abandoned infant",
    "brandName": "manage as high risk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Unknown risk, e.g. abandoned infant (manage as high risk).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "considered high",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "considered high-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "*Non",
    "brandName": "breastfeeding mother diagnosed HIV",
    "strength": "72 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "*Non-breastfeeding mother diagnosed HIV-positive >72 hours after delivery: Do not start the infant",
    "commonDosage": "72 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 11.9: Risk categories for HIV",
    "brandName": "exposed infants",
    "strength": "11.9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 11.9: Risk categories for HIV-exposed infants",
    "commonDosage": "11.9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.4: HIV prophylaxis in HIV",
    "brandName": "exposed infant at high risk after delivery",
    "strength": "11.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.4: HIV prophylaxis in HIV-exposed infant at high risk after delivery",
    "commonDosage": "11.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.5: Management of HIV",
    "brandName": "exposed infant of unknown risk",
    "strength": "11.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.5: Management of HIV-exposed infant of unknown risk",
    "commonDosage": "11.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Non",
    "brandName": "breastfeeding mother diagnosed HIV positive >72 ho",
    "strength": "72 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Non-breastfeeding mother diagnosed HIV positive >72 hours after delivery:",
    "commonDosage": "72 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1.5",
    "brandName": "1.9 kg",
    "strength": "1.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1.5-1.9 kg",
    "commonDosage": "1.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2.0",
    "brandName": "2.49 kg",
    "strength": "2.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2.0– 2.49 kg",
    "commonDosage": "2.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "0.35 mL",
    "brandName": "0.35",
    "strength": "0.35 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "0.35 mL (0.35",
    "commonDosage": "0.35 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "0.6 mL",
    "brandName": "0.6",
    "strength": "0.6 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "0.6 mL (0.6",
    "commonDosage": "0.6 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 mL",
    "brandName": "10 mg",
    "strength": "1 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 mL (10 mg)",
    "commonDosage": "1 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1.5 mL",
    "brandName": "15 mg",
    "strength": "1.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1.5 mL (15 mg)",
    "commonDosage": "1.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2 mL",
    "brandName": "20",
    "strength": "2 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2 mL (20",
    "commonDosage": "2 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 mL",
    "brandName": "30 mg",
    "strength": "3 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 mL (30 mg)",
    "commonDosage": "3 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4 mL",
    "brandName": "40 mg",
    "strength": "4 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4 mL (40 mg)",
    "commonDosage": "4 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6 mL",
    "brandName": "60",
    "strength": "6 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6 mL (60",
    "commonDosage": "6 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "11.6 MANAGEMENT OF HIV",
    "brandName": "INFECTED CHILDREN",
    "strength": "11.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "11.6 MANAGEMENT OF HIV-INFECTED CHILDREN (<10 YEARS)",
    "commonDosage": "11.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "age",
    "brandName": "appropriate tests. See Section 11.5: The HIV",
    "strength": "11.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "age-appropriate tests. See Section 11.5: The HIV-exposed infant.",
    "commonDosage": "11.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Disclosure should be child",
    "brandName": "led in terms of information required, language use",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Disclosure should be child-led in terms of information required, language used and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Encourage breastfeeding in all mothers with HIV",
    "brandName": "infected children, with introduction",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Encourage breastfeeding in all mothers with HIV-infected children, with introduction",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Height, weight, head circumference",
    "brandName": "if child <2",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Height, weight, head circumference (if child <2",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clinical assessment including medicine",
    "brandName": "related",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clinical assessment including medicine-related",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "More frequent monitoring",
    "brandName": "3 to 6 monthly",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "More frequent monitoring (3 to 6 monthly)",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If on PI",
    "brandName": "based regimen:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If on PI-based regimen:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Continue deworming and vitamin A programme as in the HIV",
    "brandName": "uninfected child.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Continue deworming and vitamin A programme as in the HIV-uninfected child.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "No indications for deferral",
    "brandName": "e.g. major organ dysfunction",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "No indications for deferral (e.g. major organ dysfunction). If medical contraindications",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "circumstances of vulnerable children",
    "brandName": "e.g. orphans",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "circumstances of vulnerable children (e.g. orphans) be addressed to facilitate",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sensitive, age",
    "brandName": "appropriate disclosure facilitates adherence.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sensitive, age-appropriate disclosure facilitates adherence.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Single medicine substitutions may only be made when medicine",
    "brandName": "specific adverse",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Single medicine substitutions may only be made when medicine-specific adverse",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "First",
    "brandName": "line ART regimens for infants and children:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "First-line ART regimens for infants and children:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ALD1: Clients on a DTG",
    "brandName": "containing regimen, having never failed a previous",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ALD1: Clients on a DTG-containing regimen, having never failed a previous regimen",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ALD2: Clients on a DTG",
    "brandName": "containing regimen, who have failed a previous reg",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ALD2: Clients on a DTG-containing regimen, who have failed a previous regimen (old",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "‘second",
    "brandName": "line’ terminology",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "‘second- line’ terminology).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fixed",
    "brandName": "dose combinations are preferred to single agents.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fixed-dose combinations are preferred to single agents.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In patients being considered for an AZT",
    "brandName": "containing regimen, monitor for anaemia prior to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In patients being considered for an AZT-containing regimen, monitor for anaemia prior to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.6: First",
    "brandName": "line paediatric ART",
    "strength": "11.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.6: First-line paediatric ART-switching algorithm for neonates/infants/children (adopted",
    "commonDosage": "11.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breastfeeding, Adolescents, Children, Infants and Neonates",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breastfeeding, Adolescents, Children, Infants and Neonates).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "On PI based regimen for <2 years: switch to DTG based regimen",
    "brandName": "no VL",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "On PI based regimen for <2 years: switch to DTG based regimen (no VL",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Consider switching to ABC/3TC/LPV/r 4",
    "brandName": "in",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Consider switching to ABC/3TC/LPV/r 4-in-1 formulation and repeating HIV VL in 3",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "copies/mL, perform an HIV drug resistance test",
    "brandName": "DR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "copies/mL, perform an HIV drug resistance test (DR).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "No mutations or only M184V",
    "brandName": "switch to ABC/3TC/DTG.",
    "strength": "184",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "No mutations or only M184V – switch to ABC/3TC/DTG.",
    "commonDosage": "184",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Switching children on PI",
    "brandName": "containing regimens to DTG regimens",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Switching children on PI-containing regimens to DTG regimens",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.7: Switching children on PI",
    "brandName": "containing regimens to DTG regimens",
    "strength": "11.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.7: Switching children on PI-containing regimens to DTG regimens (adopted from the NDoH",
    "commonDosage": "11.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "*For guidance on the step",
    "brandName": "up adherence package, refer to the National adhere",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "*For guidance on the step-up adherence package, refer to the National adherence",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidelines. https://www.nacosa.org.za/wp",
    "brandName": "content/uploads/2016/11/Integrated",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidelines. https://www.nacosa.org.za/wp-content/uploads/2016/11/Integrated-",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adherence",
    "brandName": "Guidelines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adherence-Guidelines-NDOH.pdf",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Third",
    "brandName": "line",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Third-line (patients failing ALD2)",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Application forms for third",
    "brandName": "line antiretroviral therapy",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Application forms for third-line antiretroviral therapy (patients failing ALD2) can be",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "accessed at the following link: https://knowledgehub.health.gov.za/elibrary/third",
    "brandName": "line",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "accessed at the following link: https://knowledgehub.health.gov.za/elibrary/third-line-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Important information to assist in applying for third",
    "brandName": "line antiretrovirals can be found at",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Important information to assist in applying for third-line antiretrovirals can be found at",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.8: Management of confirmed virological failure in adolescents on TLD",
    "brandName": "adopted from the",
    "strength": "11.8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.8: Management of confirmed virological failure in adolescents on TLD (adopted from the",
    "commonDosage": "11.8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breastfeeding, Adolescents, Children, Infants and Neonates",
    "brandName": ".TLD1 = TLD as a first line ART",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breastfeeding, Adolescents, Children, Infants and Neonates).TLD1 = TLD as a first line ART",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 11.9: Viral load monitoring for clients on TLD",
    "brandName": "adopted from the NDoH 2023 ART Clinical",
    "strength": "11.9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 11.9: Viral load monitoring for clients on TLD (adopted from the NDoH 2023 ART Clinical",
    "commonDosage": "11.9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 11.12: ART dosing tables for infants and children",
    "brandName": "adopted from the NDoH 2023 ART Clinical Guidelines",
    "strength": "11.12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 11.12: ART dosing tables for infants and children (adopted from the NDoH 2023 ART Clinical Guidelines for the Management of HIV in Adults,",
    "commonDosage": "11.12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Add the pellets",
    "brandName": "from the required number of capsules",
    "strength": "N/A",
    "form": "capsule",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Add the pellets (from the required number of capsules) to a spoonful of food a little at a time. For example, porridge can be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All HIV",
    "brandName": "infected infants",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All HIV-infected infants (<1 year), starting from 6 weeks of age.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Any child 1",
    "brandName": "5 years of age with CD4 <25%, or WHO stage 3 and 4",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Any child 1–5 years of age with CD4 <25%, or WHO stage 3 and 4.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5 mL",
    "brandName": "",
    "strength": "5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5 mL)",
    "commonDosage": "5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tests at least 3",
    "brandName": "6 months apart",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tests at least 3-6 months apart (regardless of clinical stage), i.e.:",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Child 1",
    "brandName": "5 years of age: CD4 >25%.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Child 1-5 years of age: CD4 >25%.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TB should be considered early in non",
    "brandName": "resolving pneumonias. At every follow up visit,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TB should be considered early in non-resolving pneumonias. At every follow up visit,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chest radiograph",
    "brandName": "CXR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chest radiograph (CXR).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Give TB prophylaxis to all HIV",
    "brandName": "infected children in whom no evidence of TB diseas",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Give TB prophylaxis to all HIV-infected children in whom no evidence of TB disease is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TST",
    "brandName": "positive",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TST-positive (this test  is only reliable the first time TPT is given).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Repeat course if an HIV",
    "brandName": "infected patient, irrespective of age, is re",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Repeat course if an HIV-infected patient, irrespective of age, is re-exposed to a TB",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "children with TB meningitis",
    "brandName": "start ART at 4 weeks regardless of CD4 count to",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "children with TB meningitis – start ART at 4 weeks regardless of CD4 count to",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the child needs to take concomitant ART and rifampicin",
    "brandName": "containing treatment:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the child needs to take concomitant ART and rifampicin-containing treatment:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Avoid using double",
    "brandName": "dose lopinavir/ritonavir solution in young childre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Avoid using double-dose lopinavir/ritonavir solution in young children. If",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Give pyridoxine",
    "brandName": "vitamin B6",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Give pyridoxine (vitamin B6) to all children on TB treatment and ART, to avoid",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer children with cognitive",
    "brandName": "learning problems",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer children with cognitive (learning problems) and motor delays for assesment and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Young women/men <35 kg or <15 years of age who are not Tanner stage 3",
    "brandName": "sexual",
    "strength": "35 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Young women/men <35 kg or <15 years of age who are not Tanner stage 3 (sexual",
    "commonDosage": "35 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "maturity",
    "brandName": "or greater.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "maturity) or greater.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tenofovir disoproxil fumarate",
    "brandName": "TDF",
    "strength": "300 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tenofovir disoproxil fumarate (TDF), oral, 300 mg daily.",
    "commonDosage": "300 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidelines*",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidelines*)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If HIV",
    "brandName": "negative, consider PrEP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If HIV-negative, consider PrEP",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To identify pre",
    "brandName": "existing renal",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To identify pre-existing renal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If HBsAg",
    "brandName": "positive, do ALT prior to PrEP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If HBsAg-positive, do ALT prior to PrEP",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ALT if HBsAg",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ALT if HBsAg-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "TDF + FTC is active against hepatitis B",
    "brandName": "HBV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "TDF + FTC is active against hepatitis B (HBV) infection. HBV infection is not a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antigen",
    "brandName": "HBsAg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antigen (HBsAg)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Negative",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Negative (-)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Frequency dependant on pregnancy status, age and co",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Frequency dependant on pregnancy status, age and co-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 11.15: Monitoring of person",
    "brandName": "s",
    "strength": "11.15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 11.15: Monitoring of person(s) on PrEP",
    "commonDosage": "11.15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gastrointestinal symptoms",
    "brandName": "diarrhoea, nausea, vomiting and flatulence",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gastrointestinal symptoms (diarrhoea, nausea, vomiting and flatulence), unintentional",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mild and self",
    "brandName": "limiting; do not require discontinuation.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mild and self-limiting; do not require discontinuation.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HBsAg",
    "brandName": "positive, with abnormal ALT.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HBsAg-positive, with abnormal ALT.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NOTE: In patients with Chronic Kidney Disease",
    "brandName": "CKD",
    "strength": "60mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NOTE: In patients with Chronic Kidney Disease (CKD) with eGFR <60mL/min, PrEP is",
    "commonDosage": "60mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "M. bovis",
    "brandName": "BCG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "M. bovis (BCG).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Exclude other active or inadequately treated diseases",
    "brandName": "including DR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Exclude other active or inadequately treated diseases (including DR-TB).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aug 27;373",
    "brandName": "9",
    "strength": "27",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aug 27;373(9):795-807. http://www.ncbi.nlm.nih.gov/pubmed/26192873",
    "commonDosage": "27",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in Africa. N Engl J Med. 2015 Aug 27;373",
    "brandName": "9",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. http://www.ncbi.nlm.nih.gov/pubmed/26193126",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Eligibility for ART",
    "brandName": "Immediate initiation of ART: Rosen S, Maskew M, Fo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Eligibility for ART- Immediate initiation of ART: Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, Sanne",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Randomized Controlled Trial. PLoS Med. 2016 May 10;13",
    "brandName": "5",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Randomized Controlled Trial. PLoS Med. 2016 May 10;13(5):e1002015. https://www.ncbi.nlm.nih.gov/pubmed/27163694",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 Immediate initiation of ART, pregnant and breastfeeding women: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Adult",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 Immediate initiation of ART, pregnant and breastfeeding women: National Department of Health: Affordable Medicines, EDP-Adult",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hospital level. Medicine Review: Dolutegravir in pregnant women and women of child",
    "brandName": "bearing potential",
    "strength": "17 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hospital level. Medicine Review: Dolutegravir in pregnant women and women of child-bearing potential (WOCP), 17 June 2021.",
    "commonDosage": "17 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4Timing of ART initiation",
    "brandName": "pulmonary TB",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4Timing of ART initiation (pulmonary TB): Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A,Nachega JB. Optimal",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Timing of Antiretroviral Therapy Initiation for HIV",
    "brandName": "Infected Adults With  Newly Diagnosed Pulmonary Tu",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With  Newly Diagnosed Pulmonary Tuberculosis: A Systematic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Review and Meta",
    "brandName": "analysis. Ann Intern Med. 2015 Jul 7;163",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Review and Meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9.http://www.ncbi.nlm.nih.gov/pubmed/26148280",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5Timing of ART initiation",
    "brandName": "tuberculous meningitis",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5Timing of ART initiation (tuberculous meningitis): Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, Dung NT, Chau NV, Bang",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapy in human immunodeficiency virus",
    "brandName": "HIV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2011 Jun;52",
    "brandName": "11",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2011 Jun;52(11):1374-83. http://www.ncbi.nlm.nih.gov/pubmed/21596680",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6 Timing of ART initiation",
    "brandName": "cryptococcal meningitis",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6 Timing of ART initiation (cryptococcal meningitis): Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antiretroviral treatment in HIV",
    "brandName": "positive people with cryptococcal meningitis. Coch",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018 Jul",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "24;7",
    "brandName": "7",
    "strength": "24",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "24;7(7):CD009012. https://pubmed.ncbi.nlm.nih.gov/30039850/",
    "commonDosage": "24",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Timing of ART initiation",
    "brandName": "cryptococcal meningitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Timing of ART initiation (cryptococcal meningitis): National Department of Health: National Consolidated Guidelines for the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7 Timing of ART initiation",
    "brandName": "asymptomatic cryptococcosis",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7 Timing of ART initiation (asymptomatic cryptococcosis): Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, Rabie",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "9Dolutegravir, oral",
    "brandName": "first",
    "strength": "9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "9Dolutegravir, oral (first-line ART): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review:",
    "commonDosage": "9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir in HIV‐infected patients commencing first‐line antiretroviral therapy, updated 27 July 2021",
    "brandName": "including addendum of use",
    "strength": "27 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir in HIV‐infected patients commencing first‐line antiretroviral therapy, updated 27 July 2021 (including addendum of use",
    "commonDosage": "27 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of dolutegravir with rifampicin",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of dolutegravir with rifampicin).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir, oral",
    "brandName": "first",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir, oral (first-line ART): Rutherford GW, Horvath H. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Systematic Review. PLoS One. 2016 Oct 13;11",
    "brandName": "10",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Systematic Review. PLoS One. 2016 Oct 13;11(10):e0162775. https://www.ncbi.nlm.nih.gov/pubmed/27736859",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir, oral",
    "brandName": "first",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir, oral (first-line ART): South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for the",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10 Dolutegravir, oral",
    "brandName": "first",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10 Dolutegravir, oral (first-line ART in pregnancy/ WOCP): National Department of Health: Affordable Medicines, EDP-Adult Hospital level.",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicine Review: Dolutegravir in pregnant women and women of child",
    "brandName": "bearing potential",
    "strength": "17 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicine Review: Dolutegravir in pregnant women and women of child-bearing potential (WOCP), 17 June 2021.",
    "commonDosage": "17 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir, oral",
    "brandName": "risk of NTDs",
    "strength": "29 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir, oral (risk of NTDs): National Department of Health. Notice: Updated guidance of dolutegravir in pregnancy, 29 June 2021",
    "commonDosage": "29 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "11 Dolutegravir, oral",
    "brandName": "first",
    "strength": "11 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "11 Dolutegravir, oral (first-line ART with concomitant rifampicin): National Department of Health: Affordable Medicines, EDP-Adult Hospital",
    "commonDosage": "11 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "level. Medicine Review: Dolutegravir in HIV‐infected patients commencing first‐line antiretroviral therapy, updated 27 July 2021",
    "brandName": "including",
    "strength": "27 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "level. Medicine Review: Dolutegravir in HIV‐infected patients commencing first‐line antiretroviral therapy, updated 27 July 2021 (including",
    "commonDosage": "27 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "addendum of use of dolutegravir with rifampicin",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "addendum of use of dolutegravir with rifampicin).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "al. Dolutegravir",
    "brandName": "based Antiretroviral Therapy for Patients Coinfect",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "review and meta",
    "brandName": "analysis. J Antimicrob Chemother. 2014 Dec;69",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "review and meta-analysis. J Antimicrob Chemother. 2014 Dec;69(12):3169-80.http://www.ncbi.nlm.nih.gov/pubmed/25074854",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15  Dual therapy",
    "brandName": "dolutegravir/lamivudine: Cahn P, Madero JS, Arriba",
    "strength": "15  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15  Dual therapy – dolutegravir/lamivudine: Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al; GEMINI Study Team.",
    "commonDosage": "15  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral",
    "brandName": "naive adults with HIV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 infection",
    "brandName": "GEMINI",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lancet. 2019 Jan 12;393",
    "brandName": "10167",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lancet. 2019 Jan 12;393(10167):143-155. https://www.ncbi.nlm.nih.gov/pubmed/30420123",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dual therapy",
    "brandName": "dolutegravir/lamivudine: Hidalgo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dual therapy – dolutegravir/lamivudine: Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, et al. DOLAMA study:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV",
    "brandName": "1",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients. Medicine",
    "brandName": "Baltimore",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients. Medicine  (Baltimore). 2019 Aug;98(32):e16813. https://www.ncbi.nlm.nih.gov/pubmed/31393412",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://knowledgehub.health.gov.za/system/files/elibdownloads/2023",
    "brandName": "",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18Dolutegravir, oral",
    "brandName": "double",
    "strength": "18",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18Dolutegravir, oral (double-dose with concomitant rifampicin): National Department of Health: Affordable Medicines, EDP-Adult Hospital",
    "commonDosage": "18",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62",
    "brandName": "1",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir",
    "brandName": "based Antiretroviral Therapy for Patients Coinfect",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2020 Feb 3;70",
    "brandName": "4",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2020 Feb 3;70(4):549-556. https://pubmed.ncbi.nlm.nih.gov/30918967/",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "20Urine dipstick: Han TM, Naicker S, Ramdial PK, Assounga AG. A cross",
    "brandName": "sectional study of HIV",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "20Urine dipstick: Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "degrees of proteinuria in South Africa. Kidney Int. 2006 Jun;69",
    "brandName": "12",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "degrees of proteinuria in South Africa. Kidney Int. 2006 Jun;69(12):2243-50. http://www.ncbi.nlm.nih.gov/pubmed/16672914",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "21 LAM urine testing",
    "brandName": "DS",
    "strength": "21 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "21 LAM urine testing (DS-TB): Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA,",
    "commonDosage": "21 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LAM urine testing",
    "brandName": "DS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LAM urine testing (DS-TB): National Department of Health. Guidance on the use of the lipoarabinomannan lateral flow assay (LF-LAM)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22Emtricitabine, oral",
    "brandName": "red cell aplasia adverse drug reaction",
    "strength": "22",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22Emtricitabine, oral (red cell aplasia adverse drug reaction): Cohen K, Viljoen C, Njuguna C, Maartens G. Emtricitabine-associated",
    "commonDosage": "22",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "red cell aplasia. AIDS. 2019 May 1;33",
    "brandName": "6",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "red cell aplasia. AIDS. 2019 May 1;33(6):1095-1096. https://www.ncbi.nlm.nih.gov/pubmed/30946164",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "23Efavirenz, oral",
    "brandName": "encephalopathy adverse drug reaction",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "23Efavirenz, oral (encephalopathy adverse drug reaction): Variava E, Sigauke FR, Norman J, Rakgokong M, Muchichwa P, Mochan A,",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Maartens  G, Martinson NA. Brief Report: Late Efavirenz",
    "brandName": "Induced Ataxia and Encephalopathy: A Case Series. ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Maartens  G, Martinson NA. Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. J Acquir Immune Defic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Syndr. 2017 Aug 15;75",
    "brandName": "5",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Syndr. 2017 Aug 15;75(5):577-579. https://www.ncbi.nlm.nih.gov/pubmed/28520619",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infants and Neonates. April 2023. https://www.knowledgehub.org.za/elibrary/national",
    "brandName": "consolidated",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infants and Neonates. April 2023. https://www.knowledgehub.org.za/elibrary/national-consolidated-guidelines-management-hiv-adults-",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dosing of ART and ADRs: Datapharm Ltd. Electronic medicines compendium",
    "brandName": "emc",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dosing of ART and ADRs: Datapharm Ltd. Electronic medicines compendium (emc). [Internet][Accessed 28 November 2019]",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dosing of ART",
    "brandName": "renal impairment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dosing of ART (renal impairment): Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al.; HIV Medicine Association",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1;59",
    "brandName": "9",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1;59(9):e96-138. http://www.ncbi.nlm.nih.gov/pubmed/25234519",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017 Jul 15;18",
    "brandName": "1",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017 Jul 15;18(1):776. doi: 10.4102/sajhivmed.v18i1.776.",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "25 ART",
    "brandName": "rifampicin drug interaction: WHO. Consolidated gui",
    "strength": "25 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "25 ART-rifampicin drug interaction: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring:",
    "commonDosage": "25 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ART",
    "brandName": "rifampicin drug interaction: South African Nationa",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ART-rifampicin drug interaction: South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for the",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atazanavir",
    "brandName": "PPI/H2",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atazanavir-PPI/H2-anatagonist interaction: University of Liverpool HIV Drug Interaction online tool. https://www.hiv-",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atazanavir",
    "brandName": "PPI interaction: Khanlou H, Farthing C. Co",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atazanavir-PPI interaction: Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Acquir Immune Defic Syndr. 2005 Aug 1;39",
    "brandName": "4",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Acquir Immune Defic Syndr. 2005 Aug 1;39(4):503. https://www.ncbi.nlm.nih.gov/pubmed/16010179",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atazanavir",
    "brandName": "PPI interaction: European Medicines Agency. Public",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atazanavir-PPI interaction: European Medicines Agency. Public Statement: Important new pharmacokinetic data demonstrating that",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.ema.europa.eu/en/documents/public",
    "brandName": "statement/important",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.ema.europa.eu/en/documents/public-statement/important-new-pharmacokinetic-data-demonstrating-reyataz-atazanavir-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cotrimoxazole, oral",
    "brandName": "indications for primary prophylaxis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cotrimoxazole, oral (indications for primary prophylaxis): WHO. Consolidated guidelines on HIV prevention, testing, treatment,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "level. Evidence summary: Is co",
    "brandName": "trimoxazole safe to use in pregnancy, March 2011. ",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "level. Evidence summary: Is co-trimoxazole safe to use in pregnancy, March 2011. http://www.health.gov.za/",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Database Syst Rev. 2003;",
    "brandName": "3",
    "strength": "2003",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Database Syst Rev. 2003;(3):CD003108. http://www.ncbi.nlm.nih.gov/pubmed/12917946",
    "commonDosage": "2003",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "30 Cotrimoxazole, oral",
    "brandName": "criteria for discontinuation",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "30 Cotrimoxazole, oral (criteria for discontinuation): WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isoniazid",
    "brandName": "IPT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isoniazid (IPT): Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isoniazid",
    "brandName": "IPT",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isoniazid (IPT): Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Rifapentine (3HP) as TPT in PLHIV on DTG-",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "regimens, November 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "regimens, November 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "32 Rifapentine",
    "brandName": "containing regimen",
    "strength": "32 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "32 Rifapentine-containing regimen (3HP): Affordable Medicines, EDP- Adult Hospital level. Medicine Review: Rifapentine (3HP) as TPT",
    "commonDosage": "32 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in PLHIV, November 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in PLHIV, November 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rifapentine",
    "brandName": "containing regimen",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rifapentine-containing regimen (3HP): Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Rifapentine (3HP) as TPT",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in PLHIV on DTG",
    "brandName": "regimens, November 2019. https://www.knowledgehub.",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in PLHIV on DTG-regimens, November 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "33 IPT in pregnancy: Affordable Medicines, EDP",
    "brandName": "Adult Hospital level. Medicine Review: Evidence re",
    "strength": "33 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "33 IPT in pregnancy: Affordable Medicines, EDP- Adult Hospital level. Medicine Review: Evidence review: IPT in pregnancy_v1.2_15 April",
    "commonDosage": "33 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2024_final approved. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2024",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2024_final approved. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "2024",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "34 ART",
    "brandName": "Candidiasis, oesophageal: WHO. Consolidated guidel",
    "strength": "34 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "34 ART - Candidiasis, oesophageal: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring:",
    "commonDosage": "34 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "35CrAg screening",
    "brandName": "CD4 <100 cells/mm3",
    "strength": "35",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "35CrAg screening (CD4 <100 cells/mm3): Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-",
    "commonDosage": "35",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV",
    "brandName": "infected persons with a CD4+ cell count <or = 100",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count <or = 100",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "CrAg screening",
    "brandName": "CD4 <100 cells/mm3",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "CrAg screening (CD4 <100 cells/mm3): Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, Vitoria M, Doherty M, Meintjes",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV",
    "brandName": "Infected Individuals: A Systematic Review and Meta",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clin Infect Dis. 2018 Mar 4;66",
    "brandName": "suppl_2",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159. https://pubmed.ncbi.nlm.nih.gov/29514236/",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV",
    "brandName": "infected persons: 2019",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "update. S Afr J HIV Med 2019;20",
    "brandName": "1",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "update. S Afr J HIV Med 2019;20(1):a1030. https://doi.org/10.4102/sajhivmed.v20i1.1030",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "38Fluconazole, oral",
    "brandName": "cryptococcosis",
    "strength": "38",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "38Fluconazole, oral (cryptococcosis): WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and",
    "commonDosage": "38",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "39 ART",
    "brandName": "delayed",
    "strength": "39 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "39 ART (delayed): Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, Hakim JG. Early versus delayed",
    "commonDosage": "39 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub",
    "brandName": "saharan Africa. Clin Infect Dis. 2010",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jun 1;50",
    "brandName": "11",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jun 1;50(11):1532-8.http://www.ncbi.nlm.nih.gov/pubmed/20415574",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ART",
    "brandName": "delayed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ART (delayed): WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guideline for the prevention, diagnosis and management of cryptococcal disease among HIV",
    "brandName": "infected persons: 2019 update. S Afr J HIV",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. S Afr J HIV",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Med 2019;20",
    "brandName": "1",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Med 2019;20(1):a1030. https://doi.org/10.4102/sajhivmed.v20i1.1030",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "birth defects. N Engl J Med. 2013 Aug 29;369",
    "brandName": "9",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "birth defects. N Engl J Med. 2013 Aug 29;369(9):830-9. http://www.ncbi.nlm.nih.gov/pubmed/23984730",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016 Jan 5;315",
    "brandName": "1",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016 Jan 5;315(1):58-67.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antivirals to treat herpes simplex",
    "brandName": "therapeutic class",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antivirals to treat herpes simplex (therapeutic class): Workowski KA, Bolan GA; Centers for Disease Control and Prevention.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64",
    "brandName": "RR",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum in: MMWR",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Recomm Rep. 2015 Aug 28;64",
    "brandName": "33",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Recomm Rep. 2015 Aug 28;64(33):924. https://www.ncbi.nlm.nih.gov/pubmed/26042815",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antivirals to treat herpes zoster",
    "brandName": "therapeutic class",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antivirals to treat herpes zoster (therapeutic class): McDonald EM, De Kock J, Ram FS. Antivirals for management of herpes zoster",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "including ophthalmicus: a systematic review of high",
    "brandName": "quality randomized controlled trials. Antiviral Th",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antiviral Therapy 2012; 17(2): 255-264.",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management HIV",
    "brandName": "infected children and adolescents: WHO. Consolidat",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management HIV-infected children and adolescents: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PMTCT",
    "brandName": "risk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PMTCT(risk-stratified): Beste S, Essajee S, Siberry G, Hannaford A, Dara J, Sugandhi N, Penazzato M. Optimal Antiretroviral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prophylaxis in Infants at High Risk of Acquiring HIV: A Systematic Review. Pediatr Infect Dis J. 2018 Feb;37",
    "brandName": "2",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prophylaxis in Infants at High Risk of Acquiring HIV: A Systematic Review. Pediatr Infect Dis J. 2018 Feb;37(2):169-175.",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "46 PMTCT",
    "brandName": "HIV prophylaxis in high risk infants",
    "strength": "46 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "46 PMTCT (HIV prophylaxis in high risk infants – management of high maternal VL after delivery): WHO. Consolidated guidelines on HIV",
    "commonDosage": "46 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "47 PMTCT",
    "brandName": "Infant of unknown HIV",
    "strength": "47 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "47 PMTCT (Infant of unknown HIV-exposure): WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and",
    "commonDosage": "47 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "48 PMTCT Nielsen",
    "brandName": "Saines K, et. al. Three Postpartum Antiretroviral ",
    "strength": "48 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "48 PMTCT Nielsen-Saines K, et. al. Three Postpartum Antiretroviral Regimens to prevent Intrapartum HIV infection. NEJM. 2012;366:2368-",
    "commonDosage": "48 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "49 Monitoring in HIV",
    "brandName": "infected children: WHO. Consolidated guidelines on",
    "strength": "49 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "49 Monitoring in HIV-infected children: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and",
    "commonDosage": "49 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Monitoring in HIV",
    "brandName": "infected children: South African National Departme",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Monitoring in HIV-infected children: South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "50 Eligibility criteria for ART",
    "brandName": "children",
    "strength": "50 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "50 Eligibility criteria for ART (children): World Health Organisation. WHO. Consolidated guidelines on HIV prevention, testing, treatment,",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Eligibility criteria for ART",
    "brandName": "children",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Eligibility criteria for ART (children): South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "51 ART regimen algorithm",
    "brandName": "children",
    "strength": "51 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "51 ART regimen algorithm (children): South African National Department of Health. 2023 Antiretroviral Therapy Clinical Guidelines for the",
    "commonDosage": "51 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "52 Adjustment of previous 1st line regimens/switching algorithm",
    "brandName": "children",
    "strength": "52 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "52 Adjustment of previous 1st line regimens/switching algorithm (children): WHO. Consolidated guidelines on HIV prevention, testing,",
    "commonDosage": "52 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adjustment of previous 1st line regimens/switching algorithm",
    "brandName": "children",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adjustment of previous 1st line regimens/switching algorithm (children): South African National Department of Health. 2023",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "53 Lopinavir/ritonavir weight",
    "brandName": "band dosing",
    "strength": "53 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "53 Lopinavir/ritonavir weight-band dosing (children): WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery",
    "commonDosage": "53 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lopinavir/ritonavir weight",
    "brandName": "band dosing",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lopinavir/ritonavir weight-band dosing (children): South African National Department of Health. 2023 Antiretroviral Therapy Clinical",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Temporal Trends in Co",
    "brandName": "trimoxazole Use Among Children on Antiretroviral T",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PrEP regimen",
    "brandName": "Tenofovir + emtricitabine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PrEP regimen (Tenofovir + emtricitabine): Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'reilly KR, Koechlin FM, Rodolph M,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hodges",
    "brandName": "Mameletzis I, Grant RM. Effectiveness and safety o",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: A systematic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "review and meta",
    "brandName": "analysis. AIDS. AIDS. 2016 Jul 31;30",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "review and meta-analysis. AIDS. AIDS. 2016 Jul 31;30(12):1973-83. http://www.ncbi.nlm.nih.gov/pubmed/27149090",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "transmission. Sci Transl Med. 2011 Dec 7;3",
    "brandName": "112",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "transmission. Sci Transl Med. 2011 Dec 7;3(112):112re4. https://www.ncbi.nlm.nih.gov/pubmed/22158861",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PrEP regimen",
    "brandName": "Tenofovir + emtricitabine: adequate dosing",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PrEP regimen (Tenofovir + emtricitabine: adequate dosing): National Department of Health. 2021 Updated guidelines for the",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "provision of oral pre",
    "brandName": "exposure prophylaxis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "provision of oral pre-exposure prophylaxis (prep) to persons at substantial risk of HIV infection. https://www.knowledgehub.org.za/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Renal function monitoring",
    "brandName": "oral PrEP",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Renal function monitoring (oral PrEP): National Department of Health. 2021 Updated guidelines for the provision of oral pre-exposure",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "prophylaxis",
    "brandName": "prep",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "prophylaxis (prep) to persons at substantial risk of HIV infection. https://www.knowledgehub.org.za/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "57 Stopping oral PrEP",
    "brandName": "Tenofovir + emtricitabine",
    "strength": "57 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "57 Stopping oral PrEP (Tenofovir + emtricitabine): National Department of Health. 2021 Updated guidelines for the provision of oral pre-",
    "commonDosage": "57 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "exposure prophylaxis",
    "brandName": "prep",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "exposure prophylaxis (prep) to persons at substantial risk of HIV infection. https://www.knowledgehub.org.za/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12.1 Vaginal discharge syndrome",
    "brandName": "VDS",
    "strength": "12.1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12.1 Vaginal discharge syndrome (VDS)",
    "commonDosage": "12.1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12.4 Scrotal swelling",
    "brandName": "SSW",
    "strength": "12.4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12.4 Scrotal swelling (SSW)",
    "commonDosage": "12.4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12.5 Genital ulcer syndrome",
    "brandName": "GUS",
    "strength": "12.5 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12.5 Genital ulcer syndrome (GUS)",
    "commonDosage": "12.5 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12.11 Genital molluscum contagiosum",
    "brandName": "MC",
    "strength": "12.11 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12.11 Genital molluscum contagiosum (MC)",
    "commonDosage": "12.11 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "12.12 Genital warts",
    "brandName": "GW",
    "strength": "12.12 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "12.12 Genital warts (GW): Condylomata Accuminata",
    "commonDosage": "12.12 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The syndromic approach to Sexually Transmitted Infections",
    "brandName": "STIs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The syndromic approach to Sexually Transmitted Infections (STIs) diagnosis and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management is to treat the signs or symptoms",
    "brandName": "syndrome",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management is to treat the signs or symptoms (syndrome) of a group of diseases rather",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Bacterial vaginosis",
    "brandName": "overgrowth",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Bacterial vaginosis (overgrowth",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is important to take a good sexual history and undertake a thorough ano",
    "brandName": "genital",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is important to take a good sexual history and undertake a thorough ano-genital",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "activity",
    "brandName": "oral, vaginal, anal sex",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "activity (oral, vaginal, anal sex), the possibility of pregnancy (females), use of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» reason for referral: presumptive diagnosis",
    "brandName": "e.g. persistent cervicitis with suspected",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» reason for referral: presumptive diagnosis (e.g. persistent cervicitis with suspected",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "resistant gonorrhoea",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "resistant gonorrhoea)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» treatment history",
    "brandName": "including all medicines with dose and duration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» treatment history (including all medicines with dose and duration)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Circumcision promotion",
    "brandName": "counselling to continue condom use",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Circumcision promotion (counselling to continue condom use).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The Rapid Plasmin Reagin",
    "brandName": "RPR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The Rapid Plasmin Reagin (RPR) measures disease activity, but is not specific for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Treponema pallidum haemagglutination",
    "brandName": "TPHA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Treponema pallidum haemagglutination (TPHA) assay.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Treponema pallidum particle agglutination",
    "brandName": "TPPA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Treponema pallidum particle agglutination (TPPA) assay.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "e.g. 1:256 improving to 1:64",
    "brandName": ", or",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "e.g. 1:256 improving to 1:64), or",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Some patients, even with successful treatment for syphilis, may retain life",
    "brandName": "long positive",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Some patients, even with successful treatment for syphilis, may retain life-long positive",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "RPR results at low titres",
    "brandName": "≤1:8",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "RPR results at low titres (≤1:8), which do not change by more than one dilution difference",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "during the first two",
    "brandName": "infectious",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "during the first two (infectious) years of syphilis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In penicillin",
    "brandName": "allergic patients or if benzathine benzylpenicilli",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "In penicillin-allergic patients or if benzathine benzylpenicillin is unavailable:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral 1 g 8 hourly for 14 days",
    "brandName": "Doctor initiated",
    "strength": "1 g",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral 1 g 8 hourly for 14 days (Doctor initiated)",
    "commonDosage": "1 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Probenecid, oral 250 mg, 8 hourly for 14 days",
    "brandName": "Doctor initiated",
    "strength": "250 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Probenecid, oral 250 mg, 8 hourly for 14 days (Doctor initiated).",
    "commonDosage": "250 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If penicillin",
    "brandName": "allergic and pregnant: Refer for penicillin desens",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "If penicillin-allergic and pregnant: Refer for penicillin desensitisation.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral 1 g 8 hourly for 28 days",
    "brandName": "Doctor initiated",
    "strength": "1 g",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral 1 g 8 hourly for 28 days (Doctor initiated)",
    "commonDosage": "1 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Probenecid, oral 250 mg, 8 hourly for 28 days",
    "brandName": "Doctor initiated",
    "strength": "250 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Probenecid, oral 250 mg, 8 hourly for 28 days (Doctor initiated).",
    "commonDosage": "250 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "**Penicillin allergic men and non",
    "brandName": "pregnant women avoid ceftriaxone and refer to rele",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "**Penicillin allergic men and non-pregnant women avoid ceftriaxone and refer to relevant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Warts on the ano",
    "brandName": "genital areas, vagina, cervix, meatus or urethra.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Warts on the ano-genital areas, vagina, cervix, meatus or urethra.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "inaccessible warts, e.g. intra",
    "brandName": "vaginal or cervical warts",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "inaccessible warts, e.g. intra-vaginal or cervical warts",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The bites cause intense itching, which often results in scratching with bacterial super",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The bites cause intense itching, which often results in scratching with bacterial super-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Apply to the eyelid margins",
    "brandName": "cover the eyelashes",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Apply to the eyelid margins (cover the eyelashes) daily for 10 days to smother lice",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Coetzee J, Unemo M. Phenotypic and genetic characterization of the first two cases of extended",
    "brandName": "spectrum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Coetzee J, Unemo M. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jun;68",
    "brandName": "6",
    "strength": "68",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jun;68(6):1267-70. https://www.ncbi.nlm.nih.gov/pubmed/23416957",
    "commonDosage": "68",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "got to do with it? South Afr J Epidemiol Infect 2013;28",
    "brandName": "2",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "got to do with it? South Afr J Epidemiol Infect 2013;28(2):77. https://journals.co.za/content/mp_sajei/28/2/EJC138699",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Remarkable increase in central Japan in 2001",
    "brandName": "2002 of Neisseria gonorrhoeae isolates with decrea",
    "strength": "2001",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin,",
    "commonDosage": "2001",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother. 2004 Aug;48",
    "brandName": "8",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother. 2004 Aug;48(8):3185-7.",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "regimens for the single",
    "brandName": "dose  treatment of gonococcal infection in Japan. ",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "regimens for the single-dose  treatment of gonococcal infection in Japan. J Infect Chemother. 2002 Mar;8(1):81-6.",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007 Aug;13",
    "brandName": "8",
    "strength": "2007 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007 Aug;13(8):1275-7. https://www.ncbi.nlm.nih.gov/pubmed/17953118",
    "commonDosage": "2007 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and untreatable gonorrhea. Future Microbiol. 2012 Dec;7",
    "brandName": "12",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and untreatable gonorrhea. Future Microbiol. 2012 Dec;7(12):1401-22. https://www.ncbi.nlm.nih.gov/pubmed/23231489",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2009 Sep;53",
    "brandName": "9",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2009 Sep;53(9):3744-51. https://www.ncbi.nlm.nih.gov/pubmed/19528266",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oct;65",
    "brandName": "10",
    "strength": "65",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oct;65(10):2141-8. https://www.ncbi.nlm.nih.gov/pubmed/20693173",
    "commonDosage": "65",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ceftriaxone, IM",
    "brandName": "Neisseria gonorrhoeae",
    "strength": "301",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ceftriaxone, IM (Neisseria gonorrhoeae): Contract circular RT301-2017: Ceftriaxone 250 mg, parenteral formulation.",
    "commonDosage": "301",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clotrimazole, topical: Vaginal discharge syndrome",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clotrimazole, topical: Vaginal discharge syndrome – non-sexually active women (monotherapy syndromic directed management –",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014",
    "brandName": "",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Syndrome aetiologies and HPV genotypes among patients attending Primary Health Care Facilities in South Africa, April 2014 –",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metronidazole, oral: Vaginal discharge syndrome",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Metronidazole, oral: Vaginal discharge syndrome – non-sexually active women (monotherapy syndromic directed management –",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycycline, oral",
    "brandName": "genital ulcer syndrome",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Doxycycline, oral (genital ulcer syndrome): World Health Organization. WHO guidelines for the treatment of Treponema pallidum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "studies. PLoS One. 2017 Jun 28;12",
    "brandName": "6",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "studies. PLoS One. 2017 Jun 28;12(6):e0180001. https://www.ncbi.nlm.nih.gov/pubmed/28658325",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pregnant women, 1st trimester",
    "brandName": "genital ulcer syndrome",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pregnant women, 1st trimester (genital ulcer syndrome): National Department of Health. Guidelines for Maternity Care in South",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Azitromycin, oral",
    "brandName": "bubo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Azitromycin, oral (bubo): González-Beiras C, Marks M, Chen CY, Roberts S, Mitjà O. Epidemiology of Haemophilus ducreyi",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infections. Emerg Infect Dis. 2016 Jan;22",
    "brandName": "1",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infections. Emerg Infect Dis. 2016 Jan;22(1):1-8. https://www.ncbi.nlm.nih.gov/pubmed/26694983",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Syphilis serology",
    "brandName": "RPR follow",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Syphilis serology (RPR follow-up test in doxycycline-treated patients not recommended): Liu HY, Han Y, Chen XS, Bai L, Guo SP,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Compared with Penicillin in HIV",
    "brandName": "infected Individuals. Acta Derm Venereol. 2016 Aug",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Compared with Penicillin in HIV-infected Individuals. Acta Derm Venereol. 2016 Aug 23;96(6):807-11.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Efficacy of Doxycycline in the Treatment of Syphilis. Antimicrob Agents Chemother. 2016 Dec 27;61",
    "brandName": "1",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Efficacy of Doxycycline in the Treatment of Syphilis. Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01092-16.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WHO guidelines for the treatment of Treponemapallidum",
    "brandName": "syphilis",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WHO guidelines for the treatment of Treponemapallidum (syphilis), 2016.",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806",
    "brandName": "eng.pdf",
    "strength": "10665",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf",
    "commonDosage": "10665",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral + probenecid, oral",
    "brandName": "Early syphilis treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral + probenecid, oral (Early syphilis treatment - pregnant/benzathine benzylpenicillin unavailable): Tanizaki R,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, et al. High",
    "brandName": "dose oral amoxicillin plus probenecid is highly ef",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with HIV infection. Clin Infect Dis. 2015;61",
    "brandName": "2",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with HIV infection. Clin Infect Dis. 2015;61(2):177-83. https://www.ncbi.nlm.nih.gov/pubmed/25829004",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Department of Health: Affordable Medicines, EDP",
    "brandName": "Adult Hospital level. Medicine Review: Amoxicllin+",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Amoxicllin+probenecid for syphilis in pregnant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Doxycycline, oral:  Late latent syphilis treatment",
    "brandName": "penicillin allergic: World Health Organization. WH",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 2",
    "description": "Doxycycline, oral:  Late latent syphilis treatment - penicillin allergic: World Health Organization. WHO guidelines for the treatment",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of Treponema pallidum",
    "brandName": "syphilis",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of Treponema pallidum (syphilis), 2016. http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "13.6 Adverse events following immunisation",
    "brandName": "AEFI",
    "strength": "13.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "13.6 Adverse events following immunisation (AEFI)",
    "commonDosage": "13.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Following Immunisation",
    "brandName": "AEFI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Following Immunisation (AEFI)).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "is needed, even if it means opening a multi",
    "brandName": "dose vial for just one person.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "is needed, even if it means opening a multi-dose vial for just one person.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "missed immunisations. These should be given according to the catch",
    "brandName": "up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "missed immunisations. These should be given according to the catch-up",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "when administered at 6 months of age. The measles/rubella vaccine can be co",
    "brandName": "",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "when administered at 6 months of age. The measles/rubella vaccine can be co-",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Treatment with locally acting",
    "brandName": "inhaled or low",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Treatment with locally acting (inhaled or low-dose topical) steroids.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "BCG",
    "brandName": "Bacillus Calmette Guérin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "BCG (Bacillus Calmette Guérin)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Administered into the skin",
    "brandName": "intradermally",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Administered into the skin (intradermally) on the right upper arm, overlying",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "occurs first.",
    "brandName": "It is acceptable to open a BCG vial for just one i",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "occurs first. (It is acceptable to open a BCG vial for just one infant)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the criteria to receive BCG are not met, i.e., the infant is: 1",
    "brandName": "Not on ART, 2",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the criteria to receive BCG are not met, i.e., the infant is: 1) Not on ART, 2) or",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the infant received the standard first",
    "brandName": "line TB treatment regimen BCG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the infant received the standard first-line TB treatment regimen BCG",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Catch",
    "brandName": "up dose of BCG vaccine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Catch-up dose of BCG vaccine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A ‘catch",
    "brandName": "up’ BCG should be administered to any child <10 ye",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A ‘catch-up’ BCG should be administered to any child <10 years of age who did",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hexavalent",
    "brandName": "DTaP",
    "strength": "0.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hexavalent (DTaP-IPV-HB-Hib), IM, 0.5 mL.",
    "commonDosage": "0.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy between 26",
    "brandName": "34 weeks’ gestation to maximise protection of pret",
    "strength": "26",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy between 26–34 weeks’ gestation to maximise protection of preterm",
    "commonDosage": "26",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If not administered between 26",
    "brandName": "34 weeks, a catch",
    "strength": "26",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If not administered between 26–34 weeks, a catch-up dose should be given at",
    "commonDosage": "26",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "any time, including in the immediate post",
    "brandName": "partum period.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "any time, including in the immediate post-partum period.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Not affected by feeding",
    "brandName": "breast or other",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Not affected by feeding (breast or other).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Protects against gastro",
    "brandName": "enteritis caused by rotavirus.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Protects against gastro-enteritis caused by rotavirus.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "RV, oral, administer the full vial",
    "brandName": "1 or 2 mL depending on the product used",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "RV, oral, administer the full vial (1 or 2 mL depending on the product used).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bloody stools, abdominal bloating and/or high fever",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bloody stools, abdominal bloating and/or high fever).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "PCV",
    "brandName": "Pneumococcal conjugated vaccine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "PCV (Pneumococcal conjugated vaccine)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Protects against invasive pneumococcal disease",
    "brandName": "meningitis, septicaemia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Protects against invasive pneumococcal disease (meningitis, septicaemia), pneumonia",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "vaccines at 6 months of age. However, it is considered safe to co",
    "brandName": "administer the",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "vaccines at 6 months of age. However, it is considered safe to co-administer the",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All vaccines should be kept in a refrigerator at a temperature of 2",
    "brandName": "8C.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All vaccines should be kept in a refrigerator at a temperature of 2–8C.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Use continuous temperature monitoring device e.g. fridge",
    "brandName": "tag for all vaccines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Use continuous temperature monitoring device e.g. fridge-tag for all vaccines (Min-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Live attenuated vaccines",
    "brandName": "BCG, OPV, measles/rubella",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Live attenuated vaccines (BCG, OPV, measles/rubella) are very sensitive to heat,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Vaccines should be stored in a purpose",
    "brandName": "built vaccine fridge. However, if unavailable",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Vaccines should be stored in a purpose-built vaccine fridge. However, if unavailable",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Middle shelf: BCG, Tdap, Hexavalent",
    "brandName": "DTaP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Middle shelf: BCG, Tdap, Hexavalent (DTaP-IPV-HB-Hib), HPV, RV, PCV and TT",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "vaccines",
    "brandName": "do not freeze",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "vaccines (do not freeze) with sufficient diluent for the BCG and measles/rubella",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Saltwater",
    "brandName": "filled bottles placed at the bottom of the fridge ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Saltwater-filled bottles placed at the bottom of the fridge can prolong the holdover",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Keep the fridge temperature between 2",
    "brandName": "8°C.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Keep the fridge temperature between 2–8°C.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "RoTavirus, HepaTiTis B and even diluenTs. Diluents",
    "brandName": "for measles/rubella and BCG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "RoTavirus, HepaTiTis B and even diluenTs. Diluents (for measles/rubella and BCG)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "temperature monitoring and recording",
    "brandName": ",",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "temperature monitoring and recording),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Discard the needle after using a multi",
    "brandName": "dose vial to avoid compromising the sterility of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Discard the needle after using a multi-dose vial to avoid compromising the sterility of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.sahpra.org.za/health",
    "brandName": "products",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.sahpra.org.za/health-products-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Protects against tetanus",
    "brandName": "post trauma",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Protects against tetanus (post trauma)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Give booster dose of TT/Tdap after every traumatic injury",
    "brandName": "unless administered in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Give booster dose of TT/Tdap after every traumatic injury (unless administered in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5 girls",
    "brandName": "≥ 9 years of age",
    "strength": "5 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5 girls (≥ 9 years of age) in public schools.",
    "commonDosage": "5 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All personnel working in a health care facility",
    "brandName": "including support staff",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All personnel working in a health care facility (including support staff) and student",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "who are HBsAg",
    "brandName": "positive or HBeAg",
    "strength": "6.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "who are HBsAg-positive or HBeAg-positive, see Section 6.6.5: Perinatal transmission of",
    "commonDosage": "6.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chronic cardiac or pulmonary conditions",
    "brandName": "including chronic heart",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chronic cardiac or pulmonary conditions (including chronic heart",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disease, hypertension, stroke, and diabetes",
    "brandName": ", chronic lung disease",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "disease, hypertension, stroke, and diabetes), chronic lung disease",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Commercially available products may differ in terms of the age",
    "brandName": "groups in which",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Commercially available products may differ in terms of the age-groups in which",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "they can be used",
    "brandName": "check the specific package insert.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "they can be used – check the specific package insert.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 Influenza vaccination: National Department of Health. Influenza Vaccination Guide, 2021. https://www.health.gov.za/nhi",
    "brandName": "edp",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 Influenza vaccination: National Department of Health. Influenza Vaccination Guide, 2021. https://www.health.gov.za/nhi-edp-stgs-eml/",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Influenza vaccination: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Primary Health Care level. Scopiing Review:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Influenza vaccination: National Department of Health: Affordable Medicines, EDP-Primary Health Care level. Scopiing Review:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Inactivated Influenza vaccines and egg allergy: A scoping review, 2023. https://www.health.gov.za/nhi",
    "brandName": "edp",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Inactivated Influenza vaccines and egg allergy: A scoping review, 2023. https://www.health.gov.za/nhi-edp-stgs-eml/",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2 Influenza vaccination",
    "brandName": "National Institute for Communicable Diseases. Infl",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2 Influenza vaccination –National Institute for Communicable Diseases. Influenza – NICD recommendations for the diagnosis,",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3 Influenza vaccination",
    "brandName": "malignancy as a priority: National Institute for C",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3 Influenza vaccination – malignancy as a priority: National Institute for Communicable Diseases. Influenza – NICD recommendations",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4 Influenza vaccination",
    "brandName": "2 doses in children: Chua H, Chiu SS, Chan ELY, Fe",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4 Influenza vaccination – 2 doses in children: Chua H, Chiu SS, Chan ELY, Feng S, Kwan MYW, Wong JSC, Peiris JSM, Cowling BJ.",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Effectiveness of Partial and Full Influenza Vaccination among Children Aged < 9 Years in Hong Kong, 2011",
    "brandName": "2019. J Infect Dis",
    "strength": "9 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Effectiveness of Partial and Full Influenza Vaccination among Children Aged < 9 Years in Hong Kong, 2011-2019. J Infect Dis",
    "commonDosage": "9 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2019;220:1568",
    "brandName": "1576. https://pubmed.ncbi.nlm.nih.gov/31290537/",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2019;220:1568–1576. https://pubmed.ncbi.nlm.nih.gov/31290537/",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Influenza vaccination",
    "brandName": "2 doses in children: Neuzil KM, Jackson LA, Nelson",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Influenza vaccination – 2 doses in children: Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F,",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine",
    "brandName": "naive 5",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "children. J Infect Dis 2006;194:1032",
    "brandName": "1039. https://pubmed.ncbi.nlm.nih.gov/16991077/",
    "strength": "2006",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "children. J Infect Dis 2006;194:1032–1039. https://pubmed.ncbi.nlm.nih.gov/16991077/",
    "commonDosage": "2006",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vaccination in Young Children. JAMA Pediatr 2020;174:643",
    "brandName": "644. https://pubmed.ncbi.nlm.nih.gov/32364577/",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vaccination in Young Children. JAMA Pediatr 2020;174:643–644. https://pubmed.ncbi.nlm.nih.gov/32364577/",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5 Influenza vaccination",
    "brandName": "2 doses in children: Chua H, Chiu SS, Chan ELY, Fe",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5 Influenza vaccination – 2 doses in children: Chua H, Chiu SS, Chan ELY, Feng S, Kwan MYW, Wong JSC, Peiris JSM, Cowling BJ.",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "6 Influenza vaccination dosing",
    "brandName": "QIV and TIV",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "6 Influenza vaccination dosing (QIV and TIV): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is usually self",
    "brandName": "limiting. May be an early manifestation of degener",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is usually self-limiting. May be an early manifestation of degenerative joint conditions",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Treat for 1 week",
    "brandName": "maximum 2 weeks",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Treat for 1 week (maximum 2 weeks) provided no new signs develop.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Squeeze test hands: Tenderness on squeezing across all 4 metarcarpo",
    "brandName": "",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Squeeze test hands: Tenderness on squeezing across all 4 metarcarpo-",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Squeeze test feet: Tenderness on squeezing across all 4 metartarso",
    "brandName": "phalangeal",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Squeeze test feet: Tenderness on squeezing across all 4 metartarso-phalangeal",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage co",
    "brandName": "morbidities.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage co-morbidities.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Modifying Anti",
    "brandName": "rheumatic Drugs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Modifying Anti-rheumatic Drugs (DMARDs).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For control of acute symptoms whilst awaiting referral",
    "brandName": "Doctor initiated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For control of acute symptoms whilst awaiting referral (Doctor initiated):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Continue for no longer than 3",
    "brandName": "6 months.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Continue for no longer than 3–6 months.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For control of acute symptoms during disease flares and in severe extra",
    "brandName": "articular",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For control of acute symptoms during disease flares and in severe extra-articular",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "manifestations e.g. scleritis",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "manifestations e.g. scleritis (Doctor prescribed):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "have no long",
    "brandName": "term disease modifying effects.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "have no long-term disease modifying effects.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NSAIDs are relatively contra",
    "brandName": "indicated in patients with significantly impaired ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NSAIDs are relatively contra-indicated in patients with significantly impaired renal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids",
    "brandName": "intermediate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids (intermediate-acting) e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In high",
    "brandName": "risk patients: > 65 years of age; history of pepti",
    "strength": "65 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In high-risk patients: > 65 years of age; history of peptic ulcer disease; on",
    "commonDosage": "65 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In many patients the 1st metatarso",
    "brandName": "phalangeal joint is initially involved. The instep",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In many patients the 1st metatarso-phalangeal joint is initially involved. The instep, ankle,",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Increase",
    "brandName": "high",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Increase (high) fluid intake.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prednisone, oral, 40 mg daily for 5 days",
    "brandName": "Doctor prescribed",
    "strength": "40 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prednisone, oral, 40 mg daily for 5 days (Doctor prescribed).",
    "commonDosage": "40 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Patients with suspected secondary gout",
    "brandName": "e.g. haematological malignancies",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Patients with suspected secondary gout (e.g. haematological malignancies).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Gout may co",
    "brandName": "exist with hypertension, diabetes mellitus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Gout may co-exist with hypertension, diabetes mellitus (as a risk factor for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "degenerative vascular disease",
    "brandName": "and chronic kidney disease. The pharmacological",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "degenerative vascular disease) and chronic kidney disease. The pharmacological",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» uric acid deposits in and around the joints and cartilages of the extremities",
    "brandName": "tophi",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» uric acid deposits in and around the joints and cartilages of the extremities (tophi)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Allopurinol, oral, 100 mg daily",
    "brandName": "Doctor initiated",
    "strength": "100 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Allopurinol, oral, 100 mg daily (Doctor initiated).",
    "commonDosage": "100 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A degenerative disorder typically affecting weight",
    "brandName": "bearing joints.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A degenerative disorder typically affecting weight-bearing joints.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 500 mg, 6",
    "brandName": "8 hourly when required.",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 500 mg, 6–8 hourly when required.",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stanislawska",
    "brandName": "Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovs",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep;62",
    "brandName": "9",
    "strength": "62",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep;62(9):2569-81. https://www.ncbi.nlm.nih.gov/pubmed/20872595",
    "commonDosage": "62",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NSAIDs",
    "brandName": "caution",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NSAIDs (caution): National Department of Health, Essential Drugs Programme: Adult Hospital level STGs and EML, 2019.",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NSAIDs",
    "brandName": "caution",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NSAIDs (caution): South African Medicines Formulary.  12th Edition.  Division of Clinical Pharmacology.  University of Cape Town,",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids",
    "brandName": "intermediate",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids (intermediate-acting): South African Medicines Formulary.  12th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prednisone, oral",
    "brandName": "acute flares",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prednisone, oral (acute flares): Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al.. EULAR",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "recommendations for the management of rheumatoid arthritis with synthetic and biological disease",
    "brandName": "modifying antirheumatic drugs: 2016",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "update. Ann Rheum Dis. 2017 Jun;76",
    "brandName": "6",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "update. Ann Rheum Dis. 2017 Jun;76(6):960-977. https://www.ncbi.nlm.nih.gov/pubmed/28264816",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Proton pump inhibitor",
    "brandName": "therapeutic class",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Proton pump inhibitor (therapeutic class): McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Final Report Update 5 [Internet]. Portland",
    "brandName": "OR",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Final Report Update 5 [Internet]. Portland (OR): Oregon Health & Science University; 2009 May.",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Proton pump inhibitor: Contract circular HP09",
    "brandName": "2014SD. http://www.health.gov.za",
    "strength": "09",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Proton pump inhibitor: Contract circular HP09-2014SD. http://www.health.gov.za",
    "commonDosage": "09",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of adverse events of low",
    "brandName": "dose aspirin and clopidogrel in randomized control",
    "strength": "2006",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624–38.",
    "commonDosage": "2006",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "gastrointestinal bleeding in patients taking low",
    "brandName": "dose aspirin for the prevention of cardiovascular ",
    "strength": "2002",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002",
    "commonDosage": "2002",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nov;16",
    "brandName": "11",
    "strength": "16",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nov;16(11):1945-53. http://www.ncbi.nlm.nih.gov/pubmed/12390104",
    "commonDosage": "16",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID",
    "brandName": "related ulcer complications. Am J",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Gastroenterol. 2009 Mar;104",
    "brandName": "3",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Gastroenterol. 2009 Mar;104(3):728-38. http://www.ncbi.nlm.nih.gov/pubmed/19240698",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NSAIDs and heart failure risk: Arfè A, Scotti L, Varas",
    "brandName": "Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NSAIDs and heart failure risk: Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Safety of Non",
    "brandName": "steroidal Anti",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium.. Non-steroidal anti-inflammatory drugs and risk of heart",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ibuprofen",
    "brandName": "aspirin interaction: Gladding PA, Webster MW, Farr",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Ibuprofen-aspirin interaction: Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "steroidal anti",
    "brandName": "inflammatory drugs and their pharmacodynamic inter",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008 Apr",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1;101",
    "brandName": "7",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1;101(7). http://www.ncbi.nlm.nih.gov/pubmed/18359332",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pharmacol.  2013 Mar;69",
    "brandName": "3",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pharmacol.  2013 Mar;69(3):365-71. http://www.ncbi.nlm.nih.gov/pubmed/22890587",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "herpetic neuralgia",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "herpetic neuralgia)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stroke consists of rapidly developing clinical signs of focal",
    "brandName": "at times global",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stroke consists of rapidly developing clinical signs of focal (at times global)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cerebral haemorrhage. A transient ischaemic attack",
    "brandName": "TIA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cerebral haemorrhage. A transient ischaemic attack (TIA) is defined as stroke",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aspirin, oral, 300 mg, as a pre",
    "brandName": "referral dose.",
    "strength": "300 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Aspirin, oral, 300 mg, as a pre-referral dose.",
    "commonDosage": "300 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» is on long",
    "brandName": "term anticoagulation therapy;",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» is on long-term anticoagulation therapy;",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "initiated at higher level of care",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "initiated at higher level of care).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All patients, if not contraindicated",
    "brandName": "e.g. haemorrhagic stroke, peptic ulcer, patients",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All patients, if not contraindicated (e.g. haemorrhagic stroke, peptic ulcer, patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "on anticoagulation therapy, etc.",
    "brandName": ":",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "on anticoagulation therapy, etc.):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lipid",
    "brandName": "lowering therapy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lipid-lowering therapy",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Refer all acute stroke cases for further management",
    "brandName": "preferably within 3",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Refer all acute stroke cases for further management (preferably within 3",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Discuss home safety risks",
    "brandName": "e.g. potential for patient to leave stove on",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Discuss home safety risks – e.g. potential for patient to leave stove on",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G20/G21.0",
    "brandName": "4/G21.8",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G20/G21.0-4/G21.8-9/G22",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disease, or secondary, i.e. drug",
    "brandName": "induced, or due to uncommon disorders that may",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disease, or secondary, i.e. drug-induced, or due to uncommon disorders that may",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» prevent complications and avoid serious drug",
    "brandName": "induced side effects.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» prevent complications and avoid serious drug-induced side effects.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G40.6",
    "brandName": "7; G41.0",
    "strength": "40.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G40.6-7; G41.0-2; G41.8-9; R56.8",
    "commonDosage": "40.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Mental health conditions, e.g., functional/dissociative seizures",
    "brandName": "also called",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Mental health conditions, e.g., functional/dissociative seizures (also called",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "psychogenic non",
    "brandName": "epileptic seizures",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "psychogenic non-epileptic seizures), rage reactions, panic attacks,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Sleep",
    "brandName": "related conditions, e.g., parasomnias, narcolepsy;",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Sleep-related conditions, e.g., parasomnias, narcolepsy;",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See https://www.epilepsydiagnosis.org/epilepsy",
    "brandName": "imitators.html for a full list of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See https://www.epilepsydiagnosis.org/epilepsy-imitators.html for a full list of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Specific criteria must be met to diagnose epilepsy",
    "brandName": "see Section 15.7: Epilepsy",
    "strength": "15.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Specific criteria must be met to diagnose epilepsy (see Section 15.7: Epilepsy).",
    "commonDosage": "15.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Epileptic seizures are diagnosed clinically, through eye",
    "brandName": "witness accounts, videos,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Epileptic seizures are diagnosed clinically, through eye-witness accounts, videos,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Epilepsy",
    "brandName": "ILAE",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Epilepsy (ILAE) into three types: focal, generalised, and unknown (see Figure 1).",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The evolution of the seizure",
    "brandName": "how it starts and progresses clinically",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The evolution of the seizure (how it starts and progresses clinically) directs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Focal seizures may present with motor signs",
    "brandName": "e.g., rhythmic jerking of one limb;",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Focal seizures may present with motor signs (e.g., rhythmic jerking of one limb;",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "automatisms such as lip",
    "brandName": "smacking",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "automatisms such as lip-smacking) or with non-motor signs (e.g., olfactory, tactile,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and whether there is progression to a tonic",
    "brandName": "clonic seizure. Consciousness is",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and whether there is progression to a tonic-clonic seizure. Consciousness is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "evaluated by assessing the levels of awareness",
    "brandName": "of themselves and their",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "evaluated by assessing the levels of awareness (of themselves and their",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "surroundings",
    "brandName": "and responsiveness",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "surroundings) and responsiveness (to other people or stimuli) of the person during",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consciousness is not known",
    "brandName": "e.g. unclear information",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consciousness is not known (e.g. unclear information).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Focal",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Focal-to-bilateral tonic-clonic seizure: the epileptic seizure progresses to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "generalised tonic",
    "brandName": "clonic seizures by a history of preceding focal si",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "generalised tonic-clonic seizures by a history of preceding focal signs (either",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "sensory or motor",
    "brandName": "occurring before complete loss of consciousness an",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "sensory or motor) occurring before complete loss of consciousness and the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "development of tonic",
    "brandName": "clonic movements. The terms ‘aura’ or ‘warning sig",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "development of tonic-clonic movements. The terms ‘aura’ or ‘warning signs’",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "− Generalised tonic",
    "brandName": "clonic seizures, with loss of consciousness and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "− Generalised tonic-clonic seizures, with loss of consciousness and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "− Generalised seizures other than tonic",
    "brandName": "clonic, including seizures with",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "− Generalised seizures other than tonic-clonic, including seizures with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "‘typical’ with abrupt loss of consciousness lasting 5",
    "brandName": "30 seconds and",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "‘typical’ with abrupt loss of consciousness lasting 5-30 seconds and",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.epilepsydiagnosis.org/seizure/seizure",
    "brandName": "classification",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.epilepsydiagnosis.org/seizure/seizure-classification-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G41.0",
    "brandName": "2; G41.8",
    "strength": "41.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G41.0-2; G41.8-9",
    "commonDosage": "41.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a continuous generalised or bilateral tonic",
    "brandName": "clonic seizure, or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a continuous generalised or bilateral tonic-clonic seizure, or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "two or more discrete generalised, or bilateral tonic",
    "brandName": "clonic seizures",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "two or more discrete generalised, or bilateral tonic-clonic seizures",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "symptoms",
    "brandName": "e.g., focal seizures with autonomic, sensory or pe",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "symptoms (e.g., focal seizures with autonomic, sensory or perceptual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metabolic conditions e.g., hypoglycaemia, hypo",
    "brandName": "or hypernatraemia,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Metabolic conditions e.g., hypoglycaemia, hypo- or hypernatraemia,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Brain lesions e.g., brain tumours, stroke and post",
    "brandName": "stroke sequelae,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Brain lesions e.g., brain tumours, stroke and post-stroke sequelae,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Poisoning or toxin ingestion",
    "brandName": "accidental or intentional as in an overdose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Poisoning or toxin ingestion (accidental or intentional as in an overdose)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Other neurological",
    "brandName": "e.g., cerebral palsy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Other neurological (e.g., cerebral palsy) or neurodegenerative (e.g.,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Epilepsies e.g., breakthrough seizures, treatment non",
    "brandName": "adherence,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Epilepsies e.g., breakthrough seizures, treatment non-adherence,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "recent changes to antiseizure medicine",
    "brandName": "ASM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "recent changes to antiseizure medicine (ASM), antiseizure medication",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» genetic/familial",
    "brandName": "syndromic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» genetic/familial (syndromic)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ischaemic encephalopathy",
    "brandName": "HIE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ischaemic encephalopathy (HIE). They rarely lead to a subsequent diagnosis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infants under 6 months of age cannot manifest generalised tonic",
    "brandName": "clonic",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infants under 6 months of age cannot manifest generalised tonic-clonic",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "from common triggers",
    "brandName": "e.g., dehydration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "from common triggers (e.g., dehydration) or rare causes (e.g., inborn",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "aetiologies",
    "brandName": "e.g., intracranial bleeds",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "aetiologies (e.g., intracranial bleeds).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "underlying focal cause",
    "brandName": "potentially a structural pathology",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "underlying focal cause (potentially a structural pathology):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ask for focality",
    "brandName": "point to the side of movement or change.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ask for focality – point to the side of movement or change.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not place anything",
    "brandName": "spoon or spatula, etc.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not place anything (spoon or spatula, etc.) in the patient's mouth.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adapted from https://www.kidshealth.org.nz/emergencies/emergencies",
    "brandName": "cpr",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adapted from https://www.kidshealth.org.nz/emergencies/emergencies-cpr",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "urgent medicine treatment for convulsive status epilepticus",
    "brandName": "refer",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "urgent medicine treatment for convulsive status epilepticus (refer",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1.1.10 Intra",
    "brandName": "Osseous Infusion in Emergencies.",
    "strength": "1.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1.1.10 Intra-Osseous Infusion in Emergencies.",
    "commonDosage": "1.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Once threat of falling no longer present, move to bed",
    "brandName": "with cot sides up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Once threat of falling no longer present, move to bed (with cot sides up), if",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, IV, 0.25mg/kg over 60 secs,",
    "brandName": "max 10mg/dose",
    "strength": "0.25mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, IV, 0.25mg/kg over 60 secs, (max 10mg/dose) (Doctor prescribed).",
    "commonDosage": "0.25mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, IV, 0.25mg/kg IV over 60 secs",
    "brandName": "max 10mg/dose",
    "strength": "0.25mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, IV, 0.25mg/kg IV over 60 secs (max 10mg/dose)",
    "commonDosage": "0.25mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, IM 0.1 mg/kg, OR buccal* 0.5 mg/kg",
    "brandName": "Doctor",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, IM 0.1 mg/kg, OR buccal* 0.5 mg/kg (Doctor",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, rectal**, 0.5 mg/kg",
    "brandName": "max 10mg/dose",
    "strength": "0.5 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, rectal**, 0.5 mg/kg (max 10mg/dose) (Doctor",
    "commonDosage": "0.5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "assist ventilation with bag",
    "brandName": "valve mask",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "assist ventilation with bag-valve mask (1 breath every 3–5 seconds) and refer",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Phenobarbital, IM 20mg/kg",
    "brandName": "Doctor prescribed",
    "strength": "20mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Phenobarbital, IM 20mg/kg (Doctor prescribed)",
    "commonDosage": "20mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "single dose",
    "brandName": "maximum dose: 4500 mg",
    "strength": "4500 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "single dose (maximum dose: 4500 mg).",
    "commonDosage": "4500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Remove needle then administer midazolam into the buccal cavity",
    "brandName": "between gum and cheeks",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Remove needle then administer midazolam into the buccal cavity (between gum and cheeks).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Remove needle then connect syringe to an NGT and gently insert into the rectum",
    "brandName": "or insert the whole barrel of the lubricated syrin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Remove needle then connect syringe to an NGT and gently insert into the rectum (or insert the whole barrel of the lubricated syringe if no NGT",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Determine the seizure type",
    "brandName": "focal or generalised",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Determine the seizure type (focal or generalised) and cause of the seizure.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Focal onset",
    "brandName": "e.g., a warning experience prior to generalised to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Focal onset (e.g., a warning experience prior to generalised tonic-clonic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "movements",
    "brandName": "and/or focal neurology warrants neuroimaging.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "movements) and/or focal neurology warrants neuroimaging.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Consider whether the criteria for a diagnosis of epilepsy are met",
    "brandName": "see Section",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Consider whether the criteria for a diagnosis of epilepsy are met (see Section",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Set up a follow up appointment to re",
    "brandName": "evaluate the diagnosis, educational and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Set up a follow up appointment to re-evaluate the diagnosis, educational and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "abnormalities",
    "brandName": "e.g. in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "abnormalities (e.g. in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "gravidarum",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "gravidarum)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» substance abuse",
    "brandName": "e.g.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» substance abuse (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» withdrawal syndromes",
    "brandName": "e.g.,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» withdrawal syndromes (e.g.,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "overdose",
    "brandName": "e.g., antiseizure",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "overdose (e.g., antiseizure",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» environmental toxins",
    "brandName": "e.g.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» environmental toxins (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.epilepsydiagnosis.org/epilepsy",
    "brandName": "imitators.html",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.epilepsydiagnosis.org/epilepsy-imitators.html).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Idiopathic generalised epilepsies",
    "brandName": "including epilepsy with generalised",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Idiopathic generalised epilepsies (including epilepsy with generalised",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epilepsy",
    "brandName": "may first present in this age group.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epilepsy) may first present in this age group.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Girls and women in child",
    "brandName": "bearing age group:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Girls and women in child-bearing age group:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ASM concentrations may become sub",
    "brandName": "therapeutic in pregnant women",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ASM concentrations may become sub-therapeutic in pregnant women",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "may be required during pregnancy",
    "brandName": "reduce dose after delivery",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "may be required during pregnancy (reduce dose after delivery).  Where",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "significant risk of birth defects",
    "brandName": "11%",
    "strength": "11%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "significant risk of birth defects (11%) and persistent",
    "commonDosage": "11%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy and in adolescents and women of child",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy and in adolescents and women of child-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epilepticus",
    "brandName": "refer to table below on medicine management and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epilepticus (refer to table below on medicine management and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, IV, 10mg",
    "brandName": "Doctor prescribed",
    "strength": "10mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, IV, 10mg (Doctor prescribed).",
    "commonDosage": "10mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, IV, 10mg administered over at least 5 minutes",
    "brandName": "not faster",
    "strength": "10mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, IV, 10mg administered over at least 5 minutes (not faster",
    "commonDosage": "10mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "than 2mg/min",
    "brandName": "",
    "strength": "2mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "than 2mg/min) (Doctor prescribed).",
    "commonDosage": "2mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "continuing to establish IV access",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "continuing to establish IV access (Doctor prescribed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, rectal, 0.2",
    "brandName": "0.5 mg/kg as a single dose",
    "strength": "0.2",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, rectal, 0.2–0.5 mg/kg as a single dose (maximum 20",
    "commonDosage": "0.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mg/dose",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mg/dose) (Doctor prescribed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a single dose",
    "brandName": "Maximum dose:  4500 mg",
    "strength": "4500 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a single dose (Maximum dose:  4500 mg)",
    "commonDosage": "4500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ventilation with bag",
    "brandName": "valve mask",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ventilation with bag-valve mask (1 breath every 3–5 seconds) and refer urgently/transfer to a high-care setting.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If there is agitation or disturbed behaviour, consider post",
    "brandName": "ictal delirium and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If there is agitation or disturbed behaviour, consider post-ictal delirium and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "manage as for delirium",
    "brandName": "see Section 21.2.4: Delirium.",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "manage as for delirium – see Section 21.2.4: Delirium.",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "investigations",
    "brandName": "e.g. lumber puncture and neuroimaging",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "investigations (e.g. lumber puncture and neuroimaging) are driven by clinical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "signs and seizure onset",
    "brandName": "e.g. focal onset",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "signs and seizure onset (e.g. focal onset).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "diagnosis of epilepsy that requires ongoing ASMs",
    "brandName": "see Section 15.7:",
    "strength": "15.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "diagnosis of epilepsy that requires ongoing ASMs (see Section 15.7:",
    "commonDosage": "15.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "On discharge, set up a follow",
    "brandName": "up appointment to reinforce the counselling",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "On discharge, set up a follow-up appointment to reinforce the counselling",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "association with a significant fever",
    "brandName": ">38.5°C",
    "strength": "38.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "association with a significant fever (>38.5°C) in the absence of an intracranial",
    "commonDosage": "38.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "are self",
    "brandName": "limiting,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "are self-limiting,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "are associated with post",
    "brandName": "ictal, focal neurological abnormalities.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "are associated with post-ictal, focal neurological abnormalities.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "seizure disorder in a first",
    "brandName": "degree relative,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "seizure disorder in a first-degree relative,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "assessment.",
    "brandName": "See Paediatric Hospital Level STGs and EML, Sectio",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "assessment. (See Paediatric Hospital Level STGs and EML, Section",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Always exclude meningitis",
    "brandName": "see Section 15.8: Meningitis",
    "strength": "15.8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Always exclude meningitis (see Section 15.8: Meningitis).",
    "commonDosage": "15.8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "meningitis has been excluded",
    "brandName": "see Section 15.8: Meningitis",
    "strength": "15.8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "meningitis has been excluded (see Section 15.8: Meningitis).",
    "commonDosage": "15.8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G40.0",
    "brandName": "9",
    "strength": "40.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G40.0-9",
    "commonDosage": "40.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "At least two unprovoked",
    "brandName": "or reflex",
    "strength": "24 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "At least two unprovoked (or reflex) seizures occurring >24 hours apart,",
    "commonDosage": "24 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "One unprovoked",
    "brandName": "or reflex",
    "strength": "60%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "One unprovoked (or reflex) seizure if there is a high risk (60% or more) of",
    "commonDosage": "60%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "having recurrent seizures within the next 10 years",
    "brandName": "i.e., if the person is",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "having recurrent seizures within the next 10 years (i.e., if the person is",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "damage such as from a stroke",
    "brandName": ",",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "damage such as from a stroke),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "brain",
    "brandName": "e.g., hypoglycaemia, alcohol withdrawal, concussio",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "brain (e.g., hypoglycaemia, alcohol withdrawal, concussion).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "is unprovoked",
    "brandName": "because of the long",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "is unprovoked) because of the long-term sequelae of the initial insult. The",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "had an age",
    "brandName": "dependent epilepsy syndrome, but are now past the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "had an age-dependent epilepsy syndrome, but are now past the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Against Epilepsy",
    "brandName": "ILAE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Against Epilepsy (ILAE) according to:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Structural",
    "brandName": "e.g., cerebral or vascular malformations, stroke,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Structural (e.g., cerebral or vascular malformations, stroke,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Genetic",
    "brandName": "the epilepsy is a direct result of chromosomal or ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Genetic (the epilepsy is a direct result of chromosomal or gene",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Infectious",
    "brandName": "e.g., post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Infectious (e.g., post-infectious sequelae of TB meningitis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metabolic",
    "brandName": "e.g., inborn errors of metabolism",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Metabolic (e.g., inborn errors of metabolism).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Immune",
    "brandName": "rare conditions involving neuroreceptor antibodies",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Immune (rare conditions involving neuroreceptor antibodies).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bilateral tonic",
    "brandName": "clonic seizures. The diagnosis is made clinically ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bilateral tonic-clonic seizures. The diagnosis is made clinically and requires a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Characterised by unprovoked generalized seizures, including tonic",
    "brandName": "clonic,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Characterised by unprovoked generalized seizures, including tonic-clonic,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with Dravet syndrome or Lennox",
    "brandName": "Gastaut syndrome.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with Dravet syndrome or Lennox-Gastaut syndrome.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.epilepsydiagnosis.org/epilepsy/epilepsy",
    "brandName": "classification",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.epilepsydiagnosis.org/epilepsy/epilepsy-classification-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neuroimaging",
    "brandName": "a CT Brain or MRI if available",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neuroimaging (a CT Brain or MRI if available) should be conducted:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "if the epilepsy features change in an individual",
    "brandName": "i.e., new symptoms",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "if the epilepsy features change in an individual (i.e., new symptoms",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the seizure presentation is atypical, a 12",
    "brandName": "lead ECG should be",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the seizure presentation is atypical, a 12-lead ECG should be",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Underlying conditions and co",
    "brandName": "morbidities",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Underlying conditions and co-morbidities",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Common co",
    "brandName": "morbidities with epilepsy which need to be managed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Common co-morbidities with epilepsy which need to be managed in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "involve brief, repetitive stiffening of the body",
    "brandName": "for 1",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "involve brief, repetitive stiffening of the body (for 1-2 seconds), typically",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "are crucial to prevent long",
    "brandName": "term developmental problems. Discuss with a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "are crucial to prevent long-term developmental problems. Discuss with a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mechanisms, including liver metabolism",
    "brandName": "increased or decreased",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mechanisms, including liver metabolism (increased or decreased) and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Girls likely to need treatment when of child",
    "brandName": "bearing potential/ after 10",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Girls likely to need treatment when of child-bearing potential/ after 10",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The potential for child",
    "brandName": "bearing must be considered in all girls requiring",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The potential for child-bearing must be considered in all girls requiring",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Choose the ASM with the least potential for harm in pregnancy",
    "brandName": "see",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Choose the ASM with the least potential for harm in pregnancy (see",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 3",
    "brandName": ".",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 3).",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment as they grow older / develop child",
    "brandName": "bearing potential, unless",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment as they grow older / develop child-bearing potential, unless",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Regulatory Agency safety leaflet",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Regulatory Agency safety leaflet).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "potential adverse effects. In the settings of apparent drug",
    "brandName": "resistant epilepsy,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "potential adverse effects. In the settings of apparent drug-resistant epilepsy,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "form of add",
    "brandName": "on management.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "form of add-on management.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "controlled. This is often at the low",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "controlled. This is often at the low-to-mid-therapeutic dose range.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "doctor about cross",
    "brandName": "titrating to another ASM. Verify that the ASM is b",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "doctor about cross-titrating to another ASM. Verify that the ASM is being",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "metabolism",
    "brandName": "enzyme induction or inhibition",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "metabolism (enzyme induction or inhibition) and protein binding.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cross",
    "brandName": "titration may be required when changing from one A",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cross-titration may be required when changing from one ASM to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "only be changed at 2 weekly intervals",
    "brandName": ".",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "only be changed at 2 weekly intervals).",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Valproate in girls approaching puberty and of child",
    "brandName": "bearing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Valproate in girls approaching puberty and of child-bearing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "choice in girls and women of child",
    "brandName": "bearing potential. As carbamazepine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "choice in girls and women of child-bearing potential. As carbamazepine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "living. In children who are controlled on phenobarbital, cross",
    "brandName": "titration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "living. In children who are controlled on phenobarbital, cross-titration",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "drug",
    "brandName": "drug interactions.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "drug-drug interactions.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "require treatment when/ if of child",
    "brandName": "bearing potential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "require treatment when/ if of child-bearing potential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If valproate used in girls 10 years and older",
    "brandName": "see",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If valproate used in girls 10 years and older - see",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "should be cross",
    "brandName": "titrated to lamotrigine.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "should be cross-titrated to lamotrigine.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Lamotrigine is the preferred first line treatment for all adult patients, including women of child",
    "brandName": "bearing potential, pregnant women, and people on",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Lamotrigine is the preferred first line treatment for all adult patients, including women of child-bearing potential, pregnant women, and people on",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Lamotrigine requires slow dose up",
    "brandName": "titration and may not be suitable in people at hig",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Lamotrigine requires slow dose up-titration and may not be suitable in people at high-risk of seizures.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If valproate is used in girls, an acknowledgment of risk form must be obtained annually, even if not of child",
    "brandName": "bearing potential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If valproate is used in girls, an acknowledgment of risk form must be obtained annually, even if not of child-bearing potential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Girls aged 10 years and older should receive effective family planning and consider a long",
    "brandName": "acting form of contraception.",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Girls aged 10 years and older should receive effective family planning and consider a long-acting form of contraception.",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "*Assess level of risk",
    "brandName": "high vs low",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "*Assess level of risk (high vs low) based on clinical judgement and discuss with a specialist if unsure. In general, high-risk patients are those with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase slowly at 2 weekly intervals to 1",
    "brandName": "5 mg/kg/dose 12",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase slowly at 2 weekly intervals to 1–5 mg/kg/dose 12–24",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rapid escalation associated with adverse effects",
    "brandName": "e.g., skin rash",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rapid escalation associated with adverse effects (e.g., skin rash).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 4: Dosing regimens when lamotrigine is used as add",
    "brandName": "on therapy:",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 4: Dosing regimens when lamotrigine is used as add-on therapy:",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mg/kg",
    "brandName": "once a day or two",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mg/kg (once a day or two",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "CAUTION",
    "brandName": "LAMOTRIGINE",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "CAUTION - LAMOTRIGINE",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamotrigine may cause Stevens",
    "brandName": "Johnson Syndrome.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamotrigine may cause Stevens-Johnson Syndrome.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Carbamazepine, oral, 5 mg/kg/day",
    "brandName": "starting dose",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Carbamazepine, oral, 5 mg/kg/day (starting dose), 8–12 hourly.",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Usual maintenance total daily dose: 10",
    "brandName": "20 mg/kg/day.",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Usual maintenance total daily dose: 10–20 mg/kg/day.",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Valproate, oral, 5 mg/kg/dose",
    "brandName": "starting dose",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Valproate, oral, 5 mg/kg/dose (starting dose), 8–12 hourly.",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase by 5 mg/kg weekly to 15",
    "brandName": "20 mg/kg/day, given 8",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase by 5 mg/kg weekly to 15–20 mg/kg/day, given 8–12 hourly",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Usual maintenance dose: 20",
    "brandName": "30 mg/kg/day.",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Usual maintenance dose: 20-30 mg/kg/day.",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Exclude liver dysfunction prior to initiating therapy",
    "brandName": "at least ALT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Exclude liver dysfunction prior to initiating therapy (at least ALT), in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Phenobarbital, oral, 3",
    "brandName": "5 mg/kg/dose as single dose at night.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Phenobarbital, oral, 3–5 mg/kg/dose as single dose at night.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suspected but undiagnosed secondary cause for seizures",
    "brandName": "e.g.,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suspected but undiagnosed secondary cause for seizures (e.g.,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "structural, metabolic, infectious, genetic causes",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "structural, metabolic, infectious, genetic causes).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Focal seizures requiring neuroimaging",
    "brandName": "MRI preferred",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Focal seizures requiring neuroimaging (MRI preferred).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neuroregression",
    "brandName": "loss of previously acquired milestones or skills",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neuroregression (loss of previously acquired milestones or skills).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "what happens during the seizure?",
    "brandName": "give a step",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "what happens during the seizure? (give a step-by-step account);",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G40.3",
    "brandName": "5",
    "strength": "40.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G40.3-5",
    "commonDosage": "40.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "immunocompromised patients",
    "brandName": ", and other investigations as clinically",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "immunocompromised patients), and other investigations as clinically",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Women and girls of child",
    "brandName": "bearing potential and pregnancy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Women and girls of child-bearing potential and pregnancy",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "differs",
    "brandName": "see Figure 4",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "differs (see Figure 4).",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NOTE: There are important drug",
    "brandName": "drug interactions between",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NOTE: There are important drug-drug interactions between",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medicines",
    "brandName": "e.g. carbamazepine, phenobarbital, phenytoin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medicines (e.g. carbamazepine, phenobarbital, phenytoin).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraceptive methods for women of child",
    "brandName": "bearing potential on ASM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraceptive methods for women of child-bearing potential on ASM",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In pregnant women, women of child",
    "brandName": "bearing potential",
    "strength": "55",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In pregnant women, women of child-bearing potential (i.e. women < 55",
    "commonDosage": "55",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "years",
    "brandName": ", and young girls who are likely to need to contin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "years), and young girls who are likely to need to continue treatment into",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "their child",
    "brandName": "bearing years, should initiate treatment with a lo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "their child-bearing years, should initiate treatment with a lower risk",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lamotrigine is best suited to low",
    "brandName": "risk patients.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lamotrigine is best suited to low-risk patients.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "effects to lamotrigine, or in high",
    "brandName": "risk patients.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "effects to lamotrigine, or in high-risk patients.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Seizure risk is based on clinical judgement",
    "brandName": "discuss with a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Seizure risk is based on clinical judgement (discuss with a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "specialist if unsure",
    "brandName": ". In general, high",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "specialist if unsure). In general, high-risk patients are those with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Valproate must not be used in pregnant women, women of child",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Valproate must not be used in pregnant women, women of child-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment into their child",
    "brandName": "bearing years.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment into their child-bearing years.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "can be seriously debilitating and permanent",
    "brandName": "e.g. delayed learning",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "can be seriously debilitating and permanent (e.g. delayed learning",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "S01_v2",
    "brandName": "Valproate",
    "strength": "01",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "S01_v2-Valproate-Annual-Risk-Acknowledgement-Form-ARF.pdf",
    "commonDosage": "01",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "normal post",
    "brandName": "partum. Increase the dose if necessary, according ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "normal post-partum. Increase the dose if necessary, according to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy and women or adolescents of child",
    "brandName": "bearing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy and women or adolescents of child-bearing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV status, child",
    "brandName": "bearing potential and pregnancy are important",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV status, child-bearing potential and pregnancy are important",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "As a general rule, a single ASM",
    "brandName": "monotherapy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "As a general rule, a single ASM (monotherapy) is best. Progressively",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "reduce and stop the first ASM over 6",
    "brandName": "8 weeks or longer if necessary.",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "reduce and stop the first ASM over 6–8 weeks or longer if necessary.",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To confirm suspected poor adherence despite self",
    "brandName": "reported good",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To confirm suspected poor adherence despite self-reported good",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HIV on ART due to drug",
    "brandName": "drug",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HIV on ART due to drug-drug",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Acknowledgement",
    "brandName": "Form",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Acknowledgement-Form-ARF.pdf.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamotrigine, oral",
    "brandName": "Doctor initiated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamotrigine, oral (Doctor initiated).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 6: Dosing table for lamotrigine as monotherapy or add",
    "brandName": "on therapy",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 6: Dosing table for lamotrigine as monotherapy or add-on therapy",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "may be increased by 50",
    "brandName": "100 mg",
    "strength": "50",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "may be increased by 50–100 mg",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "200",
    "brandName": "400 mg",
    "strength": "200",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "200–400 mg (two divided doses).",
    "commonDosage": "200",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "may be increased by 25",
    "brandName": "50 mg",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "may be increased by 25–50 mg",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase by 100",
    "brandName": "200 mg/day at weekly intervals according to",
    "strength": "100",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase by 100–200 mg/day at weekly intervals according to",
    "commonDosage": "100",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "every 2 to 4 weeks to a maximum of 1500 mg 12 hourly",
    "brandName": "3000 mg",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "every 2 to 4 weeks to a maximum of 1500 mg 12 hourly (3000 mg",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Usual starting dose: 200",
    "brandName": "300 mg 12 hourly.",
    "strength": "200",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Usual starting dose: 200–300 mg 12 hourly.",
    "commonDosage": "200",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Increase, as required, every 3 days to 2 weeks",
    "brandName": "depending on the",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Increase, as required, every 3 days to 2 weeks (depending on the",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "seizure frequency",
    "brandName": "to a maximum dose of 1200 mg 12 hourly.",
    "strength": "1200 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "seizure frequency) to a maximum dose of 1200 mg 12 hourly.",
    "commonDosage": "1200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Phenytoin, oral, 4.5",
    "brandName": "5 mg/kg",
    "strength": "4.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Phenytoin, oral, 4.5–5 mg/kg (lean body mass) daily, at night.",
    "commonDosage": "4.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contributing to non",
    "brandName": "adherence and offer guidance.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contributing to non-adherence and offer guidance.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "remedy",
    "brandName": "i.e. look for drug interactions, substance use or ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "remedy (i.e. look for drug interactions, substance use or traditional",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ASM unchanged",
    "brandName": "unless dose adjustment is necessary because of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ASM unchanged (unless dose adjustment is necessary because of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a drug interaction",
    "brandName": ". Reassess the patient within 2 weeks.",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a drug interaction). Reassess the patient within 2 weeks.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Patients with seizures other than generalised tonic",
    "brandName": "clonic seizures, including",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Patients with seizures other than generalised tonic-clonic seizures, including",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A39.0+",
    "brandName": "G01*",
    "strength": "39.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A39.0+(G01*)/G00.0-3/G00.8-9/G01/G02.0-1/G02.8/G03.0/G03.8-9",
    "commonDosage": "39.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» During the early phase of TB meningitis, malaise, low",
    "brandName": "grade fever, headache",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» During the early phase of TB meningitis, malaise, low-grade fever, headache",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and personality change rather than the above",
    "brandName": "mentioned symptoms may be",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and personality change rather than the above-mentioned symptoms may be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Maximum pre",
    "brandName": "referral dose: 2 g IM/IV.",
    "strength": "2 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Maximum pre-referral dose: 2 g IM/IV.",
    "commonDosage": "2 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ibuprofen, oral, 5",
    "brandName": "10 mg/kg/dose 8 hourly with or after a meal. See d",
    "strength": "5",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Ibuprofen, oral, 5–10 mg/kg/dose 8 hourly with or after a meal. See dosing",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "maximum of 4 g in 24 hours",
    "brandName": ".",
    "strength": "4 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "maximum of 4 g in 24 hours).",
    "commonDosage": "4 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tramadol, oral, 50",
    "brandName": "100 mg 4",
    "strength": "50",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Tramadol, oral, 50–100 mg 4–6 hourly.",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "During a listeria outbreak, ADD as a pre",
    "brandName": "referral dose:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "During a listeria outbreak, ADD as a pre-referral dose:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "water for injection",
    "brandName": "WFI",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "water for injection (WFI))",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» anyone directly exposed to the patient's oral secretions, e.g. kissing, mouth",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» anyone directly exposed to the patient's oral secretions, e.g. kissing, mouth-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Does not progress through stages like a migraine",
    "brandName": "no nausea, no visual",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Does not progress through stages like a migraine (no nausea, no visual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Defective functioning of nerves, which may involve peripheral nerves",
    "brandName": "peripheral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Defective functioning of nerves, which may involve peripheral nerves (peripheral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 10.13: Shingles",
    "brandName": "Herpes zoster",
    "strength": "10.13",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 10.13: Shingles (Herpes zoster).",
    "commonDosage": "10.13",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "E10.4/E11.4/G60.9/G62.0",
    "brandName": "1/G62.9",
    "strength": "10.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "E10.4/E11.4/G60.9/G62.0-1/G62.9",
    "commonDosage": "10.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "50 mg 8 hourly for 3 weeks, followed by 25",
    "brandName": "50 mg daily.",
    "strength": "50 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "50 mg 8 hourly for 3 weeks, followed by 25–50 mg daily.",
    "commonDosage": "50 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amitriptyline, oral, 25 mg at night",
    "brandName": "Doctor prescribed",
    "strength": "25 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Amitriptyline, oral, 25 mg at night (Doctor prescribed).",
    "commonDosage": "25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G80.0",
    "brandName": "4/G80.8",
    "strength": "80.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G80.0-4/G80.8-9",
    "commonDosage": "80.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cerebral palsy",
    "brandName": "CP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cerebral palsy (CP) is a neurodevelopmental disorder resulting from an injury to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "impairment may be bilateral",
    "brandName": "as in diplegia, quadriplegia, or triplegia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "impairment may be bilateral (as in diplegia, quadriplegia, or triplegia) or unilateral",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "referral to primary care level for long",
    "brandName": "term management. After referral, patients",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "referral to primary care level for long-term management. After referral, patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "optimise cardiorespiratory and functional",
    "brandName": "including mental health",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "optimise cardiorespiratory and functional (including mental health) performance.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "as spasticity, neurogenic bladder, DVT",
    "brandName": "prophylaxis or treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "as spasticity, neurogenic bladder, DVT (prophylaxis or treatment), and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Long term Management",
    "brandName": "Stroke",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Long term Management (Stroke): Pollock A, Baer G, Campbell P, Choo PL, Forster A, Morris J, Pomeroy VM,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "analysis of randomised trials. Lancet. 2016 Jul 23;388",
    "brandName": "10042",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "analysis of randomised trials. Lancet. 2016 Jul 23;388(10042):365-375. https://www.ncbi.nlm.nih.gov/pubmed/27209146",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta",
    "brandName": "analysis of 19 Studies. J Am Heart Assoc.",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies. J Am Heart Assoc.",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2016 May 20;5",
    "brandName": "5",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2016 May 20;5(5). pii: e003242. https://www.ncbi.nlm.nih.gov/pubmed/27207999",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "aspirin on human platelet functions and plasma plasminogen activator inhibitor",
    "brandName": "1. Cardiology. 1993;83",
    "strength": "1",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology. 1993;83(5-6):367-73.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health Care Level. Medicine Review: Aspirin, pre",
    "brandName": "referral dose for acute stroke, March 2018. http:/",
    "strength": "2018",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Health Care Level. Medicine Review: Aspirin, pre-referral dose for acute stroke, March 2018. http://www.health.gov.za/",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4 Aspirin, oral",
    "brandName": "secondary prevention",
    "strength": "4 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "4 Aspirin, oral (secondary prevention – dosing): Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and mild cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2020 Feb 26;2",
    "brandName": "2",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and mild cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2020 Feb 26;2(2):CD011961. doi:",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7 Epileptic Seizure",
    "brandName": "Definition",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7 Epileptic Seizure (Definition): International League Against Epilepsy. Diagnostic Manual of the epilepsies. Epigraph Vol. 18",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "9 Epileptic Seizure",
    "brandName": "Definition",
    "strength": "9 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "9 Epileptic Seizure (Definition): International League Against Epilepsy. Diagnostic Manual of the epilepsies. Epigraph Vol. 18",
    "commonDosage": "9 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58",
    "brandName": "4",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58 (4): 512-521.",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10 Epileptic Seizure",
    "brandName": "Definition",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10 Epileptic Seizure (Definition): Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L.  ILAE classification",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of epilepsies:  Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58",
    "brandName": "4",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of epilepsies:  Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58 (4): 512-521.",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "11 Epileptic Seizure",
    "brandName": "Definition",
    "strength": "11 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "11 Epileptic Seizure (Definition): International League Against Epilepsy. Diagnostic Manual of the epilepsies. Epigraph Vol. 18",
    "commonDosage": "11 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guide",
    "brandName": "childre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guide-childre",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15 NICE. Epilepsies in children, young people and adults. April 2022",
    "brandName": "Updated 2025",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15 NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available at",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, buccal",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Midazolam, buccal (children-status epilepticus): McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for the treatment of status epilepticus in children and young adults: a meta",
    "brandName": "analysis. Acad Emerg Med. 2010 Jun;17",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010 Jun;17(6):575-",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005 Jul 16",
    "brandName": "22;366",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005 Jul 16-22;366(9481):205-10.",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "trial. Pediatrics. 2008; 121:e58",
    "brandName": "64. http://www.ncbi.nlm.nih.gov/pubmed/18166545",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "trial. Pediatrics. 2008; 121:e58–64. http://www.ncbi.nlm.nih.gov/pubmed/18166545",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet.1999; 353:623",
    "brandName": "6.",
    "strength": "1999",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet.1999; 353:623–6.",
    "commonDosage": "1999",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Feb;40",
    "brandName": "1",
    "strength": "40",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Feb;40(1):23-25. https://www.ncbi.nlm.nih.gov/pubmed/28246432",
    "commonDosage": "40",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Programme for mental, neurological and substance use disorders in non",
    "brandName": "specialized health settings, version 2.0 Geneva:",
    "strength": "2.0 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Programme for mental, neurological and substance use disorders in non-specialized health settings, version 2.0 Geneva:",
    "commonDosage": "2.0 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NICE. Epilepsies in children, young people and adults. April 2022",
    "brandName": "Updated 2025",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available at",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "16 Diazepam",
    "brandName": "Rectal",
    "strength": "16 ",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "16 Diazepam (Rectal): NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available at",
    "commonDosage": "16 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17 Levetiracetam",
    "brandName": "NGT",
    "strength": "17 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17 Levetiracetam (NGT): Gettings JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, Goodkin HP, Loddenkemper T.",
    "commonDosage": "17 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diagnosis and management of status epilepticus: improving the status quo. Lancet Neurol. 2025 Jan;24",
    "brandName": "1",
    "strength": "2025 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Diagnosis and management of status epilepticus: improving the status quo. Lancet Neurol. 2025 Jan;24(1):65-76. doi:",
    "commonDosage": "2025 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levetiracetam",
    "brandName": "NGT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levetiracetam (NGT): Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 Nov 28;381",
    "brandName": "22",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi:",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, buccal",
    "brandName": "children",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, buccal (children-second dose): NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025)",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "19Valproate",
    "brandName": "caution in pregnancy: European Medicines Agency",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "19Valproate – caution in pregnancy: European Medicines Agency - Pharmacovigilance Risk Assessment Committee.",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "with epilepsy: a systematic review and meta",
    "brandName": "analysis of published pregnancy registries and coh",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep;81",
    "brandName": "1",
    "strength": "81",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep;81(1):1-13. https://www.ncbi.nlm.nih.gov/pubmed/18565732",
    "commonDosage": "81",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16;366",
    "brandName": "7",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16;366(7):591-600.",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.nice.org.uk/guidance/ng217NICE. Epilepsies in children, young people and adults. April 2022",
    "brandName": "Updated 2025",
    "strength": "217",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.nice.org.uk/guidance/ng217NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025)",
    "commonDosage": "217",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep 10;",
    "brandName": "9",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep 10;(9):CD003723. NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "23 Diazepam",
    "brandName": "Rectal",
    "strength": "23 ",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "23 Diazepam (Rectal): Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson",
    "commonDosage": "23 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence",
    "brandName": "Based Guideline:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "24 Levetiacetam",
    "brandName": "NGT",
    "strength": "24 ",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "24 Levetiacetam (NGT): Shibata et al. Early enteral levetiracetam in diazepam-resistant convulsive status epilepticus.",
    "commonDosage": "24 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neurology and Clinical Neuroscience 4",
    "brandName": "2016",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neurology and Clinical Neuroscience 4 (2016) 209–214. doi:10.1111/ncn3.12078",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "26 Epilepsy",
    "brandName": "Classification",
    "strength": "26 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "26 Epilepsy (Classification): Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L.  ILAE classification of",
    "commonDosage": "26 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epilepsies:  Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58",
    "brandName": "4",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epilepsies:  Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017, 58 (4): 512-521",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicines & Healthcare products Regulatory Agency safety leaflet",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicines & Healthcare products Regulatory Agency safety leaflet).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "28 Epilepsy",
    "brandName": "Focal",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "28 Epilepsy (Focal): Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur Smith C. Antiepileptic drug monotherapy for epilepsy: a",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "29Epilepsy",
    "brandName": "Medicine Treatment",
    "strength": "29",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "29Epilepsy (Medicine Treatment): NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available",
    "commonDosage": "29",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "30 Lamotrigine, oral",
    "brandName": "dose titration",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "30 Lamotrigine, oral (dose titration): University of Cape Town, Faculty of Health Sciences, Division of Clinical Pharmacology.",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://pi",
    "brandName": "pil",
    "strength": "2025",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2025/02/PI-Approved-",
    "commonDosage": "2025",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamotrigine, oral",
    "brandName": "dose titration",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamotrigine, oral (dose titration): Western Cape Department of Health, Lamotrigine dose titration protocol, 2019.",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "31 Valproic acid",
    "brandName": "caution in pregnancy and child",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "31 Valproic acid – caution in pregnancy and child-bearing potential: NICE. Epilepsies in children, young people and adults.",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "April 2022",
    "brandName": "Updated 2025",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "April 2022 (Updated 2025) Available at https://www.nice.org.uk/guidance/ng217",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "European Medicines Agency",
    "brandName": "Pharmacovigilance Risk Assessment Committee. Asses",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "European Medicines Agency - Pharmacovigilance Risk Assessment Committee. Assessment   report",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "valproate. Available at:  https://www.gov.uk/government/news/mhra",
    "brandName": "instructs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "valproate. Available at:  https://www.gov.uk/government/news/mhra-instructs-health-organisations-to-prepare-now-for-new-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "measures",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "measures-to-reduce-ongoing-serious-harms-of-valproate.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "32 Valproate",
    "brandName": "caution in pregnancy: European Medicines Agency",
    "strength": "32 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "32 Valproate – caution in pregnancy: European Medicines Agency - Pharmacovigilance Risk Assessment Committee.",
    "commonDosage": "32 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "33 Anti",
    "brandName": "epileptic drug",
    "strength": "33 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "33 Anti-epileptic drug-drug interactions: National Department of Health, Essential Drugs Programme: Adult Hospital Level",
    "commonDosage": "33 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "34 Epilepsy",
    "brandName": "Medicine Treatment",
    "strength": "34 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "34 Epilepsy (Medicine Treatment): NICE. Epilepsies in children, young people and adults. April 2022 (Updated 2025) Available",
    "commonDosage": "34 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "35 Lamotrigine, oral",
    "brandName": "dose titration",
    "strength": "35 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "35 Lamotrigine, oral (dose titration): University of Cape Town, Faculty of Health Sciences, Division of Clinical Pharmacology.",
    "commonDosage": "35 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "36 Lamotrigine, drug",
    "brandName": "drug interactions with ART",
    "strength": "36 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "36 Lamotrigine, drug-drug interactions with ART (adults): National Department of Health, Essential Drugs Programme: Adult",
    "commonDosage": "36 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamotrigine, drug",
    "brandName": "drug interactions with ART",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamotrigine, drug-drug interactions with ART (adults): National Department of Health. 2019 ART Clinical Guidelines for the",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.knowledgehub.org.za/elibrary/2019",
    "brandName": "art",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.knowledgehub.org.za/elibrary/2019-art-clinical-guidelines-management-hiv-adults-pregnancy-adolescents-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "daytime somnolence in untreated patients with temporal lobe epilepsy: changes after treatment with controlled",
    "brandName": "release",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "daytime somnolence in untreated patients with temporal lobe epilepsy: changes after treatment with controlled-release",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Seetharam S, Naicker P, Quan V, Reubenson G, Tempia S, von Mollendorf C, von Gottberg A; GERMS",
    "brandName": "SA. Declining",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Seetharam S, Naicker P, Quan V, Reubenson G, Tempia S, von Mollendorf C, von Gottberg A; GERMS-SA. Declining",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Incidence of Invasive Meningococcal Disease in South Africa: 2003",
    "brandName": "2016. Clin Infect Dis. 2019 Jul 18;69",
    "strength": "2003",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Incidence of Invasive Meningococcal Disease in South Africa: 2003-2016. Clin Infect Dis. 2019 Jul 18;69(3):495-504. doi:",
    "commonDosage": "2003",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids, intermediate",
    "brandName": "acting, oral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids, intermediate-acting, oral (therapeutic class - adults): National Department of Health, Essential Drugs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids, intermediate",
    "brandName": "acting, oral",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids, intermediate-acting, oral (therapeutic class - adults): South African Medicines Formulary, 14th Edition.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prednisone, oral",
    "brandName": "adults: within 72 hours",
    "strength": "72 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prednisone, oral (adults: within 72 hours): Madhok VB, Gagyor I, Daly F, Somasundara D, Sullivan M, Gammie F,",
    "commonDosage": "72 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prednisone, oral",
    "brandName": "adults: within 48 hours",
    "strength": "48 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prednisone, oral (adults: within 48 hours): Axelsson S, Berg T, Jonsson L, Engström M, Kanerva M, Pitkäranta A,",
    "commonDosage": "48 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stjernquist",
    "brandName": "Desatnik A. Prednisolone in Bell's palsy related t",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stjernquist-Desatnik A. Prednisolone in Bell's palsy related to treatment start and age. Otol Neurotol. 2011 Jan;32(1):141-6.",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Systematic Review. Sports Med 44, 1289",
    "brandName": "1304",
    "strength": "44",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Systematic Review. Sports Med 44, 1289–1304 (2014). https://doiorg.ez.sun.ac.za/10.1007/s40279-014-0207-5",
    "commonDosage": "44",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "aged 0 to 2 years at high risk for cerebral palsy: a systematic review. Dev Med Child Neurol. 2017 Apr;59",
    "brandName": "4",
    "strength": "0 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "aged 0 to 2 years at high risk for cerebral palsy: a systematic review. Dev Med Child Neurol. 2017 Apr;59(4):355-360. doi:",
    "commonDosage": "0 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Referral: Gaspar R, Padula N, Freitas TB, de Oliveira JPJ, Torriani",
    "brandName": "Pasin C. Physical Exercise for Individuals With",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Referral: Gaspar R, Padula N, Freitas TB, de Oliveira JPJ, Torriani-Pasin C. Physical Exercise for Individuals With",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "16.6 Psychiatric patients",
    "brandName": "general monitoring and care",
    "strength": "16.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "16.6 Psychiatric patients - general monitoring and care",
    "commonDosage": "16.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nurses with authorisation as provided by Section 56",
    "brandName": "6",
    "strength": "56",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nurses with authorisation as provided by Section 56(6) of the Nursing Act 33 of 2005 may",
    "commonDosage": "56",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "therapists",
    "brandName": "OTs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "therapists (OTs), social workers, and registered counsellors whose training includes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Specific obligations of the South African Police Service",
    "brandName": "SAPS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Specific obligations of the South African Police Service (SAPS) to protect, apprehend,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Psychoeducation",
    "brandName": "psychological education",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Psychoeducation (psychological education) involves informing a patient and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "understanding, self",
    "brandName": "care, crisis management, suicide prevention, and r",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "understanding, self-care, crisis management, suicide prevention, and relapse",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of relapse, treatment options, need for adherence to treatment, and long",
    "brandName": "term",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of relapse, treatment options, need for adherence to treatment, and long-term",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "person",
    "brandName": "centred manner. Advice on managing difficult behav",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "person-centred manner. Advice on managing difficult behaviour and emergency",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "high risk impulsive or addictive behaviour for e.g. high",
    "brandName": "risk sexual",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "high risk impulsive or addictive behaviour for e.g. high-risk sexual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "severe self",
    "brandName": "neglect,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "severe self-neglect,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "healthcare providers",
    "brandName": "including community health workers, or social work",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "healthcare providers (including community health workers, or social workers who",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "have knowledge of the person’s home",
    "brandName": ", as well as past clinical and forensic history.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "have knowledge of the person’s home), as well as past clinical and forensic history.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for others",
    "brandName": "e.g., parents, grandparents, teachers, and health ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for others (e.g., parents, grandparents, teachers, and health and social care",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "providers",
    "brandName": ", and those with previous high",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "providers), and those with previous high-risk behaviour.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "interventions, e.g., close clinical follow",
    "brandName": "up after hospital discharge with increased",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "interventions, e.g., close clinical follow-up after hospital discharge with increased",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "%20%20Clinical%20Risk%20Assessment%20and%20Management%20",
    "brandName": "",
    "strength": "20%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "%20%20Clinical%20Risk%20Assessment%20and%20Management%20-",
    "commonDosage": "20%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Psychiatric: psychosis, mania, agitated depression, neurocognitive disorders",
    "brandName": "e.g.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Psychiatric: psychosis, mania, agitated depression, neurocognitive disorders (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dementias, traumatic brain injury",
    "brandName": ", developmental disorders",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dementias, traumatic brain injury), developmental disorders (e.g. intellectual disability",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Be aware of high",
    "brandName": "risk patients e.g. those known with previous viole",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Be aware of high-risk patients e.g. those known with previous violence, substance",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Have available backup",
    "brandName": "security, SAPS, and Emergency Medical Service",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Have available backup – security, SAPS, and Emergency Medical Service (EMS).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prepare a designated calming area",
    "brandName": "suitable for regular monitoring.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prepare a designated calming area – suitable for regular monitoring.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://knowledgehub.health.gov.za/elibrary/policy",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://knowledgehub.health.gov.za/elibrary/policy-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidelines",
    "brandName": "seclusion",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidelines-seclusion-and-restraint-mental-health-care-users-2012",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Record type, sites, and duration of any restraints used, with 15",
    "brandName": "minute monitoring",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Record type, sites, and duration of any restraints used, with 15-minute monitoring",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Use restraint sparingly and with care, with mother in a supported, semi",
    "brandName": "seated",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Use restraint sparingly and with care, with mother in a supported, semi-seated",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines, e.g.:",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines, e.g.: (Doctor prescribed)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Perform thorough medical examination for non",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Perform thorough medical examination for non-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, buccal, 7.5",
    "brandName": "15 mg immediately, using the parenteral formulatio",
    "strength": "7.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, buccal, 7.5–15 mg immediately, using the parenteral formulation.",
    "commonDosage": "7.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Olanzapine, orodispersible tablet or IM, 5 to 10 mg immediately",
    "brandName": "Doctor prescribed",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Olanzapine, orodispersible tablet or IM, 5 to 10 mg immediately (Doctor prescribed).",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Use lower doses of olanzapine",
    "brandName": "2.5 to 5mg",
    "strength": "2.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Use lower doses of olanzapine (2.5 to 5mg) in elderly, frail, or medically unwell",
    "commonDosage": "2.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If previous intolerability to olanzapine",
    "brandName": "e.g., previous neuro",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If previous intolerability to olanzapine (e.g., previous neuro-malignant syndrome),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Short",
    "brandName": "acting benzodiazepines, e.g.:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Short-acting benzodiazepines, e.g.: (Doctor prescribed)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Long",
    "brandName": "acting injectable antipsychotics e.g., flupenthixo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Long-acting injectable antipsychotics e.g., flupenthixol decanoate and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "breaths/minute, call doctor urgently and ventilate with bag",
    "brandName": "valve mask",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "breaths/minute, call doctor urgently and ventilate with bag-valve mask (1 breath/3-5",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "seconds",
    "brandName": "attached to oxygen at 15 L/minute.",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "seconds) attached to oxygen at 15 L/minute.",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Physical: epilepsy",
    "brandName": "pre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Physical: epilepsy (pre-, intra-, and post-ictal), acute medical (e.g. encephalopathy,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "infection, metabolic disease, medication adverse effects",
    "brandName": "or surgical conditions,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "infection, metabolic disease, medication adverse effects) or surgical conditions,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "injuries",
    "brandName": "including traumatic brain injury",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "injuries (including traumatic brain injury).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.gov.za/documents/policy",
    "brandName": "guidelines",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.gov.za/documents/policy-guidelines-child-and-adolescent-mental-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a designated calming area",
    "brandName": "suitable for regular monitoring.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a designated calming area – suitable for regular monitoring.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "neuroleptic malignant syndrome",
    "brandName": "see Section 16.2.2: Neuroleptic malignant",
    "strength": "16.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "neuroleptic malignant syndrome (see Section 16.2.2: Neuroleptic malignant",
    "commonDosage": "16.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G21.1/G24.0/G25.8",
    "brandName": "9/Y11/Y13/Y88.0 +",
    "strength": "21.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G21.1/G24.0/G25.8-9/Y11/Y13/Y88.0 + (T43.0-6/T43.8-9)",
    "commonDosage": "21.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» At",
    "brandName": "risk groups include those with underlying medical ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» At-risk groups include those with underlying medical conditions such as epilepsy,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Acute dystonic reaction",
    "brandName": "sustained muscle contraction that causes twisting ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Acute dystonic reaction (sustained muscle contraction that causes twisting and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Parkinsonism",
    "brandName": "slow, shuffling gait, delayed responses, masked fa",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Parkinsonism (slow, shuffling gait, delayed responses, masked facies, and a pill rolling",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Akathisia",
    "brandName": "a subjective and observed motor restlessness e.g.:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Akathisia (a subjective and observed motor restlessness e.g.: pacing, rocking,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "marching, crossing and uncrossing legs",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "marching, crossing and uncrossing legs).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the face, lips, and tongue",
    "brandName": "e.g.: lip smacking or chewing, tongue protrusion",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the face, lips, and tongue (e.g.: lip smacking or chewing, tongue protrusion (“catching",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "flies”",
    "brandName": ", but occasionally also arms, legs or trunk. More ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "flies”), but occasionally also arms, legs or trunk. More common in older women,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Biperiden, IM/slow IV, 0.05",
    "brandName": "0.1 mg/kg to a maximum of:",
    "strength": "0.05",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Biperiden, IM/slow IV, 0.05–0.1 mg/kg to a maximum of:",
    "commonDosage": "0.05",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Promethazine, IM, 0.125",
    "brandName": "0.5 mg/kg to a maximum of:",
    "strength": "0.125",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Promethazine, IM, 0.125–0.5 mg/kg to a maximum of:",
    "commonDosage": "0.125",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G21.0 +",
    "brandName": "T43.0",
    "strength": "21.0 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G21.0 + (T43.0-6/T43.8-9)",
    "commonDosage": "21.0 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Neuroleptic malignant syndrome",
    "brandName": "NMS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal syndrome",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "choking feeling, shortness of breath, chest pain",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "choking feeling, shortness of breath, chest pain (non-cardiac), dizziness, numbness,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Obsessive thoughts and/or compulsive behaviours are a core feature of Obsessive",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Obsessive thoughts and/or compulsive behaviours are a core feature of Obsessive-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "conditions",
    "brandName": "e.g. heart disease, hypertension, COPD, asthma, GO",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "conditions (e.g. heart disease, hypertension, COPD, asthma, GORD, inflammatory",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Screen for, and manage, underlying or co",
    "brandName": "morbid substance use, e.g. nicotine,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Screen for, and manage, underlying or co-morbid substance use, e.g. nicotine,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "governmental organization",
    "brandName": "NGO",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "governmental organization (NGO) counselling services, e.g. SA Depression and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anxiety Group",
    "brandName": "https://www.sadag.org/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anxiety Group (https://www.sadag.org/).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "South Africa",
    "brandName": "https://famsa.org.za",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "South Africa (https://famsa.org.za).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Abuse",
    "brandName": "refer to a social worker, social welfare, and/or P",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Abuse – refer to a social worker, social welfare, and/or People Opposing Women",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If response to psychotherapy is sub",
    "brandName": "optimal, medication may be prescribed together",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If response to psychotherapy is sub-optimal, medication may be prescribed together",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Initiate at 20 mg on alternate days for 2",
    "brandName": "4 weeks.",
    "strength": "20 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Initiate at 20 mg on alternate days for 2-4 weeks.",
    "commonDosage": "20 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Increase to 20 mg daily after 2",
    "brandName": "4 weeks.",
    "strength": "20 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Increase to 20 mg daily after 2–4 weeks.",
    "commonDosage": "20 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Alternative SSRI, e.g.:",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Alternative SSRI, e.g.: (Doctor prescribed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SSRIs",
    "brandName": "e.g. fluoxetine, citalopram",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "SSRIs (e.g. fluoxetine, citalopram) may cause agitation initially.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "young adults.",
    "brandName": "See Section 16.7: Suicide risk assessment",
    "strength": "16.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "young adults. (See Section 16.7: Suicide risk assessment).",
    "commonDosage": "16.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» ≥ 3 episodes of anxiety",
    "brandName": "advise lifelong treatment",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» ≥ 3 episodes of anxiety (advise lifelong treatment).",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o 2.5",
    "brandName": "5 mg immediately.",
    "strength": "2.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o 2.5–5 mg immediately.",
    "commonDosage": "2.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Associated with cognitive impairment",
    "brandName": "reversible with short",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Associated with cognitive impairment – reversible with short-term use and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "potentially irreversible with long",
    "brandName": "term use.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "potentially irreversible with long-term use.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "functioning, and may result in unemployment, poor self",
    "brandName": "care, neglect of dependent",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "functioning, and may result in unemployment, poor self-care, neglect of dependent",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Loss of interest or pleasure",
    "brandName": "anhedonia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Loss of interest or pleasure (anhedonia): ‘not caring any more’, boredom, social",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Neuro",
    "brandName": "vegetative symptoms: loss of appetite or an increa",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Neuro-vegetative symptoms: loss of appetite or an increase in appetite, sometimes",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "decreased sleep",
    "brandName": "usually mid",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "decreased sleep (usually mid- or terminal-insomnia, i.e. waking during the night or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "early hours of the morning",
    "brandName": "; psychomotor agitation",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "early hours of the morning); psychomotor agitation (pacing, hand-wringing, rubbing of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "skin or clothing",
    "brandName": "or psychomotor retardation",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "skin or clothing) or psychomotor retardation (slowed thoughts, speech and/or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Psychological symptoms: feelings of worthlessness; unrealistic, negative self",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Psychological symptoms: feelings of worthlessness; unrealistic, negative self-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "evaluation; self",
    "brandName": "blame; and guilt",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "evaluation; self-blame; and guilt – may be over minor failings or may be of delusional",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pseudodementia",
    "brandName": "; preoccupation with thoughts of death of loved on",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pseudodementia); preoccupation with thoughts of death of loved ones, others, or self",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stress management / coping skills",
    "brandName": "refer to social worker or NGO counselling",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stress management / coping skills – refer to social worker or NGO counselling",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "services, e.g. SA Depression and Anxiety Group",
    "brandName": "https://www.sadag.org/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "services, e.g. SA Depression and Anxiety Group (https://www.sadag.org/).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Social support systems, relationship and family issues",
    "brandName": "refer to social worker or NGO",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Social support systems, relationship and family issues – refer to social worker or NGO",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "counselling, e.g., Family and Marriage Society of South Africa",
    "brandName": "https://famsa.org.za/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "counselling, e.g., Family and Marriage Society of South Africa (https://famsa.org.za/).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Alternative SSRI e.g.:",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Alternative SSRI e.g.: (Doctor prescribed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SSRIs",
    "brandName": "e.g. fluoxetine, citalopram",
    "strength": "2 ",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "SSRIs (e.g. fluoxetine, citalopram) may cause agitation during the first 2 to 4 weeks.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tricyclic antidepressants, e.g.:",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tricyclic antidepressants, e.g.: (Doctor prescribed).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Increase by 25 mg per day at 3",
    "brandName": "to 5",
    "strength": "25 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Increase by 25 mg per day at 3- to 5-day intervals.",
    "commonDosage": "25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Concomitant generalised anxiety disorder",
    "brandName": "extend treatment to at least 1 year",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Concomitant generalised anxiety disorder (extend treatment to at least 1 year).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» ≥3 episodes of depression",
    "brandName": "advise lifelong treatment",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» ≥3 episodes of depression (advise lifelong treatment).",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patient might be taking",
    "brandName": "e.g. St John’s Wort or traditional African medicin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patient might be taking (e.g. St John’s Wort or traditional African medicine).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "being manic, hypomanic, mixed, or depressive",
    "brandName": "according to accepted diagnostic criteria",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "being manic, hypomanic, mixed, or depressive (according to accepted diagnostic criteria).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "16.6: Psychiatric patients",
    "brandName": "general monitoring and care.",
    "strength": "16.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "16.6: Psychiatric patients - general monitoring and care.",
    "commonDosage": "16.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Grossly disorganised or abnormal motor behaviour",
    "brandName": "including catatonia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Grossly disorganised or abnormal motor behaviour (including catatonia).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disorganised thinking",
    "brandName": "which resolves spontaneously, usually within 1 mon",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disorganised thinking) which resolves spontaneously, usually within 1 month, with a",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mental health evaluation",
    "brandName": "see Adult Hospital STG and EML Section 15.5.1: Acu",
    "strength": "15.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mental health evaluation (see Adult Hospital STG and EML Section 15.5.1: Acute",
    "commonDosage": "15.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Address psycho",
    "brandName": "social stressors",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Address psycho-social stressors – refer to social worker, counselling services.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Women of child",
    "brandName": "bearing potential:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Women of child-bearing potential:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the patient is a parent/guardian",
    "brandName": "refer to social worker to assess home",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the patient is a parent/guardian – refer to social worker to assess home",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "use and medical conditions",
    "brandName": "e.g., metabolic syndrome",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "use and medical conditions (e.g., metabolic syndrome) are common.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» See Section 16.6: Psychiatric patients",
    "brandName": "general monitoring and care.",
    "strength": "16.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» See Section 16.6: Psychiatric patients - general monitoring and care.",
    "commonDosage": "16.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Flupenthixol decanoate, IM, 10 to 40 mg every 4 weeks.",
    "brandName": "Doctor prescribed.",
    "strength": "10 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Flupenthixol decanoate, IM, 10 to 40 mg every 4 weeks. (Doctor prescribed.)",
    "commonDosage": "10 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zuclopenthixol decanoate, IM, 100 to 400 mg every 4 weeks.",
    "brandName": "Doctor prescribed.",
    "strength": "100 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zuclopenthixol decanoate, IM, 100 to 400 mg every 4 weeks. (Doctor prescribed.)",
    "commonDosage": "100 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For breakthrough episodes on an injectable antipsychotic, consider additional short",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For breakthrough episodes on an injectable antipsychotic, consider additional short-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Risperidone, oral 2 mg daily.",
    "brandName": "Doctor prescribed.",
    "strength": "2 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Risperidone, oral 2 mg daily. (Doctor prescribed.)",
    "commonDosage": "2 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If good response to IM antipsychotic but patient has extrapyramidal side effects",
    "brandName": "EPSEs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If good response to IM antipsychotic but patient has extrapyramidal side effects (EPSEs),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anticholinergic medicines",
    "brandName": "e.g. orphenadrine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anticholinergic medicines (e.g. orphenadrine) should not be used routinely as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For management of extra",
    "brandName": "pyramidal adverse drug reactions and acute dystoni",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For management of extra-pyramidal adverse drug reactions and acute dystonic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Risperidone, oral, 2 mg daily.",
    "brandName": "Doctor prescribed.",
    "strength": "2 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Risperidone, oral, 2 mg daily. (Doctor prescribed.)",
    "commonDosage": "2 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Regular monitoring with documented nursing notes in the file should occur monthly to 6",
    "brandName": "",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Regular monitoring with documented nursing notes in the file should occur monthly to 6-",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» General health: screen at baseline and annually",
    "brandName": "weight and body mass index, blood",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» General health: screen at baseline and annually - weight and body mass index, blood",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pressure",
    "brandName": "see Section 4.7: Hypertension",
    "strength": "4.7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "pressure (see Section 4.7: Hypertension), finger-prick blood glucose test for diabetes",
    "commonDosage": "4.7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Lifestyle advice for obesity, smoking, alcohol, other substances, and high",
    "brandName": "risk sexual",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Lifestyle advice for obesity, smoking, alcohol, other substances, and high-risk sexual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hyperlipidaemia",
    "brandName": "occur, refer to a dietician and encourage regular",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hyperlipidaemia) occur, refer to a dietician and encourage regular",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "exercise. If needed, manage dyslipidaemia.",
    "brandName": "See Section: 4.1: Prevention of",
    "strength": "4.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "exercise. If needed, manage dyslipidaemia. (See Section: 4.1: Prevention of",
    "commonDosage": "4.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Monitor lithium concentration and eGFR every 6 months",
    "brandName": "3",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Monitor lithium concentration and eGFR every 6 months (3-monthly in elderly or",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Women of child",
    "brandName": "bearing potential must be on family planning; refe",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Women of child-bearing potential must be on family planning; refer all pregnant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "women on lithium immediately",
    "brandName": "See caution on lithium in Adult Hospital Level STG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "women on lithium immediately (See caution on lithium in Adult Hospital Level STGs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and EML, Chapter 15: Mental Health Conditions and Substance Misuse",
    "brandName": "Section",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and EML, Chapter 15: Mental Health Conditions and Substance Misuse - Section",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Valproate and carbamazepine: Avoid in women of child",
    "brandName": "bearing potential.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Valproate and carbamazepine: Avoid in women of child-bearing potential.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pregnancy are at significant risk of birth defects",
    "brandName": "10%",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pregnancy are at significant risk of birth defects (10%) and persistent developmental",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disorders",
    "brandName": "40%",
    "strength": "40%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disorders (40%).  Valproate is contra-indicated during pregnancy and in",
    "commonDosage": "40%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Annual",
    "brandName": "Risk",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Annual-Risk-Acknowledgement-Form-ARF.pdf",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suicide is the act of deliberately killing oneself. Self",
    "brandName": "harm refers to intentionally self",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suicide is the act of deliberately killing oneself. Self-harm refers to intentionally self-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "There are 5 important components when assessing suicide: ideation",
    "brandName": "thoughts",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "There are 5 important components when assessing suicide: ideation (thoughts), intent,",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lesbian, gay, bisexual, and transgender",
    "brandName": "LGBT",
    "strength": "16.8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lesbian, gay, bisexual, and transgender (LGBT) patients. (see Section 16.8.3: Special",
    "commonDosage": "16.8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Current thoughts/plan/act of self",
    "brandName": "harm/suicide.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Current thoughts/plan/act of self-harm/suicide.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Key population groups",
    "brandName": "LGBTQIA+",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Key population groups (LGBTQIA+) and adolescents.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage the patient who has attempted a medically serious act of self",
    "brandName": "harm: See",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage the patient who has attempted a medically serious act of self-harm: See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Current thoughts or plan of self",
    "brandName": "harm/suicide.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Current thoughts or plan of self-harm/suicide.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "History of thoughts or plan of self",
    "brandName": "harm in the past month.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "History of thoughts or plan of self-harm in the past month.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medications",
    "brandName": "and medicines known to be toxic in overdose, inclu",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "medications) and medicines known to be toxic in overdose, including paracetamol,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Maintain regular contact if possible",
    "brandName": "suggested weekly contact for the first 2 months.",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Maintain regular contact if possible – suggested weekly contact for the first 2 months.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Follow",
    "brandName": "up for as long as the risk of self",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Follow-up for as long as the risk of self-harm/suicide persists. At every contact, re-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "any thoughts of self",
    "brandName": "harm/suicide.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "any thoughts of self-harm/suicide.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "resources",
    "brandName": "e.g., brochures if available, SA Depression and An",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "resources (e.g., brochures if available, SA Depression and Anxiety Group details",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.sadag.org/",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.sadag.org/).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "community resources such as NGO or faith",
    "brandName": "based organisation crisis centres or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "community resources such as NGO or faith-based organisation crisis centres or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All patients where there is a high index of suspicion for self",
    "brandName": "harm/suicide.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All patients where there is a high index of suspicion for self-harm/suicide.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "strangers",
    "brandName": "maintain high index of suspicion for abuse.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "strangers – maintain high index of suspicion for abuse.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A supportive, caring, and secure environment is essential for well",
    "brandName": "being and contained",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A supportive, caring, and secure environment is essential for well-being and contained",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage together with social workers, occupational therapists, counsellors, and non",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage together with social workers, occupational therapists, counsellors, and non-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Low sex drive, anorgasmia",
    "brandName": "unable to achieve an orgasm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Low sex drive, anorgasmia (unable to achieve an orgasm), or impotence may occur",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "as part of the mental illness, as a result of medication side effects",
    "brandName": "e.g. fluoxetine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "as part of the mental illness, as a result of medication side effects (e.g. fluoxetine),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Specific sexual disorders, e.g. vaginismus",
    "brandName": "spasm of vagina",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Specific sexual disorders, e.g. vaginismus (spasm of vagina) or other sexual",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Disclosure to staff depends on a non",
    "brandName": "judgemental, accepting environment.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Disclosure to staff depends on a non-judgemental, accepting environment.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "one or more substances, despite significant substance",
    "brandName": "related problems",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "one or more substances, despite significant substance-related problems (including abuse",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepine, e.g.:",
    "brandName": "Doctor prescribed.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepine, e.g.: (Doctor prescribed.)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, slow IV, 10 mg.",
    "brandName": "Doctor prescribed.",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, slow IV, 10 mg. (Doctor prescribed.)",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Younger",
    "brandName": "< 12 years of age",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Younger (< 12 years of age) or older age (> 60 years of age).",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Most patients with substance",
    "brandName": "induced psychosis can be managed without medicatio",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Most patients with substance-induced psychosis can be managed without medication.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Minimise stress and stimulation",
    "brandName": "do not argue with psychotic thinking",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Minimise stress and stimulation (do not argue with psychotic thinking).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Autonomic: sweating, tachycardia, hypertension, tremors, tonic",
    "brandName": "clonic seizures, and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "» Autonomic: sweating, tachycardia, hypertension, tremors, tonic-clonic seizures, and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Typical delirium occurs 2",
    "brandName": "3 days following cessation of prolonged alcohol in",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Typical delirium occurs 2–3 days following cessation of prolonged alcohol intake, but",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, oral, 10 mg immediately.",
    "brandName": "Doctor prescribed.",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, oral, 10 mg immediately. (Doctor prescribed.)",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1  Definition",
    "brandName": "Psychoeducation",
    "strength": "1  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1  Definition (Psychoeducation): Sarkhel S, Singh OP, Arora M. Clinical Practice Guidelines for Psychoeducation in Psychiatric Disorders",
    "commonDosage": "1  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2  Definition",
    "brandName": "Risk Assessment",
    "strength": "2  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2  Definition (Risk Assessment): New South Wales Government. SESLHDGL/082 Clinical Risk Assessment and Management. 2022/04",
    "commonDosage": "2  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3  Definition",
    "brandName": "Manual Restraint",
    "strength": "3  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3  Definition (Manual Restraint): Strategies to end seclusion and restraint. WHO Quality Rights Specialized training. Course guide.",
    "commonDosage": "3  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://apps.who.int/iris/bitstream/handle/10665/329605/9789241516754",
    "brandName": "eng.pdf",
    "strength": "10665",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://apps.who.int/iris/bitstream/handle/10665/329605/9789241516754-eng.pdf",
    "commonDosage": "10665",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4  Definition",
    "brandName": "Mechanical Restraint",
    "strength": "4  ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4  Definition (Mechanical Restraint): National Department of Health. Policy Guidelines on Seclusion and Restraint of Mental Health Care",
    "commonDosage": "4  ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Users. 2012. Available from: https://www.knowledgehub.org.za/elibrary/policy",
    "brandName": "guidelines",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Users. 2012. Available from: https://www.knowledgehub.org.za/elibrary/policy-guidelines-seclusion-and-restraint-mental-health-care-",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepine oral/IM repeat dosing: Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double",
    "brandName": "blind, randomized trial of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepine oral/IM repeat dosing: Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2004 Jul;11",
    "brandName": "7",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2004 Jul;11(7):744-9. https://www.ncbi.nlm.nih.gov/pubmed/15231461",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lingford",
    "brandName": "Hughes A, McAllister",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lingford-Hughes A, McAllister-Williams H, O'Brien A, Parker C, Paterson  B, Paton C, Posporelis S, Taylor DM, Vieta E, Völlm B, Wilson-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jones C, Woods L; With co",
    "brandName": "authors",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jones C, Woods L; With co-authors (in alphabetical order):. Joint BAP NAPICU evidence-based consensus guidelines for the clinical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management of acute disturbance: De",
    "brandName": "escalation and rapid tranquillisation. J Psychopha",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management of acute disturbance: De-escalation and rapid tranquillisation. J Psychopharmacol 2018 Jun;32(6):601-640.",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Biperiden, IM/slow IV",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Biperiden, IM/slow IV (children): National Department of Health, Essential Drugs Programme: Paediatric Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Biperiden, IM/slow IV",
    "brandName": "children",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Biperiden, IM/slow IV (children): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Promethazine, IM",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Promethazine, IM (children): National Department of Health, Essential Drugs Programme: Paediatric Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Promethazine, IM",
    "brandName": "children",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Promethazine, IM (children): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Orphenadrine, oral",
    "brandName": "adults",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Orphenadrine, oral (adults): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neuroleptic malignant syndrome associated with medicines: American Psychiatric Association DSM",
    "brandName": "5 Task Force.",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neuroleptic malignant syndrome associated with medicines: American Psychiatric Association DSM-5 Task Force. (2013).",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diagnostic and statistical manual of mental disorders: DSM",
    "brandName": "5",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Washington, D.C.: American Psychiatric Association.",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluoxetine, oral",
    "brandName": "anxiety",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Fluoxetine, oral (anxiety): Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "systematic review and meta",
    "brandName": "analysis. BMJ. 2011;342:d1199. https://www.ncbi.nl",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "systematic review and meta-analysis. BMJ. 2011;342:d1199. https://www.ncbi.nlm.nih.gov/pubmed/21398351",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluoxetine, oral",
    "brandName": "anxiety",
    "strength": "14",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Fluoxetine, oral (anxiety): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of Cape",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SSRIs, oral",
    "brandName": "anxiety",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SSRIs, oral (anxiety): Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disorders: a meta",
    "brandName": "analysis. Int Clin Psychopharmacol. 2015;30",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-92. https://www.ncbi.nlm.nih.gov/pubmed/25932596",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta",
    "brandName": "analysis. Lancet Psychiatry.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2014;1",
    "brandName": "5",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2014;1(5):368-76. https://www.ncbi.nlm.nih.gov/pubmed/26361000",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "placebo",
    "brandName": "controlled trial. J Clin Psychiatry. 2003 Nov;64",
    "strength": "2003 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "placebo-controlled trial. J Clin Psychiatry. 2003 Nov;64(11):1322-7. https://www.ncbi.nlm.nih.gov/pubmed/14658946",
    "commonDosage": "2003 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "serotonin reuptake inhibitors and serotonin",
    "brandName": "norepinephrine reuptake inhibitors in older adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Soc. 2015;63",
    "brandName": "5",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Soc. 2015;63(5):1002-9. https://www.ncbi.nlm.nih.gov/pubmed/25945410",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SSRIs, oral",
    "brandName": "resolution of agitation",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SSRIs, oral (resolution of agitation – anxiety disorders South African Medicines Formulary, 14th Edition.  Division of Clinical",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "neurological and substance use disorders in non",
    "brandName": "specialized health settings: mental health Gap Act",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP), version",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines, oral",
    "brandName": "anxiety",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines, oral (anxiety): Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, et al. Antidepressants",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines, oral",
    "brandName": "anxiety",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines, oral (anxiety): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007",
    "brandName": "1",
    "strength": "2007",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007(1):CD004364.",
    "commonDosage": "2007",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SSRI/psychotherapy",
    "brandName": "anxiety",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SSRI/psychotherapy (anxiety): Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers MJ. How effective are cognitive behavior",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "anxiety disorders: a meta",
    "brandName": "analysis. IntClinPsychopharmacol. 2015;30",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "anxiety disorders: a meta-analysis. IntClinPsychopharmacol. 2015;30(4):183-92. https://www.ncbi.nlm.nih.gov/pubmed/25932596",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines",
    "brandName": "caution",
    "strength": "26 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines (caution): NICE. Generalised anxiety disorder and panicdisorder in adults: management, 26 January 2011.",
    "commonDosage": "26 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines",
    "brandName": "caution",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines (caution): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the elderly. Am J Health Syst Pharm. 2018 Jan 1;75",
    "brandName": "1",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the elderly. Am J Health Syst Pharm. 2018 Jan 1;75(1):e6-e12. https://www.ncbi.nlm.nih.gov/pubmed/29273607",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Outcomes Reported on in Epidemiologic Research. Drugs R D. 2017 Dec;17",
    "brandName": "4",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Outcomes Reported on in Epidemiologic Research. Drugs R D. 2017 Dec;17(4):493-507.",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines",
    "brandName": "caution",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines (caution – long-term use): Picton JD, Marino AB, Nealy KL. Benzodiazepine use and cognitive decline in the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "elderly. Am J Health Syst Pharm. 2018 Jan 1;75",
    "brandName": "1",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "elderly. Am J Health Syst Pharm. 2018 Jan 1;75(1): e6-e12. https://www.ncbi.nlm.nih.gov/pubmed/29273607",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "network meta",
    "brandName": "analysis. Lancet. 2018 Apr 7;391",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. https://www.ncbi.nlm.nih.gov/pubmed/29477251",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Geriatr Soc. 2015;63",
    "brandName": "5",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Geriatr Soc. 2015;63(5):1002-9. https://www.ncbi.nlm.nih.gov/pubmed/25945410",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry",
    "brandName": "WFSBP",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder",
    "brandName": "update",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "substance use disorders in non",
    "brandName": "specialized health settings: mental health Gap Act",
    "strength": "2.0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP), version 2.0. Geneva,",
    "commonDosage": "2.0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22;361",
    "brandName": "9358",
    "strength": "22",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22;361(9358):653-61. https://www.ncbi.nlm.nih.gov/pubmed/12606176",
    "commonDosage": "22",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22Acute psychosis",
    "brandName": "prognosis",
    "strength": "22",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22Acute psychosis (prognosis): Fusar-Poli P, Cappucciati M, Bonoldi I, Hui LM, Rutigliano G, Stahl DR, Borgwardt S, Politi P, Mishara",
    "commonDosage": "22",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "AL, Lawrie SM, Carpenter WT Jr, McGuire PK. Prognosis of Brief Psychotic Episodes: A Meta",
    "brandName": "analysis. JAMA Psychiatry. 2016",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "AL, Lawrie SM, Carpenter WT Jr, McGuire PK. Prognosis of Brief Psychotic Episodes: A Meta-analysis. JAMA Psychiatry. 2016",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mar;73",
    "brandName": "3",
    "strength": "73",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mar;73(3):211-20. https://www.ncbi.nlm.nih.gov/pubmed/26764163",
    "commonDosage": "73",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Physical health care monitoring",
    "brandName": "mental illnesses",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Physical health care monitoring (mental illnesses): Tosh G, Clifton AV, Xia J, White MM. Physical health care monitoring for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antipsychotics",
    "brandName": "monitoring: South African Medicines Formulary.  14",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antipsychotics - monitoring: South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Folic acid, oral: Royal College of Obstetricians & Gynaecologists. Green",
    "brandName": "top Guideline No. 68: Epilepsy in pregnancy, June ",
    "strength": "68",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Folic acid, oral: Royal College of Obstetricians & Gynaecologists. Green-top Guideline No. 68: Epilepsy in pregnancy, June 2016.",
    "commonDosage": "68",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.rcog.org.uk/en/guidelines",
    "brandName": "research",
    "strength": "68",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg68/",
    "commonDosage": "68",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thiamine: Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thiamine: Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thiamine: Lingford",
    "brandName": "Hughes AR, Welch S, Peters L, Nutt DJ; British Ass",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thiamine: Lingford-Hughes AR, Welch S, Peters L, Nutt DJ; British Association for Psychopharmacology, Expert Reviewers",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Group. BAP updated guidelines: evidence",
    "brandName": "based guidelines for the pharmacological managemen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Group. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse,  harmful use,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preliminary findings. AlcoholClinExpRes 2001; 25: 112",
    "brandName": "16. http://www.ncbi.nlm.nih.gov/pubmed/11198705",
    "strength": "2001",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preliminary findings. AlcoholClinExpRes 2001; 25: 112–16. http://www.ncbi.nlm.nih.gov/pubmed/11198705",
    "commonDosage": "2001",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "managing Wernicke’s encephalopathy in the accident and emergency department. Alcohol AlcoholSuppl 2002; 37: 513",
    "brandName": "21.",
    "strength": "2002",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "managing Wernicke’s encephalopathy in the accident and emergency department. Alcohol AlcoholSuppl 2002; 37: 513–21.",
    "commonDosage": "2002",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Alcohol AlcoholSuppl 1998; 33: 317",
    "brandName": "36. http://www.ncbi.nlm.nih.gov/pubmed/9719389",
    "strength": "1998",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Alcohol AlcoholSuppl 1998; 33: 317–36. http://www.ncbi.nlm.nih.gov/pubmed/9719389",
    "commonDosage": "1998",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Neurol. 2007 May;6",
    "brandName": "5",
    "strength": "2007 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Neurol. 2007 May;6(5):442-55. Review. http://www.ncbi.nlm.nih.gov/pubmed/17434099",
    "commonDosage": "2007 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17.2.1 Croup",
    "brandName": "laryngotracheo bronchitis",
    "strength": "17.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17.2.1 Croup (laryngotracheo bronchitis) in children",
    "commonDosage": "17.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "17.4.4 Drug",
    "brandName": "resistant tuberculosis",
    "strength": "17.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "17.4.4 Drug-resistant tuberculosis (MDR TB)",
    "commonDosage": "17.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "nomogram in Appendix I: Asthma monitoring, to predict PEFR",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "nomogram in Appendix I: Asthma monitoring, to predict PEFR).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol 100 mcg metered",
    "brandName": "dose inhaler",
    "strength": "100 mcg",
    "form": "inhaler",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol 100 mcg metered-dose inhaler (MDI),",
    "commonDosage": "100 mcg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Salbutamol inhaler 400 to 1000 mcg",
    "brandName": "4 to 10 puffs",
    "strength": "400 ",
    "form": "inhaler",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Salbutamol inhaler 400 to 1000 mcg (4 to 10 puffs) using a spacer if required and",
    "commonDosage": "400 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol 0.5%",
    "brandName": "5 mg/mL",
    "strength": "0.5%",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol 0.5% (5 mg/mL), solution,",
    "commonDosage": "0.5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o 1 mL",
    "brandName": "5 mg",
    "strength": "1 mL",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o 1 mL (5 mg) salbutamol 0.5% solution made up to 4 mL with sodium chloride",
    "commonDosage": "1 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Severe attacks",
    "brandName": "while awaiting referral",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Severe attacks (while awaiting referral)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen to keep oxygen saturation 93",
    "brandName": "95%.",
    "strength": "93",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen to keep oxygen saturation 93-95%.",
    "commonDosage": "93",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Give oxygen with care",
    "brandName": "preferably by 24% or 28% facemask, if available",
    "strength": "24%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Give oxygen with care (preferably by 24% or 28% facemask, if available). Observe",
    "commonDosage": "24%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Salbutamol 400",
    "brandName": "1000 mcg",
    "strength": "400",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Salbutamol 400–1000 mcg (4 to 10 puffs), up to 20 puffs, using a spacer.",
    "commonDosage": "400",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Ipratroprium bromide, 2 mL",
    "brandName": "0.5 mg",
    "strength": "2 mL",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Ipratroprium bromide, 2 mL (0.5 mg) added to salbutamol 1 mL (5",
    "commonDosage": "2 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ipratroprium bromide, MDI, 80 to 160 mcg",
    "brandName": "2 to 4 puffs",
    "strength": "80 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ipratroprium bromide, MDI, 80 to 160 mcg (2 to 4 puffs), using a spacer every 20 to",
    "commonDosage": "80 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Give oxygen with care",
    "brandName": "preferably by 24% or 28% facemask, if available",
    "strength": "24%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Give oxygen with care (preferably by 24% or 28% facemask, if available). Observe",
    "commonDosage": "24%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Salbutamol 0.5%, 2 mL",
    "brandName": "10 mg",
    "strength": "0.5%",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Salbutamol 0.5%, 2 mL (10 mg) plus ipratroprium bromide, 2 mL (0.5 mg) every",
    "commonDosage": "0.5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "from life",
    "brandName": "threatening to severe.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "from life-threatening to severe.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Parenteral corticosteroids",
    "brandName": "intermediate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Parenteral corticosteroids (intermediate-acting) e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oral corticosteroids",
    "brandName": "intermediate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oral corticosteroids (intermediate-acting) e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Patients needing repeated courses of oral corticosteroids",
    "brandName": "more than twice over 6",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Patients needing repeated courses of oral corticosteroids (more than twice over 6",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol inhaler 400 to 1000 mcg",
    "brandName": "4 to 10 puffs",
    "strength": "400 ",
    "form": "inhaler",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol inhaler 400 to 1000 mcg (4 to 10 puffs) using a spacer.",
    "commonDosage": "400 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol inhaler 200",
    "brandName": "600 mcg",
    "strength": "200",
    "form": "inhaler",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol inhaler 200–600 mcg (2-6 puffs) using a spacer.",
    "commonDosage": "200",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o 0.5",
    "brandName": "1 mL",
    "strength": "0.5",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o 0.5–1 mL (2.5 to 5 mg) salbutamol 0.5% solution, made up to 4 mL with sodium",
    "commonDosage": "0.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Salbutamol, 400 to 1000 mcg",
    "brandName": "4 to 10 puffs",
    "strength": "400 ",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Salbutamol, 400 to 1000 mcg (4 to 10 puffs), using a spacer.",
    "commonDosage": "400 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Ipratropium bromide, 2 mL",
    "brandName": "0.25 mg",
    "strength": "2 mL",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Ipratropium bromide, 2 mL (0.25 mg) solution, nebulised with salbutamol 0.5 mL",
    "commonDosage": "2 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrocortisone IM/slow IV, 4 mg/kg",
    "brandName": "maximum 100 mg",
    "strength": "4 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hydrocortisone IM/slow IV, 4 mg/kg (maximum 100 mg) immediately. See dosing",
    "commonDosage": "4 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Asthma must be distinguished from COPD, which is often mistaken for asthma.",
    "brandName": "See",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Asthma must be distinguished from COPD, which is often mistaken for asthma. (See",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Marked improvement with ß2",
    "brandName": "agonist.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Marked improvement with ß2-agonist.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cigarettes/day for ≥15 years",
    "brandName": ", heavy",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cigarettes/day for ≥15 years), heavy",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Little improvement with ß2",
    "brandName": "agonist.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Little improvement with ß2-agonist.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If symptoms suggest TB",
    "brandName": "e.g. weight loss, night sweats, etc.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If symptoms suggest TB (e.g. weight loss, night sweats, etc.), investigate and manage",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "minutes after inhalation of a beta2",
    "brandName": "agonist e.g. salbutamol, inhalation, 200 mcg,",
    "strength": "2",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "minutes after inhalation of a beta2-agonist e.g. salbutamol, inhalation, 200 mcg,",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "regarded as confirmation of adequate control. Ensure that pre",
    "brandName": "bronchodilator",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "regarded as confirmation of adequate control. Ensure that pre-bronchodilator",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Starting asthma treatment in children aged 6",
    "brandName": "11, adolescent >12",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Starting asthma treatment in children aged 6-11, adolescent >12",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "adolescents",
    "brandName": "adapted from the GINA 2023",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "adolescents (adapted from the GINA 2023",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to prevent the inflammation leading to bronchospasm",
    "brandName": "controller",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "to prevent the inflammation leading to bronchospasm (controller) and to relieve",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Short acting beta2",
    "brandName": "agonists",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Short acting beta2-agonists (SABAs), e.g.:",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol, inhalation, 100 to 200 mcg",
    "brandName": "1 to 2 puffs",
    "strength": "100 ",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol, inhalation, 100 to 200 mcg (1 to 2 puffs), 6 to 8 hourly as needed (until",
    "commonDosage": "100 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» No night",
    "brandName": "time cough and/or wheeze.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» No night-time cough and/or wheeze.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Once the diagnosis is confirmed, step",
    "brandName": "up treatment to STEP 3 as below:",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Once the diagnosis is confirmed, step-up treatment to STEP 3 as below:",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "technques",
    "brandName": "and consider treatment with combination of cortico",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "technques) and consider treatment with combination of corticosteroid and long-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "acting beta agonist",
    "brandName": "LABA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "acting beta agonist (LABA):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stop corticosteroid inhaler",
    "brandName": "e.g. budesonide",
    "strength": "N/A",
    "form": "inhaler",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stop corticosteroid inhaler (e.g. budesonide) and replace controller therapy with:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Inhaled long",
    "brandName": "acting beta agonist",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Inhaled long-acting beta agonist (LABA)/corticosteroid combination, e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salmeterol/fluticasone, inhalation, 50/250 mcg",
    "brandName": "1 puff",
    "strength": "50",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salmeterol/fluticasone, inhalation, 50/250 mcg (1 puff) 12 hourly.",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in the preceding 6 months, and day",
    "brandName": "time and night",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in the preceding 6 months, and day-time and night-time symptoms are well controlled.",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: In patients with new onset of exercise",
    "brandName": "related symptoms, consider other diagnoses,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: In patients with new onset of exercise-related symptoms, consider other diagnoses,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Central cyanosis or hypoxia",
    "brandName": "oxygen saturation <90% in room air",
    "strength": "90%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Central cyanosis or hypoxia (oxygen saturation <90% in room air).",
    "commonDosage": "90%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Signs of severe bronchiolitis",
    "brandName": "respiratory distress, hypoxia, apnoea, inability t",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Signs of severe bronchiolitis (respiratory distress, hypoxia, apnoea, inability to feed,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "lethargy/decreased level of consciousness",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "lethargy/decreased level of consciousness).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pollution, previous TB, and previous cannabis",
    "brandName": "dagga",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pollution, previous TB, and previous cannabis (dagga) smoking, although there are many",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "accordingly.",
    "brandName": "See Section 17.4: Pulmonary Tuberculosis",
    "strength": "17.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "accordingly. (See Section 17.4: Pulmonary Tuberculosis (TB).)",
    "commonDosage": "17.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Smoking cessation, including cannabis",
    "brandName": "dagga",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Smoking cessation, including cannabis (dagga), is the mainstay of therapy.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Perform spirometry if available. Diagnose COPD if post",
    "brandName": "bronchodilator FEV1/FVC",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Perform spirometry if available. Diagnose COPD if post-bronchodilator FEV1/FVC",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If not controlled on SABA alone and diagnosis was confirmed by spirometry",
    "brandName": "with",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If not controlled on SABA alone and diagnosis was confirmed by spirometry (with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Long",
    "brandName": "acting beta2 agonist",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Long-acting beta2 agonist (LABA), e.g.:",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Formoterol, inhaled 12 mcg",
    "brandName": "1 puff",
    "strength": "12 mcg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Formoterol, inhaled 12 mcg (1 puff) 12 hourly. (Doctor initiated.)",
    "commonDosage": "12 mcg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Croup is a common cause of potentially life",
    "brandName": "threatening airway obstruction in childhood.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Croup is a common cause of potentially life-threatening airway obstruction in childhood.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Intubate",
    "brandName": "if not possible give treatment as above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Intubate (if not possible give treatment as above).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children grade 2 or more stridor",
    "brandName": "while awaiting transfer:",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children grade 2 or more stridor- while awaiting transfer:",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Weight",
    "brandName": "based prednisone dosing for children <18 kg:",
    "strength": "18 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Weight-based prednisone dosing for children <18 kg:",
    "commonDosage": "18 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Grade 2",
    "brandName": "4 stridor,",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Grade 2-4 stridor,",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Influenza is a self",
    "brandName": "limiting viral condition that presents with headac",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Influenza is a self-limiting viral condition that presents with headache, muscular pain and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» initially: non",
    "brandName": "productive cough.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» initially: non-productive cough.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» cough, which becomes productive of rusty brown or yellow",
    "brandName": "green sputum;",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» cough, which becomes productive of rusty brown or yellow-green sputum;",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "depending on the response to initial treatment",
    "brandName": "see below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "depending on the response to initial treatment (see below).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Pneumonia: fever, cough and rapid breathing, but no chest indrawing",
    "brandName": "of the lower",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Pneumonia: fever, cough and rapid breathing, but no chest indrawing (of the lower",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "chest wall",
    "brandName": "and no flaring of nostrils.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "chest wall) and no flaring of nostrils.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃25",
    "brandName": "30 kg",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃25–30 kg",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen, using nasal cannula at 1",
    "brandName": "2 L/minute before and during transfer.",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen, using nasal cannula at 1–2 L/minute before and during transfer.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All children with severe pneumonia, i.e. chest indrawing",
    "brandName": "of the lower chest wall",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All children with severe pneumonia, i.e. chest indrawing (of the lower chest wall),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A chest X",
    "brandName": "ray should ideally be taken in all patients to con",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A chest X-ray should ideally be taken in all patients to confirm the diagnosis. Send one",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "from a poor socio",
    "brandName": "economic background,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "from a poor socio-economic background,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">40",
    "brandName": "56 kg",
    "strength": "40",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">40–56 kg",
    "commonDosage": "40",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pulmonary TB is diagnosed on sputum by TB nucleic acid amplification tests",
    "brandName": "TB",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pulmonary TB is diagnosed on sputum by TB nucleic acid amplification tests (TB-NAAT)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "presentation and chest X",
    "brandName": "ray are suggestive of TB, treat for drug",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "presentation and chest X-ray are suggestive of TB, treat for drug-sensitive TB",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "sputum specimen for baseline smear microscopy",
    "brandName": "the smear is used for reporting,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "sputum specimen for baseline smear microscopy (the smear is used for reporting,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "not for diagnosis",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "not for diagnosis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tuberculosis in adults",
    "brandName": ". Collect sputum sample for reflex testing of fluo",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tuberculosis in adults). Collect sputum sample for reflex testing of fluoroquinolone",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If TB",
    "brandName": "NAAT is negative and patient is living with HIV: s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If TB-NAAT is negative and patient is living with HIV: send sputum for TB culture",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and perform chest X",
    "brandName": "ray. If CD4 <200 within the last 6 months and they",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and perform chest X-ray. If CD4 <200 within the last 6 months and they have signs",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "after completion of appropriate anti",
    "brandName": "TB treatment.  To diagnose a new episode of TB",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "after completion of appropriate anti-TB treatment.  To diagnose a new episode of TB",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "progestin",
    "brandName": "only implants, resulting in possible unplanned pre",
    "strength": "7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "progestin-only implants, resulting in possible unplanned pregnancies. (See Chapter 7:",
    "commonDosage": "7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Family planning.",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Family planning.)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Women choosing to use a progestin",
    "brandName": "only subdermal implant should be advised to use",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Women choosing to use a progestin-only subdermal implant should be advised to use",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dose adjustment in renal impairment",
    "brandName": "eGFR <30 mL/min",
    "strength": "30 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dose adjustment in renal impairment (eGFR <30 mL/min).",
    "commonDosage": "30 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ethambutol 15",
    "brandName": "25mg/kg three times weekly.",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ethambutol 15 – 25mg/kg three times weekly.",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pyrazinamide 20",
    "brandName": "30 mg/kg three times weekly.",
    "strength": "20 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pyrazinamide 20 – 30 mg/kg three times weekly.",
    "commonDosage": "20 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Administer standard weight",
    "brandName": "based dosing of RH on Tuesday, Thursday,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Administer standard weight-based dosing of RH on Tuesday, Thursday,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not require dose adjustment. Continue daily weight",
    "brandName": "based dosing of RH.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not require dose adjustment. Continue daily weight-based dosing of RH.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Hepatitis",
    "brandName": "drug induced liver injury",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Hepatitis (drug induced liver injury):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Patient may present with jaundice and/or complaining of hepatitis symptoms",
    "brandName": "e.g.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Patient may present with jaundice and/or complaining of hepatitis symptoms (e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Refer to hospital for urgent",
    "brandName": "same day",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Refer to hospital for urgent (same day) ALT and further management.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "immunosuppressed",
    "brandName": "HIV and AIDS",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "immunosuppressed (HIV and AIDS) children, and children <5 years of age, are at",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A chest X",
    "brandName": "ray suggestive of TB,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A chest X-ray suggestive of TB,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A positive  TB",
    "brandName": "NAAT and/or smear microscopy and/or culture, on ea",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A positive  TB-NAAT and/or smear microscopy and/or culture, on early morning gastric",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tuberculin skin test",
    "brandName": "TST",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tuberculin skin test (TST), e.g. Mantoux:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The following may be evident on chest X",
    "brandName": "ray:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The following may be evident on chest X-ray:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Exclude active TB",
    "brandName": "i.e. no signs or symptoms suggestive of TB",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Exclude active TB (i.e. no signs or symptoms suggestive of TB):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If any signs or symptoms of pulmonary TB are present, refer for chest X",
    "brandName": "ray.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If any signs or symptoms of pulmonary TB are present, refer for chest X-ray.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "protect the child against subsequent TB exposure/ infection",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "protect the child against subsequent TB exposure/ infection).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Preventive therapy in case of drug",
    "brandName": "sensitive TB contact:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Preventive therapy in case of drug-sensitive TB contact:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">10",
    "brandName": "14.9 kg",
    "strength": "10",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">10–14.9 kg",
    "commonDosage": "10",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">15",
    "brandName": "19.9 kg",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">15–19.9 kg",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">20",
    "brandName": "24.9 kg",
    "strength": "20",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">20–24.9 kg",
    "commonDosage": "20",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: For adults and adolescents initiating a DTG",
    "brandName": "containing ART regimen, isoniazid",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: For adults and adolescents initiating a DTG-containing ART regimen, isoniazid",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "suppressed on a DTG",
    "brandName": "based regimen, a weekly combination of isoniazid",
    "strength": "900mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "suppressed on a DTG-based regimen, a weekly combination of isoniazid (900mg if",
    "commonDosage": "900mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "weight >30 kg",
    "brandName": "plus rifapentine",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "weight >30 kg) plus rifapentine (900mg if weight >30 kg) for three months may be",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preferred. Do not use rifapentine",
    "brandName": "containing TPT in patients on protease inhibitor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preferred. Do not use rifapentine-containing TPT in patients on protease inhibitor-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "interchange database for details regarding the rifapentine",
    "brandName": "containing TPT regimen].",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "interchange database for details regarding the rifapentine-containing TPT regimen].",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isoniazid, oral, 10 mg/kg daily for 6 months",
    "brandName": "see table above",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isoniazid, oral, 10 mg/kg daily for 6 months (see table above).",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Daily",
    "brandName": "mg/kg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Daily (mg/kg)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "enlargement and/or lung field opacification, or simple pleural effusion on chest x",
    "brandName": "ray.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "enlargement and/or lung field opacification, or simple pleural effusion on chest x-ray.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children ≤ 8 years of age or <25 kg",
    "brandName": ":",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children ≤ 8 years of age or <25 kg):",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "* For each dose, dissolve 150 mg dispersible",
    "brandName": "1 tablet",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "* For each dose, dissolve 150 mg dispersible (1 tablet) in 3 mL of water to prepare a concentration of 50 mg/mL (150 mg/3 mL)",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "RHZ",
    "brandName": "75/50/150 mg",
    "strength": "75",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "RHZ (75/50/150 mg)",
    "commonDosage": "75",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children ≥ 8 years and adolescents",
    "brandName": "and ≥25 kg",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children ≥ 8 years and adolescents (and ≥25 kg)",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children ≤8 years of age",
    "brandName": "or <25 kg",
    "strength": "8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children ≤8 years of age (or <25 kg):",
    "commonDosage": "8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Intensive phase: Standard dose 4",
    "brandName": "drug therapy daily",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Intensive phase: Standard dose 4-drug therapy daily (RHZE) for 2 months.",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Continuation phase: Standard dose 2",
    "brandName": "drug therapy daily for 4 to 7 months.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Continuation phase: Standard dose 2-drug therapy daily for 4 to 7 months.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "* PZA: For each dose, dissolve 150 mg dispersible",
    "brandName": "1 tablet",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "* PZA: For each dose, dissolve 150 mg dispersible (1 tablet) in 3 mL of water to prepare a concentration of 50 mg/mL (150 mg/3mL).",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "** EMB: For each dose, crush 400 mg",
    "brandName": "1 tablet",
    "strength": "400 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "** EMB: For each dose, crush 400 mg (1 tablet) to a fine powder and dissolve in 8 mL of water to prepare a concentration of",
    "commonDosage": "400 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children <12 years of age for a chest X",
    "brandName": "ray for diagnostic purposes.",
    "strength": "12 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children <12 years of age for a chest X-ray for diagnostic purposes.",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children with previously treated TB requiring re",
    "brandName": "treatment.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children with previously treated TB requiring re-treatment.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "People living with HIV",
    "brandName": "PLHIV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "People living with HIV (PLHIV) with suspected TB should have one negative sputum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» active cough",
    "brandName": "any duration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» active cough (any duration)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Consult the most recent National DR",
    "brandName": "TB Programme Guidelines.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Consult the most recent National DR-TB Programme Guidelines.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "that is resistant to rifampicin, with or without resistance to other anti",
    "brandName": "TB drugs.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "that is resistant to rifampicin, with or without resistance to other anti-TB drugs.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Extensively drug",
    "brandName": "resistant TB",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Extensively drug-resistant TB (XDR-TB) is TB disease caused by a strain of M.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Screen all close contacts for signs and symptoms of drug",
    "brandName": "resistant TB and by sputum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Screen all close contacts for signs and symptoms of drug-resistant TB and by sputum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suspect drug",
    "brandName": "resistant TB when any of the features listed below",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suspect drug-resistant TB when any of the features listed below is present:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A known source case",
    "brandName": "or contact",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A known source case (or contact) with drug resistant TB or high-risk source case, e.g.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» History of treatment interruption",
    "brandName": "<1 month",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» History of treatment interruption (<1 month) or relapse at some point during their TB",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "D'Amato G, Vitale C, Lanza M, et al. Near fatal asthma: treatment and prevention. Eur Ann Allergy Clin Immunol. 2016;48",
    "brandName": "4",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "D'Amato G, Vitale C, Lanza M, et al. Near fatal asthma: treatment and prevention. Eur Ann Allergy Clin Immunol. 2016;48(4):116-",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol MDI",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol MDI (adults): Rodrigo C, Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "nebulizer. Am J Emerg Med. 1998 Nov16",
    "brandName": "7",
    "strength": "1998 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "nebulizer. Am J Emerg Med. 1998 Nov16(7):637-42. https://www.ncbi.nlm.nih.gov/pubmed/9827736",
    "commonDosage": "1998 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol MDI",
    "brandName": "adults",
    "strength": "2019",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol MDI (adults): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML, 2019.",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol nebulisation",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol nebulisation (adults): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ipratropium bromide 0.5 mg nebulisation",
    "brandName": "adults",
    "strength": "0.5 mg",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Ipratropium bromide 0.5 mg nebulisation (adults): Global initiative for asthma (GINA) Guidelines, 2018. http://ginasthma.org/",
    "commonDosage": "0.5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ipratropium bromide  MDI",
    "brandName": "adults",
    "strength": "2018",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Ipratropium bromide  MDI (adults ): Global initiative for asthma (GINA) Guidelines, 2018. http://ginasthma.org/",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15 6 breaths:  Levin ME.  Optimal aerosol delivery.  Current Allergy & Clinical Immunology.  2011; 24",
    "brandName": "1",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15 6 breaths:  Levin ME.  Optimal aerosol delivery.  Current Allergy & Clinical Immunology.  2011; 24(1):27-30",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ipratropium bromide nebulisation",
    "brandName": "paediatrics",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Ipratropium bromide nebulisation (paediatrics): Kling S, Zar HJ, Levin ME, Green RJ, Jeena PM, Risenga SM, Thula SA ,Goussard",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "P, Gie RP, for the South African Childhood Asthma Working Group",
    "brandName": "SACAWG",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "P, Gie RP, for the South African Childhood Asthma Working Group (SACAWG)S Afr Med J 2013;103(3):199-207.",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Step",
    "brandName": "wise assessment: Global Initiative for Asthma. Glo",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Step-wise assessment: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Available from:",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "22 Low",
    "brandName": "dose ICS with SABA MDI",
    "strength": "22 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "22 Low-dose ICS with SABA MDI (Rescue use): Global Initiative for Asthma. Global Strategy for asthma management and",
    "commonDosage": "22 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LP. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short",
    "brandName": "acting bronchodilators alone is",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LP. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "inhaler for mild asthma. N Engl J Med. 2007 May 17;356",
    "brandName": "20",
    "strength": "2007 ",
    "form": "inhaler",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52. https://www.ncbi.nlm.nih.gov/pubmed/17507703",
    "commonDosage": "2007 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "randomised, double",
    "brandName": "blind trial. Lancet. 2003 Mar 29;361",
    "strength": "2003 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "randomised, double-blind trial. Lancet. 2003 Mar 29;361(9363):1071-6. https://www.ncbi.nlm.nih.gov/pubmed/12672309",
    "commonDosage": "2003 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "prevention of death from asthma. N Engl J Med. 2000 Aug 3;343",
    "brandName": "5",
    "strength": "2000 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "prevention of death from asthma. N Engl J Med. 2000 Aug 3;343(5):332-6. https://www.ncbi.nlm.nih.gov/pubmed/10922423.",
    "commonDosage": "2000 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Investigators Group. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma",
    "brandName": "START",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Investigators Group. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up:",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy ClinImmunol. 2008May;121",
    "brandName": "5",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy ClinImmunol. 2008May;121(5):1167-",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Inhaled corticosteroids",
    "brandName": "Patients on protease inhibitors",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Inhaled corticosteroids (Patients on protease inhibitors): Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2010 Sep;47",
    "brandName": "7",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2010 Sep;47(7):830-1. https://www.ncbi.nlm.nih.gov/pubmed/20653496",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "budesonide interaction. Ann Pharmacother. 2011 Jun;45",
    "brandName": "6",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "budesonide interaction. Ann Pharmacother. 2011 Jun;45(6):823-4. https://www.ncbi.nlm.nih.gov/pubmed/21558486",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract. 2013 Nov",
    "brandName": "",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract. 2013 Nov-",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dec;19",
    "brandName": "6",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dec;19(6):e138-41. https://www.ncbi.nlm.nih.gov/pubmed/23807527",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2012 Jul;23",
    "brandName": "7",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2012 Jul;23(7):520-1. https://www.ncbi.nlm.nih.gov/pubmed/22844010",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LABA/ICS",
    "brandName": "Salmeterol/fluticasone",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "LABA/ICS (Salmeterol/fluticasone) MDI (adults): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotics",
    "brandName": "lower airway obstruction: 2023 Global Strategy for",
    "strength": "2023 G",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotics – lower airway obstruction: 2023 Global Strategy for Asthma Management and Prevention (GINA 2023), pg 142.",
    "commonDosage": "2023 G",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LABA",
    "brandName": "Formoterol",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LABA (Formoterol) MDI (adults): National Department of Health, Essential Drugs Programme: Adult Hospital Level STGs and EML,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Chest x",
    "brandName": "ray diagnosis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Chest x-ray diagnosis (follow-up for community acquired pneumonia): Tang KL, Eurich DT,Minhas-Sandhu JK,Marrie TJ,Majumdar",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2011;171:1193",
    "brandName": "1198. https://www.ncbi.nlm.nih.gov/pubmed/21518934",
    "strength": "2011",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2011;171:1193–1198. https://www.ncbi.nlm.nih.gov/pubmed/21518934",
    "commonDosage": "2011",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Med. 2010 Jan;123",
    "brandName": "1",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Med. 2010 Jan;123(1):66-71. https://www.ncbi.nlm.nih.gov/pubmed/20102994",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Crothers K, et al. Diagnosis and Treatment of Adults with Community",
    "brandName": "acquired Pneumonia. An Official Clinical Practice ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2009 Oct;64 Suppl 3:iii1",
    "brandName": "55. https://www.ncbi.nlm.nih.gov/pubmed/19783532",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2009 Oct;64 Suppl 3:iii1-55. https://www.ncbi.nlm.nih.gov/pubmed/19783532",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jan;123",
    "brandName": "1",
    "strength": "123",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jan;123(1):66-71. https://www.ncbi.nlm.nih.gov/pubmed/20102994",
    "commonDosage": "123",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "LAM",
    "brandName": "for the diagnosis of tuberculosis in people living",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "LAM) for the diagnosis of tuberculosis in people living with HIV, Update February 2021. http://www.health.gov.za/",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "38 Rifapentine",
    "brandName": "containing regimen",
    "strength": "38 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "38 Rifapentine-containing regimen (3HP): Affordable Medicines, EDP- Adult Hospital level. Medicine Review: Rifapentine (3HP) as TPT",
    "commonDosage": "38 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rifampicin, oral",
    "brandName": "Isoniazid mono",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rifampicin, oral - Isoniazid mono-resistant contact:  National Department of Health, Essential Drugs Programme: Paediatric Hospital",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Isoniazid, oral",
    "brandName": "Rifampicin mono",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Isoniazid, oral - Rifampicin mono-resistant contact: National Department of Health, Essential Drugs Programme: Paediatric Hospital",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dispersible paediatric FDC TB formulations",
    "brandName": "dosing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dispersible paediatric FDC TB formulations (dosing): National Department of Health, Essential Drugs Programme: Paediatric",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.who.int/news/item/27",
    "brandName": "01",
    "strength": "27",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis",
    "commonDosage": "27",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Levofloxacin, oral",
    "brandName": "with rifampicin, ethambutamol, pyrazinamide",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Levofloxacin, oral (with rifampicin, ethambutamol, pyrazinamide): Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid",
    "brandName": "resistant tuberculosis: an individual patient data",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "analysis. Lancet Respir Med. 2018;6",
    "brandName": "4",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "analysis. Lancet Respir Med. 2018;6(4):265-75. https://www.ncbi.nlm.nih.gov/pubmed/29595509",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Drug",
    "brandName": "resistant Tuberculosis Treatment 2019.Available fr",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Drug-resistant Tuberculosis Treatment 2019.Available from: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18.1.2 Conjunctivitis, bacterial",
    "brandName": "excluding",
    "strength": "18.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18.1.2 Conjunctivitis, bacterial (excluding",
    "commonDosage": "18.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "agents",
    "brandName": "e.g. lymphocytes, macrophages",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "agents (e.g. lymphocytes, macrophages) at a cellular level.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If no response within 7 days or history of recurrent",
    "brandName": "seasonal",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If no response within 7 days or history of recurrent (seasonal)/chronic allergic",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sodium cromoglycate, 2 % eye drops, instil 1 drop 6 hourly.",
    "brandName": "Doctor initiated.",
    "strength": "2 %",
    "form": "drops",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sodium cromoglycate, 2 % eye drops, instil 1 drop 6 hourly. (Doctor initiated.)",
    "commonDosage": "2 %",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Use may be seasonal",
    "brandName": "1 to 3 months",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Use may be seasonal (1 to 3 months) or long-term.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Redness especially of conjunctival angles",
    "brandName": "fornices",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Redness especially of conjunctival angles (fornices).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Educate patient on personal hygiene to avoid spread e.g. do not use the same face",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Educate patient on personal hygiene to avoid spread e.g. do not use the same face-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral, 500 mg to 1 g 4 to 6 hourly when required",
    "brandName": "to a maximum of 4 g in",
    "strength": "500 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral, 500 mg to 1 g 4 to 6 hourly when required (to a maximum of 4 g in",
    "commonDosage": "500 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Generally, conjunctivitis of the newborn is either mild",
    "brandName": "small amount of sticky",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Generally, conjunctivitis of the newborn is either mild (small amount of sticky",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sticky eye",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sticky eye(s) without purulent discharge:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in 2 mL WFI",
    "brandName": "",
    "strength": "2 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in 2 mL WFI)",
    "commonDosage": "2 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃2.5",
    "brandName": "3.5 kg",
    "strength": "2.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃2.5–3.5 kg",
    "commonDosage": "2.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃3.5",
    "brandName": "5.5 kg",
    "strength": "3.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃3.5–5.5 kg",
    "commonDosage": "3.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Watery discharge",
    "brandName": "a yellow discharge indicates a secondary bacterial",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Watery discharge (a yellow discharge indicates a secondary bacterial infection).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Enlarged pre",
    "brandName": "auricular lymph node.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Enlarged pre-auricular lymph node.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The condition is self",
    "brandName": "limiting but eye irritation and discharge may get ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The condition is self-limiting but eye irritation and discharge may get worse for the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Herpes virus causes a branching",
    "brandName": "dendritic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Herpes virus causes a branching (dendritic) ulcer which can recur and relapse over the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Ensure that eye is irrigated so that the fluid runs away from the unaffected side",
    "brandName": "ie.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Ensure that eye is irrigated so that the fluid runs away from the unaffected side (ie.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and penetrating open",
    "brandName": "globe injuries with prolapse of eye contents.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and penetrating open-globe injuries with prolapse of eye contents.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Perforation e.g. teardrop",
    "brandName": "shaped pupil indicating uveal prolapse.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Perforation e.g. teardrop-shaped pupil indicating uveal prolapse.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Acute closed angle glaucoma is damage to the optic nerve caused by raised intra",
    "brandName": "ocular",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Acute closed angle glaucoma is damage to the optic nerve caused by raised intra-ocular",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» coloured haloes around lights",
    "brandName": "bright rings",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» coloured haloes around lights (bright rings),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» eye feels hard, compared to the other eye, when measured with finger palpation",
    "brandName": "this",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» eye feels hard, compared to the other eye, when measured with finger palpation (this",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emergency medicine treatment before referral",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emergency medicine treatment before referral (Doctor prescribed)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» All patients",
    "brandName": "excluding those with conjunctivitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» All patients (excluding those with conjunctivitis):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "one or both sides, difficulty speaking or swallowing",
    "brandName": "possible stroke; see Section",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "one or both sides, difficulty speaking or swallowing (possible stroke; see Section",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» eyelashes rubbing on the cornea",
    "brandName": "trichiasis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» eyelashes rubbing on the cornea (trichiasis),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» ptosis",
    "brandName": "drooping eyelid",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» ptosis (drooping eyelid).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If vision is diminished",
    "brandName": "less than 6/12",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If vision is diminished (less than 6/12) perform the following tests:",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Urgent: within 12",
    "brandName": "24 hours",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Urgent: within 12–24 hours",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management. Clin Ophthalmol. 2020 Mar 12;14:805",
    "brandName": "813. doi: 10.2147/OPTH.S236571. PMID: 32210533; PM",
    "strength": "2020 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management. Clin Ophthalmol. 2020 Mar 12;14:805-813. doi: 10.2147/OPTH.S236571. PMID: 32210533; PMCID: PMC7075432.",
    "commonDosage": "2020 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;",
    "brandName": "6",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015 Jun 1;(6):CD009566.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Practice Pattern®. Ophthalmology. 2019 Jan;126",
    "brandName": "1",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Practice Pattern®. Ophthalmology. 2019 Jan;126(1):P94-P169. https://www.ncbi.nlm.nih.gov/pubmed/30366797",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Care Health Facilities in the South",
    "brandName": "East Asia Region, 2004. http://apps.searo.who.int/",
    "strength": "2004",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Care Health Facilities in the South-East Asia Region, 2004. http://apps.searo.who.int/pds_docs/B3516.pdf",
    "commonDosage": "2004",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ophthalmology, 63",
    "brandName": "2",
    "strength": "63",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ophthalmology, 63(2), pp.214-235.",
    "commonDosage": "63",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For long",
    "brandName": "term use in adults and school going children:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For long-term use in adults and school going children:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Colds are self",
    "brandName": "limiting viral conditions that may last up to 14 d",
    "strength": "14 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Colds are self-limiting viral conditions that may last up to 14 days. Colds begin to clear",
    "commonDosage": "14 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Diffuse: An infection of the ear canal, often due to Gram negative bacilli",
    "brandName": "especially P.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Diffuse: An infection of the ear canal, often due to Gram negative bacilli (especially P.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "aeruginosa",
    "brandName": ". Pain is increased when chewing and the lining of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "aeruginosa). Pain is increased when chewing and the lining of the canal may be either",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Keep the ear clean and dry",
    "brandName": "dry mopping",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Keep the ear clean and dry (dry mopping).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Instil 3",
    "brandName": "4 drops after cleaning and drying the ear.",
    "strength": "3",
    "form": "drops",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Instil 3–4 drops after cleaning and drying the ear.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cefalexin, oral, 12",
    "brandName": "25 mg/kg/dose 6 hourly for 5 days. See dosing tabl",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cefalexin, oral, 12–25 mg/kg/dose 6 hourly for 5 days. See dosing table: Chapter 23.",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For patients with upper respiratory tract congestion, secondary to allergy:",
    "brandName": "T78.4",
    "strength": "78.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For patients with upper respiratory tract congestion, secondary to allergy: (T78.4)",
    "commonDosage": "78.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Severe pain, fever or vomiting, not responding to treatment after 72 hours",
    "brandName": "if otoscopy",
    "strength": "72 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Severe pain, fever or vomiting, not responding to treatment after 72 hours (if otoscopy",
    "commonDosage": "72 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "clinical features suggestive of TB are present",
    "brandName": "e.g. cough, weight loss, failure to thrive,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "clinical features suggestive of TB are present (e.g. cough, weight loss, failure to thrive,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fungal MC+S",
    "brandName": "microscopy, culture and sensitivity",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fungal MC+S (microscopy, culture and sensitivity) or for microscopy and culture for",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of pharyngitis/tonsillitis, and may result in rheumatic fever",
    "brandName": "which can cause serious heart",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of pharyngitis/tonsillitis, and may result in rheumatic fever (which can cause serious heart",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "petechiae, inflamed tongue mucosal papillae",
    "brandName": "strawberry tongue",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "petechiae, inflamed tongue mucosal papillae (strawberry tongue), a scarlitiniform (i.e.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "rough, diffuse, fine papular",
    "brandName": "rash.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "rough, diffuse, fine papular) rash.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2.5 mL",
    "brandName": "½ medicine measure",
    "strength": "2.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2.5 mL (½ medicine measure) of table salt in 200 mL lukewarm water.",
    "commonDosage": "2.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "who are at risk for rheumatic fever",
    "brandName": "3",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "who are at risk for rheumatic fever (3–21 years of age) if they have:",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Tonsillitis accompanied by difficulty in opening the mouth",
    "brandName": "trismus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Tonsillitis accompanied by difficulty in opening the mouth (trismus).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids, topical nasal",
    "brandName": "children > 6 years of age",
    "strength": "6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids, topical nasal (children > 6 years of age): South African Medicines Formulary.  12th Edition.  Division of Clinical",
    "commonDosage": "6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Corticosteroids, topical nasal",
    "brandName": "therapeutic class",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Corticosteroids, topical nasal (therapeutic class): Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluticasone, topical, aqueous nasal spray: Contract circular HP07",
    "brandName": "2017DAI. http://www.health.gov.za/",
    "strength": "07",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Fluticasone, topical, aqueous nasal spray: Contract circular HP07-2017DAI. http://www.health.gov.za/",
    "commonDosage": "07",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Beclomethasone, topical, aqueous nasal spray",
    "brandName": "drug",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Beclomethasone, topical, aqueous nasal spray (drug-drug interaction with protease inhibitors): Foisy MM, Yakiwchuk EM, Chiu I,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "literature. HIV Med. 2008 Jul;9",
    "brandName": "6",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "literature. HIV Med. 2008 Jul;9(6):389-96. https://www.ncbi.nlm.nih.gov/pubmed/18459946",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "interaction database. https://www.hiv",
    "brandName": "druginteractions.org/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "interaction database. https://www.hiv-druginteractions.org/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "woman with HIV infection. Int J STD AIDS. 2012 Jul;23",
    "brandName": "7",
    "strength": "2012 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "woman with HIV infection. Int J STD AIDS. 2012 Jul;23(7):520-1. https://www.ncbi.nlm.nih.gov/pubmed/22844010",
    "commonDosage": "2012 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "comparing the efficacy and safety of fexofenadine hydrochloride",
    "brandName": "120 and 180 mg once daily",
    "strength": "120 ",
    "form": "tablet",
    "category": "Antihistamines",
    "schedule": "Schedule 2",
    "description": "comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.",
    "commonDosage": "120 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "J Allergy ClinImmunol. 1999;104",
    "brandName": "5",
    "strength": "1999",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "J Allergy ClinImmunol. 1999;104(5):927-933. https://www.ncbi.nlm.nih.gov/pubmed/10550734",
    "commonDosage": "1999",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Postep Derm Alergol. 2014, 3: 182",
    "brandName": "186. https://www.ncbi.nlm.nih.gov/pubmed/25097491",
    "strength": "2014",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Postep Derm Alergol. 2014, 3: 182–186. https://www.ncbi.nlm.nih.gov/pubmed/25097491",
    "commonDosage": "2014",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Review: Non",
    "brandName": "sedating antihistamines for persistent allergic rh",
    "strength": "23 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Review: Non-sedating antihistamines for persistent allergic rhinitis, 23 November 2017. http://www.health.gov.za/",
    "commonDosage": "23 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol, oral: NICE Clinical Guideline",
    "brandName": "Feverish illness in children: assessment and initi",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol, oral: NICE Clinical Guideline-Feverish illness in children: assessment and initial management in children younger",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "American Academy of Pediatrics Guidelines 2013. Arch Dis Child Educ Pract Ed. 2015 Aug;100",
    "brandName": "4",
    "strength": "2013",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "American Academy of Pediatrics Guidelines 2013. Arch Dis Child Educ Pract Ed. 2015 Aug;100(4):193-7.",
    "commonDosage": "2013",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tract infections in South Africa. S Afr Med J. 2015 Apr 6;105",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tract infections in South Africa. S Afr Med J. 2015 Apr 6;105(5):344-52. https://www.ncbi.nlm.nih.gov/pubmed/26242659",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotics, oral",
    "brandName": "AOM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotics, oral (AOM-children): Venekamp RP, Sanders SL, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "media in children. Cochrane Database Syst Rev. 2015 Jun 23;",
    "brandName": "6",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "media in children. Cochrane Database Syst Rev. 2015 Jun 23;(6):CD000219. https://www.ncbi.nlm.nih.gov/pubmed/26099233",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotics, oral",
    "brandName": "AOM",
    "strength": "91",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotics, oral (AOM-children): NICE. Otitis media (acute): antimicrobial prescribing. Clinical guideline NG91, March 2018.",
    "commonDosage": "91",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin, oral",
    "brandName": "AOM",
    "strength": "7 ",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin, oral (AOM – children > 7 years of age and adults): Brink AJ, Cotton M, Feldman C, Finlayson H, Friedman R, Green",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management of upper respiratory tract infections in South Africa. S Afr Med J. 2015 Apr 6;105",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management of upper respiratory tract infections in South Africa. S Afr Med J. 2015 Apr 6;105(5):344-52.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin/clavulanate, oral",
    "brandName": "AOM",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin/clavulanate, oral (AOM – children): Siddiq S, Grainger J. The diagnosis and management of acute otitis media:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "respiratory tract infections in South Africa. S Afr Med J. 2015 Apr 6;105",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "respiratory tract infections in South Africa. S Afr Med J. 2015 Apr 6;105(5):344-52. https://www.ncbi.nlm.nih.gov/pubmed/26242659",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetamol",
    "brandName": "acetaminophen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antihistamines, oral",
    "brandName": "Cetirizine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Antihistamines",
    "schedule": "Schedule 2",
    "description": "Antihistamines, oral (Cetirizine): Griffin G, Flynn CA. Antihistamines and/or decongestants for otitis media with effusion (OME) in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "children. Cochrane Database Syst Rev. 2011 Sep 7;",
    "brandName": "9",
    "strength": "2011 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "children. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD003423. https://www.ncbi.nlm.nih.gov/pubmed/21901683",
    "commonDosage": "2011 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diseases Society of America",
    "brandName": "IDSA",
    "strength": "2013 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis. 2013 Aug;57(4):e22-e121.",
    "commonDosage": "2013 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antibiotics",
    "brandName": "Tonsillitis and pharyngitis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "Antibiotics (Tonsillitis and pharyngitis): Engel MF, Bruns AH, Hulscher ME, Gaillard CA, Sankatsing SU, Teding van Berkhout F,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emmelot",
    "brandName": "Vonk MH, Kuck EM, Steeghs MH, den Breeijen JH, Ste",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emmelot-Vonk MH, Kuck EM, Steeghs MH, den Breeijen JH, Stellato RK, Hoepelman AI, Oosterheert JJ. A tailored implementation",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "strategy to reduce the duration of intravenous antibiotic treatment in community",
    "brandName": "acquired pneumonia: a controlled before",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 3",
    "description": "strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "study. Eur J Clin Microbiol Infect Dis. 2014 Nov;33",
    "brandName": "11",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "study. Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1897-908. https://www.ncbi.nlm.nih.gov/pubmed/24859925",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "group A beta",
    "brandName": "haemolytic streptococcal pharyngitis. Arch Dis Chi",
    "strength": "2008 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "group A beta-haemolytic streptococcal pharyngitis. Arch Dis Child. 2008 Jun;93(6):474-8.",
    "commonDosage": "2008 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "infections in South Africa. S Afr Med J. 2015 Apr 6;105",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "infections in South Africa. S Afr Med J. 2015 Apr 6;105(5):344-52. http://www.ncbi.nlm.nih.gov/pubmed/26242659",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The gold standard of pain assessment is self",
    "brandName": "report. Consider using self",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The gold standard of pain assessment is self-report. Consider using self-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "report tools from >5 years",
    "brandName": "e.g. revised faces pain scale, visual analogue",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "report tools from >5 years (e.g. revised faces pain scale, visual analogue",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Legs, Activity, Cry, and Consolability",
    "brandName": "R",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Legs, Activity, Cry, and Consolability (R-FLACC) scale.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "diagnose 1 to 3",
    "brandName": "mild discomfort",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "diagnose 1 to 3 (mild discomfort),  4 to 6 (moderate), or 7 to 10 (severe pain),",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "agitation. Breath",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "agitation. Breath-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4 g in 24 hours",
    "brandName": ".",
    "strength": "4 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4 g in 24 hours).",
    "commonDosage": "4 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "0.1 mg/kg/dose 4",
    "brandName": "6 hourly.",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "0.1 mg/kg/dose 4-6 hourly.",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "0.2",
    "brandName": "0.4 mg/kg/dose 4",
    "strength": "0.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "0.2–0.4 mg/kg/dose 4-6 hourly.",
    "commonDosage": "0.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See dosing table:Chapter 23.",
    "brandName": "Doctor prescribed.",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See dosing table:Chapter 23. (Doctor prescribed.)",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Starting dose: 5 mg",
    "brandName": "maximum 0.2 mg/kg",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Starting dose: 5 mg (maximum 0.2 mg/kg) 4 hourly.",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Elderly or frail patients: 2.5 to 5 mg",
    "brandName": "maximum 0.1 mg/kg",
    "strength": "2.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Elderly or frail patients: 2.5 to 5 mg (maximum 0.1 mg/kg) 4 hourly.",
    "commonDosage": "2.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, IV, to a total maximum dose of 10 mg.",
    "brandName": "Doctor prescribed.",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, IV, to a total maximum dose of 10 mg. (Doctor prescribed.)",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "− tissue damage",
    "brandName": "nociceptive pain",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "− tissue damage (nociceptive pain), e.g. arthritis, lower back pain, pleuritic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "− injury to nerves",
    "brandName": "neuropathic pain",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "− injury to nerves (neuropathic pain) e.g. post herpetic neuralgia (pain",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "following shingles",
    "brandName": ", trigeminal neuralgia, diabetic neuropathy, HIV r",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "following shingles), trigeminal neuralgia, diabetic neuropathy, HIV related",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "nerve damage",
    "brandName": "central pain",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "nerve damage (central pain),  e.g. fibromyalgia, irritable bowel syndrome.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Assess pain severity, functional status, medication use including self",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Assess pain severity, functional status, medication use including self-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Address psycho",
    "brandName": "social problems e.g. stress, anxiety, sleep distur",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Address psycho-social problems e.g. stress, anxiety, sleep disturbances.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "To manage chronic non",
    "brandName": "cancer conditions such as genetic conditions, nerv",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "To manage chronic non-cancer conditions such as genetic conditions, nerve",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If still no relief to simple analgesics",
    "brandName": "paracetamol and/or ibuprofen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "If still no relief to simple analgesics (paracetamol and/or ibuprofen), as above",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tramadol, oral, 50 to 100mg, 6 hourly as a starting dose.",
    "brandName": "Doctor prescribed.",
    "strength": "50 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Tramadol, oral, 50 to 100mg, 6 hourly as a starting dose. (Doctor prescribed.)",
    "commonDosage": "50 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amitriptyline, oral, 10 mg at night.",
    "brandName": "Doctor initiated.",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Amitriptyline, oral, 10 mg at night. (Doctor initiated.).",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Under",
    "brandName": "recognition of pain and under",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Under-recognition of pain and under-dosing of analgesics is common in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Conditions difficult to treat e.g. Complex Regional Pain Syndrome",
    "brandName": "CRPS",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Conditions difficult to treat e.g. Complex Regional Pain Syndrome (CRPS) and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "post",
    "brandName": "herpetic neuralgia.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "post-herpetic neuralgia.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Manage contributing psycho",
    "brandName": "social factors.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Manage contributing psycho-social factors.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, long",
    "brandName": "acting, oral, 12 hourly.",
    "strength": "12 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, long-acting, oral, 12 hourly. (Doctor prescribed.)",
    "commonDosage": "12 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» There is no maximum dose for morphine",
    "brandName": "titrate the dose against the effect",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "» There is no maximum dose for morphine – titrate the dose against the effect",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pain. See dosing table: Chapter 23.",
    "brandName": "Doctor prescribed.",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pain. See dosing table: Chapter 23. (Doctor prescribed.)",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A common problem due to long",
    "brandName": "term use of opioids, which can be prevented and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A common problem due to long-term use of opioids, which can be prevented and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, oral, 0.04 mg/kg/dose 8 to 12 hourly.",
    "brandName": "Doctor prescribed.",
    "strength": "0.04 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, oral, 0.04 mg/kg/dose 8 to 12 hourly. (Doctor prescribed.)",
    "commonDosage": "0.04 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "0.2 mg/kg/dose",
    "brandName": "see table below",
    "strength": "0.2 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "0.2 mg/kg/dose (see table below) .",
    "commonDosage": "0.2 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, oral, 0.2 mg/kg/dose 8 to 12 hourly.",
    "brandName": "Doctor prescribed.",
    "strength": "0.2 mg",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, oral, 0.2 mg/kg/dose 8 to 12 hourly. (Doctor prescribed.)",
    "commonDosage": "0.2 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "location as the background",
    "brandName": "controlled",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "location as the background (controlled) pain.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Treat breakthrough pain by giving an extra dose of immediate",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Treat breakthrough pain by giving an extra dose of immediate-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "release morphine equal to the regular 4 hour dose",
    "brandName": "i.e. one sixth of the total",
    "strength": "4 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "release morphine equal to the regular 4 hour dose (i.e. one sixth of the total",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» The regular 4",
    "brandName": "hourly dosage should be titrated upward against th",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» The regular 4-hourly dosage should be titrated upward against the effect on",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.iasp",
    "brandName": "pain.org/resources/terminology/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.iasp-pain.org/resources/terminology/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "General Principles",
    "brandName": "Pain",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "General Principles (Pain): Mash B, Brits H, Naidoo M. (2023). South African Family Practice Manual. (4th ed). Van",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pediatric Nurse 23",
    "brandName": "3",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pediatric Nurse 23(3): 293-297, 1997. Copyright: Jannetti Co. University of Michigan Medical Centre.",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Reliability and Validity for Pain Assessment in Children with Cognitive Impairment.",
    "brandName": "Pediatric Anesthesia 16: 258",
    "strength": "16",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Reliability and Validity for Pain Assessment in Children with Cognitive Impairment. (Pediatric Anesthesia 16: 258-265).",
    "commonDosage": "16",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "scoring postoperative pain in young children. Pediatric Nursing, 23",
    "brandName": "3",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "scoring postoperative pain in young children. Pediatric Nursing, 23(3), 293–297. The FLACC scale was developed by",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Merkel, S. et al. The FLACC: A Behavioural Scale for Scoring Postoperative Pain in Young Children, Pediatric Nurse 23",
    "brandName": "3",
    "strength": "23",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Merkel, S. et al. The FLACC: A Behavioural Scale for Scoring Postoperative Pain in Young Children, Pediatric Nurse 23(3):",
    "commonDosage": "23",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "293",
    "brandName": "297, 1997. Copyright: Jannetti Co. University of M",
    "strength": "293",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "293-297, 1997. Copyright: Jannetti Co. University of Michigan Medical Centre.",
    "commonDosage": "293",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fcaes Pain Scale Revised: International Assicuatioin for the Study of Pain. https://www.iasp",
    "brandName": "pain.org/resources/faces",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fcaes Pain Scale Revised: International Assicuatioin for the Study of Pain. https://www.iasp-pain.org/resources/faces-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986 Jul;40",
    "brandName": "1",
    "strength": "1986 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986 Jul;40(1):1-7.",
    "commonDosage": "1986 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pain. 2019 Jan;160",
    "brandName": "1",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pain. 2019 Jan;160(1):19-27. https://pubmed.ncbi.nlm.nih.gov/30586067/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "DG, Eccleston C. Paracetamol",
    "brandName": "acetaminophen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "DG, Eccleston C. Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents. Cochrane",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Wee B. Oral nonsteroidal anti",
    "brandName": "inflammatory drugs",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986 Jul;40",
    "brandName": "1",
    "strength": "1986 ",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986 Jul;40(1):1-7.",
    "commonDosage": "1986 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, long",
    "brandName": "acting: National Department of Health, Essential D",
    "strength": "2015",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, long-acting: National Department of Health, Essential Drugs Programme: Adult Hospital level STG, 2015.",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, long",
    "brandName": "acting, oral: South African Medicines Formulary, 1",
    "strength": "14",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, long-acting, oral: South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, long",
    "brandName": "acting, oral: National Department of Health: Affor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, long-acting, oral: National Department of Health: Affordable Medicines, EDP-PHC. Medicine Review.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pain ladder",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pain ladder (children): World Health Organisation. WHO Guidelines on the Pharmacological Treatment of Persisting",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NSAIDs, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NSAIDs, oral (children – chronic cancer pain): Cooper TE, Heathcote LC, Anderson B, Grégoire MC, Ljungman G,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Eccleston C. Non",
    "brandName": "steroidal anti",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Eccleston C. Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. Cochrane",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Opioids, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Opioids, oral (children – chronic cancer pain): Wiffen PJ, Cooper TE, Anderson AK, Gray AL, Grégoire MC, Ljungman",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "G, Zernikow  B. Opioids for cancer",
    "brandName": "related pain in children and adolescents. Cochrane",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "G, Zernikow  B. Opioids for cancer-related pain in children and adolescents. Cochrane Database Syst Rev. 2017 Jul",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breakthrough Pain: Charlesworth, S.",
    "brandName": "Ed.",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breakthrough Pain: Charlesworth, S. (Ed.). (2020). Palliative Care Formulary (7th ed.). Pharmaceutical Press",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "dosage, route of administration",
    "brandName": "on the patient’s notes and on the referral letter.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "dosage, route of administration) on the patient’s notes and on the referral letter.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 21.1: Advanced cardiac arrest algorithm",
    "brandName": "adapted with permission from the Resuscitation Cou",
    "strength": "21.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 21.1: Advanced cardiac arrest algorithm (adapted with permission from the Resuscitation Council of South",
    "commonDosage": "21.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "EML for guidance on use of anti",
    "brandName": "arrhythmics",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "EML for guidance on use of anti-arrhythmics)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Figure 21.2: Advanced cardiac arrest algorithm",
    "brandName": "suspected respiratory communicable disease",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Figure 21.2: Advanced cardiac arrest algorithm - suspected respiratory communicable disease (adapted with",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Follow instructions as per the appropriate algorithm",
    "brandName": "Fig 21.1 or 21.2",
    "strength": "21.1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Follow instructions as per the appropriate algorithm (Fig 21.1 or 21.2) and below.",
    "commonDosage": "21.1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Initiate CAB",
    "brandName": "Circulation Airway Breathing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Initiate CAB (Circulation Airway Breathing) sequence of CPR.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If there is no normal breathing, give 2 breaths with bag",
    "brandName": "valve",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If there is no normal breathing, give 2 breaths with bag-valve-mask resuscitator and",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "correctly sized oropharyngeal airway and try again after 30 compressions",
    "brandName": ".",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "correctly sized oropharyngeal airway and try again after 30 compressions).",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Defibrillate, as indicated per algorithm",
    "brandName": "1 shock",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Defibrillate, as indicated per algorithm (1 shock).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Administer adrenaline",
    "brandName": "epinephrine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Administer adrenaline (epinephrine) as per algorithm and medicine treatment",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline",
    "brandName": "epinephrine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline (epinephrine) is the mainstay of treatment. Give immediately, IV, IO, or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline",
    "brandName": "epinephrine 1 mg",
    "strength": "1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline (epinephrine 1 mg), 1:1 000, 1 mL , IV immediately as a single dose.",
    "commonDosage": "1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Flush with 5",
    "brandName": "10 mL of sterile water or sodium chloride 0.9%.",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Flush with 5–10 mL of sterile water or sodium chloride 0.9%.",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Repeat every 3",
    "brandName": "5 minutes during resuscitation.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Repeat every 3–5 minutes during resuscitation.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Connect bag",
    "brandName": "valve",
    "strength": "100%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Connect bag-valve-mask resuscitator to 100% oxygen at 10-15L/min flow.",
    "commonDosage": "100%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Assess continuously",
    "brandName": "every 2 minutes",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Assess continuously (every 2 minutes) until the patient shows signs of recovery.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» neurotoxic envenomation",
    "brandName": "e.g. black and green mamba or Cape cobra snakebite",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» neurotoxic envenomation (e.g. black and green mamba or Cape cobra snakebite)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "poor respiratory effort",
    "brandName": "e.g. prolonged seizures, poisoning, neuromuscular ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "poor respiratory effort (e.g. prolonged seizures, poisoning, neuromuscular weakness",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Document timings of interventions, medication and any response to these.",
    "brandName": "Ideally,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Document timings of interventions, medication and any response to these. (Ideally,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "during resuscitation, one staff member should act as a ‘scribe’.",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "during resuscitation, one staff member should act as a ‘scribe’.)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If there is no pulse",
    "brandName": "or pulse <60 beats/minute",
    "strength": "60 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If there is no pulse (or pulse <60 beats/minute) with no signs of life, give 30 chest",
    "commonDosage": "60 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "preferably with bag",
    "brandName": "valve",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "preferably with bag-valve-mask resuscitator.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mouth",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mouth-to-nose (covering child’s mouth AND nose with your mouth).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Keep patient covered and warm while resuscitating",
    "brandName": "although the patient should be",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Keep patient covered and warm while resuscitating (although the patient should be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fully exposed for short periods during examination",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fully exposed for short periods during examination).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Weight [kg] =",
    "brandName": "Age [yrs] + 4",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Weight [kg] = (Age [yrs] + 4) X 2",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline",
    "brandName": "epinephrine",
    "strength": "0.1 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline (epinephrine), IV, 0.1 mL/kg of 1:10 000 solution.",
    "commonDosage": "0.1 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o To make an 1:10 000 adrenaline",
    "brandName": "epinephrine",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o To make an 1:10 000 adrenaline (epinephrine) solution, dilute 1 mL ampoule of",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃17.5",
    "brandName": "25 kg",
    "strength": "17.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃17.5–25 kg",
    "commonDosage": "17.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃35",
    "brandName": "55 kg",
    "strength": "35",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃35–55 kg",
    "commonDosage": "35",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dextrose 10%, solution, IV, 2",
    "brandName": "5 mL/kg.",
    "strength": "10%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dextrose 10%, solution, IV, 2–5 mL/kg.",
    "commonDosage": "10%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o After dextrose bolus, commence dextrose 5",
    "brandName": "10% infusion, 3",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o After dextrose bolus, commence dextrose 5–10% infusion, 3–5 mL/kg/hour to",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Re",
    "brandName": "check the blood glucose after 15 minutes: if blood",
    "strength": "15 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Re-check the blood glucose after 15 minutes: if blood sugar is still low: give further",
    "commonDosage": "15 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "neurotoxic envenomation",
    "brandName": "e.g.black and green mamba or Cape cobra snakebite",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "neurotoxic envenomation (e.g.black and green mamba or Cape cobra snakebite) –",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breathing: give oxygen to target pulse oximeter saturation of 94",
    "brandName": "98%.",
    "strength": "94",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breathing: give oxygen to target pulse oximeter saturation of 94–98%.",
    "commonDosage": "94",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrogen ion",
    "brandName": "acidosis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hydrogen ion (acidosis)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o To make 1:10 000 adrenaline",
    "brandName": "epinephrine",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o To make 1:10 000 adrenaline (epinephrine) solution: dilute 1 mL ampoule of",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Administer dose every 3",
    "brandName": "5 minutes, according to table below.",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Administer dose every 3–5 minutes, according to table below.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atropine, IV, 0.02 mg/kg/dose as a single dose.",
    "brandName": "Doctor prescribed.",
    "strength": "0.02 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atropine, IV, 0.02 mg/kg/dose as a single dose. (Doctor prescribed.)",
    "commonDosage": "0.02 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Children: tachydysrhythmias refers to a pulse rate >normal range for age",
    "brandName": "see table 21.2",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Children: tachydysrhythmias refers to a pulse rate >normal range for age (see table 21.2",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Normal heart rate range",
    "brandName": "beats/minute",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Normal heart rate range (beats/minute)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Carotid sinus massage",
    "brandName": "not in elderly or those with",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Carotid sinus massage (not in elderly or those with",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Synchronised cardioversion at 0.5",
    "brandName": "1 J/kg initially",
    "strength": "0.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Synchronised cardioversion at 0.5-1 J/kg initially (max 4 J/kg).",
    "commonDosage": "0.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "followed by re",
    "brandName": "assessment of breathing. Repeat as a cycle until",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "followed by re-assessment of breathing. Repeat as a cycle until",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "foreign body each time before giving breaths",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "foreign body each time before giving breaths).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If this is ineffective turn the baby over",
    "brandName": "face up",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If this is ineffective turn the baby over (face up) and lay on the rescuer’s thigh in the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "abdominal thrusts",
    "brandName": "Heimlich manoeuvre",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "abdominal thrusts (Heimlich manoeuvre) in place of chest thrust.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In the lying",
    "brandName": "supine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In the lying (supine) position, the rescuer to kneel astride the victim and do the same",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ensure that they have received appropriate training in at least providing basic",
    "brandName": "and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ensure that they have received appropriate training in at least providing basic (and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The Emergency Triage Assessment and Treatment",
    "brandName": "ETAT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The Emergency Triage Assessment and Treatment (ETAT) triage process,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For croup see Section 17.2.1: Croup",
    "brandName": "laryngotracheobronchitis",
    "strength": "17.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For croup see Section 17.2.1: Croup (laryngotracheobronchitis) in children.",
    "commonDosage": "17.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 4.3: Angina pectoris, unstable/ Non",
    "brandName": "ST elevation myocardial infarction",
    "strength": "4.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 4.3: Angina pectoris, unstable/ Non-ST elevation myocardial infarction",
    "commonDosage": "4.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and cognition",
    "brandName": "e.g. deficits in memory, language, visuospatial ab",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and cognition (e.g. deficits in memory, language, visuospatial ability, or perception). It is",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "condition, substance intoxication or withdrawal",
    "brandName": "including prescription or over the counter",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "condition, substance intoxication or withdrawal (including prescription or over the counter",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medications and recreational substances",
    "brandName": ", exposure to a toxin, or multiple aetiologies.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medications and recreational substances), exposure to a toxin, or multiple aetiologies.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a fluctuating course and disturbances of the sleep",
    "brandName": "wake cycle",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a fluctuating course and disturbances of the sleep-wake cycle",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "treatment of which is the primary management",
    "brandName": "e.g. hypoglycaemia, hypoxia, pain",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "treatment of which is the primary management (e.g. hypoglycaemia, hypoxia, pain",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Drugs",
    "brandName": "Intoxication and withdrawal. Consider Wernicke’s e",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Drugs (Intoxication and withdrawal. Consider Wernicke’s encephalopathy).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metabolic, e.g. hypoglycaemia, electrolyte abnormalities",
    "brandName": "e.g. hyponatraemia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Metabolic, e.g. hypoglycaemia, electrolyte abnormalities (e.g. hyponatraemia);",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "organ failure",
    "brandName": "e.g. liver failure, renal dysfunction",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "organ failure (e.g. liver failure, renal dysfunction), CO2 narcosis.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen deficit",
    "brandName": "including hypoxia, carbon monoxide poisoning",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen deficit (including hypoxia, carbon monoxide poisoning).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "restraints used. 15",
    "brandName": "minute monitoring of vital signs, the mental state",
    "strength": "15",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "restraints used. 15-minute monitoring of vital signs, the mental state, restraint sites,",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "In the short",
    "brandName": "term, benzodiazepines can aggravate delirium.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "In the short-term, benzodiazepines can aggravate delirium.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 9.3.2: Severe hyperglycaemia",
    "brandName": "Diabetic ketoacidosis",
    "strength": "9.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 9.3.2: Severe hyperglycaemia (Diabetic ketoacidosis (DKA) & hyperosmolar",
    "commonDosage": "9.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hypoglycaemia is a blood glucose concentration <3 mmol/L",
    "brandName": "<2.6 mmol/L in neonate",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hypoglycaemia is a blood glucose concentration <3 mmol/L (<2.6 mmol/L in neonate)",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "those with long",
    "brandName": "standing diabetes mellitus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "those with long-standing diabetes mellitus",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All children who have had documented hypoglycaemia",
    "brandName": "unless the cause is clearly",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All children who have had documented hypoglycaemia (unless the cause is clearly",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "identified and safe management instituted to prevent recurrence",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "identified and safe management instituted to prevent recurrence).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Control bleeding by pinching the nasal wings",
    "brandName": "alae",
    "strength": "5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Control bleeding by pinching the nasal wings (alae) together for 5–10 minutes.",
    "commonDosage": "5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If this fails, insert nasal tampons or BIPP stripping into bleeding nostril",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If this fails, insert nasal tampons or BIPP stripping into bleeding nostril(s), if available.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Common causes include acute heart failure and acute renal failure",
    "brandName": "e.g. acute nephritis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Common causes include acute heart failure and acute renal failure (e.g. acute nephritis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Place the patient in a sitting or semi",
    "brandName": "Fowlers position.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Place the patient in a sitting or semi-Fowlers position.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Shock is a life",
    "brandName": "threatening condition characterised by any evidenc",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Shock is a life-threatening condition characterised by any evidence of inadequate organ",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Low blood pressure",
    "brandName": "systolic BP <80 mmHg",
    "strength": "80 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Low blood pressure (systolic BP <80 mmHg) is the key sign of shock.",
    "commonDosage": "80 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prolonged capillary filling",
    "brandName": ">3 seconds",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prolonged capillary filling (>3 seconds).",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Age of child",
    "brandName": "years",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Age of child (years)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Systolic BP",
    "brandName": "mmHg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Systolic BP (mmHg)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Source: The Hands",
    "brandName": "on Guide to Practical Paediatrics, First Edition. ",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Source: The Hands-on Guide to Practical Paediatrics, First Edition. Rebecca Hewitson and Caroline Fertleman. © 2014 John Wiley &",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for cardiogenic shock and septic shock",
    "brandName": "as fluid",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for cardiogenic shock and septic shock (as fluid-overloaded patients do not need",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fluid replacement",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fluid replacement) – these patients should receive a fluid challenge as detailed",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "perfusion",
    "brandName": "in addition to a good urine output, rather than an",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "perfusion) in addition to a good urine output, rather than an absolute blood",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o If no adequate response to fluid challenge",
    "brandName": "as described above",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o If no adequate response to fluid challenge (as described above), suspect septic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "exposure to an allergen, but may be delayed for up to 1 hour. The reaction can be short",
    "brandName": "",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "exposure to an allergen, but may be delayed for up to 1 hour. The reaction can be short-",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "reactions are usually the most severe and/or life",
    "brandName": "threatening.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "reactions are usually the most severe and/or life-threatening.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Urticaria",
    "brandName": "hives",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Urticaria (hives) or angioedema.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If signs and symptoms are generalised",
    "brandName": "involving more than 2 body systems,",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If signs and symptoms are generalised – involving more than 2 body systems,",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If signs and symptoms are serious or life",
    "brandName": "threatening, even if only one body",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If signs and symptoms are serious or life-threatening, even if only one body",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "system is involved",
    "brandName": "including hypotension, respiratory distress, signi",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "system is involved (including hypotension, respiratory distress, significant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "swelling of lips or tongue",
    "brandName": ", treat as anaphylaxis.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "swelling of lips or tongue), treat as anaphylaxis.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consciousness",
    "brandName": "<1 minute",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consciousness (<1 minute), relieved by raising the legs when supine, transient",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Collapsing after vaccination usually occurs 5 to 10 minutes post",
    "brandName": "vaccination,",
    "strength": "5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Collapsing after vaccination usually occurs 5 to 10 minutes post-vaccination,",
    "commonDosage": "5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Source: Immunization stress",
    "brandName": "related response. A manual for program managers an",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Source: Immunization stress-related response. A manual for program managers and health professionals to prevent,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Adults: 1:1000, IM, 0.5 mg",
    "brandName": "0.5 mL",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Adults: 1:1000, IM, 0.5 mg (0.5 mL) as a single dose, into the lateral thigh.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen, 8",
    "brandName": "10 L/minute via facemask or up to 100% oxygen, as ",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen, 8-10 L/minute via facemask or up to 100% oxygen, as needed.",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If hypotension not responding promptly to adrenaline",
    "brandName": "epinephrine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If hypotension not responding promptly to adrenaline (epinephrine), also give:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Salbutamol 0.5%,",
    "brandName": "5 mg/mL",
    "strength": "0.5%",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Salbutamol 0.5%, (5 mg/mL) solution, nebulised, with high flow oxygen.",
    "commonDosage": "0.5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Children: 0.5 to 1 mL",
    "brandName": "2.5 to 5 mg",
    "strength": "0.5 ",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Children: 0.5 to 1 mL (2.5 to 5 mg) salbutamol 0.5% solution,",
    "commonDosage": "0.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Adults: 1 mL",
    "brandName": "5 mg",
    "strength": "1 mL",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Adults: 1 mL (5 mg) salbutamol 0.5% solution,",
    "commonDosage": "1 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Children: Ipratropium bromide 0.25 mg/2ml; nebuliser solution: 2 mL",
    "brandName": "0.25 mg",
    "strength": "0.25 mg",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Children: Ipratropium bromide 0.25 mg/2ml; nebuliser solution: 2 mL (0.25 mg)",
    "commonDosage": "0.25 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Adults: Ipratropium bromide 0.5 mg/2ml; nebuliser solution, 2 mL",
    "brandName": "0.5 mg",
    "strength": "0.5 mg",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "o Adults: Ipratropium bromide 0.5 mg/2ml; nebuliser solution, 2 mL (0.5 mg)",
    "commonDosage": "0.5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Check blood glucose",
    "brandName": "exclude hypoglycaemia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Check blood glucose (exclude hypoglycaemia).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Remove needle then administer midazolam into the buccal cavity",
    "brandName": "between gum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Remove needle then administer midazolam into the buccal cavity (between gum",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Monitor closely for respiratory depression. If this occurs, assist ventilation with bag",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Monitor closely for respiratory depression. If this occurs, assist ventilation with bag-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "valve mask",
    "brandName": "1 breath every 3 to 5 seconds",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "valve mask (1 breath every 3 to 5 seconds) and refer urgently.",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Wild animals e.g. jackals, mongooses",
    "brandName": "including meerkats",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Wild animals e.g. jackals, mongooses (including meerkats), bats.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "no bleeding",
    "brandName": "for example",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "no bleeding (for example",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "existing scratches",
    "brandName": ", any",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "existing scratches), any",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 21.6: Algorithm for rabies post exposure prophylaxis",
    "brandName": "PEP",
    "strength": "21.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 21.6: Algorithm for rabies post exposure prophylaxis (PEP)",
    "commonDosage": "21.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clean wound thoroughly, dress",
    "brandName": "avoid compressive dressings",
    "strength": "48",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clean wound thoroughly, dress (avoid compressive dressings), and review after 48",
    "commonDosage": "48",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "patients with cancer on chemotherapy/radiotherapy, and patients on long",
    "brandName": "term",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "patients with cancer on chemotherapy/radiotherapy, and patients on long-term",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "corticosteroids dosed at 20 mg/day for ≥2 weeks, should be evaluated on a case",
    "brandName": "by",
    "strength": "20 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "corticosteroids dosed at 20 mg/day for ≥2 weeks, should be evaluated on a case-by-case",
    "commonDosage": "20 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: HIV",
    "brandName": "infected individuals receiving ART who are clinica",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: HIV-infected individuals receiving ART who are clinically monitored and well",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rabies immunoglobulin",
    "brandName": "RIG",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rabies immunoglobulin (RIG) – doctor prescribed:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Human",
    "brandName": "derived rabies immunoglobulin",
    "strength": "20 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Human-derived rabies immunoglobulin (HRIG), IM 20 IU/kg (doctor prescribed).",
    "commonDosage": "20 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Equine",
    "brandName": "derived rabies Immunoglobulin",
    "strength": "40 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Equine-derived rabies Immunoglobulin (ERIG), IM 40 IU/kg (doctor prescribed).",
    "commonDosage": "40 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "managed.",
    "brandName": "Refer to Section 21.2.10.",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "managed. (Refer to Section 21.2.10.)",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2 mL vial",
    "brandName": "",
    "strength": "2 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2 mL vial)",
    "commonDosage": "2 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mL vials",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mL vials).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5 mL vial",
    "brandName": ".",
    "strength": "5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5 mL vial).",
    "commonDosage": "5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rabies vaccine, 1 amp, IM anterolateral thigh",
    "brandName": "doctor initiated",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rabies vaccine, 1 amp, IM anterolateral thigh (doctor initiated).",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not administer rabies vaccine into buttocks",
    "brandName": "gluteus maximus",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not administer rabies vaccine into buttocks (gluteus maximus).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tetanus toxoid vaccine",
    "brandName": "TT",
    "strength": "0.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tetanus toxoid vaccine (TT), IM, 0.5 mL.",
    "commonDosage": "0.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Amoxicillin/clavulanic acid, oral, 15",
    "brandName": "25 mg/kg/dose of amoxicillin component, 8 hourly",
    "strength": "15",
    "form": "tablet",
    "category": "Antibiotics",
    "schedule": "Schedule 3",
    "description": "Amoxicillin/clavulanic acid, oral, 15–25 mg/kg/dose of amoxicillin component, 8 hourly",
    "commonDosage": "15",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Possible rabies exposure",
    "brandName": "for immunoglobulin and vaccination",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Possible rabies exposure (for immunoglobulin and vaccination).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Do not suture bite wounds unless on the head/face. Clean thoroughly, dress",
    "brandName": "avoid",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Do not suture bite wounds unless on the head/face. Clean thoroughly, dress (avoid",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "compressive dressings",
    "brandName": ". Review after 48 hours for secondary closure at t",
    "strength": "48 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "compressive dressings). Review after 48 hours for secondary closure at that time.",
    "commonDosage": "48 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tetanus toxoid",
    "brandName": "TT",
    "strength": "0.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tetanus toxoid (TT), IM, 0.5 mL.",
    "commonDosage": "0.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hepatitis B prophylaxis",
    "brandName": "if bite is severe enough to cause bleeding",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hepatitis B prophylaxis (if bite is severe enough to cause bleeding):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The risk of HIV transmission through biting is negligible. Post",
    "brandName": "exposure prophylaxis is not",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The risk of HIV transmission through biting is negligible. Post-exposure prophylaxis is not",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Venom is usually mild but may provoke severe allergic reactions",
    "brandName": "see Section 21.2.10:",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Venom is usually mild but may provoke severe allergic reactions (see Section 21.2.10:",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Treat anaphylaxis",
    "brandName": "bee/wasp stings",
    "strength": "21.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Treat anaphylaxis (bee/wasp stings). See Section 21.2.10: Anaphylaxis.",
    "commonDosage": "21.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If secondary skin infection",
    "brandName": "site red, swollen, hot, tender, pus may be present",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If secondary skin infection (site red, swollen, hot, tender, pus may be present), manage",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For possible antivenom",
    "brandName": "neurotoxic spider bites or scorpion stings",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For possible antivenom (neurotoxic spider bites or scorpion stings), if applicable,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "smaller adders and spitting cobras, stiletto snake, rinkhals",
    "brandName": "cytotoxic as well as",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "smaller adders and spitting cobras, stiletto snake, rinkhals (cytotoxic as well as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Examples include: black and green mamba, non",
    "brandName": "spitting cobras",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Examples include: black and green mamba, non-spitting cobras (Cape, forest,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "snouted",
    "brandName": ", berg adder",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "snouted), berg adder (neurotoxic as well as cytotoxic), rinkhals (cytotoxic as well as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Skeletal muscle weakness",
    "brandName": "descending paralysis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Skeletal muscle weakness (descending paralysis), which may cause:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rarely bleeding",
    "brandName": "epistaxis, haematuria, haematemesis or haemoptysis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rarely bleeding (epistaxis, haematuria, haematemesis or haemoptysis).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Be prepared to support ventilation in neurotoxic bites as this can be life",
    "brandName": "saving.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Be prepared to support ventilation in neurotoxic bites as this can be life-saving.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of symptoms and signs for 6",
    "brandName": "8 hours usually indicates a harmless bite.",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of symptoms and signs for 6–8 hours usually indicates a harmless bite.",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Non",
    "brandName": "opioid analgesics according to severity. See Secti",
    "strength": "20.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Non-opioid analgesics according to severity. See Section 20.3: Chronic non-cancer",
    "commonDosage": "20.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adverse reactions to antivenom",
    "brandName": "including anaphylaxis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adverse reactions to antivenom (including anaphylaxis) are common and may be",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hospital for advice",
    "brandName": "antivenom should be given as soon as possible, how",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hospital for advice (antivenom should be given as soon as possible, however",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "is continued clinical deterioration indicating ongoing venom activity",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "is continued clinical deterioration indicating ongoing venom activity).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "physical agents, e.g. electrical/lightning",
    "brandName": "or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "physical agents, e.g. electrical/lightning) or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Clothing: remove non",
    "brandName": "sticking clothing especially if hot or smouldering",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Clothing: remove non-sticking clothing especially if hot or smouldering or constrictive",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cover: with a non",
    "brandName": "adherent dressing.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cover: with a non-adherent dressing.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 21.9: Estimated body surface area",
    "brandName": "BSA",
    "strength": "21.9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 21.9: Estimated body surface area (BSA) percentages",
    "commonDosage": "21.9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "These diagrams indicate percentages for the whole leg/arm/head",
    "brandName": "and neck",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "These diagrams indicate percentages for the whole leg/arm/head (and neck",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "stabilisation protocol. S Afr Med J. 2007. Aug;97",
    "brandName": "8",
    "strength": "2007",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "stabilisation protocol. S Afr Med J. 2007. Aug;97(8):574-7. https://www.ncbi.nlm.nih.gov/pubmed/17966146",
    "commonDosage": "2007",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Total % burn x weight",
    "brandName": "kg",
    "strength": "4 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Total % burn x weight (kg) x 4 mL.",
    "commonDosage": "4 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluid volume",
    "brandName": "mL per hour",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fluid volume (mL per hour) for the 1st 8 hours in burns of > 10% in PHC clinics",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Fluid volume",
    "brandName": "mL per hour",
    "strength": "16 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Fluid volume (mL per hour) for the next 16 hours in burns of > 10% in PHC",
    "commonDosage": "16 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cover the dressing with plastic wrap",
    "brandName": "e.g. cling film",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cover the dressing with plastic wrap (e.g. cling film).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For patients not requiring transfer",
    "brandName": "burns that can be treated at home",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For patients not requiring transfer (burns that can be treated at home)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All burns >5% in children 1",
    "brandName": "2 years of age.",
    "strength": "5%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All burns >5% in children 1–2 years of age.",
    "commonDosage": "5%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Burns of special areas",
    "brandName": "face, hands, feet, genitalia, perineum and major j",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Burns of special areas – face, hands, feet, genitalia, perineum and major joints.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Burn injury in a patient with pre",
    "brandName": "existing medical disorders which could complicate",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Burn injury in a patient with pre-existing medical disorders which could complicate",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Note: Poisoning from all pesticides",
    "brandName": "i.e. agricultural stock remedies",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Note: Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antihypertensive and anti",
    "brandName": "diabetic agents",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antihypertensive and anti-diabetic agents",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "mushroom poisoning",
    "brandName": "Amanita phalloides",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "mushroom poisoning (Amanita phalloides)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "petroleum products",
    "brandName": "e.g. petrol or paraffin",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "petroleum products (e.g. petrol or paraffin)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "other corrosive agents",
    "brandName": "e.g. household",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "other corrosive agents (e.g. household",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "detergents",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "detergents)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Table 21.12: Activated charcoal for poisoning",
    "brandName": "s",
    "strength": "21.12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Table 21.12: Activated charcoal for poisoning(s)",
    "commonDosage": "21.12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Activated charcoal, oral, 50 g",
    "brandName": "36 level medicine measures",
    "strength": "50 g",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Activated charcoal, oral, 50 g (36 level medicine measures) diluted in 100 mL water.",
    "commonDosage": "50 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen, 100% by non",
    "brandName": "rebreather mask.",
    "strength": "100%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen, 100% by non-rebreather mask.",
    "commonDosage": "100%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hypersecretions",
    "brandName": "hypersalivation, sweating, lacrimation, rhinorrhoe",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hypersecretions (hypersalivation, sweating, lacrimation, rhinorrhoea)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Poisoning from all pesticides",
    "brandName": "i.e. agricultural stock remedies",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Poisoning from all pesticides (i.e. agricultural stock remedies) is a notifiable",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "only",
    "brandName": "i.e. patients requiring ventilatory support",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "only (i.e. patients requiring ventilatory support) or as a single test dose for uncertain",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If patient is apnoeic or has slow/shallow respirations, assist ventilation with bag",
    "brandName": "valve",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If patient is apnoeic or has slow/shallow respirations, assist ventilation with bag-valve",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Repeat 0.1 mg/kg",
    "brandName": "maximum 2 mg/dose",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Repeat 0.1 mg/kg (maximum 2 mg/dose), up to",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Double the dose each time",
    "brandName": "e.g.: 0.8 mg, 2 mg, 4",
    "strength": "0.8 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Double the dose each time (e.g.: 0.8 mg, 2 mg, 4",
    "commonDosage": "0.8 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "All symptomatic patients or those with a history of significant single ingestion",
    "brandName": "≥200 mg/kg",
    "strength": "200 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "All symptomatic patients or those with a history of significant single ingestion (≥200 mg/kg",
    "commonDosage": "200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "or 10 g, whichever is less",
    "brandName": "should be referred urgently for paracetamol blood ",
    "strength": "10 g",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "or 10 g, whichever is less) should be referred urgently for paracetamol blood level (taken",
    "commonDosage": "10 g",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "at least 4 hours post",
    "brandName": "ingestion",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "at least 4 hours post-ingestion) and consideration of N-acetylcysteine.",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Avoid giving oral N",
    "brandName": "acetylcysteine together with activated charcoal, a",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Avoid giving oral N-acetylcysteine together with activated charcoal, as",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anaphylactoid reactions to N",
    "brandName": "acetylcysteine do occur and the loading dose shoul",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anaphylactoid reactions to N-acetylcysteine do occur and the loading dose should",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Toxic alcohols",
    "brandName": "ethylene glycol and methanol poisoning",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Toxic alcohols (ethylene glycol and methanol poisoning)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "paracetamol ≥200 mg/kg or 10 g",
    "brandName": "whichever is less",
    "strength": "200 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "paracetamol ≥200 mg/kg or 10 g (whichever is less),",
    "commonDosage": "200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "sulphonylureas",
    "brandName": "antidiabetic agents",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "sulphonylureas (antidiabetic agents),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "a significant occupational exposure to infectious material from a patient",
    "brandName": "includes blood,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "a significant occupational exposure to infectious material from a patient (includes blood,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Test all source patients",
    "brandName": "see monitoring table",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Test all source patients (see monitoring table).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Offer comprehensive and confidential pre",
    "brandName": "test HIV counselling.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Offer comprehensive and confidential pre-test HIV counselling.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Advise HCW about the need to take precautions, e.g. condom use",
    "brandName": "for 4 months",
    "strength": "4 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Advise HCW about the need to take precautions, e.g. condom use (for 4 months), to",
    "commonDosage": "4 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If higher risk exposure",
    "brandName": "defined above",
    "strength": "72",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If higher risk exposure (defined above) consider initiation of treatment beyond 72",
    "commonDosage": "72",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The source is HIV sero",
    "brandName": "negative unless there are features suggesting sero",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The source is HIV sero-negative unless there are features suggesting sero-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tenofovir",
    "brandName": "TDF",
    "strength": "300 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tenofovir (TDF), oral, 300 mg daily for 4 weeks (provided baseline eGFR is >50",
    "commonDosage": "300 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamivudine",
    "brandName": "3TC",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamivudine (3TC), oral, 300 mg daily for 4 weeks.",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir",
    "brandName": "DTG",
    "strength": "50 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir (DTG), oral 50 mg once daily for 4 weeks.",
    "commonDosage": "50 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emtricitabine",
    "brandName": "FTC",
    "strength": "200 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emtricitabine (FTC), oral, 200 mg daily for 4 weeks.",
    "commonDosage": "200 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lopinavir/ritonavir",
    "brandName": "LPV/r",
    "strength": "200",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lopinavir/ritonavir (LPV/r) 200/50 mg, oral, 2 tablets 12 hourly for 4 weeks.",
    "commonDosage": "200",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zidovudine",
    "brandName": "AZT",
    "strength": "300 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zidovudine (AZT), oral, 300 mg 12 hourly for 4 weeks.",
    "commonDosage": "300 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medicines, e.g. aminoglycosides",
    "brandName": "check baseline creatinine clearance",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medicines, e.g. aminoglycosides (check baseline creatinine clearance). Where TDF",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medico",
    "brandName": "legal examination,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medico-legal examination,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consequences of that act",
    "brandName": "including the risk of contracting sexually transmi",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consequences of that act - including the risk of contracting sexually transmitted diseases",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sexual offence victims must be regarded as emergencies but do not displace life",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sexual offence victims must be regarded as emergencies but do not displace life-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for medico",
    "brandName": "legal investigation.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for medico-legal investigation.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Offer 1st dose of antiretroviral PEP in all cases of suspected rape",
    "brandName": "the following",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Offer 1st dose of antiretroviral PEP in all cases of suspected rape - the following",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Parents or caregivers of children who are not competent to sign consent",
    "brandName": "but the child",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Parents or caregivers of children who are not competent to sign consent (but the child",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "to their age and development",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "to their age and development).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "consent for HIV testing and PEP",
    "brandName": "alleged rape in children is a medical emergency",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "consent for HIV testing and PEP (alleged rape in children is a medical emergency).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If the patient declines, give a 3",
    "brandName": "day starter pack of PEP and encourage the patient ",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If the patient declines, give a 3–day starter pack of PEP and encourage the patient to",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Explain the side effects of ARVs, e.g. tiredness, nausea and flu",
    "brandName": "like symptoms.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Explain the side effects of ARVs, e.g. tiredness, nausea and flu-like symptoms.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Psycho",
    "brandName": "emotional",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Psycho-emotional-social effects of the sexual assault according to their level of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Inform the patient of the signs and symptoms of post",
    "brandName": "traumatic stress syndrome",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Inform the patient of the signs and symptoms of post-traumatic stress syndrome",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ensure case opened",
    "brandName": "patient usually brought by",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ensure case opened (patient usually brought by",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Further baseline and follow",
    "brandName": "up investigations are the same as for occupational",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Further baseline and follow-up investigations are the same as for occupational HIV",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Offer PEP if the patient presents within 72 hours of being raped and is HIV",
    "brandName": "uninfected",
    "strength": "72 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Offer PEP if the patient presents within 72 hours of being raped and is HIV-uninfected",
    "commonDosage": "72 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "It is important to manage the medical condition before medico",
    "brandName": "legal examination. Most",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "It is important to manage the medical condition before medico-legal examination. Most",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dolutegravir",
    "brandName": "DTG",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dolutegravir (DTG), oral, for 28 days.",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Perfom HIV test 4",
    "brandName": "weeks after initiating PrEP.",
    "strength": "4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Perfom HIV test 4-weeks after initiating PrEP.",
    "commonDosage": "4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "development",
    "brandName": "DO NOT REGARD MENARCHE AS AN INDICATION",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "development (DO NOT REGARD MENARCHE AS AN INDICATION). Refer all pregnant",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Enzyme inducers",
    "brandName": "including efavirenz and carbamazepine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Enzyme inducers (including efavirenz and carbamazepine) cause a significant reduction in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃14",
    "brandName": "18 kg",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃14–18 kg",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "600",
    "brandName": "800 mg",
    "strength": "600",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "600–800 mg",
    "commonDosage": "600",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "sero",
    "brandName": "positive persons often requires clinical judgement",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "sero-positive persons often requires clinical judgement and includes:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Management of inadvertent",
    "brandName": "non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Management of inadvertent (non-occupational) HIV and hepatitis B exposure is the same",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For exposures of a sexual nature",
    "brandName": "e.g. consensual sex with a burst",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For exposures of a sexual nature (e.g. consensual sex with a burst",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "condom",
    "brandName": ", consider emergency contraception and STI prophyl",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "condom), consider emergency contraception and STI prophylaxis on a case-by-case",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Major injuries: it is important to recognise potentially life",
    "brandName": "threatening injuries. Indicators",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Major injuries: it is important to recognise potentially life-threatening injuries. Indicators",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pedestrian thrown out of his/her shoes, fall from height of more than 2 stories",
    "brandName": "more",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pedestrian thrown out of his/her shoes, fall from height of more than 2 stories (more",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "than thrice the patient’s height in a child",
    "brandName": ", multiple gunshot wounds.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "than thrice the patient’s height in a child), multiple gunshot wounds.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Anatomical distribution:",
    "brandName": "suspicion of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Anatomical distribution: (suspicion of) injuries to more than one body region (face,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Head injuries: moderate head injuries",
    "brandName": "i.e. any GCS 11",
    "strength": "11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Head injuries: moderate head injuries (i.e. any GCS 11-14), facial fractures (airway",
    "commonDosage": "11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "stable patient: e.g. abdominal bruising",
    "brandName": "including seat belt sign in children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "stable patient: e.g. abdominal bruising (including seat belt sign in children),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Extremity injuries: major open wounds, degloving injuries",
    "brandName": "boggy feel under intact",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Extremity injuries: major open wounds, degloving injuries (boggy feel under intact",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "saturation. If needed, support breathing using a Bag",
    "brandName": "Valve",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "saturation. If needed, support breathing using a Bag-Valve-Mask device (‘AMBU bag’).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Look for signs of pneumothorax",
    "brandName": "affected site is hyperinflated, hypertympanic and ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Look for signs of pneumothorax (affected site is hyperinflated, hypertympanic and has",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "90 mmHg. If actively bleeding, it is permissible to maintain SBP≥ 80 mmHg",
    "brandName": "or a palpable",
    "strength": "90 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "90 mmHg. If actively bleeding, it is permissible to maintain SBP≥ 80 mmHg (or a palpable",
    "commonDosage": "90 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fall below",
    "brandName": "70 + [2 x age]",
    "strength": "70 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fall below (70 + [2 x age]) mmHg.",
    "commonDosage": "70 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "intoxication, inability to communicate or a distracting injury",
    "brandName": "cut the patient’s clothes off, so",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "intoxication, inability to communicate or a distracting injury) cut the patient’s clothes off, so",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the patient’s regular medication",
    "brandName": "including contraceptives and OTC medication",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the patient’s regular medication (including contraceptives and OTC medication)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "First examine patient from the front, then log",
    "brandName": "roll the patient and examine the back",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "First examine patient from the front, then log-roll the patient and examine the back (include",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Bloods may include FBC, clotting profile, cross",
    "brandName": "match and U & Es.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Bloods may include FBC, clotting profile, cross-match and U & Es.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bite, dress with povidone",
    "brandName": "iodine and refer for surgical debridement.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bite, dress with povidone-iodine and refer for surgical debridement.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in moist or hairy areas",
    "brandName": "axillae/perineum",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in moist or hairy areas (axillae/perineum), if needing high level of precision (hairline or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "wounds, wounds with contaminated tissue",
    "brandName": ". Wounds on the scalp can be glued but",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "wounds, wounds with contaminated tissue). Wounds on the scalp can be glued but",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tissue adhesive",
    "brandName": "glue",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tissue adhesive (glue):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Appose wound edges",
    "brandName": "bring wound edges together",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Appose wound edges (bring wound edges together). Ensure patient is positioned",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Gently brush adhesive over laceration",
    "brandName": "avoid contact with gloves/ instruments and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Gently brush adhesive over laceration (avoid contact with gloves/ instruments and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "avoid pushing adhesive into wound",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "avoid pushing adhesive into wound).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Apply three layers of adhesive",
    "brandName": "maximum bonding strength is achieved within 2.5",
    "strength": "2.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Apply three layers of adhesive (maximum bonding strength is achieved within 2.5",
    "commonDosage": "2.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lidocaine without adrenaline",
    "brandName": "epinephrine",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lidocaine without adrenaline (epinephrine), injection.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cardiac pulmonary arrest",
    "brandName": "COVID",
    "strength": "19 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cardiac pulmonary arrest – COVID-19 considerations: Resuscitation Council of South Africa. Advanced Cardiac Arrest Algorithm for",
    "commonDosage": "19 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Cardiovascular Care Committee and Get With the Guidelines",
    "brandName": "Resuscitation, Adult and Pediatric Task Forces of ",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Cardiovascular Care Committee and Get With the Guidelines-Resuscitation, Adult and Pediatric Task Forces of the American Heart",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID",
    "brandName": "19: From the Emergency",
    "strength": "19",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19: From the Emergency",
    "commonDosage": "19",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Care Anesthesiologists, and American Society of Anesthesiologists. Circ Cardiovasc Qual Outcomes. 2022 Apr;15",
    "brandName": "4",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Care Anesthesiologists, and American Society of Anesthesiologists. Circ Cardiovasc Qual Outcomes. 2022 Apr;15(4):e008900.",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "et al. Risk for Acquiring Coronavirus Disease Illness among Emergency Medical Service Personnel Exposed to Aerosol",
    "brandName": "Generating",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "et al. Risk for Acquiring Coronavirus Disease Illness among Emergency Medical Service Personnel Exposed to Aerosol-Generating",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Procedures. Emerg Infect Dis. 2021 Sep;27",
    "brandName": "9",
    "strength": "2021 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Procedures. Emerg Infect Dis. 2021 Sep;27(9):2340-2348. https://pubmed.ncbi.nlm.nih.gov/34197282/",
    "commonDosage": "2021 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in critically ill people. Cochrane Database Syst Rev. 2018 Aug 3;8",
    "brandName": "8",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in critically ill people. Cochrane Database Syst Rev. 2018 Aug 3;8(8):CD000567. http://www.ncbi.nlm.nih.gov/pubmed/23450531",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sodium Chloride, 0.9%: National Department of Health, Essential Drugs Programme. Medicine review",
    "brandName": "Hydroxyethyl Starch",
    "strength": "0.9%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sodium Chloride, 0.9%: National Department of Health, Essential Drugs Programme. Medicine review - Hydroxyethyl Starch",
    "commonDosage": "0.9%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sodium chloride 0.9%: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Adult Hospital level. Medicine Review: Ringer",
    "strength": "0.9%",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sodium chloride 0.9%: National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Ringer",
    "commonDosage": "0.9%",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lactate for resuscitation in adults, updated review, August 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lactate for resuscitation in adults, updated review, August 2019. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline/epinephrine, IO",
    "brandName": "Bradycardia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline/epinephrine, IO (Bradycardia-children): Resuscitation Council of South Africa. Advanced Cardiac Arrest Algorithm, Adult",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Asystole >20 minutes",
    "brandName": "termination of resuscitation",
    "strength": "20 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Asystole >20 minutes (termination of resuscitation): 2020 American Heart Association. 2020 American Heart Association Guidelines",
    "commonDosage": "20 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for CPR and ECC https://cpr.heart.org/en/resuscitation",
    "brandName": "science/cpr",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for CPR and ECC https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aug;36",
    "brandName": "8",
    "strength": "36",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aug;36(8):479-484.",
    "commonDosage": "36",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emerg Med. 2022 Mar 27;22",
    "brandName": "1",
    "strength": "2022 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emerg Med. 2022 Mar 27;22(1):53. https://pubmed.ncbi.nlm.nih.gov/35346055/",
    "commonDosage": "2022 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Estimating paediatric body weight with paediatric resuscitation tape",
    "brandName": "PAWPER tape:  Manyoni MJ, Goldstein LN, Wells M. A",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Estimating paediatric body weight with paediatric resuscitation tape – PAWPER tape:  Manyoni MJ, Goldstein LN, Wells M. A",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "comparison of four weight estimation systems for paediatric resuscitation. S Afr J Surg. 2019 Jun;57",
    "brandName": "2",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "comparison of four weight estimation systems for paediatric resuscitation. S Afr J Surg. 2019 Jun;57(2):40-46.",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "MAC tape for total body weight estimation in preschool children from low",
    "brandName": "and middle",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "MAC tape for total body weight estimation in preschool children from low- and middle-income countries. PLoS One. 2019 Jan",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7;14",
    "brandName": "1",
    "strength": "7",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7;14(1):e0210332. https://pubmed.ncbi.nlm.nih.gov/30615693/",
    "commonDosage": "7",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Monteith I. The accuracy of the Broselow tape as a weight estimation tool and a drug",
    "brandName": "dosing guide",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Monteith I. The accuracy of the Broselow tape as a weight estimation tool and a drug-dosing guide - A systematic review and meta-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "analysis. Resuscitation. 2017 Dec;121:9",
    "brandName": "33. https://pubmed.ncbi.nlm.nih.gov/28958796/",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "analysis. Resuscitation. 2017 Dec;121:9-33. https://pubmed.ncbi.nlm.nih.gov/28958796/",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Estimating paediatric body weight",
    "brandName": "formula",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Estimating paediatric body weight (formula): Advanced Life Support Group (ALSG). Advanced Paediatric Life Support: A Practical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Approach to Emergencies, 6th Edition. Chichester",
    "brandName": "West Sussex, UK",
    "strength": "6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Approach to Emergencies, 6th Edition. Chichester (West Sussex, UK): BMJ Books; 2016.",
    "commonDosage": "6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adrenaline/epinephrine, IV",
    "brandName": "Bradycardia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adrenaline/epinephrine, IV (Bradycardia-children): National Department of Health, Essential Drugs Programme. Paediatric Hospital",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Atropine, IV",
    "brandName": "Bradycardia",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Atropine, IV (Bradycardia-children): National Department of Health, Essential Drugs Programme. Paediatric Hospital Level STGs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Olanzapine, oral/oral dispersible tablet/IM/: National Department of Health: Affordable Medicines, EDP",
    "brandName": "Adult Hospital level. Medicine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Olanzapine, oral/oral dispersible tablet/IM/: National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Review: Olanzapine for delirium, 9 August 2022. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "9 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Review: Olanzapine for delirium, 9 August 2022. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-",
    "commonDosage": "9 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Benzodiazepines/ Haloperidol",
    "brandName": "dosing in the elderly",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Benzodiazepines/ Haloperidol (dosing in the elderly): South African Medicines Formulary.  14th Edition.  Division of Clinical",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NICE CG103: Delirium: prevention, diagnosis and management in hospital and long",
    "brandName": "term care https://www.nice.org.uk/guidance/cg103",
    "strength": "103",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NICE CG103: Delirium: prevention, diagnosis and management in hospital and long-term care https://www.nice.org.uk/guidance/cg103",
    "commonDosage": "103",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Thiamine",
    "brandName": "alcohol withdrawal/ Wernicke’s encephalopathy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Thiamine (alcohol withdrawal/ Wernicke’s encephalopathy): Ambrose ML, Bowden SC, Whelan G. Thiamin treatment and working",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "memory function of alcohol",
    "brandName": "dependent people: preliminary findings. Alcohol Cl",
    "strength": "2001 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "memory function of alcohol-dependent people: preliminary findings. Alcohol Clin Exp Res. 2001 Jan;25(1):112-6.",
    "commonDosage": "2001 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1;2013",
    "brandName": "7",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1;2013(7):CD004033. https://pubmed.ncbi.nlm.nih.gov/23818100",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "accident and Emergency Department. Alcohol Alcohol. 2002 Nov",
    "brandName": "Dec;37",
    "strength": "2002 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "accident and Emergency Department. Alcohol Alcohol. 2002 Nov-Dec;37(6):513-21. Erratum in: Alcohol Alcohol. 2003 May-",
    "commonDosage": "2002 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jun;38",
    "brandName": "3",
    "strength": "38",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jun;38(3):291. https://pubmed.ncbi.nlm.nih.gov/12414541/",
    "commonDosage": "38",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "controlled trial. Emerg Med J. 2005 Jul;22",
    "brandName": "7",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "controlled trial. Emerg Med J. 2005 Jul;22(7):512-5. https://www.ncbi.nlm.nih.gov/pubmed/15983093",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "alcohol",
    "brandName": "dependent people: preliminary findings. Alcohol Cl",
    "strength": "2001 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "alcohol-dependent people: preliminary findings. Alcohol Clin Exp Res. 2001 Jan;25(1):112-6. https://pubmed.ncbi.nlm.nih.gov/11198705/",
    "commonDosage": "2001 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine for the treatment of acute pulmonary distress, May 2022. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2022",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine for the treatment of acute pulmonary distress, May 2022. https://www.knowledgehub.org.za/content/standard-treatment-",
    "commonDosage": "2022",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "oedema: A rapid systematic review. S Afr Med J. 2023 Aug 3;113",
    "brandName": "8",
    "strength": "2023 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "oedema: A rapid systematic review. S Afr Med J. 2023 Aug 3;113(8):39-43. doi: 10.7196/SAMJ.2023.v113i8.348. PMID: 37882120.",
    "commonDosage": "2023 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cut",
    "brandName": "off for acutely ill medical inpatients, 9 Septembe",
    "strength": "9 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cut-off for acutely ill medical inpatients, 9 September 2021. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "9 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "JD, Alhazzani W. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy",
    "brandName": "IOTA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "JD, Alhazzani W. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "review and meta",
    "brandName": "analysis. Lancet. 2018 Apr 28;391",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-1705. https://www.ncbi.nlm.nih.gov/pubmed/29726345",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Oxygen",
    "brandName": "anaphylaxis",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Oxygen (anaphylaxis): Resuscitation Council of Southern Africa: Emergency management of anaphylaxis algorithm, 2021.",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ipratropium nebulisation",
    "brandName": "anaphylaxis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Respiratory",
    "schedule": "Schedule 2",
    "description": "Ipratropium nebulisation (anaphylaxis): Resuscitation Council of Southern Africa: Emergency management of anaphylaxis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "the treatment of status epilepticus in children and young adults: a meta",
    "brandName": "analysis. Acad Emerg Med. 2010 Jun;17",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010 Jun;17(6):575-82.",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2008; 121:e58",
    "brandName": "64. http://www.ncbi.nlm.nih.gov/pubmed/18166545",
    "strength": "2008",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2008; 121:e58–64. http://www.ncbi.nlm.nih.gov/pubmed/18166545",
    "commonDosage": "2008",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, IM vs other benzodiazepines",
    "brandName": "any route of administration",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, IM vs other benzodiazepines (any route of administration), 31 August 2017. http://health.gov.za/",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta",
    "brandName": "analysis. Epilepsy",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. Epilepsy",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "research. 2016;122:47",
    "brandName": "55. https://www.ncbi.nlm.nih.gov/pubmed/26922313",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "research. 2016;122:47-55. https://www.ncbi.nlm.nih.gov/pubmed/26922313",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Phenobarbital, oral via naso",
    "brandName": "gastric tube",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Phenobarbital, oral via naso-gastric tube (children-status epilepticus): Wilmshurst JM, van der Walt JS, Ackermann S, Karlsson MO,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Blockman M. Rescue therapy with high",
    "brandName": "dose oral phenobarbitone loading for refractory st",
    "strength": "2010",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Blockman M. Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. J Paediatr Child Health. 2010",
    "commonDosage": "2010",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jan;46",
    "brandName": "1",
    "strength": "46",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jan;46(1-2):17-22. https://www.ncbi.nlm.nih.gov/pubmed/19943867",
    "commonDosage": "46",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, IM",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, IM (adults-status epilepticus):Silbergleit R, Durkalski V,Lowenstein D,Conwit R,Pancioli A,Palesch Y,Barsan W; NETT",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. NEnglJMed. 2012Feb16; 366",
    "brandName": "7",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. NEnglJMed. 2012Feb16; 366(7):591-600.",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, IV",
    "brandName": "adults",
    "strength": "N/A",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, IV (adults-status epilepticus): Brophy GM, Bell R, Claassen J, Alldredge B, BleckTP, Glauser T, Laroche SM, RivielloJJ",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Aug;17",
    "brandName": "1",
    "strength": "17",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Aug;17(1):3-23.",
    "commonDosage": "17",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Diazepam, IV",
    "brandName": "Adults status epilepticus: South African Medicines",
    "strength": "14",
    "form": "tablet",
    "category": "Mental Health",
    "schedule": "Schedule 2",
    "description": "Diazepam, IV - Adults status epilepticus: South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "28 Wound washing",
    "brandName": "rabid animal bite",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "28 Wound washing (rabid animal bite): World Health Organisation. Rabies vaccines: WHO position paper – April 2018. Weekly",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "epidemiological record: No 16, 2018, 93, 201",
    "brandName": "220. http://www.who.int/wer",
    "strength": "16",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "epidemiological record: No 16, 2018, 93, 201–220. http://www.who.int/wer",
    "commonDosage": "16",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "29 Immunocomprised individuals",
    "brandName": "dosing of rabies vaccine",
    "strength": "29 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "29 Immunocomprised individuals  (dosing of rabies vaccine): World Health Organisation. Rabies vaccines: WHO position paper – April",
    "commonDosage": "29 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Immunocomprised individuals",
    "brandName": "dosing of rabies vaccine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Immunocomprised individuals  (dosing of rabies vaccine): Sirikwin S, Likanonsakul S, Waradejwinyoo S, Pattamadilok S,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HumanImmunodeficiency Virus. Vaccine. 2009 Jul 9;27",
    "brandName": "32",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HumanImmunodeficiency Virus. Vaccine. 2009 Jul 9;27(32):4350‐4. https://pubmed.ncbi.nlm.nih.gov/19487057/",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Mostafavi E, et al. Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination",
    "brandName": "PVRV",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Mostafavi E, et al. Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in: PLoS One. 2015;10",
    "brandName": "10",
    "strength": "2015",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in: PLoS One. 2015;10(10):e0142244. https://pubmed.ncbi.nlm.nih.gov/26440665/",
    "commonDosage": "2015",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "AIDS. 2014 Feb 20;28",
    "brandName": "4",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "AIDS. 2014 Feb 20;28(4):531‐41. https://pubmed.ncbi.nlm.nih.gov/24468996/",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "30 HRIG and ERIG",
    "brandName": "directions of administration",
    "strength": "30 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "30 HRIG and ERIG (directions of administration):  Madhusudana SN, Ashwin BY, Sudarshan S. Feasibility of reducing rabies",
    "commonDosage": "30 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sep;9",
    "brandName": "9",
    "strength": "9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sep;9(9):1914‐7. https://pubmed.ncbi.nlm.nih.gov/23792347/",
    "commonDosage": "9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HRIG and ERIG",
    "brandName": "directions of administration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HRIG and ERIG (directions of administration):  Bharti OK, Madhusudana SN, Wilde H.. Injecting rabies immunoglobulin (RIG) into",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "rabies. Hum Vaccin Immunother. 2016; 12",
    "brandName": "3",
    "strength": "2016",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "rabies. Hum Vaccin Immunother. 2016; 12(3):837–842. https://pubmed.ncbi.nlm.nih.gov/26317441/",
    "commonDosage": "2016",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "HRIG and ERIG",
    "brandName": "directions of administration",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "HRIG and ERIG (directions of administration):  World Health Organisation. Rabies vaccines: WHO position paper – April 2018.",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Weekly epidemiological record: No 16, 2018, 93, 201",
    "brandName": "220. http://www.who.int/wer",
    "strength": "16",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Weekly epidemiological record: No 16, 2018, 93, 201–220. http://www.who.int/wer",
    "commonDosage": "16",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "31 HRIG and ERIG",
    "brandName": "summary of regimen",
    "strength": "31 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "31 HRIG and ERIG (summary of regimen):  National Institute of Communicable Diseases. Updated: human rabies prophylaxis guideline,",
    "commonDosage": "31 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "32 Rabies vaccine dosing: World Health Organisation. Rabies vaccines: WHO position paper",
    "brandName": "April 2018. Weekly epidemiological record:",
    "strength": "32 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "32 Rabies vaccine dosing: World Health Organisation. Rabies vaccines: WHO position paper – April 2018. Weekly epidemiological record:",
    "commonDosage": "32 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jul 9;27",
    "brandName": "32",
    "strength": "9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jul 9;27(32):4350‐4. https://pubmed.ncbi.nlm.nih.gov/19487057/",
    "commonDosage": "9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "rabies vaccination. Vaccine. 2001 Jan 8;19",
    "brandName": "11‐12",
    "strength": "2001 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "rabies vaccination. Vaccine. 2001 Jan 8;19(11‐12):1534‐7. https://pubmed.ncbi.nlm.nih.gov/11163679/",
    "commonDosage": "2001 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "exposed to suspect rabid animals. Vaccine. 2005 Jan 19;23",
    "brandName": "9",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "exposed to suspect rabid animals. Vaccine. 2005 Jan 19;23(9):1102‐5. https://pubmed.ncbi.nlm.nih.gov/15629352/",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "antiretroviral treatment strategies in HIV‐infected children on immunogenicity of vaccines during infancy. AIDS. 2014 Feb 20;28",
    "brandName": "4",
    "strength": "2014 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "antiretroviral treatment strategies in HIV‐infected children on immunogenicity of vaccines during infancy. AIDS. 2014 Feb 20;28(4):531‐",
    "commonDosage": "2014 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tetanus vaccination",
    "brandName": "human bites",
    "strength": "1992 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tetanus vaccination (human bites): Muguti GI, Dixon MS. Tetanus following human bite. Br J Plast Surg. 1992 Nov-Dec;45(8):614-",
    "commonDosage": "1992 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tetanus vaccination",
    "brandName": "human bites",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tetanus vaccination (human bites): Patil PD, Panchabhai TS, Galwankar SC. Managing human bites. J Emerg Trauma Shock.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2009 Sep;2",
    "brandName": "3",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2009 Sep;2(3):186-90. https://www.ncbi.nlm.nih.gov/pubmed/20009309",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "35 Tetatnus toxoid vaccine",
    "brandName": "scorpion stings and spider bites",
    "strength": "35 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "35 Tetatnus toxoid vaccine (scorpion stings and spider bites): National Department of Health, Essential Drugs Programme. Adult Hospital",
    "commonDosage": "35 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Local anaesthetic ophthamlmic drops",
    "brandName": "therapeutic group",
    "strength": "N/A",
    "form": "drops",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Local anaesthetic ophthamlmic drops (therapeutic group): Lawrenson JG, Edgar DF, Tanna GK, Gudgeon AC. Comparison of the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Snake polyvalent antivenom",
    "brandName": "indications",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Snake polyvalent antivenom (indications): South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "40 Povidone iodine 5% cream",
    "brandName": "septic burns",
    "strength": "40 ",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "40 Povidone iodine 5% cream (septic burns): Affordable Medicines, EDP-PHC Review: Burns dressings scoping review, October 2021.",
    "commonDosage": "40 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Activated charcoal",
    "brandName": "single dose",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Activated charcoal (single dose): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Single dose activated charcoal for poisonings, May 2019. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "2019",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Single dose activated charcoal for poisonings, May 2019. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "2019",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Centres and Clinical Toxicologists. Position statement: single",
    "brandName": "dose activated charcoal. J Toxicol Clin Toxicol 19",
    "strength": "1997",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Centres and Clinical Toxicologists. Position statement: single-dose activated charcoal. J Toxicol Clin Toxicol 1997;35(7):721-41.",
    "commonDosage": "1997",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1981; 6:161",
    "brandName": "192. https://www.ncbi.nlm.nih.gov/pubmed/7016383",
    "strength": "1981",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1981; 6:161– 192. https://www.ncbi.nlm.nih.gov/pubmed/7016383",
    "commonDosage": "1981",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "paracetamol",
    "brandName": "acetaminophen",
    "strength": "2000",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 0",
    "description": "paracetamol (acetaminophen) overdose. Br J Clin Pharmacol 2000; 49:11–14. https://www.ncbi.nlm.nih.gov/pubmed/7016383",
    "commonDosage": "2000",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. Ther Drug Monit 1997; 19:46",
    "brandName": "50.",
    "strength": "1997",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. Ther Drug Monit 1997; 19:46– 50.",
    "commonDosage": "1997",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "still effective? J Toxicol Clin Toxicol 2001; 39:601",
    "brandName": "605. https://www.ncbi.nlm.nih.gov/pubmed/11762668",
    "strength": "2001",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "still effective? J Toxicol Clin Toxicol 2001; 39:601– 605. https://www.ncbi.nlm.nih.gov/pubmed/11762668",
    "commonDosage": "2001",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Jun;8",
    "brandName": "2",
    "strength": "8",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Jun;8(2):108-17. http://www.ncbi.nlm.nih.gov/pubmed/22351300",
    "commonDosage": "8",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Naloxone, IV/IM",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Naloxone, IV/IM (children): Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, Berg MD, de",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Emergency Cardiovascular Care.Circulation. 2010 Nov 2;122",
    "brandName": "18 Suppl 3",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Emergency Cardiovascular Care.Circulation. 2010 Nov 2;122(18 Suppl 3):S876-908. https://www.ncbi.nlm.nih.gov/pubmed/20956230",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Naloxone, IV/IM",
    "brandName": "children",
    "strength": "2016 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Naloxone, IV/IM (children): Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 Mar;81(3):428-36.",
    "commonDosage": "2016 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "45 Naloxone, IV/IM",
    "brandName": "adults",
    "strength": "45 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "45 Naloxone, IV/IM (adults): Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 Mar;81(3):428-36.",
    "commonDosage": "45 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "poisoning. Ann Emerg Med. 2009 Oct;54",
    "brandName": "4",
    "strength": "2009 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "poisoning. Ann Emerg Med. 2009 Oct;54(4):606‐14. https://www.ncbi.nlm.nih.gov/pubmed/19556028",
    "commonDosage": "2009 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hour oral, and 72‐hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther. 2013 Jan;20",
    "brandName": "1",
    "strength": "72",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hour oral, and 72‐hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther. 2013 Jan;20(1):37‐40.",
    "commonDosage": "72",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "duration: past, present and future. Clin Toxicol",
    "brandName": "Phila",
    "strength": "2012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "duration: past, present and future. Clin Toxicol (Phila) 2012;50(2):91‐98. https://www.ncbi.nlm.nih.gov/pubmed/22320209",
    "commonDosage": "2012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ToxicolClinToxicol. 1995;33",
    "brandName": "5",
    "strength": "1995",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ToxicolClinToxicol. 1995;33(5):407-16. Review. http://www.ncbi.nlm.nih.gov/pubmed/7650765",
    "commonDosage": "1995",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Whole bowel irrigation:Mayer AL, Sitar DS, Tenenbein M. Multiple",
    "brandName": "dose charcoal and whole",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Whole bowel irrigation:Mayer AL, Sitar DS, Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "clearance of absorbed salicylate. Arch Intern Med. 1992 Feb;152",
    "brandName": "2",
    "strength": "1992 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "clearance of absorbed salicylate. Arch Intern Med. 1992 Feb;152(2):393-6. http://www.ncbi.nlm.nih.gov/pubmed/1739372",
    "commonDosage": "1992 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Paracetmaol poisoning cut",
    "brandName": "off",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Paracetmaol poisoning cut-off (children): National Department of Health, Essential Drugs Programme. Paediatric Hospital Level",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "50Monitoring in occupational exposures: National Department of Health. National Clinical Guidelines of post",
    "brandName": "exposure prophylaxis",
    "strength": "50",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "50Monitoring in occupational exposures: National Department of Health. National Clinical Guidelines of post-exposure prophylaxis",
    "commonDosage": "50",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "51 Dolutegravir",
    "brandName": "based PEP regimen: WHO. Consolidated guidelines on",
    "strength": "51 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "51 Dolutegravir-based PEP regimen: WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring:",
    "commonDosage": "51 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "tenofovir disoproxil fumarate",
    "brandName": "emtricitabine as HIV postexposure prophylaxis in g",
    "strength": "2017",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS. 2017;31(9):1291–5.",
    "commonDosage": "2017",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "in occupational and non",
    "brandName": "occupational exposures, December 2020. https://www",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "in occupational and non-occupational exposures, December 2020. https://www.knowledgehub.org.za/elibrary/national-clinical-",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "52Protease",
    "brandName": "inhibitor",
    "strength": "52",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "52Protease-inhibitor- based PEP regimen: Ford N, Shubber Z, Calmy A, Irvine C, Rapparini C, Ajose O, et al. Choice of antiretroviral drugs",
    "commonDosage": "52",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Protease",
    "brandName": "inhibitor",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Protease-inhibitor- based PEP regimen: National Department of Health. National Clinical Guidelines of post-exposure prophylaxis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hepatitis B immunoglobulin:",
    "brandName": "administration within 7 days",
    "strength": "7 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hepatitis B immunoglobulin: (administration within 7 days): Joint Formulary Committee. British National Formulary. London: BMJ",
    "commonDosage": "7 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hepatitis B vaccine and hepatitis B immunoglobulin",
    "brandName": "HCW",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hepatitis B vaccine and hepatitis B immunoglobulin (HCW-occupational prophylaxis): National Department of Health, Essential",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Drugs Programme. Adult Hospital Level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Drugs Programme. Adult Hospital Level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2015 Update. South Afr J HIV Med. 2015 Nov 10;16",
    "brandName": "1",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2015 Update. South Afr J HIV Med. 2015 Nov 10;16(1):399. https://www.ncbi.nlm.nih.gov/pubmed/29568597",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Guidelines: Post exposure Prophylaxis to Prevent Hepatitis B Virus Infection. MMWR 2006,56",
    "brandName": "RR",
    "strength": "2006",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Guidelines: Post exposure Prophylaxis to Prevent Hepatitis B Virus Infection. MMWR 2006,56(RR-16), Appendix B.",
    "commonDosage": "2006",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Medicines, EDP",
    "brandName": "PHC level. Medicine review: Human Hepatitis B immu",
    "strength": "2018",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Medicines, EDP-PHC level. Medicine review: Human Hepatitis B immunoglobulin for hepatitis exposure, March 2018.",
    "commonDosage": "2018",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for post",
    "brandName": "exposure prophylaxis: Updated recommendations. S A",
    "strength": "2023",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for post-exposure prophylaxis: Updated recommendations. S Afr J HIV Med. 2023;24(1), a1522. https://doi.org/10.4102/",
    "commonDosage": "2023",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "56Copper IUD",
    "brandName": "emergency contraception",
    "strength": "56",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "56Copper IUD (emergency contraception): Turok DK, Jacobson JC, Dermish AI, Simonsen SE, Gurtcheff S, McFadden M, Murphy",
    "commonDosage": "56",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "57Levonorgestrel 1.5 mg oral",
    "brandName": "emergency contraception",
    "strength": "57",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "57Levonorgestrel 1.5 mg oral (emergency contraception): Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency",
    "commonDosage": "57",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "contraception. Cochrane Database Syst Rev. 2019 Jan 20;1",
    "brandName": "1",
    "strength": "2019 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "contraception. Cochrane Database Syst Rev. 2019 Jan 20;1(1):CD001324. https://pubmed.ncbi.nlm.nih.gov/30661244/",
    "commonDosage": "2019 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "58Levonorgesterol, oral",
    "brandName": "emergency contraception",
    "strength": "58",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "58Levonorgesterol, oral - emergency contraception (double dose): Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S.",
    "commonDosage": "58",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70",
    "brandName": "4",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70",
    "brandName": "4",
    "strength": "2021",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-",
    "commonDosage": "2021",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "61 Hepatitis B vaccine and hepatitis B immunoglobulin",
    "brandName": "HCW",
    "strength": "61 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "61 Hepatitis B vaccine and hepatitis B immunoglobulin (HCW-occupational prophylaxis): National Department of Health, Essential Drugs",
    "commonDosage": "61 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Programme. Adult Hospital level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard",
    "brandName": "treatment",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Programme. Adult Hospital level STGs and EML, draft. https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Palliative care improves the quality of life of patients facing life",
    "brandName": "threatening illnesses and",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Palliative care improves the quality of life of patients facing life-threatening illnesses and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "their family members, regardless of whether or not they also receive life",
    "brandName": "prolonging",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "their family members, regardless of whether or not they also receive life-prolonging",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Palliative care patients who are down",
    "brandName": "referred from higher levels of care with a care pl",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Palliative care patients who are down-referred from higher levels of care with a care plan",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The SPICTTM",
    "brandName": "SA is a generic tool",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The SPICTTM-SA is a generic tool (https://www.spict.org.uk/the-spict/spict-sa/), designed",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for the South African setting, to help identify adults with advanced life",
    "brandName": "limiting illnesses",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for the South African setting, to help identify adults with advanced life-limiting illnesses",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "common symptoms alongside disease directed care and symptoms associated with end",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "common symptoms alongside disease directed care and symptoms associated with end-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "For management of opioid",
    "brandName": "induced constipation:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "For management of opioid-induced constipation:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "See Section 2.4: Nausea and vomiting, non",
    "brandName": "specific.",
    "strength": "2.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "See Section 2.4: Nausea and vomiting, non-specific.",
    "commonDosage": "2.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 9",
    "brandName": "11 kg",
    "strength": "9",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 9–11 kg",
    "commonDosage": "9",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 11",
    "brandName": "14 kg",
    "strength": "11",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 11–14 kg",
    "commonDosage": "11",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 14",
    "brandName": "17.5 kg",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 14–17.5 kg",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 17.5",
    "brandName": "25 kg",
    "strength": "17.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 17.5–25 kg",
    "commonDosage": "17.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 25",
    "brandName": "35 kg",
    "strength": "25",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 25–35 kg",
    "commonDosage": "25",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃ 35",
    "brandName": "55 kg",
    "strength": "35",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃ 35–55 kg",
    "commonDosage": "35",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "irreversible with long",
    "brandName": "term use.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "irreversible with long-term use.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Avoid use in people at high risk of addiction",
    "brandName": "personality disorders",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Avoid use in people at high risk of addiction – personality disorders",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Delirium",
    "brandName": "confusion",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Delirium (confusion) is common in the terminal stages of advanced disease, but is rarely",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Remove factors that can agitate patient",
    "brandName": "full bladders, thirst, pain, constipation",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Remove factors that can agitate patient (full bladders, thirst, pain, constipation).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tricyclic antidepressants",
    "brandName": "Doctor prescribed",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tricyclic antidepressants (Doctor prescribed), e.g.:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dyspnoea associated with hypoxia for consideration of home",
    "brandName": "based oxygen.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dyspnoea associated with hypoxia for consideration of home-based oxygen.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The management of a patient who is imminently terminal",
    "brandName": "death suspected to occur within",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The management of a patient who is imminently terminal (death suspected to occur within",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Decision making as to the preferred place of death",
    "brandName": "home, hospice, hospital",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Decision making as to the preferred place of death (home, hospice, hospital) and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010 Nov;40",
    "brandName": "5",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010 Nov;40(5):761-73.",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010 Nov;40",
    "brandName": "5",
    "strength": "2010 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010 Nov;40(5):761-73.",
    "commonDosage": "2010 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Nov;40",
    "brandName": "5",
    "strength": "40",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Nov;40(5):761-73. https://www.ncbi.nlm.nih.gov/pubmed/21075273",
    "commonDosage": "40",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015 May 13;",
    "brandName": "5",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015 May 13;(5):CD003448.",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metoclopramide, oral nausea and vomiting",
    "brandName": ": South African Medicines Formulary, 14th Edition.",
    "strength": "14",
    "form": "tablet",
    "category": "Gastrointestinal",
    "schedule": "Schedule 2",
    "description": "Metoclopramide, oral nausea and vomiting): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metoclopramide, oral nausea and vomiting",
    "brandName": ": Charlesworth, S.",
    "strength": "2020",
    "form": "tablet",
    "category": "Gastrointestinal",
    "schedule": "Schedule 2",
    "description": "Metoclopramide, oral nausea and vomiting): Charlesworth, S. (Ed.). (2020). Palliative Care Formulary (7th ed.). Pharmaceutical",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metoclopramide, oral oral",
    "brandName": "renal dosing",
    "strength": "14",
    "form": "tablet",
    "category": "Gastrointestinal",
    "schedule": "Schedule 2",
    "description": "Metoclopramide, oral oral (renal dosing): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Metoclopramide, oral",
    "brandName": "children",
    "strength": "N/A",
    "form": "tablet",
    "category": "Gastrointestinal",
    "schedule": "Schedule 2",
    "description": "Metoclopramide, oral (children): National Department of Health. Essential Drugs Programme: Paediatric Hospital Level STGs and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Health Syst Pharm. 2018 Jan 1;75",
    "brandName": "1",
    "strength": "2018 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Health Syst Pharm. 2018 Jan 1;75(1):e6-e12. https://www.ncbi.nlm.nih.gov/pubmed/29273607",
    "commonDosage": "2018 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adverse Outcomes Reported on in Epidemiologic Research. Drugs R D. 2017 Dec;17",
    "brandName": "4",
    "strength": "2017 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adverse Outcomes Reported on in Epidemiologic Research. Drugs R D. 2017 Dec;17(4):493-507.",
    "commonDosage": "2017 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "delirium in palliative care: a review. Curr Psychiatry Rep. 2015 Mar;17",
    "brandName": "3",
    "strength": "2015 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "delirium in palliative care: a review. Curr Psychiatry Rep. 2015 Mar;17(3):550. https://www.ncbi.nlm.nih.gov/pubmed/25663153",
    "commonDosage": "2015 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Midazolam, oral",
    "brandName": "delirium",
    "strength": "14",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Midazolam, oral (delirium – elderly, liver failure): South African Medicines Formulary.  14th Edition.  Division of Clinical Pharmacology.",
    "commonDosage": "14",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18Tricyclic antidepressants",
    "brandName": "note",
    "strength": "18",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18Tricyclic antidepressants (note): South African Medicines Formulary, 14th Edition.  Division of Clinical Pharmacology.  University of",
    "commonDosage": "18",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dyspnoea: Wearne, N., Davidson, B., Motsohi, T., McCulloch, M., & Krause, R.",
    "brandName": "2020",
    "strength": "2020",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dyspnoea: Wearne, N., Davidson, B., Motsohi, T., McCulloch, M., & Krause, R. (2020). Radically Rethinking Renal Supportive",
    "commonDosage": "2020",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine syrup",
    "brandName": "Adults: palliative dyspnoea",
    "strength": "N/A",
    "form": "syrup",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine syrup (Adults: palliative dyspnoea): Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Pharmacol Ther. 2005 Oct;10",
    "brandName": "4",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Pharmacol Ther. 2005 Oct;10(4):200-14. https://www.ncbi.nlm.nih.gov/pubmed/23118638",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "doses. The weight",
    "brandName": "band dosing tables below are standardised doses of",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "doses. The weight-band dosing tables below are standardised doses of a medicine for children for specific",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1.6 Management of HIV",
    "brandName": "infected children",
    "strength": "1.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1.6 Management of HIV-infected children",
    "commonDosage": "1.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Abacavir, oral, 8 mg/kg 12 hourly or 16 mg/kg daily.",
    "brandName": "see Annexure A",
    "strength": "8 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Abacavir, oral, 8 mg/kg 12 hourly or 16 mg/kg daily. (see Annexure A)",
    "commonDosage": "8 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃35 kg",
    "brandName": "55 kg",
    "strength": "35 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃35 kg–55 kg",
    "commonDosage": "35 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">35",
    "brandName": "55 kg",
    "strength": "35",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">35–55 kg",
    "commonDosage": "35",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3.2.1.1 Complicated severe acute malnutrition",
    "brandName": "SAM",
    "strength": "3.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3.2.1.1 Complicated severe acute malnutrition (SAM)-use as a single dose; 10.8 Measles (initial dose for measles with",
    "commonDosage": "3.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "moist or weeping; 10.8 Measles",
    "brandName": "children with otitis media",
    "strength": "10.8 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "moist or weeping; 10.8 Measles (children with otitis media); 10.14 Tick bite fever; 17.3.4.1 Pneumonia in children; 19.4.1 Otitis,",
    "commonDosage": "10.8 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">18",
    "brandName": "25 kg",
    "strength": "18",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">18-25 kg",
    "commonDosage": "18",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "fever; 14.3 Arthritis, septic; 17.2.1 Croup",
    "brandName": "laryngotracheobronchitis",
    "strength": "14.3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "fever; 14.3 Arthritis, septic; 17.2.1 Croup (laryngotracheobronchitis) in children;17.3.4.1 Pneumonia in children; 21.2.9 Shock",
    "commonDosage": "14.3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3.5 mL WFI",
    "brandName": "",
    "strength": "3.5 mL",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3.5 mL WFI)",
    "commonDosage": "3.5 mL",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃5.5",
    "brandName": "7 kg",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃5.5–7 kg",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Ceftriaxone IM/IV, 100 mg/kg/dose",
    "brandName": "immediately as a single dose",
    "strength": "100 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Ceftriaxone IM/IV, 100 mg/kg/dose (immediately as a single dose)",
    "commonDosage": "100 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "3.5",
    "brandName": "5.0 kg",
    "strength": "3.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "3.5–5.0 kg",
    "commonDosage": "3.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.1",
    "brandName": "7.4 kg",
    "strength": "5.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.1-7.4 kg",
    "commonDosage": "5.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "7.5",
    "brandName": "10 kg",
    "strength": "7.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "7.5-10 kg",
    "commonDosage": "7.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.1",
    "brandName": "14.kg",
    "strength": "10.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.1-14.kg",
    "commonDosage": "10.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "14.1",
    "brandName": "18 kg",
    "strength": "14.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "14.1-18 kg",
    "commonDosage": "14.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "18.1",
    "brandName": "25 kg",
    "strength": "18.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "18.1-25 kg",
    "commonDosage": "18.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.2 Itching",
    "brandName": "pruritus",
    "strength": "5.2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.2 Itching (pruritus); 5.8.1 Eczema, atopic; 5.8.2 Eczema, acute, moist or weeping; 5.10.1 Urticaria; 5.10.4 Papular urticaria;",
    "commonDosage": "5.2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "˃12",
    "brandName": "21 kg",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "˃12–21 kg",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "cancer pain",
    "brandName": "pruritis",
    "strength": "21.3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "cancer pain (pruritis); 21.3.1.3 Insect stings, scorpion stings and spider bites.",
    "commonDosage": "21.3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "11.5 The HIV",
    "brandName": "exposed infant; 11.6 Management of HIV infected ch",
    "strength": "11.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "11.5 The HIV-exposed infant; 11.6 Management of HIV infected children; 11.7 Opportunistic infections, prophylaxis in children;",
    "commonDosage": "11.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15.4.1 Meningitis, acute",
    "brandName": "or suspected meningitis or  suspected listeria men",
    "strength": "15.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15.4.1 Meningitis, acute – or suspected meningitis or  suspected listeria meningitis (pre-referral dose only).",
    "commonDosage": "15.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Efavirenz, oral, at night.",
    "brandName": "see Annexure A",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Efavirenz, oral, at night. (see Annexure A)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Epinephrine",
    "brandName": "adrenaline",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Epinephrine (adrenaline), 1:1000, IM, 0.01 mL/kg as a single dose.",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 mg/mL",
    "brandName": "1:1 000",
    "strength": "1 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 mg/mL (1:1 000)",
    "commonDosage": "1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": ">12",
    "brandName": "17.5 kg",
    "strength": "12",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": ">12–17.5 kg",
    "commonDosage": "12",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.4.1 Boil, abscess; 5.4.2 Impetigo; 5.4.3 Cellulitis; 5.8.2 Eczema, acute, moist or weeping; 19.4.1 Otitis, externa",
    "brandName": "furuncular",
    "strength": "5.4",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.4.1 Boil, abscess; 5.4.2 Impetigo; 5.4.3 Cellulitis; 5.8.2 Eczema, acute, moist or weeping; 19.4.1 Otitis, externa (furuncular)",
    "commonDosage": "5.4",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "5.5.2.3 Scalp infections",
    "brandName": "tinea capitis",
    "strength": "5.5",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "5.5.2.3 Scalp infections – tinea capitis (for 28 days); 11.8.2 Candidiasis, oesophageal (for 21 days).",
    "commonDosage": "5.5",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "4.6.2 Cardiac failure, Congestive",
    "brandName": "CCF",
    "strength": "4.6",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "4.6.2 Cardiac failure, Congestive (CCF); 8.1 Chronic kidney disease (CKD); 8.2 Acute kidney injury; 21.2.8 Pulmonary",
    "commonDosage": "4.6",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hydrocortisone IM /slow IV, 4mg/kg",
    "brandName": "maximum 100 mg",
    "strength": "4mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Hydrocortisone IM /slow IV, 4mg/kg (maximum 100 mg)  immediately.",
    "commonDosage": "4mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lamivudine, oral, 4 mg/kg 12 hourly or 8 mg/kg daily.",
    "brandName": "see Annexure A",
    "strength": "4 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lamivudine, oral, 4 mg/kg 12 hourly or 8 mg/kg daily. (see Annexure A)",
    "commonDosage": "4 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Lopinavir/ritonavir, oral 300/75mg/m2",
    "brandName": "administered 12 hourly.",
    "strength": "300",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Lopinavir/ritonavir, oral 300/75mg/m2 – administered 12 hourly. (see Annexure A)",
    "commonDosage": "300",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Injection formulation",
    "brandName": "buccal",
    "strength": "N/A",
    "form": "injection",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Injection formulation (buccal",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "administration",
    "brandName": "5 mg/mL",
    "strength": "5 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "administration) 5 mg/mL",
    "commonDosage": "5 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine , oral, 0.05 mg/kg/dose 6 hourly in children aged 0",
    "brandName": "1 month.",
    "strength": "0.05 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine , oral, 0.05 mg/kg/dose 6 hourly in children aged 0-1 month.",
    "commonDosage": "0.05 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, oral, 0.1 mg/kg/dose 4",
    "brandName": "6 hourly in children 1",
    "strength": "0.1 mg",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, oral, 0.1 mg/kg/dose 4-6 hourly in children 1-11 months.",
    "commonDosage": "0.1 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Morphine, oral, 0.2",
    "brandName": "0.4 mg/kg/dose 4",
    "strength": "0.2",
    "form": "tablet",
    "category": "Analgesics",
    "schedule": "Schedule 2",
    "description": "Morphine, oral, 0.2–0.4 mg/kg/dose 4–6 hourly in children > 12 months.",
    "commonDosage": "0.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10.2 Chickenpox; 10.5 Fever; 10.7.1 Malaria, uncomplicated",
    "brandName": "fever in children < 5 years of age",
    "strength": "10.2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10.2 Chickenpox; 10.5 Fever; 10.7.1 Malaria, uncomplicated (fever in children < 5 years of age); 10.8 Measles; 10.10 Mumps;",
    "commonDosage": "10.2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "15.5 Headache, mild, non",
    "brandName": "specific; 17.2.1 Croup",
    "strength": "15.5 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "15.5 Headache, mild, non-specific; 17.2.1 Croup (laryngotracheobronchitis) in children; 17.3.1 Influenza; 18.1.2 Conjunctivitis,",
    "commonDosage": "15.5 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "bacterial",
    "brandName": "excluding conjunctivitis of the newborn",
    "strength": "18.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "bacterial (excluding conjunctivitis of the newborn); 18.1.4 Conjunctivitis, viral (pink eye); 18.3.1 Eye injury, chemical burn; 18.3.3",
    "commonDosage": "18.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Eye injury",
    "brandName": "blunt or penetrating",
    "strength": "19.2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Eye injury (blunt or penetrating); 19.2 Viral rhinitis (common cold); 19.4.2 Otitis, media, acute; 19.5 Sinusitis, acute, bacterial;",
    "commonDosage": "19.2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "19.6 Tonsillitis and pharyngitis; 20.2 Acute pain; 20.3 Chronic non",
    "brandName": "cancer pain; 20.4 Chronic cancer pain; 21.3.1.3 In",
    "strength": "19.6 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "19.6 Tonsillitis and pharyngitis; 20.2 Acute pain; 20.3 Chronic non-cancer pain; 20.4 Chronic cancer pain; 21.3.1.3 Insect",
    "commonDosage": "19.6 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Zidovudine, oral, 180",
    "brandName": "240 mg/m2 12 hourly.",
    "strength": "180",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Zidovudine, oral, 180-240 mg/m2 12 hourly. (see antiretroviral drug dosing chart for children below)",
    "commonDosage": "180",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tabs 60 mg",
    "brandName": "scored,",
    "strength": "60 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tabs 60 mg (scored,",
    "commonDosage": "60 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "300 mg",
    "brandName": "not scored",
    "strength": "300 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "300 mg (not scored)",
    "commonDosage": "300 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tabs 150 mg",
    "brandName": "scored",
    "strength": "150 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tabs 150 mg (scored)",
    "commonDosage": "150 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "10 mg, film coated",
    "brandName": "FC",
    "strength": "10 mg",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "10 mg, film coated (FC)",
    "commonDosage": "10 mg",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Consult with a clinician experienced in paediatric ARV prescribing for neonates",
    "brandName": "< 28 days of age",
    "strength": "28 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Consult with a clinician experienced in paediatric ARV prescribing for neonates (< 28 days of age) and infants weighing < 3 kg.",
    "commonDosage": "28 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "stopping rifampicin",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "stopping rifampicin)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Number Need to Treat",
    "brandName": "NNT",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Number Need to Treat (NNT):  gives the number of patients who need to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Motivating information",
    "brandName": "Level of evidence based on the SORT system",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Motivating information (Level of evidence based on the SORT system)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "evidence",
    "brandName": "intermediate or physiologic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "evidence (intermediate or physiologic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "quality systematic reviews or peer",
    "brandName": "reviewed high quality randomised controlled",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "quality systematic reviews or peer-reviewed high quality randomised controlled",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "1 Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy",
    "brandName": "SORT",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "1 Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "approach to grading evidence in the medical literature. Am Fam Physician. 2004;69:550",
    "brandName": "6.",
    "strength": "2004",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "approach to grading evidence in the medical literature. Am Fam Physician. 2004;69:550-6.",
    "commonDosage": "2004",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "o Cost per daily dose or course of therapy",
    "brandName": "for long term or chronic",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "o Cost per daily dose or course of therapy – for long term or chronic",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "outcome. By calculating a summary measurement of efficiency",
    "brandName": "a cost",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "outcome. By calculating a summary measurement of efficiency (a cost-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The rationale for decision",
    "brandName": "making may be sourced from the relevant medicine r",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The rationale for decision-making may be sourced from the relevant medicine reviews,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Department of Health website at: https://www.health.gov.za/nhi",
    "brandName": "edp",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Department of Health website at: https://www.health.gov.za/nhi-edp-stgs-eml/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Generic name",
    "brandName": "or International Non",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Generic name (or International Non-proprietary Name):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Prevalence of condition",
    "brandName": "based on epidemiological data, if any",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Prevalence of condition (based on epidemiological data, if any):",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2.2: Motivating information",
    "brandName": "Level of evidence based on the SORT system",
    "strength": "2.2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2.2: Motivating information (Level of evidence based on the SORT system)",
    "commonDosage": "2.2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A. Newer product: High quality systematic reviews or peer",
    "brandName": "reviewed high quality randomised",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A. Newer product: High quality systematic reviews or peer-reviewed high quality randomised",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The South African Health Products Regulatory Authority",
    "brandName": "SAHPRA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The South African Health Products Regulatory Authority (SAHPRA) has a responsibility",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "What is an Adverse Drug Reaction",
    "brandName": "ADR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "What is an Adverse Drug Reaction (ADR)?",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SAHPRA defines an Adverse Drug Reaction",
    "brandName": "ADR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SAHPRA defines an Adverse Drug Reaction (ADR) as a response to a medicine which",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "According to Regulation 40 of the Medicines and Related Substances Act, 1965",
    "brandName": "Act",
    "strength": "40 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "According to Regulation 40 of the Medicines and Related Substances Act, 1965 (Act",
    "commonDosage": "40 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "possible and where possible provide an accurate diagnosis.",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "possible and where possible provide an accurate diagnosis.)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "package insert or other reference?",
    "brandName": "If the reaction is not documented in the",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "package insert or other reference? (If the reaction is not documented in the",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Did the patient take the medicine again after the reaction abated",
    "brandName": "i.e. rechallenge",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Did the patient take the medicine again after the reaction abated (i.e. rechallenge).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "If so, did the same reaction occur again?",
    "brandName": "In most situations it is not possible or",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "If so, did the same reaction occur again? (In most situations it is not possible or",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Can this reaction be explained by other causes",
    "brandName": "e.g. underlying disease/s; other",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Can this reaction be explained by other causes (e.g. underlying disease/s; other",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "medicine/s; toxins or foods",
    "brandName": "?",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "medicine/s; toxins or foods)? (It is essential that the patient is thoroughly",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "South African Health Products Regulatory Authority",
    "brandName": "SAHPRA",
    "strength": "828",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "South African Health Products Regulatory Authority (SAHPRA), Private Bag X828",
    "commonDosage": "828",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tel:",
    "brandName": "012",
    "strength": "012",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tel: (012) 5010311; E-mail: adr@sahpra.org.za",
    "commonDosage": "012",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "GLF",
    "brandName": "CEM",
    "strength": "06",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "GLF-CEM-PV-06A",
    "commonDosage": "06",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ADVERSE DRUG REACTION",
    "brandName": "ADR",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ADVERSE DRUG REACTION (ADR)/ PRODUCT",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Height",
    "brandName": "cm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Height (cm)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suspect Medicine",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suspect Medicine(s) [Medicines suspected to have caused the ADR], Concomitant [Other medicines taken together with the suspect medicine(s)] OR",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Interacting [Other medicines taken together with the suspect medicine",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Interacting [Other medicines taken together with the suspect medicine(s) and may have interacted with the suspect medicine(s)] [Including over the counter",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Dose",
    "brandName": "mg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Dose (mg) and",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "☐ Other intervention",
    "brandName": "e.g., dialysis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "☐ Other intervention (e.g., dialysis): _________________________",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "drug/similar drug",
    "brandName": "rechallenge",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "drug/similar drug (rechallenge): ☐N ☐Y",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "• medications",
    "brandName": "medicines and biologicals",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "• medications (medicines and biologicals),",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "• complementary / alternative medicines",
    "brandName": "including traditional,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "• complementary / alternative medicines (including traditional,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Report Adverse Events Following Immunisation",
    "brandName": "AEFI",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Report Adverse Events Following Immunisation (AEFI)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SAHPRA portal: https://www.sahpra.org.za/health",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SAHPRA portal: https://www.sahpra.org.za/health-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "products",
    "brandName": "vigilance/",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "products-vigilance/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "SAHPRA portal: https://www.sahpra.org.za/complaints",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "SAHPRA portal: https://www.sahpra.org.za/complaints-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "relating",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "relating-to-medicine-and-medical-devices/",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ADRs/adverse event following immunisations",
    "brandName": "AEFIs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ADRs/adverse event following immunisations (AEFIs). It is the preferred reporting tool by SAHPRA and allows for a seamless",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "purpose of reporting a suspected adverse reaction.  The reporter acknowledges that this information may be used a",
    "brandName": "to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "purpose of reporting a suspected adverse reaction.  The reporter acknowledges that this information may be used a) to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "when required; b",
    "brandName": "in the generation of statistics; and c",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "when required; b) in the generation of statistics; and c) to make policy decisions relating to safe use of medicines.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "The International Health Regulations, 2005",
    "brandName": "IHR",
    "strength": "2005 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "The International Health Regulations, 2005 (IHR) and the National Health Act, 61 0f 2003",
    "commonDosage": "2005 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "diseases within the population. Real",
    "brandName": "time surveillance and reporting NMCs provides an",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "diseases within the population. Real-time surveillance and reporting NMCs provides an",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Notifiable medical conditions have been sub",
    "brandName": "divided into two categories according",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Notifiable medical conditions have been sub-divided into two categories according",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "an Outbreak Case Line Listing Form as well through the notification form",
    "brandName": "GW17/5",
    "strength": "17",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "an Outbreak Case Line Listing Form as well through the notification form (GW17/5)",
    "commonDosage": "17",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Electronic reporting via the NMC mobile or web",
    "brandName": "based APP:",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Electronic reporting via the NMC mobile or web-based APP:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Complete the case",
    "brandName": "based form",
    "strength": "17",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Complete the case-based form (GW 17/5)",
    "commonDosage": "17",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "that when estimating the “Case Fatality Rate”",
    "brandName": "CFR%",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "that when estimating the “Case Fatality Rate” (CFR%), all deaths in the numerator",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Sms/whatsup line",
    "brandName": "for copy/photograph submissions",
    "strength": "072 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Sms/whatsup line (for copy/photograph submissions): 072 621 3805",
    "commonDosage": "072 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Category 1: Immediate notification",
    "brandName": "within 24 hours",
    "strength": "1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Category 1: Immediate notification (within 24 hours) of diagnosis",
    "commonDosage": "1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Maternal death",
    "brandName": "pregnancy, childbirth and puerperium",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Maternal death (pregnancy, childbirth and puerperium)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tuberculosis: multidrug",
    "brandName": "resistant",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tuberculosis: multidrug-resistant (MDR-TB)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Tuberculosis: extensively drug",
    "brandName": "resistant",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Tuberculosis: extensively drug-resistant (XDR-TB)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "caregiver",
    "brandName": "and the child. This is important as the booklet co",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "caregiver) and the child. This is important as the booklet contains",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Well child visit routine care",
    "brandName": "incl. growth, TB status, PMTCT HIV status,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Well child visit routine care (incl. growth, TB status, PMTCT HIV status,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "feeding etc.",
    "brandName": ".",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "feeding etc.).",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Any clinical notes",
    "brandName": "ideally using IMCI classification, treatment and f",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Any clinical notes (ideally using IMCI classification, treatment and follow up",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Boy’s Weight",
    "brandName": "for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Boy’s Weight-for-Age",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "This Weight",
    "brandName": "for",
    "strength": "0",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "This Weight-for-Age Chart shows body-weight relative to age in comparison to the Median (0-line).",
    "commonDosage": "0",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A boy whose weight",
    "brandName": "for",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A boy whose weight-for-age is below the -2 line, is underweight.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A boy whose weight",
    "brandName": "for",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A boy whose weight-for-age is below the -3 line, is severely underweight. Clinical signs of",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Girl’s Weight",
    "brandName": "for",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Girl’s Weight-for-Age",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A girl whose weight",
    "brandName": "for",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A girl whose weight-for-age is below the -2 line, is underweight.",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A girl whose weight",
    "brandName": "for",
    "strength": "3 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A girl whose weight-for-age is below the -3 line, is severely underweight. Clinical signs of",
    "commonDosage": "3 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Length / Height in centimetre",
    "brandName": "cm",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Length / Height in centimetre (cm)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Weight in kilogram",
    "brandName": "kg",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Weight in kilogram (kg)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "shows body",
    "brandName": "weight relative to length/height in comparison",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "shows body-weight relative to length/height in comparison",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "A girl whose weight",
    "brandName": "for",
    "strength": "1 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "A girl whose weight-for-length/height is above the +1 line, shows possible risk of",
    "commonDosage": "1 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Suggested reference peak expiratory flow",
    "brandName": "PEF",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Suggested reference peak expiratory flow (PEF) values for children:",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Adapted with permission from Nunn AJ Gregg I, Br Med J 1989:298;1068",
    "brandName": "70",
    "strength": "1989",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Adapted with permission from Nunn AJ Gregg I, Br Med J 1989:298;1068-70",
    "commonDosage": "1989",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "e.g. 200, 180, 190 performed",
    "brandName": "so take 200.",
    "strength": "200",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "e.g. 200, 180, 190 performed – so take 200.",
    "commonDosage": "200",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Repeat peak flow testing to obtain a post",
    "brandName": "bronchodilator peak flow.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Repeat peak flow testing to obtain a post-bronchodilator peak flow.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Subtract the pre",
    "brandName": "bronchodilator reading from the post",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Subtract the pre-bronchodilator reading from the post-bronchodilator",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Divide the difference by the pre",
    "brandName": "bronchodilator reading.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Divide the difference by the pre-bronchodilator reading.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "diagnosis of asthma.",
    "brandName": "See Sections 16.1: Asthma, acute and 16.2: Asthma,",
    "strength": "16.1",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "diagnosis of asthma. (See Sections 16.1: Asthma, acute and 16.2: Asthma,",
    "commonDosage": "16.1",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113",
    "brandName": "1",
    "strength": "2004 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59-65.",
    "commonDosage": "2004 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "150",
    "brandName": "250 mL",
    "strength": "150",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "150–250 mL",
    "commonDosage": "150",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» If patients are switched between different types of devices",
    "brandName": "e.g. from MDI to",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» If patients are switched between different types of devices (e.g. from MDI to",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Breathe out slowly through the nose and rest for a few breaths",
    "brandName": "30",
    "strength": "30",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Breathe out slowly through the nose and rest for a few breaths (30–60",
    "commonDosage": "30",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Repeat steps 2",
    "brandName": "8 for each puff prescribed, waiting at least 30 se",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Repeat steps 2–8 for each puff prescribed, waiting at least 30 seconds",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Repeat steps 3",
    "brandName": "6 for each puff prescribed, waiting at least 30 se",
    "strength": "3",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Repeat steps 3–6 for each puff prescribed, waiting at least 30 seconds",
    "commonDosage": "3",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Stand or sit up straight and breathe out completely",
    "brandName": "away from the device,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Stand or sit up straight and breathe out completely (away from the device,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Optimise positioning and repeat steps 2",
    "brandName": "5 for each puff prescribed, waiting",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Optimise positioning and repeat steps 2–5 for each puff prescribed, waiting",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "jet nebulizers is 2",
    "brandName": "3 mL.",
    "strength": "2",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "jet nebulizers is 2-3 mL.",
    "commonDosage": "2",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» Rapid or forceful inhalation",
    "brandName": "including crying",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» Rapid or forceful inhalation (including crying)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "» A loose",
    "brandName": "fitting facemask or placing the nebuliser near a c",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "» A loose-fitting facemask or placing the nebuliser near a child’s nose and mouth",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Rubin BK Fink JB. Optimizing aerosol delivery by pressurized metered",
    "brandName": "dose inhalers. Respir Care 2005; 50",
    "strength": "2005",
    "form": "inhaler",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Rubin BK Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 2005; 50 (9):",
    "commonDosage": "2005",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Devadason SG. Recent advances in aerosol therapy for children with asthma. J Aerosol Med. 2006 Spring;19",
    "brandName": "1",
    "strength": "2006 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Devadason SG. Recent advances in aerosol therapy for children with asthma. J Aerosol Med. 2006 Spring;19(1):61-",
    "commonDosage": "2006 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Esposito",
    "brandName": "Festen JE, Ates B, van Vliet FJ, Verbraak AF, de J",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Esposito-Festen JE, Ates B, van Vliet FJ, Verbraak AF, de Jongste JC, Tiddens HA. Effect of a facemask leak on",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Spring;17",
    "brandName": "1",
    "strength": "17",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Spring;17(1):1-6.",
    "commonDosage": "17",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "angiotensin",
    "brandName": "converting",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "angiotensin-converting-enzyme inhibitor",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Bacillus Calmette",
    "brandName": "Guérin vaccine",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Bacillus Calmette–Guérin vaccine",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "multi drug",
    "brandName": "resistant tuberculosis",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "multi drug-resistant tuberculosis",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "degree",
    "brandName": "s",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "degree(s) Celsius",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "capsule",
    "brandName": "s",
    "strength": "N/A",
    "form": "capsule",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "capsule(s)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Multi",
    "brandName": "month dispensing",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Multi-month dispensing",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Disease Modifying Anti",
    "brandName": "rheumatic Drugs",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Disease Modifying Anti-rheumatic Drugs",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Vaginal route",
    "brandName": "of administration",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Vaginal route (of administration)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "short",
    "brandName": "acting beta2 agonist",
    "strength": "2 ",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "short-acting beta2 agonist",
    "commonDosage": "2 ",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "hepatitis B e",
    "brandName": "antigen",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "hepatitis B e-antigen",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Hypertension",
    "brandName": "mediated organ damage",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 4",
    "description": "Hypertension-mediated organ damage",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "thyroid",
    "brandName": "stimulating hormone",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "thyroid-stimulating hormone",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "ung emulisificans aqueosum",
    "brandName": "aqueous cream",
    "strength": "N/A",
    "form": "cream",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "ung emulisificans aqueosum (aqueous cream)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "which financial or other interests may unduly influence decision",
    "brandName": "making.",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "which financial or other interests may unduly influence decision-making.",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NICD influenza guidelines: annual. Abbott",
    "brandName": "TB LAM presentation at SA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NICD influenza guidelines: annual. Abbott - TB LAM presentation at SA",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Employed by Ophthalmology Society of South Africa",
    "brandName": "OSSA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Employed by Ophthalmology Society of South Africa (OSSA) which has",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "for Professional Development",
    "brandName": "FPD",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "for Professional Development (FPD) to assist FPD and the Knowledge",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Guideline Management",
    "brandName": "; Novartis SA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Guideline Management); Novartis SA (Pty) Ltd: Consultancy to develop a",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Heart Failure Tool box; Boehringer",
    "brandName": "Ingelheim, Novonordisk,",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Heart Failure Tool box; Boehringer–Ingelheim, Novonordisk,",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Eli",
    "brandName": "Lilly, AstraZeneca and Adcock Ingram: Speaker Fees",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Eli-Lilly, AstraZeneca and Adcock Ingram: Speaker Fees for Webinars &",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "III Trial; Wits University/TAKEDA: Research Grant",
    "brandName": "Fabry’s Disease in",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "III Trial; Wits University/TAKEDA: Research Grant - Fabry’s Disease in",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "2022: IQVIA Health",
    "brandName": "Project regarding Analysis and summary of the",
    "strength": "2022",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "2022: IQVIA Health – Project regarding Analysis and summary of the",
    "commonDosage": "2022",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "registry",
    "brandName": "probably in oncology",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "registry (probably in oncology) which may result in data to inform clinical",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "NICD hotline",
    "brandName": "e.g. Rabies, Viral Haemmorhagic Fever",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "NICD hotline (e.g. Rabies, Viral Haemmorhagic Fever",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "outbreak, emerging respiratory pathogens",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "outbreak, emerging respiratory pathogens)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Regulatory Authority",
    "brandName": "SAHPRA",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Regulatory Authority (SAHPRA)",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://primaryreporting.who",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://primaryreporting.who-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "Antiretroviral therapy: drug",
    "brandName": "drug interactions",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "Antiretroviral therapy: drug-drug interactions",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.framinghamheartstudy.org/fhs",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.framinghamheartstudy.org/fhs-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.mdcalc.com/ideal",
    "brandName": "body",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.mdcalc.com/ideal-body-weight-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "adjusted",
    "brandName": "body",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "adjusted-body-weight",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "https://www.sahpra.org.za/wp",
    "brandName": "",
    "strength": "N/A",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "https://www.sahpra.org.za/wp-",
    "commonDosage": "N/A",
    "commonFrequency": "As prescribed"
  },
  {
    "genericName": "content/uploads/2025/05/GLF",
    "brandName": "CEM",
    "strength": "2025",
    "form": "tablet",
    "category": "Other",
    "schedule": "Schedule 2",
    "description": "content/uploads/2025/05/GLF-CEM-PV-S01_v2-",
    "commonDosage": "2025",
    "commonFrequency": "As prescribed"
  }
]